<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2201233141
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KYPROLIS 60 mg Powder For Solution For Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARFILZOMIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4235.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ONYX PHARMACEUTICALS INC.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX45 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Carfilzomib is the active ingredient in Kyprolis.</p><p>&nbsp;</p><p>Kyprolis is a type of medicine used to treat patients with multiple myeloma who have received at least one previous treatment for multiple myeloma. Multiple myeloma is a cancer of plasma cells (a type of white blood cell that produces a type of protein called immunoglobulins).</p><p>&nbsp;</p><p>Kyprolis, also called carfilzomib, is a proteasome inhibitor. Proteasomes play an important role in cell function and growth by breaking down proteins that are damaged or no longer needed. Kyprolis blocks proteasomes, which can lead to an excessive build-up of proteins within cells. In some cells, Kyprolis can cause cell death, especially in cancer cells because they are more likely to contain a higher amount of abnormal proteins.</p><p>&nbsp;</p><p>Kyprolis may be given to you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on its own,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with lenalidomide and dexamethasone,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with dexamethasone and daratumumab, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; only with dexamethasone.</p><p>&nbsp;</p><p>Lenalidomide, dexamethasone, and daratumumab are other medicines used to treat multiple myeloma.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Kyprolis:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic (hypersensitive)</strong> to carfilzomib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are breast-feeding.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Before you take Kyprolis, your doctor needs to know if you have any of the problems listed below. Talk to your doctor, nurse, or pharmacist if any of these apply to you before using Kyprolis. You may need extra tests to check that your heart, kidneys, and liver are working properly.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart problems, including a history of chest pain (angina), heart attack, irregular heartbeat, high blood pressure or if you have ever taken a medicine for your heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung problems, including a history of shortness of breath at rest or with activity (dyspnea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems, including kidney failure or if you have ever received dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver problems, including a history of hepatitis, fatty liver, or if you have ever been told your liver is not working properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual bleeding, including easy bruising, bleeding from an injury, such as a cut that does not stop bleeding in a normal amount of time, or internal bleeding, which can indicate you have low platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in your veins</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any other major medical disease for which you were hospitalized or received medication</p><p>&nbsp;</p><p>Kyprolis can make some conditions worse or cause serious side effects, including life-threatening complications.</p><p>&nbsp;</p><p><strong>Tell your doctor, pharmacist or nurse immediately if you get any of the following:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pains, shortness of breath, or if there is swelling of your ankles and feet, which may be symptoms of heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing, including shortness of breath at rest or with activity or a cough (dyspnea), rapid breathing, feeling like you can&#39;t breathe in enough air, wheezing, or cough, which can be signs of lung toxicities</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extremely high blood pressure, severe chest pain, severe headache, confusion, blurred vision, nausea and vomiting, or severe anxiety, which may be signs of a condition known as hypertensive crises</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath with everyday activities or at rest, irregular heartbeat, racing pulse, tiredness, dizziness, and fainting spells, which can be signs of a condition known as pulmonary hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen ankles, feet, or hands; loss of appetite; passing less urine; or abnormal blood tests, which may be symptoms of kidney problems or kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A side effect called Tumor Lysis Syndrome, which may be caused by the rapid breakdown of tumor cells which results in abnormal blood tests and may cause irregular heart beat or kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reaction to Kyprolis infusion, which can include the following symptoms:&nbsp;fever, chills or shaking, joint pain, muscle pain, facial flushing or swelling, swelling of the throat, weakness, shortness of breath, low blood pressure, fainting, chest tightness, or chest pain or bradycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual bruising or bleeding, such as a cut that does not stop bleeding in a normal amount of time or internal bleeding such as coughing up blood, vomiting up blood, dark tarry stools, or bright red blood in your stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leg pain (which could be a symptom of blood clots in the deep veins of the leg), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver problems, including liver failure, which may cause yellowing of your skin and eyes (jaundice), abdominal pain or swelling, nausea or vomiting. If you have ever had hepatitis B infection, treatment with Kyprolis may cause the hepatitis B infection to become active again</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding, bruising, weakness, confusion, fever, nausea, vomiting and diarrhea, and acute kidney failure, which may be signs of a blood condition known as thrombotic microangiopathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches, confusion, seizures, visual loss, and high blood pressure (hypertension), which may be symptoms of a neurologic condition known as Posterior Reversible Encephalopathy Syndrome (PRES)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred or double vision, vision loss, difficulty speaking, weakness in an arm or a leg, a change in the way you walk, problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion which may be symptoms of a central nervous system infection known as Progressive Multifocal Leukoencephalopathy (PML)</p><p>&nbsp;</p><p>You must look out for certain symptoms while you are taking Kyprolis to reduce the risk of any problems. See section 4 for a full list of possible side effects.</p><p>&nbsp;</p><p>Your doctor will examine you and review your full medical history. You will be monitored closely during treatment. Prior to starting Kyprolis, and during treatment, you will undergo blood testing. This is to verify that you have enough blood cells and your liver and kidneys are working properly. Prior to receiving Kyprolis, your doctor or healthcare professional will ensure you are getting enough fluids.</p><p>&nbsp;</p><p>You must read the package leaflet of all medicines that you take in combination with Kyprolis so that you understand the information related to those medicines.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>&nbsp;</p><p>Tell your healthcare professional the name of all the medications you are currently taking, have recently taken, or might take in the future. This includes any medicines obtained without a prescription, such as vitamins or herbal remedies.</p><p>&nbsp;</p><p>Tell your doctor or nurse if you are taking medicines used to prevent pregnancy such as oral contraceptives or other hormonal contraceptives since these may not be suitable for use with Kyprolis.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and contraception</strong></p><p>&nbsp;</p><p><u>For women taking Kyprolis</u></p><p><u>&nbsp;</u></p><p>Kyprolis should not be taken if you are trying to become pregnant or are pregnant. Treatment with Kyprolis has not been evaluated in pregnant women. While taking Kyprolis and for 180&nbsp;days after stopping treatment, you should use a reliable method of birth control to ensure you do not become pregnant. It is important that you tell your healthcare professional if you are pregnant, think you may be pregnant, or plan on becoming pregnant. If you become pregnant while taking Kyprolis, notify your healthcare professional immediately.</p><p>&nbsp;</p><p>Do not breast-feed during and for at least 2 days after treatment with Kyprolis. It is not known if Kyprolis passes into breast milk in humans. It is important to tell your healthcare professional if you are breast-feeding or plan to do so.</p><p>&nbsp;</p><p><u>For men taking Kyprolis</u></p><p>&nbsp;</p><p>While taking Kyprolis and for 90&nbsp;days after stopping treatment, you should use a reliable method of birth control, such as a condom, to ensure your partner does not become pregnant. You should talk to your doctor or nurse about reliable methods of birth control.</p><p>&nbsp;</p><p>If your partner becomes pregnant while you are taking Kyprolis or within 90&nbsp;days after stopping treatment, notify your doctor or nurse immediately.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Patients being treated with Kyprolis may experience fatigue, dizziness, fainting, and/or a drop in blood pressure. This may impair your ability to drive or operate machinery. If you have these symptoms, you should not drive a car or operate machinery.</p><p>&nbsp;</p><p><strong>Kyprolis contains Sodium</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains 216 mg sodium per 60 mg vial. This is equivalent to 11% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p><p>Kyprolis contains cyclodextrin</p><p>&nbsp;</p><p>This medicine contains 3000 mg sodium sulfobutylether beta-cyclodextrin per 60 mg vial. This is equivalent to 88 mg/kg for a 70 kg adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Kyprolis will be given to you by a healthcare professional. Kyprolis once weekly will be infused into your vein each week for 3 weeks, followed by one week without dosing. Kyprolis twice weekly will be infused into your vein 2&nbsp;days in a row, each week for 3&nbsp;weeks, followed by one week without dosing. Each&nbsp;28‑day period is considered one treatment cycle. This means that Kyprolis will be given on Days 1, 8, and 15 for once weekly dosing and Days&nbsp;1, 2, 8, 9, 15, and 16 for twice weekly dosing of each 28‑day cycle.</p><p>&nbsp;</p><p>When Kyprolis is given alone or with lenalidomide and dexamethasone, the doses on Day&nbsp;8 and 9 of each cycle will not be given from Cycle&nbsp;13 onwards.</p><p>&nbsp;</p><p>The dose will be calculated based on your height and weight (body surface area). Your healthcare professional will determine the dose of Kyprolis that you receive.</p><p>&nbsp;</p><p>Most patients will receive treatment until their disease progresses (gets worse). However, Kyprolis treatment may also be stopped if you experience side effects that cannot be managed.</p><p>&nbsp;</p><p>If you are given too much Kyprolis</p><p>&nbsp;</p><p>As this medicine is being given by a doctor or nurse, it is unlikely that you will be given too much. However, if you are given too much Kyprolis your doctor will monitor you for side effects.</p><p>&nbsp;</p><p>If you have any further questions on the use of Kyprolis, ask your healthcare professional.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Kyprolis can cause side effects, although not everybody will get them. However, be sure to contact your healthcare professional if you experience any of the following side effects or if you notice any other side effects not listed here.</p><p>&nbsp;</p><p>Other side effects include the following:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cell count (anemia), which may cause tiredness and fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low platelets, which may cause easy bruising or bleeding (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cell count, which may decrease your ability to fight infection and may be associated with fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombotic microangiopathy, including Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS), which may cause the following symptoms: bleeding, bruising, weakness, confusion, fever, nausea, vomiting and diarrhea and acute kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart disease including heart attack and congestive heart failure that could cause death, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid, strong, or irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal amount of fluid between the heart and the lining around the heart (pericardial effusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling and irritation of the lining around the heart (pericarditis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, cough, cough with phlegm, nose bleed, change in voice or hoarseness, fluid in the lungs, blood clot in the lungs, pain in the throat, wheezing, difficulty breathing, rapid breathing, bleeding in the lungs, swelling of the throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears (tinnitus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision, cataract</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea, nausea, constipation, vomiting, indigestion, stomach pain, toothache, perforation in stomach, small intestine, or large bowel (GI perforation), bleeding in the stomach and bowels, intestinal blockage, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue), fever, swelling of the hands, feet or ankles, muscle weakness, chills, pain, multi-organ failure, infusion site reaction (pain, redness, irritation, or swelling where you received the injection into your vein), chest pain, general feeling of illness or discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver failure or other liver problems including an increase in your liver enzymes, bilirubin, or bile acids in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Runny nose or nasal congestion, sore throat, inflammation of the nose and throat, bronchitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu like symptoms (influenza)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sepsis (systemic infection including infection in the blood) and/or septic shock (a life‑threatening form of sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viral infection (Herpes Zoster)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the stomach and intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the colon caused by a bacteria called Clostridium difficile</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the back of the eye (cytomegalovirus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood levels of sugar, calcium, uric acid, or potassium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased blood levels of protein, potassium, magnesium, calcium, sodium or phosphate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor lysis syndrome, which may be caused by rapid breakdown of tumor cells and increase the levels of potassium, uric acid, phosphate in your blood, and may lead to acute kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain, joint pain, pain in limbs, hands, or feet, bone pain, muscle pain, muscle spasms, muscle weakness, aching muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness, numbness, tingling, or decreased sensation in hands and/or feet, stroke, Posterior Reversible Encephalopathy Syndrome (PRES), with symptoms of headaches, confusion, seizures, visual loss, and high blood pressure (hypertension), bleeding in the brain, loss of hearing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insomnia (difficulty sleeping), anxiety, delirium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itchy skin, redness of the skin, increased sweating, angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure (hypertension), low blood pressure (hypotension), blood clots in the veins (deep vein thrombosis), extremely high blood pressure (hypertensive crises), feeling too hot</p><p>&nbsp;</p><p>Reporting of side effects:</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Kyprolis will be stored in the pharmacy.</p><p>&nbsp;</p><p>Keep this medicine out of sight and reach of children.</p><p>&nbsp;</p><p><u>Vial</u></p><p>&nbsp;</p><p>Unopened vials should be stored in a refrigerator (2&deg;C to 8&deg;C). Keep the vial in the original package to protect it from light.</p><p>&nbsp;</p><p>Do not use Kyprolis after the expiry date printed on the vial and the carton.</p><p>&nbsp;</p><p><u>Reconstituted solution</u></p><p>&nbsp;</p><p>Shelf life after reconstitution: 4&nbsp;hours at room temperature (15&deg;C to 30&deg;C) or 24&nbsp;hours at 2&deg;C to 8&deg;C.</p><p>&nbsp;</p><p>A total time from reconstitution to administration should not exceed 24&nbsp;hours.</p><p>&nbsp;</p><p>The reconstituted product should be a clear, colourless to slightly yellow solution and should not be administered if any discolouration or particulate matter is observed.</p><p>&nbsp;</p><p>Kyprolis is for single-use only. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Active ingredient: carfilzomib; after reconstitution Kyprolis contains 2&nbsp;mg/mL of carfilzomib.</p><p>&nbsp;</p><p>Inactive ingredients: sodium sulfobutylether beta-cyclodextrin 3000&nbsp;mg, anhydrous citric acid 57.7&nbsp;mg and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Kyprolis is supplied in a sterile vial and looks like white to off-white powder. The single-use vial is distributed individually in a carton and contains a dose of 60 mg of carfilzomib.
	
	Each pack contains 1 vial.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer</strong></p><p>&nbsp;</p><p><strong>Marketing Authorization Holder:</strong></p><p>Onyx Pharmaceuticals Inc.</p><p>One Amgen Center Drive</p><p>Thousand Oaks, CA 91320-1799</p><p>USA</p><p>&nbsp;</p><p><strong>Site of Manufacture of the Drug Product:</strong></p><p>Amgen Technology (Ireland) Unlimited Company</p><p>Pottery Road, Dun Laoghaire</p><p>Co. Dublin, Ireland</p><p>or</p><p>Patheon Manufacturing Services LLC</p><p>5900 Martin Luther King Jr. Highway</p><p>Greenville, NC 27834-8628</p><p>USA</p><p>&nbsp;</p><p><strong>Site of Batch Release:</strong></p><p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>4817 ZK Breda</p><p>The Netherlands</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إن مادة كارفيلزوميب هي المكون الفعال في كايبروليس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كايبروليس هو نوع من الأدوية المستخدمة لعلاج المرضى المصابين بالمايلوما المتعددة والذين تلقوا سابقا ما لا يقل عن علاج واحد للمايلوما المتعددة. المايلوما المتعددة هي سرطان يصيب خلايا البلازما (نوع من خلايا الدم البيضاء ينتج نوعا من البروتين يسمى الجلوبيولينات المناعية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كايبروليس، والذي يُسمى أيضا كارفيلزوميب، هو مادة مثبطة للبروتيزوم. تلعب البروتيزومات دورا هاما في نمو وعمل الخلية عن طريق تكسير البروتينات التالفة أو التي لم تعُد هناك حاجة لها. يوقف كايبروليس عمل البروتيزومات، مما يؤدي إلى تراكم البروتينات داخل الخلايا بشكل متزايد. في بعض الخلايا، يمكن أن يسبب كايبروليس موت الخلايا، خاصة في حالة الخلايا السرطانية حيث إنه من المرجح أكثر أن تحتوي على كميات أكبر من البروتينات غير الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُعطى كايبروليس لك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بمفرده،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو بالتزامن مع ليناليدوميد وديكساميثازون،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو بالتزامن مع ديكساميثازون وداراتوموماب، أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالتزامن مع ديكساميثازون فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليناليدوميد، ديكساميثازون وداراتوموماب هي عبارة عن أدوية أخرى تستخدم لعلاج المايلوما المتعددة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم كايبروليس في الحالات الآتية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك حساسية</strong> (فرط الحساسية) ضد الكارفيلزوميب، أو ضد أي مكون آخر من مكونات هذا الدواء (مذكورة في القسم&nbsp;٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت ترضعين رضاعة طبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل أن تتلقى كايبروليس، يحتاج طبيبك لمعرفة ما إذا كنت تعاني من أي من المشكلات المذكورة أدناه. تحدث إلى طبيبك أو الممرضة أو الصيدلي قبل استخدام كايبروليس إذا كانت أي من تلك الحالات تنطبق عليك. قد تكون بحاجة إلى اختبارات إضافية للتحقق من عمل كل من قلبك وكليتيك وكبدك كما ينبغي.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في القلب، بما في ذلك تاريخ من آلام الصدر (الذبحة) أو الأزمة القلبية أو عدم انتظام ضربات القلب أو ارتفاع ضغط الدم أو إذا كنت قد تناولت دواء للقلب من قبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الرئة، بما في ذلك تاريخ من ضيق التنفس أثناء الراحة أو أثناء ممارسة الأنشطة (ضيق التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلى، بما في ذلك الفشل الكلوي أو إذا كنت قد خضعت لغسيل الكلى من قبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكبد، بما في ذلك تاريخ من الإصابة بالتهاب الكبد أو الكبد الدهني، أو إذا كنت قد أُخبرت من قبل بأن كبدك لا يعمل كما ينبغي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف غير الاعتيادي، بما في ذلك سهولة الكدمات والنزيف من مواضع الإصابات، مثل ألا يتوقف الجرح عن النزيف خلال الفترة الزمنية الطبيعية، أو النزيف الداخلي، ما قد يشير إلى نقص الصفائح الدموية لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون جلطات دموية في أوردتك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مرض آخر طبي خطير تم إدخالك إلى المستشفى بسببه أو تلقيت دواء لعلاجه</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد كايبروليس بعض الحالات سوء أو قد يسبب آثارا جانبية خطيرة، بما في ذلك مضاعفات مهددة للحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي أو الممرضة على الفور إذا أصبت بأي مما يلي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الصدر أو ضيق التنفس أو تورم كاحليك وقدميك وهي أعراض يمكن أن تشير إلى وجود مشكلات في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس، بما في ذلك ضيق التنفس أثناء الراحة أو أثناء ممارسة الأنشطة أو السعال (ضيق التنفس)، أو التنفس المتسارع والشعور بأنك لا تستطيع استنشاق ما يكفي من الهواء أو أزيز الصدر أو السعال، ما قد يكون من علامات تسمم الرئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتفاع الشديد في ضغط الدم أو آلام الصدر الشديدة أو الصداع الشديد أو الارتباك أو عدم وضوح الرؤية أو الغثيان والقيء أو القلق الشديد، والتي قد تكون علامات لحالة تسمى نوبة ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس أثناء ممارسة الأنشطة اليومية أو أثناء الراحة وعدم انتظام ضربات القلب وتسارع النبض والتعب والدوار ونوبات الإغماء، والتي قد تكون علامات لحالة تسمى ارتفاع ضغط الدم الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الكاحلين أو القدمين أو اليدين أو فقدان الشهية أو تمرير أقل للبول أو النتائج غير الطبيعية لاختبارات الدم، والتي قد تكون من أعراض وجود مشكلات في الكلى أو الفشل الكلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثر جانبي يسمى بمتلازمة انحلال خلايا الورم، والذي قد يحدث نتيجة التكسر السريع لخلايا الورم مما يتسبب في ظهور نتائج غير طبيعية لاختبارات الدم وقد يسبب عدم انتظام ضربات القلب أو الفشل الكلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد تفاعلات تلقي كايبروليس عبر التسريب الوريدي، والذي قد يشتمل على الإصابة بالأعراض التالية:&nbsp;الحمى أو القشعريرة أو الارتجاف أو آلام المفاصل أو آلام العضلات أو تورد الوجه أو تورم الوجه أو تورم في الحلق أو الضعف أو ضيق التنفس أو انخفاض ضغط الدم أو الإغماء أو ضيق الصدر أو الألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكدمات أو النزيف غير الاعتياديين، مثل ألا يتوقف الجرح عن النزيف خلال الفترة الزمنية الطبيعية أو النزيف الداخلي مثل السعال الدموي أو القيء الدموي أو البراز القطراني الداكن أو خروج دم ذي لون أحمر زاه مع البراز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الساق (الذي قد يكون أحد أعراض تكون جلطات دموية في الأوردة العميقة للساق) أو ألم في الصدر أو ضيق التنفس (وهو ما قد يكون عرضا لتكون جلطات دموية في الرئتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الكبد، بما في ذلك الفشل الكبدي، والذي يمكن أن يؤدي إلى اصفرار لون الجلد والعينين (اليرقان)، أو آلام أو تورم البطن أو الغثيان أو القيء. إذا كنت قد أصبت في أي وقت مضى بعدوى التهاب الكبد البائي، فقد يتسبب العلاج بكايبروليس بتنشيط عدوى التهاب الكبد البائي مرة أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف والكدمات والضعف والارتباك والحمى والغثيان والقيء والإسهال والفشل الكلوي الحاد، وهي علامات قد تشير إلى حالة تصيب الدم تسمى اعتلال الأوعية الدقيقة الخثاري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع والارتباك والنوبات وفقدان الرؤية وارتفاع ضغط الدم، وهي أعراض قد تشير إلى حالة تصيب الأعصاب تعرف بمتلازمة الاعتلال الدماغي الخلفي القابلة للعكس (PRES)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية أو ازدواجها أو فقدان الرؤية أو صعوبة الكلام أو ضعف في الذراع أو الساق أو تغيير في طريقة المشي أو مشاكل في توازنك أو خدر مستمر أو انخفاض الشعور أو فقدانه أو فقدان الذاكرة أو الارتباك، وقد تكون هذه الأعراض مرتبطة بعدوى في الجهاز العصبي المركزي معروفة باعتلال بيضاء الدماغ المتعدد البؤر المترقي (PML&rlm;)&rlm;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك الانتباه إلى أعراض معينة أثناء تلقيك لكايبروليس للتقليل من خطر حدوث أي مشكلات. انظر القسم&nbsp;٤ للاطلاع على القائمة الكاملة الخاصة بالآثار الجانبية المحتملة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بفحصك ومراجعة تاريخك الطبي الكامل. ستتم مراقبتك عن كثب أثناء العلاج. قبل البدء في استخدام كايبروليس وأثناء العلاج، سوف تخضع لاختبارات للدم. وذلك بهدف التحقق من أن لديك العدد الكافي من خلايا الدم ومن أن كبدك وكليتيك تعمل كما ينبغي. قبل تلقي كايبروليس، سيتأكد طبيبك أو أخصائي الرعاية الصحية الخاص بك من تناولك لكمية كافية من السوائل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك قراءة النشرات الداخلية لعبوات جميع الأدوية التي تتناولها بالتزامن مع كايبروليس حتى تستوعب المعلومات ذات الصلة بهذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى، أو أعشاب، أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر أخصائي الرعاية الصحية الخاص بك بأسماء جميع الأدوية التي تتناولها حاليا أو التي تناولتها مؤخرا أو التي قد تتناولها في المستقبل، بما في ذلك أي أدوية حصلت عليها بدون وصفة طبية، مثل الفيتامينات أو العلاجات العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبكِ أو الممرضة إذا كنتِ تتناولين الأدوية المستخدمة لمنع الحمل مثل موانع الحمل الفموية أو موانع الحمل الهرمونية الأخرى حيث إن استخدامها قد لا يكون مناسبا مع كايبروليس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية ومنع الحمل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>بالنسبة للسيدات اللاتي يستخدمن كايبروليس</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">ينبغي عدم استخدام كايبروليس إذا كنتِ تحاولين الحمل أو إذا كنتِ حاملا بالفعل. لم يتم بعد تقييم العلاج باستخدام كايبروليس في حالات النساء الحوامل. أثناء استخدام كايبروليس ولمدة ١٨٠&nbsp;يوما بعد إيقاف العلاج، ينبغي عليكِ استخدام وسيلة فعالة لمنع الحمل لضمان عدم حملكِ. من المهم أن تُخبري أخصائي الرعاية الصحية إذا كنتِ حاملا أو تعتقدين أنك حاملا أو تخططين للحمل. إذا أصبحت حاملا أثناء استخدام كايبروليس، عليكِ إخبار أخصائي الرعاية الصحية الخاص بك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقومي بالارضاع الطبيعي أثناء ولا بعد يومين على الأقل من العلاج بكايبروليس. من غير المعروف ما إذا كان كايبروليس يمر إلى حليب الأم لدى البشر أم لا. من المهم أن تخبري أخصائي الرعاية الصحية الخاص بك إذا كنتِ ترضعين رضاعة طبيعية أو تخططين لذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>بالنسبة للرجال الذين يستخدمون كايبروليس</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء استخدام كايبروليس ولمدة ٩٠&nbsp;يوما بعد إيقاف العلاج، ينبغي عليك استخدام وسيلة فعالة لمنع الحمل، مثل الواقي الذكري، لضمان عدم حمل زوجتك. ينبغي عليك التحدث إلى طبيبك أو الممرضة حول وسائل منع الحمل الموثوق بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت زوجتك حاملا أثناء استخدامك لكايبروليس أو خلال ٩٠&nbsp;يوما من إيقاف العلاج، فأخبر طبيبك أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يعاني المرضى الذين يعالَجون بكايبروليس من إرهاق، دوار، إغماء و/أو انخفاض مفاجئ في ضغط الدم. وقد يؤثر هذا بالسلب على قدرتك على القيادة أو تشغيل الآلات. إذا ظهرت عليك تلك الأعراض، ينبغي عليك ألا تقود السيارة أو تشغل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كايبروليس على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على ٢١٦&nbsp;مجم من الصوديوم لكل قنينة ٦۰&nbsp;مجم. هذا يعادل ١١٪ من الجرعة اليومية القصوى الموصى بها من قبل منظمة الصحة العالمية والذي يبلغ ٢&nbsp;جم من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كايبروليس على السیكلودكسترین</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على ٣٠٠٠&nbsp;مجم من سلفوبوتيل اتار بيتا سيكلودكسترين الصوديوم لكل قنينة ٦۰&nbsp;مجم. هذا يعادل ۸۸&nbsp;مجم/كجم لبالغ وزنه ٧۰&nbsp;كجم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يتم تلقيك لكايبروليس بواسطة أخصائي رعاية صحية. سيتم تسريب كايبروليس في وريدك مرة واحدة في الأسبوع وهذا كل أسبوع لمدة ثلاث أسابيع، تتبعها فترة أسبوع واحد دون جرعات. سيتم تسريب كايبروليس في وريدك مرتين في الأسبوع لمدة يومين متتالين كل أسبوع لمدة ثلاث أسابيع، تتبعها فترة أسبوع واحد دون جرعات. وتعتبر كل فترة متكونة من ۲۸&nbsp;يوما دورة علاج واحدة. وهذا يعني أن كايبروليس سيُعطى في الأيام&nbsp;١ و٨ و١٥ بالنسبة لنظام جرعة مرة واحدة أسبوعيا وفي الأيام&nbsp;١ و٢ و٨ و٩ و١٥ و١٦ بالنسبة لنظام جرعة مرتين في الأسبوع من كل دورة مدتها ٢٨&nbsp;يوما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند إعطاء كايبروليس بمفرده أو بالتزامن مع ليناليدوميد وديكساميثازون، لا يتم إعطاء الجرعات الخاصة باليومين&nbsp;٨ و٩ من كل دورة ابتداء من الدورة&nbsp;١٣ فما بعدها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم احتساب الجرعة على أساس وزنك وطولك (مساحة سطح الجسم). سيقرر أخصائي الرعاية الصحية الخاص بك جرعة كايبروليس التي ستتلقاها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتلقى معظم المرضى العلاج الا إذا تطور مرضهم (للأسوأ). ولكن قد يتم وقف العلاج باستخدام كايبروليس إذا عانيت من آثار جانبية لا يمكن السيطرة عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال تم إعطاؤك كمية كبيرة من كايبروليس</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المرجح أن يتم إعطاؤك كمية كبيرة من هذا الدواء، لأنه يتم إعطاؤه بواسطة طبيب أو ممرضة. مع ذلك، سيراقب طبيبك الآثار الجانبية في حالة إعطائك كمية كبيرة من كايبروليس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي استفسارات أخرى بشأن استخدام كايبروليس، فاسأل أخصائي الرعاية الصحية الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب كايبروليس كغيره من الأدوية آثارا جانبية، إلا أنها قد لن تصيب الجميع. ومع ذلك احرص على التواصل مع أخصائي الرعاية الصحية الخاص بك إذا أصبت بأي من الآثار الجانبية التالية أو لاحظت ظهور أي آثار جانبية أخرى غير مذكورة هنا.</p><p dir="RTL">&nbsp;</p><p>تشتمل الآثار الجانبية الأخرى على ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم الحمراء (فقر الدم)، مما يمكن أن يسبب التعب والإرهاق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد الصفائح الدموية، مما يمكن أن يسبب سهولة الكدمات أو النزيف (نقص الصفائح الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء، مما يمكن أن يقلل من قدرتك على مكافحة العدوى وقد يكون مصحوبا بحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الأوعية الدقيقة الخثاري، بما في ذلك فرفرية نقص الصفيحات الخثارية/متلازمة انحلال الدم اليوريمية (TTP/HUS&rlm;)&rlm;&nbsp;والتي قد تسبب الأعراض التالية: النزيف والكدمات والضعف والارتباك والحمى والغثيان والقيء والإسهال والفشل الكلوي الحاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض القلب بما في ذلك النوبة القلبية وقصور القلب الاحتقاني الذي قد يسبب الوفاة، تسارع دقات القلب البطيني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب السريعة أو القوية أو غير المنتظمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كمية غير طبيعية من السوائل بين القلب والبطانة المحيطة بالقلب (الانصباب التأموري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وتهيج البطانة المحيطة بالقلب (التهاب التأمور)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، السعال، السعال المصحوب بالبلغم، نزيف الأنف، تغير أو بحة الصوت، وجود سوائل في الرئتين، وجود جلطات دموية في الرئتين، آلام الحلق، أزيز الصدر، صعوبة التنفس، التنفس المتسارع، نزيف في الرئتين، تورم في الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين الأذنين (طَنين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، إعتمام عدسة العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، الغثيان، الإمساك، القيء، عسر الهضم، آلام المعدة، آلام الأسنان، انثقاب المعدة أو الأمعاء الدقيقة أو الغليظة (الانثقاب المعدي المعوي)، نزيف المعدة والأمعاء، انسداد الأمعاء، التهاب البنكرياس الحاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب (الإرهاق)، الحمى، تورم اليدين أو القدمين أو الكاحلين، ضعف العضلات، القشعريرة، الآلام، فشل الأعضاء المتعدد، تفاعلات موضع التسريب (ألم أو احمرار أو تهيج أو تورم في موضع تلقيك للحقن في وريدك)، ألم الصدر، شعور عام بالمرض أو عدم الارتياح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكبدي أو مشكلات الكبد الأخرى بما في ذلك زيادة إنزيمات الكبد أو البيليروبين أو وجود الأحماض الصفراوية في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف أو احتقان الأنف، احتقان الحلق، التهاب الأنف والحلق، التهاب الشعب الهوائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأعراض المشابهة لأعراض الإنفلونزا (نزلة البرد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتان (عدوى جهازية تشتمل على عدوى في الدم) و/ أو الصدمة الإنتانية (شكل من أشكال الإنتان المهدد للحياة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروسية (الحلأ النطاقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون الناتج عن البكتيريا المطثية العسيرة (كلوستريديوم ديفيسيل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب مؤخرة العين (فيروس مضخم للخلايا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات السكر أو الكالسيوم أو حمض اليوريك أو البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البروتين أو البوتاسيوم أو المغنيسيوم أو الكالسيوم أو الصوديوم أو الفوسفات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة انحلال خلايا الورم، والتي قد تحدث نتيجة التكسر السريع لخلايا الورم وزيادة مستويات البوتاسيوم وحمض اليوريك والفوسفات في الدم، وقد تؤدي إلى فشل كلوي حاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر، آلام المفاصل، آلام الأطراف أو اليدين أو القدمين، آلام العظام، آلام العضلات، تشنج العضلات، ضعف العضلات، وجع العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع؛ الدوار؛ الخدر؛ التنميل؛ أو انخفاض الشعور في اليدين و/أو القدمين؛ السكتة الدماغية، متلازمة الاعتلال الدماغي الخلفي القابلة للعكس (PRES&rlm;)، مع أعراض الصداع والارتباك والنوبات وفقدان الرؤية وارتفاع ضغط الدم ونزيف المخ وفقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرق (صعوبة النوم)، القلق، الهذيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي الحاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، حكة الجلد، احمرار الجلد، زيادة التعرق، وذمة وعائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، انخفاض ضغط الدم، تكون جلطات دموية في الأوردة (الخثار الوريدي العميق)، الارتفاع الشديد في ضغط الدم (نوبات من ارتفاع ضغط الدم)، الشعور بالحرارة الشديدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي آثار جانبية، تحدث إلى طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم الاحتفاظ بكايبروليس في الصيدلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قنينة</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن تُحفظ القناني غير المفتوحة في الثلاجة (٢&deg;م إلى ٨&deg;م). وتُحفظ القنينة داخل عبوتها الأصلية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم كايبروليس بعد تاريخ انتهاء الصلاحية المطبوع على كل من القنينة والعبوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المحلول المعاد تكوينه</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">فترة الصلاحية بعد التكوين: ٤&nbsp;ساعات في درجة حرارة الغرفة (١٥&deg;م إلى ٣٠&deg;م) أو ٢٤&nbsp;ساعة في درجة حرارة ٢&deg;م إلى ٨&deg;م.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي ألا يتجاوز الوقت الإجمالي الفاصل بين التكوين والإعطاء ٢٤&nbsp;ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يكون المنتج المعاد تكوينه محلولا صافيا عديم اللون إلى أصفر باهت ولا يجب إعطاؤه إذا لوحظ أي تغير في لونه أو وجود جسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كايبروليس مخصص للاستعمال مرة واحدة فقط. ينبغي التخلص من أي منتج غير مستخدم أو مخلفات وفقا للمتطلبات المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المكون الفعال: الكارفيلزوميب؛ بعد التكوين، يحتوي كايبروليس على ۲&nbsp;مجم من الكارفيلزوميب / مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات غير الفعالة: سلفوبوتيل اتار بيتا سيكلودكسترين الصوديوم ٣٠٠٠&nbsp;مجم، وحمض الستریك اللامائي ٥٧٫٧&nbsp;مجم وھیدروكسید الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم توفير كايبروليس في صورة مسحوق أبيض أو أبيض مائل إلى الاصفرار في قنينة معقمة. يتم توزيع القنينة المخصصة للاستخدام مرة واحدة بشكل منفرد في علبة وتحتوي على جرعة قدرها ٦٠&nbsp;مجم من كارفيلزوميب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على قنينة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق والجهة المصنعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صاحب ترخيص التسويق:</strong></p><p dir="RTL">Onyx Pharmaceuticals Inc.&lrm;</p><p dir="RTL">One Amgen Center Drive</p><p dir="RTL">Thousand Oaks, CA 91320-1799</p><p dir="RTL">الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موقع تصنيع المُنتج الدوائي:</strong></p><p dir="RTL">Amgen Technology (Ireland)Unlimited Company</p><p dir="RTL">Pottery Road, Dun Laoghaire</p><p dir="RTL">Co. Dublin</p><p dir="RTL">ايرلندا</p><p dir="RTL">او</p><p dir="RTL">Patheon Manufacturing Services LLC</p><p dir="RTL">‪5900 Martin Luther King Jr. Highway</p><p dir="RTL">Greenville, NC 27834-8628</p><p dir="RTL">الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موقع إصدار الدفعة:</strong></p><p dir="RTL">‪Amgen Europe B.V.‪</p><p dir="RTL">Minervum 7061</p><p dir="RTL">4817&nbsp;ZK&nbsp;Breda</p><p dir="RTL">هولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             أغسطس  ٢٠٢١.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kyprolis® 60 mg powder for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 60 mg of carfilzomib.

The reconstituted solution contains 2 mg/mL carfilzomib. 

Kyprolis for injection, for intravenous use is a sterile, white to off white lyophilized powder in a single dose vial. Each vial contains 60 mg of carfilzomib, 3000 mg sodium sulfobutylether beta-cyclodextrin, 57.7 mg anhydrous citric acid, and sodium hydroxide for pH adjustment (target pH 3.5).

Carfilzomib is a proteasome inhibitor. The chemical name for carfilzomib is (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2 yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4 phenylbutanamido)-4-methylpentanamide.

Carfilzomib is a crystalline substance with a molecular weight of 719.9. The molecular formula is C40H57N5O7. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions.

Excipient with known effect

Each vial contains 216 mg sodium. 
Each vial contains 3000 mg of sodium sulfobutylether beta-cyclodextrin
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection.

For injection: 60 mg as a lyophilized cake or powder in single dose vial for reconstitution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Relapsed or refractory multiple myeloma</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lenalidomide and dexamethasone; or</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dexamethasone; or</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Daratumumab and dexamethasone; or</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Daratumumab and hyaluronidase-fihj and dexamethasone.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kyprolis is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Administration precautions</u></p><p>&nbsp;</p><p><em>Hydration</em></p><p>&nbsp;</p><p>Adequate hydration is required prior to dosing in Cycle&nbsp;1, especially in patients at high-risk of tumor lysis syndrome (TLS) or renal toxicity. Consider hydration with both oral fluids (30&nbsp;mL per kg at least 48&nbsp;hours before Cycle&nbsp;1, Day&nbsp;1) and intravenous fluids (250&nbsp;mL to 500&nbsp;mL of appropriate intravenous fluid prior to each dose in Cycle&nbsp;1). If needed, give an additional 250&nbsp;mL to 500&nbsp;mL of intravenous fluids following Kyprolis administration. Continue oral and/or intravenous hydration, as needed, in subsequent cycles.</p><p>&nbsp;</p><p>Monitor patients for evidence of volume overload and adjust hydration to individual patient needs, especially in patients with or at risk for cardiac failure (see section 4.4).</p><p>&nbsp;</p><p><em>Electrolyte Monitoring</em></p><p>&nbsp;</p><p>Monitor serum potassium levels regularly during treatment with Kyprolis (see section 4.8).</p><p>&nbsp;</p><p><em>Premedications</em> <em>and Concomitant Medications</em></p><p>&nbsp;</p><p>Premedicate with the recommended dose of dexamethasone for monotherapy or dexamethasone administered as part of the combination therapy (see section 4.2). Administer dexamethasone orally or intravenously at least 30&nbsp;minutes but no more than 4&nbsp;hours prior to all doses of Kyprolis during Cycle&nbsp;1 to reduce the incidence and severity of infusion-related reactions (see section 4.4). Reinstate dexamethasone premedication if these symptoms occur during subsequent cycles.</p><p>&nbsp;</p><p>Provide thromboprophylaxis for patients being treated with Kyprolis in combination with other therapies (see section 4.4).</p><p>&nbsp;</p><p>Consider antiviral prophylaxis to decrease the risk of herpes zoster reactivation (see section 4.8).</p><p>&nbsp;</p><p><em>Dose Calculation</em></p><p>&nbsp;</p><p>For patients with body surface area (BSA) of 2.2&nbsp;m<sup>2</sup> or less, calculate the Kyprolis dose using actual BSA. Dose adjustments do not need to be made for weight changes of 20% or less.</p><p>&nbsp;</p><p>For patients with a BSA greater than 2.2&nbsp;m<sup>2</sup>, calculate the Kyprolis dose using a BSA of 2.2&nbsp;m<sup>2</sup>.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Kyprolis in combination with </u></em><em><u>lenalidomide and </u></em><em><u>dexamethasone</u></em></p><p>&nbsp;</p><p>Administer Kyprolis intravenously as a 10‑minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28‑day cycle in combination with lenalidomide and dexamethasone until Cycle 12 as shown in Table&nbsp;1<em> </em>(see section 5.1). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Days&nbsp;1 and&nbsp;2. If tolerated, escalate the dose to 27&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Day&nbsp;8. From Cycle&nbsp;13, administer Kyprolis on Days 1, 2, 15, 16 until Cycle 18. Discontinue Kyprolis after Cycle&nbsp;18. Continue lenalidomide and dexamethasone until disease progression or unacceptable toxicity occurs. Refer to the Prescribing Information for lenalidomide and dexamethasone for additional dosage information.</p><p>&nbsp;</p><p>Table&nbsp;1: Kyprolis 20/27&nbsp;mg/m<sup>2 </sup>twice weekly (10‑minute infusion) in combination with lenalidomide and dexamethasone</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="14" style="vertical-align:top"><p><strong>Cycle&nbsp;1</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week&nbsp;1</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week&nbsp;2</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Week&nbsp;3</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Day<br />1</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />2</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />3&ndash;7</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />8</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />9</strong></p></td><td style="vertical-align:bottom"><p><strong>Days&nbsp;<br />10&ndash;14</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Day<br />15</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Day<br />16</strong></p></td><td style="vertical-align:bottom"><p><strong>Days&nbsp;<br />17&ndash;21</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />22</strong></p></td><td style="vertical-align:bottom"><p><strong>Days 23-28</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td colspan="3"><p>27</p></td><td colspan="2"><p>27</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="3" style="vertical-align:top"><p>40</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Lenalidomide</strong></p></td><td colspan="12" style="vertical-align:top"><p>25&nbsp;mg daily on Days&nbsp;1‑21</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="14" style="vertical-align:bottom"><p><strong>Cycles&nbsp;2 to 12</strong></p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Week&nbsp;1</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>Week&nbsp;2</strong></p></td><td colspan="5" style="vertical-align:bottom"><p><strong>Week&nbsp;3</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Day<br />1</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />2</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />3&ndash;7</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />8</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />9</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Days&nbsp;<br />10&ndash;14</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Day<br />15</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />16</strong></p></td><td style="vertical-align:bottom"><p><strong>Days&nbsp;<br />17&ndash;21</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />22</strong></p></td><td style="vertical-align:bottom"><p><strong>Days 23-28</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td colspan="3"><p>-</p></td><td colspan="2"><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="3" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Lenalidomide</strong></p></td><td colspan="12" style="vertical-align:top"><p>25&nbsp;mg daily on Days&nbsp;1-21</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="14" style="vertical-align:bottom"><p><strong>Cycles&nbsp;13 and later<sup>a</sup></strong></p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Week&nbsp;1</strong></p></td><td colspan="5" style="vertical-align:bottom"><p><strong>Week&nbsp;2</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>Week&nbsp;3</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Day<br />1</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />2</strong></p></td><td style="vertical-align:bottom"><p><strong>Days&nbsp;<br />3&ndash;7</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />8</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />9</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Days&nbsp;<br />10&ndash;14</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Day<br />15</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />16</strong></p></td><td style="vertical-align:bottom"><p><strong>Days&nbsp;<br />17&ndash;21</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />22</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />23-28</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td colspan="3"><p>-</p></td><td colspan="2"><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="3" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Lenalidomide</strong></p></td><td colspan="12" style="vertical-align:top"><p>25&nbsp;mg daily on Days&nbsp;1‑21</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="15" style="vertical-align:top"><p><sup>a</sup> Kyprolis is administered through Cycle&nbsp;18; lenalidomide and dexamethasone continue thereafter.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Once weekly 20/70&nbsp;mg/m<sup>2</sup> regimen by 30-minute infusion</em></p><p>Administer Kyprolis intravenously as a 30‑minute infusion on Days 1, 8, and 15 of each 28-day cycle in combination with dexamethasone until disease progression or unacceptable toxicity as shown in Table 2<em> </em>(see section 5.1). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Day&nbsp;1. If tolerated, escalate the dose to 70&nbsp;mg/m<sup>2</sup> on Cycle 1, Day&nbsp;8. Administer dexamethasone 30&nbsp;minutes to 4&nbsp;hours before Kyprolis. Refer to Prescribing Information for dexamethasone for additional dosage information.</p><p>&nbsp;</p><p>Table&nbsp;2: Kyprolis 20/70&nbsp;mg/m<sup>2</sup> once weekly (30‑minute infusion) in combination with dexamethasone</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:top"><p>Cycle&nbsp;1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>20</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:bottom"><p>Cycles&nbsp;2 to 9</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>&nbsp;</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:top"><p><strong>Cycles 10 and later</strong></p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Week&nbsp;1</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Week&nbsp;2</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Week&nbsp;3</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Day<br />1</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />2</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />3&ndash;7</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />8</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />9</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />10&ndash;14</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />15</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />16</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />17&ndash;21</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />22</strong></p></td><td style="vertical-align:bottom"><p><strong>Day<br />23</strong></p></td><td style="vertical-align:bottom"><p><strong>Days<br />24-28</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em><u>Kyprolis in Combination with Dexamethasone</u></em></p><p><u>&nbsp;</u></p><p><em>Twice weekly 20/56&nbsp;mg/m<sup>2</sup> regimen by 30‑minute infusion</em></p><p>Administer Kyprolis intravenously as a 30‑minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle in combination with dexamethasone until disease progression or unacceptable toxicity as shown in Table&nbsp;3 (see section 5.1). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Days&nbsp;1 and 2. If tolerated, escalate the dose to 56&nbsp;mg/m<sup>2</sup> on Cycle 1, Day&nbsp;8. Administer dexamethasone 30&nbsp;minutes to 4&nbsp;hours before Kyprolis. Refer to the Prescribing Information for dexamethasone for additional dosage information.</p><p>&nbsp;</p><p>Table&nbsp;3: Kyprolis 20/56&nbsp;mg/m<sup>2</sup> twice weekly (30‑minute infusion) in combination with dexamethasone</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:top"><p>Cycle&nbsp;1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />3-7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />10-14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />17-21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:bottom"><p>Cycles&nbsp;2 and later</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3-7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10-14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17-21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em><u>Kyprolis in Combination with Daratumumab and Dexamethasone</u></em><u> or Daratumumab and Hyaluronidase-fihj and Dexamethasone</u></p><p><u>&nbsp;</u></p><p><em>Twice weekly 20/56&nbsp;mg/m<sup>2</sup> regimen by 30‑minute infusion</em></p><p>Administer Kyprolis intravenously as a 30‑minute infusion on Days 1, 2, 8, 9, 15 and 16 of each 28‑day cycle in combination the daratumumab and dexamethasone or daratumumab and hyaluronidase-fihj and dexamethasone until disease progression or unacceptable toxicity as shown in Table 4 (see section 5.1). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> on Cycle 1, Days 1 and 2. If tolerated, escalate the dose to 56&nbsp;mg/m<sup>2</sup> on Cycle 1, Day 8 and thereafter. Administer dexamethasone 30 minutes to 4 hours before Kyprolis and 1 to 3 hours before daratumumab or daratumumab and hyaluronidase-fihj. Refer to the Prescribing Information for daratumumab, daratumumab and hyaluronidase-fihj and dexamethasone for additional dosage information.</p><p>&nbsp;</p><p>Table 4: Kyprolis 20/56&nbsp;mg/m<sup>2</sup> twice weekly (30‑minute infusion) in combination with daratumumab or daratumumab and hyaluronidase-fihj and dexamethasone</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:116%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:top"><p>Cycle&nbsp;1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)*</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>8</p></td><td><p>8</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:bottom"><p>Cycle&nbsp;2</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)* </strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>Cycles 3-6</strong></p></td></tr><tr><td colspan="3"><p><strong>Week&nbsp;1</strong></p></td><td colspan="3"><p><strong>Week&nbsp;2</strong></p></td><td colspan="3"><p><strong>Week&nbsp;3</strong></p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)*</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>Cycles 7 and onwards</strong></p></td></tr><tr><td colspan="3"><p><strong>Week&nbsp;1</strong></p></td><td colspan="3"><p><strong>Week&nbsp;2</strong></p></td><td colspan="3"><p><strong>Week&nbsp;3</strong></p></td><td colspan="3"><p><strong>Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)*</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>*For patients &gt;&nbsp;75 years of age, administer 20&nbsp;mg of dexamethasone orally or intravenously weekly after the first week.</p><p>&nbsp;</p><p><em>Once weekly 20/70&nbsp;mg/m<sup>2</sup> regimen by 30‑minute infusion</em></p><p>Administer Kyprolis intravenously as a 30‑minute infusion on Days 1, 8 and 15 of each 28-day cycle in combination with daratumumab and dexamethasone or daratumumab and hyaluronidase-fihj and dexamethasone until disease progression or unacceptable toxicity as shown in Table 5 (see section 5.1). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> on Cycle 1, Day 1. If tolerated, escalate the dose to 70&nbsp;mg/m<sup>2</sup> on Cycle 1, Day 8 and thereafter. Administer dexamethasone 30 minutes to 4 hours before Kyprolis and 1 to 3 hours before daratumumab or daratumumab and hyaluronidase-fihj. Refer to the Prescribing Information for daratumumab, daratumumab and hyaluronidase-fihj, and dexamethasone for additional dosage information.</p><p><strong>&nbsp;</strong></p><p><strong>Table 5: Kyprolis 20/70&nbsp;mg/m<sup>2</sup> once weekly (30‑minute infusion) in combination with daratumumab or daratumumab and hyaluronidase-fihj and dexamethasone</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:116%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:top"><p>Cycle&nbsp;1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days&nbsp;<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>20</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)*</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>8</p></td><td><p>8</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:bottom"><p>Cycle&nbsp;2</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;3</p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)* </strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>Cycles 3-6</strong></p></td></tr><tr><td colspan="3"><p><strong>Week&nbsp;1</strong></p></td><td colspan="3"><p><strong>Week&nbsp;2</strong></p></td><td colspan="3"><p><strong>Week&nbsp;3</strong></p></td><td colspan="3" style="vertical-align:bottom"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)*</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase-fihj </strong><strong>subcutaneous </strong><strong>(mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>Cycles 7 and </strong><strong>onwards</strong></p></td></tr><tr><td colspan="3"><p><strong>Week&nbsp;1</strong></p></td><td colspan="3"><p><strong>Week&nbsp;2</strong></p></td><td colspan="3"><p><strong>Week&nbsp;3</strong></p></td><td colspan="3"><p><strong>Week&nbsp;4</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Day<br />1</p></td><td style="vertical-align:bottom"><p>Day<br />2</p></td><td style="vertical-align:bottom"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:bottom"><p>Day<br />8</p></td><td style="vertical-align:bottom"><p>Day<br />9</p></td><td style="vertical-align:bottom"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:bottom"><p>Day<br />15</p></td><td style="vertical-align:bottom"><p>Day<br />16</p></td><td style="vertical-align:bottom"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:bottom"><p>Day<br />22</p></td><td style="vertical-align:bottom"><p>Day<br />23</p></td><td style="vertical-align:bottom"><p>Days<br />24-28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>70</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone (mg)*</strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td><td><p>40</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p>with intravenous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab intravenous (mg/kg)</strong></p></td><td><p>16</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="12"><p><strong>OR</strong> with subcutaneous daratumumab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Daratumumab and hyaluronidase (mg/units)</strong></p></td><td><p><strong>1,800/30,000</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>*For patients &gt;&nbsp;75 years of age, administer 20&nbsp;mg of dexamethasone orally or intravenously weekly after the first week.</p><p><u>&nbsp;</u></p><p><em><u>Kyprolis monotherapy</u></em></p><p>&nbsp;</p><p><em>20/27&nbsp;mg/m<sup>2</sup> twice weekly regimen by 10‑minute infusion</em></p><p>Administer Kyprolis intravenously as a 10‑minute infusion (see section 5.1). In Cycles&nbsp;1 through 12, administer Kyprolis on Days 1, 2, 8, 9, 15 and 16 of each 28‑day cycle as shown in Table&nbsp;6. From Cycle&nbsp;13, administer Kyprolis on Days 1, 2, 15 and 16 of each 28-day cycle. Premedicate with dexamethasone 4&nbsp;mg orally or intravenously 30&nbsp;minutes to 4&nbsp;hours before each Kyprolis dose in Cycle&nbsp;1, then as needed to minimize infusion-related reactions (see section 4.2). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> in Cycle&nbsp;1 on Days&nbsp;1 and 2. If tolerated, escalate the dose to 27&nbsp;mg/m<sup>2</sup> on Day&nbsp;8 of Cycle&nbsp;1 and thereafter. Continue Kyprolis until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Table&nbsp;6: Kyprolis monotherapy 20/27&nbsp;mg/m<sup>2</sup><em> </em>twice weekly (10-minute infusion)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:top"><p>Cycle&nbsp;1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p>Day<br />1</p></td><td style="vertical-align:top"><p>Day<br />2</p></td><td style="vertical-align:top"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:top"><p>Day<br />8</p></td><td style="vertical-align:top"><p>Day<br />9</p></td><td style="vertical-align:top"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:top"><p>Day<br />15</p></td><td style="vertical-align:top"><p>Day<br />16</p></td><td style="vertical-align:top"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:top"><p>Days<br />22&ndash;28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)<sup>a</sup></strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:top"><p>Cycles&nbsp;2 to 12</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p>Day<br />1</p></td><td style="vertical-align:top"><p>Day<br />2</p></td><td style="vertical-align:top"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:top"><p>Day<br />8</p></td><td style="vertical-align:top"><p>Day<br />9</p></td><td style="vertical-align:top"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:top"><p>Day<br />15</p></td><td style="vertical-align:top"><p>Day<br />16</p></td><td style="vertical-align:top"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:top"><p>Days<br />22&ndash;28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:top"><p>Cycles&nbsp;13 and later</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p>Day<br />1</p></td><td style="vertical-align:top"><p>Day<br />2</p></td><td style="vertical-align:top"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:top"><p>Day<br />8</p></td><td style="vertical-align:top"><p>Day<br />9</p></td><td style="vertical-align:top"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:top"><p>Day<br />15</p></td><td style="vertical-align:top"><p>Day<br />16</p></td><td style="vertical-align:top"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:top"><p>Days<br />22&ndash;28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>27</p></td><td><p>27</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td colspan="11" style="vertical-align:top"><p><sup>a</sup> Dexamethasone premedication is required for each Kyprolis dose in Cycle&nbsp;1.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>20/56&nbsp;mg/m<sup>2</sup> twice weekly regimen by 30‑minute infusion</em></p><p>&nbsp;</p><p>Administer Kyprolis intravenously as a 30‑minute infusion (see section 5.1). In Cycles&nbsp;1 through 12, administer Kyprolis on Days 1, 2, 8, 9, 15 and 16 of each 28‑day cycle as shown in Table&nbsp;7. From Cycle&nbsp;13, administer Kyprolis on Days 1, 2, 15 and 16 of each 28-day cycle. Premedicate with dexamethasone 8&nbsp;mg orally or intravenously 30&nbsp;minutes to 4&nbsp;hours before each Kyprolis dose in Cycle&nbsp;1, then as needed to minimize infusion-related reactions (see section 4.2). The recommended starting dose of Kyprolis is 20&nbsp;mg/m<sup>2</sup> in Cycle&nbsp;1 on Days&nbsp;1 and 2. If tolerated, escalate the dose to 56&nbsp;mg/m<sup>2</sup> on Day&nbsp;8 of Cycle&nbsp;1. Continue Kyprolis until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Table&nbsp;7: Kyprolis monotherapy 20/56&nbsp;mg/m<sup>2</sup><em> </em>twice weekly (30‑minute infusion)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:102%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p><strong><sup>&nbsp;</sup></strong></p></td><td colspan="10" style="vertical-align:top"><p>Cycle&nbsp;1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p>Day<br />1</p></td><td style="vertical-align:top"><p>Day<br />2</p></td><td style="vertical-align:top"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:top"><p>Day<br />8</p></td><td style="vertical-align:top"><p>Day<br />9</p></td><td style="vertical-align:top"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:top"><p>Day<br />15</p></td><td style="vertical-align:top"><p>Day<br />16</p></td><td style="vertical-align:top"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:top"><p>Days<br />22&ndash;28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)<sup>a</sup></strong></p></td><td><p>20</p></td><td><p>20</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="10" style="vertical-align:top"><p>Cycles&nbsp;2 to 12</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p>Day<br />1</p></td><td style="vertical-align:top"><p>Day<br />2</p></td><td style="vertical-align:top"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:top"><p>Day<br />8</p></td><td style="vertical-align:top"><p>Day<br />9</p></td><td style="vertical-align:top"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:top"><p>Day<br />15</p></td><td style="vertical-align:top"><p>Day<br />16</p></td><td style="vertical-align:top"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:top"><p>Days<br />22&ndash;28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:top"><p>Cycles&nbsp;13 and later</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week&nbsp;1</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;2</p></td><td colspan="3" style="vertical-align:top"><p>Week&nbsp;3</p></td><td style="vertical-align:top"><p>Week&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p>Day<br />1</p></td><td style="vertical-align:top"><p>Day<br />2</p></td><td style="vertical-align:top"><p>Days<br />3&ndash;7</p></td><td style="vertical-align:top"><p>Day<br />8</p></td><td style="vertical-align:top"><p>Day<br />9</p></td><td style="vertical-align:top"><p>Days<br />10&ndash;14</p></td><td style="vertical-align:top"><p>Day<br />15</p></td><td style="vertical-align:top"><p>Day<br />16</p></td><td style="vertical-align:top"><p>Days<br />17&ndash;21</p></td><td style="vertical-align:top"><p>Days<br />22&ndash;28</p></td></tr><tr><td style="vertical-align:top"><p><strong>Kyprolis (mg/m<sup>2</sup>)</strong></p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>56</p></td><td><p>56</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td colspan="11" style="vertical-align:top"><p><sup>a</sup> Dexamethasone premedication is required for each Kyprolis dose in Cycle&nbsp;1.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Dosage</em><em> modifications</em><em> </em><em>for adverse reactions</em></p><p>&nbsp;</p><p>Recommended actions and dosage modifications for Kyprolis are presented in Table 8. Dose level reductions are presented in Table&nbsp;9. See the lenalidomide, intravenous daratumumab, and dexamethasone Prescribing Information respectively for recommended dosage modifications associated with each product.</p><p>&nbsp;</p><p>Table&nbsp;8: Dosage modifications for adverse reactions<sup>a</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Hematologic toxicity</strong></p><p>(see sections 4.4 and 4.8)</p></td><td><p><strong>Recommended action</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; ANC less than&nbsp;0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold dose</p><p>&middot;&nbsp;&nbsp; If recovered to greater than or equal to&nbsp;0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L, continue at the same dose level</p><p>&middot;&nbsp;&nbsp; For subsequent drops to less than 0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L, follow the same recommendations as above and consider 1 dose level reduction when restarting Kyprolis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Febrile neutropenia: ANC less than 0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L and an oral temperature more than&nbsp;38.5&deg;C or two consecutive readings of more than&nbsp;38.0&deg;C for 2&nbsp;hours</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold dose</p><p>&middot;&nbsp;&nbsp; If ANC returns to baseline grade and fever resolves, resume at the same dose level</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Platelets less than&nbsp;10&nbsp;&times;&nbsp;10<sup>9</sup>/L or evidence of bleeding with thrombocytopenia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold dose</p><p>&middot;&nbsp;&nbsp; If recovered to greater than or equal to&nbsp;10&nbsp;&times;&nbsp;10<sup>9</sup>/L and/or bleeding is controlled, continue at the same dose level</p><p>&middot;&nbsp;&nbsp; For subsequent drops to less than 10&nbsp;&times;&nbsp;10<sup>9</sup>/L, follow the same recommendations as above and consider 1&nbsp;dose level reduction when restarting Kyprolis<sup>a</sup></p></td></tr><tr><td><p><strong>Renal toxicity </strong></p><p>(see section 4.4)</p></td><td><p><strong>Recommended action</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Serum creatinine greater than or equal to&nbsp;2&nbsp;&times;&nbsp;baseline, or</p><p>&middot;&nbsp;&nbsp; Creatinine clearance less than&nbsp;15&nbsp;mL/min, or creatinine clearance decreases to less than or equal to&nbsp;50% of baseline, or need for hemodialysis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold dose and continue monitoring renal function (serum creatinine or creatinine clearance)</p><p>&middot;&nbsp;&nbsp; If attributable to Kyprolis, resume when renal function has recovered to within 25% of baseline; start at 1&nbsp;dose level reduction<sup>a</sup></p><p>&middot;&nbsp;&nbsp; If not attributable to Kyprolis, dosing may be resumed at the discretion of the healthcare provider</p><p>&middot;&nbsp; For patients on hemodialysis receiving Kyprolis, the dose is to be administered after the hemodialysis procedure</p></td></tr><tr><td><p><strong>Other non‑hematologic toxicity</strong></p><p>(see section 4.8)</p></td><td><p><strong>Recommended action</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; All other severe or life‑threatening<sup>b</sup> non‑hematological toxicities</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Withhold until resolved or returned to baseline</p><p>&middot;&nbsp;&nbsp; Consider restarting the next scheduled treatment at 1&nbsp;dose level reduction<sup>a</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ANC&nbsp;=&nbsp;absolute neutrophil count</p><p><sup>a</sup> See Table 9 for dose level reductions.</p><p><sup>b</sup> Grade&nbsp;3 and&nbsp;4.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>9: Dose level reductions for</strong> a<strong>dverse reactions </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:bottom"><p><strong>Regimen</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose</strong></p></td><td style="vertical-align:bottom"><p><strong>First dose reduction</strong></p></td><td style="vertical-align:bottom"><p><strong>Second dose reduction</strong></p></td><td style="vertical-align:bottom"><p><strong>Third dose reduction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Kyprolis and dexamethasone</p><p>OR</p><p>Kyprolis, daratumumab and dexamethasone (once weekly)</p></td><td><p>70&nbsp;mg/m<sup>2</sup></p></td><td><p>56&nbsp;mg/m<sup>2</sup></p></td><td><p>45&nbsp;mg/m<sup>2</sup></p></td><td><p>36&nbsp;mg/m<sup>2a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Kyprolis and dexamethasone</p><p>OR</p><p>Kyprolis, daratumumab, and dexamethasone</p><p>OR</p><p>Kyprolis monotherapy (twice weekly)</p></td><td><p>56&nbsp;mg/m<sup>2</sup></p></td><td><p>45&nbsp;mg/m<sup>2</sup></p></td><td><p>36&nbsp;mg/m<sup>2</sup></p></td><td><p>27&nbsp;mg/m<sup>2a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Kyprolis, lenalidomide, and dexamethasone</p><p>OR</p><p>Kyprolis monotherapy (twice weekly)</p></td><td><p>27&nbsp;mg/m<sup>2</sup></p></td><td><p>20&nbsp;mg/m<sup>2</sup></p></td><td><p>15&nbsp;mg/m<sup>2a</sup></p></td><td><p>&mdash;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Note: Infusion times remain unchanged during dose reduction(s).</p><p><sup>a</sup> If toxicity persists, discontinue Kyprolis treatment.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Dosage modifications for hepatic impairment</em></p><p>&nbsp;</p><p>For patients with mild (total bilirubin 1 to 1.5&nbsp;&times;&nbsp;ULN and any AST or total bilirubin &le; ULN and AST &gt; ULN) or moderate (total bilirubin &gt;&nbsp;1.5 to 3&nbsp;&times;&nbsp;ULN and any AST) hepatic impairment, reduce the dose of Kyprolis by 25% (see sections 4.8 and 5.2).</p><p>&nbsp;</p><p><em>Recommended dosage </em><em>for</em><em> end stage renal disease (ESRD)</em></p><p>&nbsp;</p><p>For patients with end stage renal disease (ESRD) who are on hemodialysis, administer Kyprolis after the hemodialysis procedure.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Kyprolis should be administered over 10 or 30&nbsp;minutes depending on the Kyprolis dose regimen. Do not administer as an intravenous push or bolus. Flush the intravenous administration line with normal saline or 5% dextrose injection, immediately before and after Kyprolis administration. Do not mix Kyprolis with or administer as an infusion with other medicinal products.</p><p>&nbsp;</p><p>For instructions on the handling and preparation of the medicinal product before administration (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Women who are breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardiac </u><u>toxicities</u></p><p>&nbsp;</p><p>New onset or worsening of pre‑existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis. Some events occurred in patients with normal baseline ventricular function. In clinical studies with Kyprolis, these events occurred throughout the course of Kyprolis therapy. Death due to cardiac arrest has occurred within one day of Kyprolis administration. In randomized, open‑label, multicenter trials for combination therapies, the incidence of cardiac failure events was 8% and that of arrythmias was 8% (majority of which were atrial fibrillation and sinus tachycardia) (see section 4.8).</p><p>&nbsp;</p><p>Monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold Kyprolis for Grade&nbsp;3 or 4 cardiac adverse reactions until recovery and consider whether to restart Kyprolis at 1 dose level reduction based on a benefit/risk assessment (see section 4.2).</p><p>&nbsp;</p><p>While adequate hydration is required prior to each dose in Cycle&nbsp;1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate in patients with baseline cardiac failure or who are at risk for cardiac failure (see section&nbsp;4.2).</p><p>&nbsp;</p><p>In patients &ge;&nbsp;75&nbsp;years of age, the risk of cardiac failure is increased compared to younger patients. Patients with New York Heart Association Class&nbsp;III&nbsp;and&nbsp;IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias uncontrolled by medications were not eligible for the clinical trials. These patients may be at greater risk for cardiac complications; for these patients, complete a comprehensive medical assessment (including blood pressure control and fluid management) prior to starting treatment with Kyprolis and remain under close follow‑up (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Electrocardiographic changes</u></p><p><u>&nbsp;</u></p><p>There have been cases of QT interval prolongation reported in clinical studies. An effect of Kyprolis on QT interval cannot be excluded.</p><p>&nbsp;</p><p><u>Acute </u><u>renal failure</u></p><p>&nbsp;</p><p>Cases of acute renal failure have occurred in patients receiving Kyprolis. Some of these events have been fatal. Renal insufficiency (including renal failure) has occurred in approximately 9% of patients who received Kyprolis. Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received Kyprolis monotherapy. The risk of fatal renal failure was greater in patients with a baseline reduced estimated creatinine clearance (calculated using Cockcroft-Gault equation). Monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance. Reduce or withhold dose as appropriate (see section 4.2).</p><p>&nbsp;</p><p><u>Tumor lysis syndrome</u></p><p>&nbsp;</p><p>Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis. Patients with multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS.</p><p>&nbsp;</p><p>Administer oral and intravenous fluids before administration of Kyprolis in Cycle&nbsp;1 and in subsequent cycles as needed. Consider uric acid‑lowering drugs in patients at risk for TLS. Monitor for TLS during treatment and manage promptly, including interruption of Kyprolis until TLS is resolved (see section 4.2).</p><p>&nbsp;</p><p><u>Pulmonary toxicity</u></p><p>&nbsp;</p><p>Acute Respiratory Distress Syndrome (ARDS) and acute respiratory failure have occurred in approximately 2% of patients who received Kyprolis. In addition, acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease occurred in approximately 2% of patients who received Kyprolis. Some events were fatal. In the event of drug‑induced pulmonary toxicity, discontinue Kyprolis.</p><p>&nbsp;</p><p><u>Pulmonary hypertension</u></p><p>&nbsp;</p><p>Pulmonary arterial hypertension was reported in approximately 2% of patients who received Kyprolis, with Grade&nbsp;3 or greater in less than 1%. Evaluate with cardiac imaging and/or other tests as indicated. Withhold Kyprolis for pulmonary hypertension until resolved or returned to baseline and consider whether to restart Kyprolis based on a benefit/risk assessment.</p><p>&nbsp;</p><p><u>Dyspnea</u></p><p>&nbsp;</p><p>Dyspnea was reported in 25% of patients treated with Kyprolis, with Grade&nbsp;3 or greater in 4%. Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Stop Kyprolis for Grade&nbsp;3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart Kyprolis based on a benefit/risk assessment (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>&nbsp;</p><p>Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis. In ASPIRE, the incidence of hypertension events was 17% in the KRd arm <em>versus</em> 9% in the Rd arm. In ENDEAVOR, the incidence of hypertension events was 34% in the Kd arm <em>versus</em> 11% in the Vd arm. In CANDOR, the incidence of hypertension events was 31% in the DKd arm <em>versus </em>28% in the Kd arm. Some of these events have been fatal. &nbsp;</p><p>&nbsp;</p><p>Optimize blood pressure prior to starting Kyprolis. Monitor blood pressure regularly in all patients while on Kyprolis. If hypertension cannot be adequately controlled, withhold Kyprolis and evaluate. Consider whether to restart Kyprolis based on a benefit/risk assessment.</p><p>&nbsp;</p><p><u>Venous thrombosis</u></p><p>&nbsp;</p><p>Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis. In ASPIRE, with thromboprophylaxis used in both arms, the incidence of venous thromboembolic events in the first 12&nbsp;cycles was 13% in the KRd arm <em>versus</em> 6% in the Rd arm. In ENDEAVOR, the incidence of venous thromboembolic events in months&nbsp;1&ndash;6 was 9% in the Kd arm <em>versus</em> 2% in the Vd arm. With Kyprolis monotherapy, the incidence of venous thromboembolic events was 2%.</p><p>&nbsp;</p><p>Provide thromboprophylaxis for patients being treated with Kyprolis in combination with lenalidomide and dexamethasone; with dexamethasone; or with intravenous daratumumab and dexamethasone. Select the thromboprophylaxis regimen based on the patient&rsquo;s underlying risks.</p><p>&nbsp;</p><p>For patients using oral contraceptives or hormonal contraception associated with a risk of thrombosis, consider non-hormonal contraception during treatment when Kyprolis is administered in combination (see section 4.6).</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>&nbsp;</p><p>Infusion-related reactions, including life‑threatening reactions, have occurred in patients receiving Kyprolis. Signs and symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, laryngeal edema, vomiting, weakness, shortness of breath, hypotension, syncope, bradycardia, chest tightness, or angina. These reactions can occur immediately following or up to 24&nbsp;hours after administration of Kyprolis. Administer dexamethasone prior to Kyprolis to reduce the incidence and severity of infusion-related reactions (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>Hemorrhage</u></p><p>&nbsp;</p><p>Fatal or serious cases of hemorrhage have been reported in patients treated with Kyprolis (see section 4.8). Hemorrhagic events have included gastrointestinal, pulmonary, and intracranial hemorrhage and epistaxis. The bleeding can be spontaneous and intracranial hemorrhage has occurred without trauma. Hemorrhage has been reported in patients having either low or normal platelet counts. Hemorrhage has also been reported in patients who were not on antiplatelet therapy or anticoagulation.</p><p>&nbsp;</p><p>Promptly evaluate signs and symptoms of blood loss. Reduce or withhold dose as appropriate (see section 4.2).</p><p>&nbsp;</p><p><u>Thrombocytopenia</u></p><p>&nbsp;</p><p>Kyprolis causes thrombocytopenia with platelet nadirs observed between Day&nbsp;8 and Day&nbsp;15 of each 28‑day cycle, with recovery to baseline platelet count usually by the start of the next cycle (see section&nbsp;4.8). Thrombocytopenia was reported in approximately 32% of patients in clinical trials with Kyprolis. Hemorrhage may occur (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>Monitor platelet counts frequently during treatment with Kyprolis. Reduce or withhold dose as appropriate (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic </u><u>toxicity and hepatic failure</u></p><p>&nbsp;</p><p>Cases of hepatic failure, including fatal cases, have been reported (2%) during treatment with Kyprolis. Kyprolis can cause increased serum transaminases (see section 4.8).</p><p>&nbsp;</p><p>Monitor liver enzymes regularly, regardless of baseline values. Reduce or withhold dose as appropriate (see section 4.2).</p><p>&nbsp;</p><p><u>Thrombotic </u><u>microangiopathy</u><u> </u></p><p>&nbsp;</p><p>Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported in patients who received Kyprolis. Some of these events have been fatal. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop Kyprolis and evaluate. If the diagnosis of TTP/HUS is excluded, Kyprolis may be restarted. The safety of reinitiating Kyprolis therapy in patients previously experiencing TTP/HUS is not known.</p><p>&nbsp;</p><p><u>Posterior reversible encephalopathy syndrome</u></p><p>&nbsp;</p><p>Cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving Kyprolis. PRES, formerly termed reversible posterior leukoencephalopathy syndrome (RPLS), is a neurological disorder which can present with seizure, headache, lethargy, confusion, blindness, altered consciousness, and other visual and neurological disturbances, along with hypertension, and the diagnosis is confirmed by neuro-radiological imaging (MRI). Discontinue Kyprolis if PRES is suspected and evaluate. The safety of reinitiating Kyprolis therapy in patients previously experiencing PRES is not known.</p><p><u>&nbsp;</u></p><p><u>Progressive multifocal leukoencephalopathy</u></p><p>&nbsp;</p><p>Progressive multifocal leukoencephalopathy (PML), which can be fatal, has been reported with Kyprolis. In addition to Kyprolis, other possible contributory factors include prior or concurrent immunosuppressive therapy that may cause immunosuppression. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms. If PML is suspected, discontinue Kyprolis and initiate evaluation for PML including neurology consultation.</p><p><u>&nbsp;</u></p><p><u>Increased fatal and serious toxicities in combination with melphalan and prednisone in newly diagnosed transplant‑ineligible patients</u></p><p>&nbsp;</p><p>In CLARION, a clinical trial of 955 transplant‑ineligible patients with newly diagnosed multiple myeloma randomized to Kyprolis (20/36&nbsp;mg/m<sup>2</sup> by 30‑minute infusion twice weekly for four of each six‑week cycle), melphalan and prednisone (KMP) or bortezomib, melphalan and prednisone (VMP), a higher incidence of fatal adverse reactions (7% <em>versus</em> 4%) and serious adverse reactions (50% <em>versus</em> 42%) were observed in the KMP arm compared to patients in the VMP arm, respectively. Patients in the KMP arm were observed to have a higher incidence of any grade adverse reactions involving cardiac failure (11% <em>versus</em> 4%), hypertension (25% <em>versus</em> 8%), acute renal failure (14% <em>versus</em> 6%), and dyspnea (18% <em>versus</em> 9%). This study did not meet its primary outcome measure of superiority in progression‑free survival (PFS) for the KMP arm. Kyprolis in combination with melphalan and prednisone is not indicated for transplant‑ineligible patients with newly diagnosed multiple myeloma.</p><p>&nbsp;</p><p><u>Embryo-fetal toxicity</u></p><p>&nbsp;</p><p>Based on the mechanism of action and findings in animals, Kyprolis can cause fetal harm when administered to a pregnant woman. Carfilzomib administered intravenously to pregnant rabbits during organogenesis at a dose approximately 40% of the clinical dose of 27&nbsp;mg/m<sup>2</sup> based on BSA caused post-implantation loss and a decrease in fetal weight.</p><p>&nbsp;</p><p>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Kyprolis and for 6 months following the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Kyprolis and for 3 months following the last dose.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains 216&nbsp;mg sodium per 60&nbsp;mg vial which is equivalent to 11% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p><p>&nbsp;</p><p><u>Cyclodextrin content</u></p><p>&nbsp;</p><p>This medicinal product contains 3000&nbsp;mg sodium sulfobutylether beta-cyclodextrin per 60&nbsp;mg vial which is equivalent to 88&nbsp;mg/kg for a 70&nbsp;kg adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinical studies</u></p><p>&nbsp;</p><p><em>Effect of</em> <em>carfilzomib</em><em> on sensitive CYP3A substrate: </em></p><p>&nbsp;</p><p>Midazolam (a sensitive CYP3A substrate) pharmacokinetics was not affected by concomitant administration of carfilzomib.</p><p><em>&nbsp;</em></p><p><em><u>In vitro</u></em><u> studies</u></p><p>&nbsp;</p><p><em>Effect of Carfilzomib on cytochrome P450 (CYP) enzymes: </em></p><p>&nbsp;</p><p>Carfilzomib showed direct and time‑dependent inhibition of CYP3A but did not induce CYP1A2 and CYP3A4 <em>in vitro</em>.</p><p>&nbsp;</p><p><em>In vitro</em> studies indicated that carfilzomib did not induce human CYP3A4 in cultured human hepatocytes. A clinical trial using oral midazolam as a CYP3A probe conducted with carfilzomib at a dose of 27&nbsp;mg/m<sup>2</sup> (2‑10 minute infusion) demonstrated that the pharmacokinetics of midazolam were unaffected by concomitant carfilzomib administration, indicating that carfilzomib is not expected to inhibit the metabolism of CYP3A4/5 substrates and is not a CYP3A4 inducer in human subjects. No clinical trial was conducted with a dose of 56&nbsp;mg/m<sup>2</sup>. However, it is unknown whether carfilzomib is an inducer of CYP1A2, 2C8, 2C9, 2C19 and 2B6 at therapeutic concentrations. Caution should be observed when carfilzomib is combined with medicinal products that are substrates of these enzymes, such as oral contraceptives. Effective measures to avoid pregnancy should be taken (see section 4.4, and refer also to the current lenalidomide summary of product characteristics), an alternative method of effective contraception should be used if the patient is using oral contraceptives.</p><p>&nbsp;</p><p>Carfilzomib does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19 and 2D6 <em>in vitro</em> and is therefore not expected to influence exposure of medicinal products that are substrates of these enzymes as a result of inhibition.</p><p>&nbsp;</p><p><em>Effect of transporters on Carfilzomib: </em>Carfilzomib is a P‑glycoprotein (P-gp) substrate <em>in vitro</em>.</p><p>&nbsp;</p><p><em>Effect of Carfilzomib on transporters: </em></p><p>&nbsp;</p><p>Carfilzomib inhibits P-gp <em>in vitro</em>. However, given that Kyprolis is administered intravenously and is extensively metabolized, the pharmacokinetics of Kyprolis is unlikely to be affected by P‑gp inhibitors or inducers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Kyprolis can cause fetal harm based on findings from animal studies and its mechanism of action (see section 5.1). There are no available data on Kyprolis use in pregnant women to evaluate for drug-associated risks. Kyprolis caused embryo‑fetal lethality in rabbits at doses lower than the clinical dose (see section 5.3). Advise pregnant women of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>&nbsp;</p><p>It is unknown whether carfilzomib or its metabolites are excreted in human milk. Based on its pharmacological properties, a risk to the suckling child cannot be excluded. Consequently, as a precautionary measure, breast‑feeding is contra‑indicated during and for at least 2&nbsp;days after treatment with Kyprolis.</p><p>&nbsp;</p><p><u>Pregnancy testing</u></p><p>&nbsp;</p><p>Conduct pregnancy testing on females of reproductive potential prior to initiating Kyprolis treatment.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>&nbsp;</p><p><em>Females</em></p><p>&nbsp;</p><p>Advise females of reproductive potential to use effective contraception during treatment with Kyprolis and for 6 months following the last dose.</p><p>&nbsp;</p><p><em>Males</em></p><p>&nbsp;</p><p>Advise males with female sexual partners of reproductive potential to use effective contraception during treatment with Kyprolis and for 3 months following the last dose.</p><p>&nbsp;</p><p><u>Infertility</u></p><p><u>&nbsp;</u></p><p>Based on the mechanism of action, Kyprolis may have an effect on either male or female fertility (see sections 5.1 and 5.3). There are no data on the effect of Kyprolis on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Advise patients that Kyprolis may cause fatigue, dizziness, fainting, and/or drop in blood pressure. Advise patients not to drive or operate machinery if they experience any of these symptoms (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are discussed in greater detail in section 4.4:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac toxicities</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute renal failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor lysis syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary toxicity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thrombosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion-related reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic toxicity and hepatic failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombotic microangiopathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Posterior reversible encephalopathy syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Progressive multifocal leukoencephalopathy</p><p><u>&nbsp;</u></p><p><u>Clinical trials experience</u></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The pooled safety population described in the section 4.4 <em>Special warnings and precautions for use</em> reflect exposure to Kyprolis in 1789 patients administered in combination with other drugs in ASPIRE, ENDEAVOR, A.R.R.O.W., and CANDOR. The most common adverse reactions occurring in at least 20% of patients who received Kyprolis in combination were anemia, diarrhea, fatigue, hypertension, pyrexia, upper respiratory tract infection, thrombocytopenia, cough, dyspnea, and insomnia.</p><p>&nbsp;</p><p><em><u>Kyprolis in combination with lenalidomide and dexamethasone </u></em></p><p><strong><u>&nbsp;</u></strong></p><p>The safety of Kyprolis 20/27&nbsp;mg/m<sup>2</sup> twice weekly in combination with lenalidomide and dexamethasone (KRd) was evaluated in ASPIRE (see section 5.1). The median number of cycles initiated was 22&nbsp;cycles for the KRd arm and 14&nbsp;cycles for the Rd arm.</p><p>&nbsp;</p><p>Deaths due to adverse reactions within 30&nbsp;days of the last dose of any therapy in the KRd arm occurred in 45/392 (12%) patients compared with 42/389 (11%) patients who died due to adverse reactions within 30&nbsp;days of the last dose of any Rd therapy. The most frequent cause of deaths occurring in patients (%) in the two arms (KRd <em>versus</em> Rd) included infection 12 (3%) <em>versus</em> 11 (3%), cardiac 10 (3%) <em>versus</em> 9 (2%), and other adverse reactions 23 (6%) <em>versus</em> 22 (6%). Serious adverse reactions were reported in 65% of the patients in the KRd arm and 57% of the patients in the Rd arm. The most frequent serious adverse reactions reported in the KRd arm as compared with the Rd arm were pneumonia (17% <em>versus</em> 13%), respiratory tract infection (4% <em>versus</em> 2%), pyrexia (4% <em>versus</em> 3%), and pulmonary embolism (3% <em>versus</em> 2%). Discontinuation due to any adverse reaction occurred in 33% in the KRd arm <em>versus</em> 30% in the Rd arm. Adverse reactions leading to discontinuation of Kyprolis occurred in 12% of patients and the most common reactions included pneumonia (1%), myocardial infarction (0.8%), and upper respiratory tract infection (0.8%). The incidence of cardiac failure events was 7% in the KRd arm <em>versus</em> 4% in the Rd arm.</p><p>&nbsp;</p><p>Table 10 summarizes the adverse reactions in the first 12&nbsp;cycles in ASPIRE.</p><p>&nbsp;</p><p>Table&nbsp;10: Adverse reactions (&ge;&nbsp;10%) occurring in Cycles 1&ndash;12 in patients who received KRd (20/27&nbsp;mg/m<sup>2</sup> regimen) in ASPIRE</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:619px"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p>Adverse reactions</p></td><td colspan="2" style="vertical-align:bottom"><p>KRd<br />(N&nbsp;=&nbsp;392)<br />n (%)</p></td><td colspan="2" style="vertical-align:bottom"><p>Rd<br />(N&nbsp;=&nbsp;389)<br />n (%)</p></td></tr><tr><td style="vertical-align:bottom"><p>Any grade</p></td><td style="vertical-align:bottom"><p>&ge;&nbsp;Grade&nbsp;3</p></td><td style="vertical-align:bottom"><p>Any grade</p></td><td style="vertical-align:bottom"><p>&ge;&nbsp;Grade&nbsp;3</p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>138 (35)</p></td><td style="vertical-align:top"><p>53 (14)</p></td><td style="vertical-align:top"><p>127 (33)</p></td><td style="vertical-align:top"><p>47 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>124 (32)</p></td><td style="vertical-align:top"><p>104 (27)</p></td><td style="vertical-align:top"><p>115 (30)</p></td><td style="vertical-align:top"><p>89 (23)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>100 (26)</p></td><td style="vertical-align:top"><p>58 (15)</p></td><td style="vertical-align:top"><p>75 (19)</p></td><td style="vertical-align:top"><p>39 (10)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>119 (30)</p></td><td style="vertical-align:top"><p>8 (2)</p></td><td style="vertical-align:top"><p>106 (27)</p></td><td style="vertical-align:top"><p>12 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>68 (17)</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>55 (14)</p></td><td style="vertical-align:top"><p>1 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>63 (16)</p></td><td style="vertical-align:top"><p>1 (0)</p></td><td style="vertical-align:top"><p>43 (11)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>113 (29)</p></td><td style="vertical-align:top"><p>23 (6)</p></td><td style="vertical-align:top"><p>107 (28)</p></td><td style="vertical-align:top"><p>20 (5)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>93 (24)</p></td><td style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>64 (17)</p></td><td style="vertical-align:top"><p>1 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Edema peripheral</p></td><td style="vertical-align:top"><p>59 (15)</p></td><td style="vertical-align:top"><p>3 (1)</p></td><td style="vertical-align:top"><p>48 (12)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>54 (14)</p></td><td style="vertical-align:top"><p>11 (3)</p></td><td style="vertical-align:top"><p>49 (13)</p></td><td style="vertical-align:top"><p>7 (2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>87 (22)</p></td><td style="vertical-align:top"><p>7 (2)</p></td><td style="vertical-align:top"><p>54 (14)</p></td><td style="vertical-align:top"><p>4 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>55 (14)</p></td><td style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>40 (10)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Viral upper respiratory tract infection</p></td><td style="vertical-align:top"><p>55 (14)</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>44 (11)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia<sup>a</sup></p></td><td style="vertical-align:top"><p>54 (14)</p></td><td style="vertical-align:top"><p>35 (9)</p></td><td style="vertical-align:top"><p>43 (11)</p></td><td style="vertical-align:top"><p>27 (7)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>78 (20)</p></td><td style="vertical-align:top"><p>22 (6)</p></td><td style="vertical-align:top"><p>35 (9)</p></td><td style="vertical-align:top"><p>12 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>55 (14)</p></td><td style="vertical-align:top"><p>10 (3)</p></td><td style="vertical-align:top"><p>39 (10)</p></td><td style="vertical-align:top"><p>5 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>43 (11)</p></td><td style="vertical-align:top"><p>18 (5)</p></td><td style="vertical-align:top"><p>33 (9)</p></td><td style="vertical-align:top"><p>15 (4)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>92 (24)</p></td><td style="vertical-align:top"><p>3 (1)</p></td><td style="vertical-align:top"><p>75 (19)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>41 (11)</p></td><td style="vertical-align:top"><p>4 (1)</p></td><td style="vertical-align:top"><p>54 (14)</p></td><td style="vertical-align:top"><p>6 (2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathies<sup>b</sup></p></td><td style="vertical-align:top"><p>43 (11)</p></td><td style="vertical-align:top"><p>7 (2)</p></td><td style="vertical-align:top"><p>39 (10)</p></td><td style="vertical-align:top"><p>4 (1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td colspan="4"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>64 (16)</p></td><td style="vertical-align:top"><p>6 (2)</p></td><td style="vertical-align:top"><p>51 (13)</p></td><td style="vertical-align:top"><p>8 (2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>c</sup></p></td><td style="vertical-align:top"><p>93 (24)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>54 (14)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>d</sup></p></td><td style="vertical-align:top"><p>71 (18)</p></td><td style="vertical-align:top"><p>8 (2)</p></td><td style="vertical-align:top"><p>61 (16)</p></td><td style="vertical-align:top"><p>6 (2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>45 (12)</p></td><td style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>54 (14)</p></td><td style="vertical-align:top"><p>5 (1)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Embolic and thrombotic events<sup>e</sup></p></td><td style="vertical-align:top"><p>49 (13)</p></td><td style="vertical-align:top"><p>16 (4)</p></td><td style="vertical-align:top"><p>23 (6)</p></td><td style="vertical-align:top"><p>9 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>f</sup></p></td><td style="vertical-align:top"><p>41 (11)</p></td><td style="vertical-align:top"><p>12 (3)</p></td><td style="vertical-align:top"><p>15 (4)</p></td><td style="vertical-align:top"><p>4 (1)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>KRd&nbsp;=&nbsp;Kyprolis, lenalidomide, and dexamethasone; Rd&nbsp;=&nbsp;lenalidomide and dexamethasone</p><p><sup>a</sup> Pneumonia includes pneumonia and bronchopneumonia.</p><p><sup>b</sup> Peripheral neuropathies includes peripheral neuropathy, peripheral sensory neuropathy, and peripheral motor neuropathy.</p><p><sup>c</sup> Cough includes cough and productive cough.</p><p><sup>d</sup> Dyspnea includes dyspnea and dyspnea exertional.</p><p><sup>e</sup> Embolic and thrombotic<sup> </sup>events, venous includes deep vein thrombosis, pulmonary embolism, thrombophlebitis superficial, thrombophlebitis, venous thrombosis limb, post thrombotic syndrome, venous thrombosis.</p><p><sup>f</sup> Hypertension includes hypertension, hypertensive crisis.</p></td></tr></tbody></table><p>&nbsp;</p><p>There were 274 (70%) patients in the KRd arm who received treatment beyond Cycle&nbsp;12. There were no new clinically relevant adverse reactions that emerged in the later treatment cycles.</p><p>&nbsp;</p><p><em>Adverse reactions occurring at a frequency of &lt;&nbsp;10%</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood and lymphatic system disorders:</strong> febrile neutropenia, lymphopenia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, pericardial effusion, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ear and labyrinth disorders:</strong> deafness, tinnitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye disorders:</strong> cataract, vision blurred</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders:</strong> abdominal pain, abdominal pain upper, dyspepsia, gastrointestinal hemorrhage, toothache, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> chills, infusion site reaction, multi‑organ failure, pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> clostridium difficile colitis, influenza, lung infection, rhinitis, sepsis, urinary tract infection, viral infection (Herpes Zoster, Cytomegalovirus infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders:</strong> dehydration, hyperkalemia, hyperuricemia, hypoalbuminemia, hyponatremia, tumor lysis syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue disorders:</strong> muscular weakness, myalgia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system disorders:</strong> hypoesthesia, intracranial hemorrhage, paresthesia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Psychiatric disorders:</strong> anxiety, delirium, confusional state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal and urinary disorders:</strong> renal failure, renal failure acute, renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory, thoracic and mediastinal disorders:</strong> dysphonia, epistaxis, oropharyngeal pain, pulmonary embolism, pulmonary edema, pulmonary hemorrhage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin and subcutaneous tissue disorders:</strong> erythema, hyperhidrosis, pruritus, angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> deep vein thrombosis, hemorrhage, hypotension</p><p>&nbsp;</p><p>Grade&nbsp;3 and higher adverse reactions that occurred during Cycles&nbsp;1&ndash;12 with a substantial difference (&ge;&nbsp;2%) between the two arms were neutropenia, thrombocytopenia, hypokalemia, and hypophosphatemia.</p><p>&nbsp;</p><p>Table&nbsp;11 describes Grade&nbsp;3&ndash;4 laboratory abnormalities reported in ASPIRE.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>11: Grade 3&ndash;4&nbsp;laboratory abnormalities (&ge;&nbsp;10%) in Cycles&nbsp;1&ndash;12</strong> <strong>in patients who received KRd</strong><strong> (20/27&nbsp;mg/m<sup>2</sup> regimen) in </strong><strong>ASPIRE</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>Laboratory abnormality</p></td><td style="vertical-align:bottom"><p>KRd<br />(N&nbsp;=&nbsp;392)<br />n (%)</p></td><td style="vertical-align:bottom"><p>Rd<br />(N&nbsp;=&nbsp;389)<br />n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased lymphocytes</p></td><td style="vertical-align:top"><p>182 (46)</p></td><td style="vertical-align:top"><p>119 (31)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased absolute neutrophil count</p></td><td style="vertical-align:top"><p>152 (39)</p></td><td style="vertical-align:top"><p>141 (36)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased phosphorus</p></td><td style="vertical-align:top"><p>122 (31)</p></td><td style="vertical-align:top"><p>106 (27)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased platelets</p></td><td style="vertical-align:top"><p>101 (26)</p></td><td style="vertical-align:top"><p>59 (15)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased total white blood cell count</p></td><td style="vertical-align:top"><p>97 (25)</p></td><td style="vertical-align:top"><p>71 (18)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased hemoglobin</p></td><td style="vertical-align:top"><p>58 (15)</p></td><td style="vertical-align:top"><p>68 (18)</p></td></tr><tr><td style="vertical-align:top"><p>Increased glucose</p></td><td style="vertical-align:top"><p>53 (14)</p></td><td style="vertical-align:top"><p>30 (8)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased potassium</p></td><td style="vertical-align:top"><p>41 (11)</p></td><td style="vertical-align:top"><p>23 (6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>KRd&nbsp;=&nbsp;Kyprolis, lenalidomide, and dexamethasone; Rd&nbsp;=&nbsp;lenalidomide and dexamethasone</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Kyprolis in combination with dexamethasone </u></em></p><p>&nbsp;</p><p>The safety of Kyprolis in combination with dexamethasone was evaluated in two open‑label, randomized trials (ENDEAVOR and A.R.R.O.W.).</p><p>&nbsp;</p><p><em>ENDEAVOR</em><em> </em></p><p>&nbsp;</p><p>The safety of Kyprolis 20/56&nbsp;mg/m<sup>2</sup> twice weekly in combination with dexamethasone (Kd) was evaluated in ENDEAVOR (see section 5.1). Patients received treatment for a median duration of 48&nbsp;weeks in the Kd arm and 27&nbsp;weeks in the bortezomib/dexamethasone (Vd) arm.</p><p>&nbsp;</p><p>Deaths due to adverse reactions within 30&nbsp;days of last study treatment occurred in 32/463&nbsp;(7%) patients in the Kd arm and 21/456 (5%) patients in the Vd arm. The causes of death occurring in patients (%) in the two arms (Kd <em>versus</em> Vd) included cardiac 4 (1%) <em>versus</em> 5 (1%), infections 8 (2%) <em>versus</em> 8 (2%), disease progression 7 (2%) <em>versus</em> 4 (1%), pulmonary 3 (1%) <em>versus</em> 2 (&lt;&nbsp;1%), renal 1 (&lt;&nbsp;1%) <em>versus</em> 0 (0%), and other adverse reactions 9&nbsp;(2%) <em>versus</em> 2 (&lt;&nbsp;1%). Serious adverse reactions were reported in 59% of the patients in the Kd arm and 40% of the patients in the Vd arm. In both arms, pneumonia was the most frequently reported serious adverse reaction (8% <em>versus</em> 9%).</p><p>&nbsp;</p><p>Discontinuation due to any adverse reaction occurred in 29% in the Kd arm <em>versus</em> 26% in the Vd arm. The most frequent adverse reaction leading to discontinuation was cardiac failure in the Kd arm (n&nbsp;=&nbsp;8, 2%) and peripheral neuropathy in the Vd arm (n&nbsp;=&nbsp;22, 5%). The incidence of cardiac failure events was 11% in the Kd arm <em>versus</em> 3% in the Vd arm.</p><p>&nbsp;</p><p>Adverse reactions in the first 6&nbsp;months of therapy that occurred at a rate of 10% or greater in the Kd arm are presented in Table&nbsp;12.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>12: Adverse reactions (&ge;&nbsp;10%) occurring in months&nbsp;1&ndash;6 </strong><strong>in patients who received Kd</strong> <strong>(20/56&nbsp;mg/m<sup>2</sup> regimen) in ENDEAVOR</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:602px"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse reactions </strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Kd</strong></p><p><strong>(N&nbsp;=&nbsp;463)<br />n (%)</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Vd</strong></p><p><strong>(N&nbsp;=&nbsp;456)<br />n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p><strong>Any grade</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Grade&nbsp;&ge;&nbsp;3</strong></p></td><td style="vertical-align:bottom"><p><strong>Any grade</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade&nbsp;&ge;&nbsp;3</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>161 (35)</p></td><td colspan="2" style="vertical-align:top"><p>57 (12)</p></td><td style="vertical-align:top"><p>112 (25)</p></td><td style="vertical-align:top"><p>43 (9)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>a</sup></p></td><td style="vertical-align:top"><p>125 (27)</p></td><td colspan="2" style="vertical-align:top"><p>45 (10)</p></td><td style="vertical-align:top"><p>112 (25)</p></td><td style="vertical-align:top"><p>64 (14)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>117 (25)</p></td><td colspan="2" style="vertical-align:top"><p>14 (3)</p></td><td style="vertical-align:top"><p>149 (33)</p></td><td style="vertical-align:top"><p>27 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>70 (15)</p></td><td colspan="2" style="vertical-align:top"><p>4 (1)</p></td><td style="vertical-align:top"><p>68 (15)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>60 (13)</p></td><td colspan="2" style="vertical-align:top"><p>1 (0)</p></td><td style="vertical-align:top"><p>113 (25)</p></td><td style="vertical-align:top"><p>6 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>45 (10)</p></td><td colspan="2" style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>33 (7)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td colspan="2" style="vertical-align:top"><p>116 (25)</p></td><td style="vertical-align:top"><p>14 (3)</p></td><td style="vertical-align:top"><p>126 (28)</p></td><td style="vertical-align:top"><p>25 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td colspan="2" style="vertical-align:top"><p>102 (22)</p></td><td style="vertical-align:top"><p>9 (2)</p></td><td style="vertical-align:top"><p>52 (11)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td colspan="2" style="vertical-align:top"><p>73 (16)</p></td><td style="vertical-align:top"><p>9 (2)</p></td><td style="vertical-align:top"><p>65 (14)</p></td><td style="vertical-align:top"><p>13 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral edema</p></td><td colspan="2" style="vertical-align:top"><p>62 (13)</p></td><td style="vertical-align:top"><p>3 (1)</p></td><td style="vertical-align:top"><p>62 (14)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td colspan="2" style="vertical-align:top"><p>67 (15)</p></td><td style="vertical-align:top"><p>4 (1)</p></td><td style="vertical-align:top"><p>55 (12)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td colspan="2" style="vertical-align:top"><p>54 (12)</p></td><td style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>25 (6)</p></td><td style="vertical-align:top"><p>2 (0)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>70 (15)</p></td><td colspan="2" style="vertical-align:top"><p>1 (0)</p></td><td style="vertical-align:top"><p>23 (5)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>64 (14)</p></td><td colspan="2" style="vertical-align:top"><p>8 (2)</p></td><td style="vertical-align:top"><p>61 (13)</p></td><td style="vertical-align:top"><p>10 (2)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>67 (15)</p></td><td colspan="2" style="vertical-align:top"><p>4 (1)</p></td><td style="vertical-align:top"><p>39 (9)</p></td><td style="vertical-align:top"><p>2 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathies<sup>b,c</sup></p></td><td style="vertical-align:top"><p>56 (12)</p></td><td colspan="2" style="vertical-align:top"><p>7 (2)</p></td><td style="vertical-align:top"><p>170 (37)</p></td><td style="vertical-align:top"><p>23 (5)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>105 (23)</p></td><td colspan="2" style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>116 (25)</p></td><td style="vertical-align:top"><p>10 (2)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>d</sup></p></td><td style="vertical-align:top"><p>128 (28)</p></td><td colspan="2" style="vertical-align:top"><p>23 (5)</p></td><td style="vertical-align:top"><p>69 (15)</p></td><td style="vertical-align:top"><p>8 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>e</sup></p></td><td style="vertical-align:top"><p>97 (21)</p></td><td colspan="2" style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>61 (13)</p></td><td style="vertical-align:top"><p>2 (0)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>f</sup></p></td><td style="vertical-align:top"><p>83 (18)</p></td><td colspan="2" style="vertical-align:top"><p>30 (7)</p></td><td style="vertical-align:top"><p>33 (7)</p></td><td style="vertical-align:top"><p>12 (3)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Kd&nbsp;=&nbsp;Kyprolis and dexamethasone; Vd&nbsp;=&nbsp;bortezomib and dexamethasone</p><p><sup>a</sup> Thrombocytopenia includes platelet count decreased and thrombocytopenia.</p><p><sup>b</sup> Peripheral neuropathies includes peripheral neuropathy, peripheral sensory neuropathy, and peripheral motor neuropathy.</p><p><sup>c</sup> See section 5.1.</p><p><sup>d</sup> Dyspnea includes dyspnea and dyspnea exertional.</p><p><sup>e</sup> Cough includes cough and productive cough.</p><p><sup>f</sup> Hypertension includes hypertension, hypertensive crisis, and hypertensive emergency.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>The event rate of &ge;&nbsp;Grade&nbsp;2 peripheral neuropathy in the Kd arm was 7% (95%&nbsp;CI: 5, 9) <em>versus</em> 35% (95%&nbsp;CI: 31, 39) in the Vd arm.</p><p>&nbsp;</p><p><em>Adverse reactions occurring at a frequency of &lt;&nbsp;10%</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood and lymphatic system disorders:</strong> febrile neutropenia, leukopenia, lymphopenia, neutropenia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> atrial fibrillation, cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, palpitations, tachycardia, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ear and labyrinth disorders:</strong> tinnitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye disorders:</strong> cataract, vision blurred</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders:</strong> abdominal pain, abdominal pain upper, dyspepsia, gastrointestinal hemorrhage, toothache, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> chest pain, chills, influenza like illness, infusion site reactions (including inflammation, pain, and erythema), malaise, pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatobiliary disorders:</strong> cholestasis, hepatic failure, hyperbilirubinemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Immune system disorders:</strong> drug hypersensitivity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> bronchopneumonia, gastroenteritis, influenza, lung infection, nasopharyngitis, pneumonia, rhinitis, sepsis, urinary tract infection, viral infection (Herpes Zoster, Cytomegalovirus infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders:</strong> decreased appetite, dehydration, hypercalcemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, tumor lysis syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue disorders:</strong> muscular weakness, musculoskeletal chest pain, musculoskeletal pain, myalgia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system disorders:</strong> cerebrovascular accident, dizziness, hypoesthesia, paresthesia, posterior reversible encephalopathy syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Psychiatric disorders:</strong> anxiety, confusional state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal and urinary disorders:</strong> renal failure, renal failure acute, renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory, thoracic and mediastinal disorders:</strong> acute respiratory distress syndrome, dysphonia, epistaxis, interstitial lung disease, oropharyngeal pain, pneumonitis, pulmonary embolism, pulmonary edema, pulmonary hypertension, wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin and subcutaneous tissue disorders:</strong> erythema, hyperhidrosis, pruritus, rash, angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> deep vein thrombosis, flushing, hypotension</p><p>&nbsp;</p><p>Table&nbsp;13 describes Grade&nbsp;3&ndash;4 laboratory abnormalities reported at a rate of &ge;&nbsp;10% in the Kd arm.</p><p>&nbsp;</p><p>Table&nbsp;13: Grade&nbsp;3&ndash;4 laboratory abnormalities (&ge;&nbsp;10%) in months&nbsp;1&ndash;6 in patients who received Kd (20/56&nbsp;mg/m<sup>2</sup> regimen) in ENDEAVOR</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td style="vertical-align:bottom"><p><strong>Laboratory abnormality</strong></p></td><td style="vertical-align:bottom"><p><strong>Kd</strong></p><p><strong>(N&nbsp;=&nbsp;463)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Vd</strong></p><p><strong>(N&nbsp;=&nbsp;456)</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Decreased lymphocytes</p></td><td style="vertical-align:top"><p>249 (54)</p></td><td style="vertical-align:top"><p>180 (40)</p></td></tr><tr><td style="vertical-align:top"><p>Increased uric acid</p></td><td style="vertical-align:top"><p>244 (53)</p></td><td style="vertical-align:top"><p>198 (43)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased hemoglobin</p></td><td style="vertical-align:top"><p>79 (17)</p></td><td style="vertical-align:top"><p>68 (15)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased platelets</p></td><td style="vertical-align:top"><p>85 (18)</p></td><td style="vertical-align:top"><p>77 (17)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased phosphorus</p></td><td style="vertical-align:top"><p>74 (16)</p></td><td style="vertical-align:top"><p>61 (13)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased creatinine clearance<sup>a</sup></p></td><td style="vertical-align:top"><p>65 (14)</p></td><td style="vertical-align:top"><p>49 (11)</p></td></tr><tr><td style="vertical-align:top"><p>Increased potassium</p></td><td style="vertical-align:top"><p>55 (12)</p></td><td style="vertical-align:top"><p>21 (5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Kd&nbsp;=&nbsp;Kyprolis and dexamethasone; Vd&nbsp;=&nbsp;bortezomib and dexamethasone</p><p><sup>a </sup>Calculated using the Cockcroft‑Gault formula.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>A.R.R.O.W. </em></p><p>&nbsp;</p><p>The safety of Kyprolis in combination with dexamethasone was evaluated in A.R.R.O.W.<em> </em>(see section 5.1). Patients received treatment for a median duration of 38&nbsp;weeks in the Kd 20/70&nbsp;mg/m<sup>2</sup> arm once weekly and 29.1&nbsp;weeks in the Kd 20/27&nbsp;mg/m<sup>2</sup> twice weekly arm. The safety profile for the once weekly Kd 20/70&nbsp;mg/m<sup>2</sup> regimen was similar to the twice weekly Kd 20/27&nbsp;mg/m<sup>2</sup> regimen.</p><p>&nbsp;</p><p>Deaths due to adverse reactions within 30 days of last study treatment occurred in 22/238 (9%) patients in the Kd 20/70&nbsp;mg/m<sup>2</sup> arm and 18/235 (8%) patients in the Kd 20/27&nbsp;mg/m<sup>2</sup> arm. The most frequent fatal adverse reactions occurring in patients (%) in the two arms (once weekly Kd 20/70&nbsp;mg/m<sup>2</sup> <em>versus</em> twice weekly Kd 20/27&nbsp;mg/m<sup>2</sup>) were sepsis 2 (&lt;&nbsp;1%) <em>versus</em> 2 (&lt;&nbsp;1%), septic shock 2 (&lt;&nbsp;1%) <em>versus</em> 1 (&lt;&nbsp;1%), and infection 2 (&lt;&nbsp;1%) versus 0 (0%).</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 43% of the patients in the Kd 20/70&nbsp;mg/m<sup>2</sup> arm and 41% of the patients in the Kd 20/27&nbsp;mg/m<sup>2</sup> arm. In both arms, pneumonia was the most frequently reported serious adverse reaction (8% <em>versus</em> 7%). Discontinuation due to any adverse reaction occurred in 13% in the Kd 20/70&nbsp;mg/m<sup>2</sup> arm <em>versus</em> 12% in the Kd 20/27&nbsp;mg/m<sup>2</sup> arm. The most frequent adverse reaction leading to discontinuation was acute kidney injury (2% <em>versus </em>2%). The incidence of cardiac failure events was 3.8% in the once weekly Kd 20/70&nbsp;mg/m<sup>2</sup> arm <em>versus</em> 5.1% in the twice weekly Kd 20/27&nbsp;mg/m<sup>2</sup> arm.</p><p>&nbsp;</p><p>Adverse reactions that occurred at a rate of 10% or greater in either Kd arm are presented in Table&nbsp;14.</p><p>&nbsp;</p><p>Table&nbsp;14: Adverse reactions in patients who received Kd (&ge;&nbsp;10% in either Kd arm) in A.R.R.O.W.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse reactions </strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Once weekly Kd 20/70&nbsp;mg/m<sup>2</sup><br />(N&nbsp;=&nbsp;238)</strong></p><p><strong>n (%)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Twice weekly Kd 20/27&nbsp;mg/m<sup>2</sup><br />(N&nbsp;=&nbsp;235)</strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p><strong>Any grade</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Grade&nbsp;&ge; 3</strong></p></td><td style="vertical-align:bottom"><p><strong>Any grade</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade &ge;&nbsp;3</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>a</sup></p></td><td style="vertical-align:top"><p>64 (27)</p></td><td colspan="2" style="vertical-align:top"><p>42 (18)</p></td><td style="vertical-align:top"><p>76 (32)</p></td><td style="vertical-align:top"><p>42 (18)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>b</sup></p></td><td style="vertical-align:top"><p>53 (22)</p></td><td colspan="2" style="vertical-align:top"><p>26 (11)</p></td><td style="vertical-align:top"><p>41 (17)</p></td><td style="vertical-align:top"><p>27 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>c</sup></p></td><td style="vertical-align:top"><p>30 (13)</p></td><td colspan="2" style="vertical-align:top"><p>21 (9)</p></td><td style="vertical-align:top"><p>27 (12)</p></td><td style="vertical-align:top"><p>17 (7)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>44 (19)</p></td><td colspan="2" style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>47 (20)</p></td><td style="vertical-align:top"><p>3 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>34 (14)</p></td><td colspan="2" style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td><td style="vertical-align:top"><p>26 (11)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td colspan="2" style="vertical-align:top"><p>55 (23)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>38 (16)</p></td><td style="vertical-align:top"><p>4 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td colspan="2" style="vertical-align:top"><p>48 (20)</p></td><td style="vertical-align:top"><p>11 (5)</p></td><td style="vertical-align:top"><p>47 (20)</p></td><td style="vertical-align:top"><p>5 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td colspan="2" style="vertical-align:top"><p>24 (10)</p></td><td style="vertical-align:top"><p>3 (1)</p></td><td style="vertical-align:top"><p>25 (11)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral edema</p></td><td colspan="2" style="vertical-align:top"><p>18 (8)</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>25 (11)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract infection<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>70 (29)</p></td><td style="vertical-align:top"><p>7 (3)</p></td><td style="vertical-align:top"><p>79 (34)</p></td><td style="vertical-align:top"><p>7 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td colspan="2" style="vertical-align:top"><p>28 (12)</p></td><td style="vertical-align:top"><p>24 (10)</p></td><td style="vertical-align:top"><p>20 (9)</p></td><td style="vertical-align:top"><p>16 (7)</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td colspan="2" style="vertical-align:top"><p>27 (11)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>25 (11)</p></td><td style="vertical-align:top"><p>5 (2)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>28 (12)</p></td><td colspan="2" style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>28 (12)</p></td><td style="vertical-align:top"><p>4 (2)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>25 (11)</p></td><td colspan="2" style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td><td style="vertical-align:top"><p>23 (10)</p></td><td style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>35 (15)</p></td><td colspan="2" style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>47 (20)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>e</sup></p></td><td style="vertical-align:top"><p>37 (16)</p></td><td colspan="2" style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>31 (13)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>f</sup></p></td><td style="vertical-align:top"><p>28 (12)</p></td><td colspan="2" style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td><td style="vertical-align:top"><p>26 (11)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>g</sup></p></td><td style="vertical-align:top"><p>51 (21)</p></td><td colspan="2" style="vertical-align:top"><p>13 (6)</p></td><td style="vertical-align:top"><p>48 (20)</p></td><td style="vertical-align:top"><p>12 (5)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Kd&nbsp;=&nbsp;Kyprolis and dexamethasone</p><p><sup>a</sup> Anemia includes anemia, hematocrit decreased, and hemoglobin decreased.</p><p><sup>b</sup> Thrombocytopenia includes platelet count decreased and thrombocytopenia.</p><p><sup>c</sup> Neutropenia includes neutrophil count decreased and neutropenia.</p><p><sup>d</sup> Respiratory tract infection includes respiratory tract infection, lower respiratory tract infection, upper respiratory tract infection, and viral upper respiratory tract infection.</p><p><sup>e</sup> Cough includes cough and productive cough.</p><p><sup>f</sup> Dyspnea includes dyspnea and dyspnea exertional.</p><p><sup>g</sup> Hypertension includes hypertension and hypertensive crisis.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Adverse reactions occurring at a frequency of &lt;&nbsp;10%</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood and lymphatic system disorders:</strong> febrile neutropenia, leukopenia, lymphopenia, neutropenia, thrombotic microangiopathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> atrial fibrillation, cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, palpitations, pericardial effusion, tachycardia, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ear and labyrinth disorders:</strong> tinnitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye disorders:</strong> cataract, vision blurred</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders:</strong> abdominal pain, abdominal pain upper, constipation, dyspepsia, toothache, vomiting, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> chest pain, chills, influenza like illness, infusion site reactions (including inflammation, pain, and erythema), malaise, pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatobiliary disorders:</strong> cholestasis, hepatic failure, hyperbilirubinemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> clostridium difficile colitis, gastroenteritis, influenza, lung infection, nasopharyngitis, rhinitis, sepsis, septic shock, urinary tract infection, viral infection (Herpes Zoster, Cytomegalovirus infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders:</strong> decreased appetite, dehydration, hypercalcemia, hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, tumor lysis syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue disorders:</strong> muscle spasms, muscular weakness, musculoskeletal chest pain, musculoskeletal pain, myalgia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system disorders:</strong> cerebrovascular accident, dizziness, paresthesia, peripheral neuropathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Psychiatric disorders:</strong> anxiety, delirium, confusional state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal and urinary disorders:</strong> acute kidney injury, renal failure, renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory, thoracic and mediastinal disorders:</strong> acute respiratory distress syndrome, dysphonia, epistaxis, interstitial lung disease, oropharyngeal pain, pneumonitis, pulmonary hemorrhage, pulmonary embolism, pulmonary hypertension, pulmonary edema, wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin and subcutaneous tissue disorders:</strong> erythema, hyperhidrosis, pruritus, rash, angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> deep vein thrombosis, flushing, hypotension</p><p>&nbsp;</p><p><em><u>Kyprolis in </u></em><em><u>combination with intravenous daratumumab and dexamethasone </u></em></p><p><em><u>&nbsp;</u></em></p><p>The safety of Kyprolis in combination with intravenous daratumumab and dexamethasone was evaluated in two trials (CANDOR and EQUULEUS).</p><p>&nbsp;</p><p><em>CANDOR</em></p><p><em>&nbsp;</em></p><p>The safety of Kyprolis 20/56&nbsp;mg/m<sup>2</sup> twice weekly in combination with intravenous daratumumab and dexamethasone (DKd) was evaluated in CANDOR (see section 5.1). Patients received Kyprolis for a median duration of 58 weeks in the DKd arm and 40 weeks in the Kd arm.</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 56% of the patients in the DKd arm and 46% of the patients in the Kd arm. The most frequent serious adverse reactions reported in the DKd arm as compared with the Kd arm were pneumonia (14% <em>versus </em>9%), pyrexia (4.2% <em>versus </em>2.0%), influenza (3.9% <em>versus</em> 1.3%), sepsis (3.9% <em>versus</em> 1.3%), anemia (2.3% <em>versus </em>0.7%), bronchitis (1.9% <em>versus </em>0%) and diarrhea (1.6% <em>versus </em>0%). Fatal adverse reactions within 30 days of the last dose of any study treatment occurred in 10% of 308 patients in the DKd arm compared with 5% of 153 patients in the Kd arm. The most frequent fatal adverse reaction (DKd <em>versus</em> Kd) was infection 4.5% <em>versus</em> 2.6%.</p><p>&nbsp;</p><p>Permanent discontinuation due to an adverse reaction in patients who received Kyprolis occurred in 21% of patients in the DKd arm <em>versus </em>22% in the Kd arm. The most frequent adverse reactions leading to discontinuation of Kyprolis were cardiac failure (1.9%) and fatigue (1.9%) in the DKd arm and cardiac failure (2.0%), hypertension (2.0%) and acute kidney injury (2.0%) in the Kd arm. Interruption of Kyprolis due to adverse reactions occurred in 71% of patients in DKd arm <em>versus </em>63% in the Kd arm. Dose reduction of Kyprolis due to adverse reactions occurred in 25% of patients in DKd arm <em>versus </em>20% in the Kd arm.</p><p>&nbsp;</p><p>Infusion-related reactions that occurred following the first Kyprolis dose was 13% in the DKd arm <em>versus </em>1% in the Kd arm. &nbsp;</p><p>&nbsp;</p><p>Table&nbsp;15 summarizes the adverse reactions in CANDOR.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 15: Adverse Reactions (&ge; 15%) in patients who received either DKd or Kd (20/56&nbsp;mg/m<sup>2 </sup>regimen) in CANDOR</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:580px"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse reactions </strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Twice weekly DKd<br />(N = 308)</strong><br />&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Twice weekly Kd<br />(N = 153)</strong><br />&nbsp;</p></td></tr><tr><td><p><strong>All grades (%)</strong></p></td><td><p><strong>Grade 3 or 4 (%)</strong></p></td><td><p><strong>All grades (%)</strong></p></td><td><p><strong>Grade 3 or 4 (%)</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infusion-related reaction<sup>a</sup></p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>b</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract infection<sup>c</sup></p></td><td style="vertical-align:top"><p>40<sup>g</sup></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>18<sup>g</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>d</sup></p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>e</sup></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>f</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1.3</p></td></tr></tbody></table><p>DKd = Kyprolis, daratumumab, and dexamethasone; Kd = Kyprolis and dexamethasone</p><p><sup>a </sup>The incidence of infusion-related reactions is based on a group of symptoms (including hypertension, pyrexia, rash, myalgia, hypotension, blood pressure increased, urticaria, acute kidney injury, bronchospasm, face edema, hypersensitivity, syncope, wheezing, eye pruritus, eyelid edema, renal failure, swelling face) related to infusion reactions which occurred within 1 day after DKd or Kd administration.&nbsp;</p><p><sup>b </sup>Fatigue includes fatigue and asthenia.&nbsp;</p><p><sup>c </sup>Respiratory tract infection includes respiratory tract infection, lower respiratory tract infection, upper respiratory tract infection and viral upper respiratory tract infection.</p><p><sup>d </sup>Thrombocytopenia includes platelet count decreased and thrombocytopenia.</p><p><sup>e </sup>Anemia includes anemia, hematocrit decreased and hemoglobin decreased.</p><p><sup>f </sup>Cough includes productive cough and cough.</p><p><sup>g</sup> Includes fatal adverse reactions.</p><p><em>&nbsp;</em></p><p><em>Adverse reactions occurring at a frequency of &lt;&nbsp;15%</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood and lymphatic system disorders:</strong> febrile neutropenia, thrombotic thrombocytopenic purpura</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> atrial fibrillation, cardiac arrest, cardiac failure, cardiomyopathy, myocardial infarction, myocardial ischemia, tachycardia, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye disorders:</strong> cataract</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders:</strong> abdominal pain, gastrointestinal hemorrhage, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> chest pain, malaise</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> gastroenteritis, influenza, lung infection, nasopharyngitis, sepsis, septic shock, urinary tract infection, viral infection (Herpes Zoster, Cytomegalovirus infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Investigations:</strong> alanine aminotransferase increased, blood creatinine increased, C‑reactive protein increased, ejection fraction decreased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders:</strong> dehydration, hyperglycemia, hyperkalemia, hypokalemia, hyponatremia, tumor lysis syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue disorders:</strong> pain in extremity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system disorders:</strong> cerebrovascular accident, intracranial hemorrhage, posterior reversible encephalopathy syndrome, peripheral neuropathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Psychiatric disorders:</strong> anxiety, confusional state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal and urinary disorders:</strong> acute kidney injury, renal failure, renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory, thoracic and mediastinal disorders:</strong> acute respiratory failure, epistaxis, interstitial lung disease, pneumonitis, pulmonary embolism, pulmonary hypertension, pulmonary edema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin and subcutaneous tissue disorders: </strong>rash, angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> deep vein thrombosis, hypertensive crisis</p><p><em>&nbsp;</em></p><p><em>EQUULEUS</em></p><p><em>&nbsp;</em></p><p>The safety of Kyprolis 20/70&nbsp;mg/m<sup>2</sup> once weekly in combination with intravenous daratumumab and dexamethasone (DKd) was evaluated in EQUULEUS<em> </em>(see section 5.1). Patients received Kyprolis for a median duration of 66 weeks.</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 48% of patients. The most frequent serious adverse reactions reported were pneumonia (4.7%), upper respiratory tract infection (4.7%), basal cell carcinoma (4.7%), influenza (3.5%), general physical health deterioration (3.5%) and hypercalcemia (3.5%). Fatal adverse reactions within 30 days of the last dose of any study treatment occurred in 3.5% of patients who died of general physical health deterioration, multi‑organ failure secondary to pulmonary aspergillosis, and disease progression.</p><p>&nbsp;</p><p>Discontinuation of Kyprolis occurred in 19% of patients. The most frequent adverse reaction leading to discontinuation was asthenia (2%). Interruption of Kyprolis due to adverse reactions occurred in 77% of patients. Dose reduction of Kyprolis due to adverse reactions occurred in 31% of patients in DKd.</p><p>&nbsp;</p><p>Infusion-related reactions that occurred following the first Kyprolis dose was 11%. Pulmonary hypertension adverse reactions were reported in 4.7% of patients in EQUULEUS.</p><p>&nbsp;</p><p>Table&nbsp;16 summarizes the adverse reactions in EQUULEUS.</p><p>&nbsp;</p><p><strong>Table 16: Adverse reactions (&ge; 15%) in patients who received DKd (20/70&nbsp;mg/m<sup>2</sup> regimen) in EQUULEUS</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse reactions </strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Once weekly DKd<br />(N = 85)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p><strong>All grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>e</sup></p></td><td colspan="2" style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Infusion-related reaction<sup>f</sup></p></td><td colspan="2" style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td colspan="2" style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections</strong></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract infection<sup>g</sup></p></td><td colspan="2" style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>3.5</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td colspan="2" style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td colspan="2" style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Influenza</p></td><td colspan="2" style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>3.5</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>42</p></td><td colspan="2" style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>40</p></td><td colspan="2" style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>38</p></td><td colspan="2" style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>17</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea</p></td><td style="vertical-align:top"><p>35</p></td><td colspan="2" style="vertical-align:top"><p>3.5</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>h</sup></p></td><td style="vertical-align:top"><p>33</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>33</p></td><td colspan="2" style="vertical-align:top"><p>20</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>33</p></td><td colspan="2" style="vertical-align:top"><p>4.7</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>27</p></td><td colspan="2" style="vertical-align:top"><p>1.2</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>25</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>15</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>DKd = Kyprolis, daratumumab, and dexamethasone; Kd = Kyprolis and dexamethasone</p><p><sup>a </sup>Thrombocytopenia includes platelet count decreased and thrombocytopenia.</p><p><sup>b </sup>Anemia includes anemia, hematocrit decreased and hemoglobin decreased.</p><p><sup>c </sup>Neutropenia includes neutrophil count decreased and neutropenia.</p><p><sup>d </sup>Lymphopenia includes lymphocyte count decreased and lymphopenia.</p><p><sup>e </sup>Fatigue includes fatigue and asthenia.&nbsp;</p><p><sup>f </sup>The incidence of infusion-related reactions is based on a group of symptoms (including hypertension, pyrexia, rash, myalgia, hypotension, blood pressure increased, urticaria, acute kidney injury, bronchospasm, face edema, hypersensitivity, syncope, wheezing, eye pruritus, eyelid edema, renal failure, swelling face) related to infusion reactions which occurred within 1 day after DKd administration.</p><p><sup>g </sup>Respiratory tract infection includes respiratory tract infection, lower respiratory tract infection, upper respiratory tract infection and viral upper respiratory tract infection.</p><p><sup>h </sup>Cough includes productive cough and cough.</p><p><em>&nbsp;</em></p><p><em>Adverse reactions occurring at a frequency of &lt;&nbsp;15%</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood and lymphatic system disorders:</strong> febrile neutropenia, thrombotic microangiopathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> cardiac failure, myocardial ischemia, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders: </strong>abdominal pain, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> multiple organ dysfunction syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> pneumonia, sepsis, septic shock</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders:</strong> dehydration, hypercalcemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal and urinary disorders:</strong> acute kidney injury, renal failure, renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory, thoracic and mediastinal disorders:</strong> pulmonary embolism, pulmonary hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> hypotension</p><p><u>&nbsp;</u></p><p><em><u>Kyprolis in combination with subcutaneous daratumumab and dexamethasone </u></em></p><p>&nbsp;</p><p>The safety of Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone was evaluated in PLEIADES (see section 5.1).</p><p><em>&nbsp;</em></p><p><em>PLEIADES</em></p><p>The safety of Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone (DKd) was evaluated in a single-arm cohort of PLEIADES<em>. </em>Patients received Kyprolis as a 30-minute IV infusion once weekly for three weeks (Days 1, 8, and 15), followed by a 13-day rest period (Days 16 to 28) and continued until disease progression or unacceptable toxicity (N&nbsp;=&nbsp;66) in combination with daratumumab and hyaluronidase-fihj and dexamethasone. Among these patients, 77% were exposed for 6 months or longer and 27% were exposed for greater than one year.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 27% of patients who received Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone. Fatal adverse reactions occurred in 3% of patients who received Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone.</p><p>&nbsp;</p><p>Permanent discontinuation of Kyprolis due to an adverse reaction occurred in 6% of patients who received Kyprolis.</p><p>&nbsp;</p><p>Dosage interruptions due to an adverse reaction occurred in 46% of patients who received Kyprolis.</p><p>&nbsp;</p><p>The most common adverse reactions (&ge;20%) were upper respiratory tract infection, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea and edema peripheral.</p><p>&nbsp;</p><p>Table 17 summarizes the adverse reactions in patients who received Kyprolis with subcutaneous daratumumab and dexamethasone (DKd) in PLEIADES.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table&nbsp;17: Adverse reactions (&ge;10%) in patients who received Kyprolis with subcutaneous daratumumab and dexamethasone (DKd) in PLEIADES</p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse reactions</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>DKd</strong></p><p><strong>(N=66) </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>All grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade &ge;3 </strong></p><p><strong>(%)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>a</sup></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis<sup>b</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>2<sup>#</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>c</sup></p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>2<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>2<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Edema peripheral<sup>d</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>6<sup>#</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>e</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>21<sup>#</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>f</sup></p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>g</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>2<sup>#</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral sensory neuropathy</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal chest pain</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral pharyngitis, and viral upper respiratory tract infection.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Bronchitis includes bronchitis, and bronchitis viral.</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Fatigue includes asthenia, and fatigue.</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Edema peripheral includes generalized edema, edema peripheral, and peripheral swelling.</p><p><sup>e&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Hypertension includes blood pressure increased, and hypertension.</p><p><sup>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Cough includes cough, and productive cough.</p><p><sup>g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Dyspnea includes dyspnea, and dyspnea exertional.</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp; Only Grade&nbsp;3 adverse reactions occurred.</p></td></tr></tbody></table><p>&nbsp;</p><p>Clinically relevant adverse reactions in &lt;10% of patients who received Kyprolis with subcutaneous daratumumab and dexamethasone include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders: </strong>abdominal pain, constipation, pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infection and infestations:</strong> pneumonia, influenza, urinary tract infection, herpes zoster, sepsis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders: </strong>hyperglycemia, decreased appetite, hypocalcemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue disorders:</strong> muscle spasms, arthralgia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system disorders: </strong>paresthesia, dizziness, syncope</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> injection site reaction, infusion reactions, chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin and subcutaneous tissue disorders: </strong>rash, pruritus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> cardiac failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> hypotension</p><p>&nbsp;</p><p>Table 18 summarizes the laboratory abnormalities in patients who received Kyprolis with subcutaneous daratumumab and dexamethasone in PLEIADES.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 18: Select laboratory abnormalities (&ge;30%) worsening from baseline in patients who received DKd in PLEIADES</p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Laboratory abnormality</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>DKd<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grades 3-4 (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased platelets</p></td><td style="vertical-align:top"><p>88</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Decreased lymphocytes</p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>Decreased leukocytes</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Decreased neutrophils</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Decreased hemoglobin</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Decreased corrected calcium</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Increased alanine aminotransferase (ALT)</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Denominator is based on the safety population treated with DKd (N=66).</p><p>&nbsp;</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em><u>Kyprolis in patients </u></em><em><u>who received monotherapy </u></em></p><p>&nbsp;</p><p>The safety of Kyprolis 20/27&nbsp;mg/m<sup>2</sup> as a 10‑minute infusion was evaluated in clinical trials consisting of 598&nbsp;patients with relapsed and/or refractory myeloma (see section 5.1). Premedication with dexamethasone 4&nbsp;mg was required before each dose in Cycle&nbsp;1 and was optional for subsequent cycles. The median age was 64&nbsp;years (range 32&ndash;87), and approximately 57% were male. The patients received a median of 5 (range 1&ndash;20) prior regimens. The median number of cycles initiated was 4&nbsp;(range 1&ndash;35).</p><p>&nbsp;</p><p>Deaths due to adverse reactions within 30&nbsp;days of the last dose of Kyprolis occurred in 30/598 (5%) patients receiving Kyprolis monotherapy. These adverse reactions were related to cardiac disorders in 10 (2%) patients, infections in 8 (1%) patients, renal disorders in 4&nbsp;(&lt;&nbsp;1%)&nbsp;patients, and other adverse reactions in 8 (1%)&nbsp;patients.</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 50% of patients in the pooled Kyprolis monotherapy studies (N&nbsp;=&nbsp;598). The most frequent serious adverse reactions were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).&nbsp;</p><p>&nbsp;</p><p>In FOCUS, a randomized trial comparing Kyprolis as a single agent <em>versus</em> corticosteroids with optional oral cyclophosphamide for patients with relapsed and refractory multiple myeloma, mortality was higher in the patients treated with Kyprolis in comparison to the control arm in the subgroup of 48&nbsp;patients &ge;&nbsp;75&nbsp;years of age. The most common cause of discontinuation due to an adverse reaction was acute renal failure (2%).</p><p>&nbsp;</p><p>Safety of Kyprolis monotherapy dosed at 20/56&nbsp;mg/m<sup>2</sup> by 30‑minute infusion was evaluated in a multicenter, open‑label study in patients with relapsed and/or refractory multiple myeloma<em> </em>(see section&nbsp;5.1). The patients received a median of 4 (range 1&ndash;10) prior regimens.</p><p>&nbsp;</p><p>Adverse reactions occurring with Kyprolis monotherapy are presented in Table&nbsp;19.</p><p>&nbsp;</p><p><strong>Table&nbsp;1</strong><strong>9: Adverse reactions (&ge;&nbsp;20%) with Kyprolis monotherapy </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:597px"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse reactions</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>20/56&nbsp;mg/m<sup>2</sup></strong></p><p><strong>by 30‑minute infusion</strong></p><p><strong>(N&nbsp;=&nbsp;24)</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>20/27&nbsp;mg/m<sup>2</sup></strong></p><p><strong>by 2‑ to 10‑minute infusion</strong></p><p><strong>(N&nbsp;=&nbsp;598)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>All grades<br />n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Grades&nbsp;3-5<br />n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>All grades<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grades&nbsp;3-5<br />n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>14 (58)</p></td><td style="vertical-align:top"><p>2 (8)</p></td><td style="vertical-align:top"><p>238 (40)</p></td><td style="vertical-align:top"><p>25 (4)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>a</sup></p></td><td style="vertical-align:top"><p>14 (58)</p></td><td style="vertical-align:top"><p>2 (8)</p></td><td style="vertical-align:top"><p>202 (34)</p></td><td style="vertical-align:top"><p>21 (4)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>14 (58)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>177 (30)</p></td><td style="vertical-align:top"><p>11 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>13 (54)</p></td><td style="vertical-align:top"><p>13 (54)</p></td><td style="vertical-align:top"><p>220 (37)</p></td><td style="vertical-align:top"><p>152 (25)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>13 (54)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>211 (35)</p></td><td style="vertical-align:top"><p>7 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>10 (42)</p></td><td style="vertical-align:top"><p>7 (29)</p></td><td style="vertical-align:top"><p>291 (49)</p></td><td style="vertical-align:top"><p>141 (24)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>b</sup></p></td><td style="vertical-align:top"><p>10 (42)</p></td><td style="vertical-align:top"><p>3 (13)</p></td><td style="vertical-align:top"><p>90 (15)</p></td><td style="vertical-align:top"><p>22 (4)</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>9 (38)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>73 (12)</p></td><td style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>8 (33)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>141 (24)</p></td><td style="vertical-align:top"><p>7 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>c</sup></p></td><td style="vertical-align:top"><p>8 (33)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>134 (22)</p></td><td style="vertical-align:top"><p>2 (&lt;&nbsp;1)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>8 (33)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>104 (17)</p></td><td style="vertical-align:top"><p>4 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>8 (33)</p></td><td style="vertical-align:top"><p>8 (33)</p></td><td style="vertical-align:top"><p>85 (14)</p></td><td style="vertical-align:top"><p>73 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>7 (29)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>75 (13)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>7 (29)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>64 (11)</p></td><td style="vertical-align:top"><p>5 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>6 (25)</p></td><td style="vertical-align:top"><p>1 (4)</p></td><td style="vertical-align:top"><p>160 (27)</p></td><td style="vertical-align:top"><p>8 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>6 (25)</p></td><td style="vertical-align:top"><p>1 (4)</p></td><td style="vertical-align:top"><p>103 (17)</p></td><td style="vertical-align:top"><p>15 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral edema</p></td><td style="vertical-align:top"><p>5 (21)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>118 (20)</p></td><td style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>5 (21)</p></td><td style="vertical-align:top"><p>1 (4)</p></td><td style="vertical-align:top"><p>115 (19)</p></td><td style="vertical-align:top"><p>19 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>5 (21)</p></td><td style="vertical-align:top"><p>1 (4)</p></td><td style="vertical-align:top"><p>112 (19)</p></td><td style="vertical-align:top"><p>15 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>5 (21)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>89 (15)</p></td><td style="vertical-align:top"><p>2 (&lt;&nbsp;1)</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>5 (21)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>62 (10)</p></td><td style="vertical-align:top"><p>2 (&lt;&nbsp;1)</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>5 (21)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>20 (3)</p></td><td style="vertical-align:top"><p>1 (&lt;&nbsp;1)</p></td></tr></tbody></table><p><sup>a</sup> Dyspnea includes dyspnea and dyspnea exertional.</p><p><sup>b</sup> Hypertension includes hypertension, hypertensive crisis, and hypertensive emergency.</p><p><sup>c</sup> Cough includes cough and productive cough.</p><p>&nbsp;</p><p><em>Adverse reactions occurring at a frequency of &lt;&nbsp;20%</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood and lymphatic system disorders:</strong> febrile neutropenia, leukopenia, neutropenia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac disorders:</strong> cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, ventricular tachycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ear and labyrinth disorders: </strong>tinnitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Eye disorders:</strong> cataract, blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gastrointestinal disorders:</strong> abdominal pain, abdominal pain upper, constipation, dyspepsia, gastrointestinal hemorrhage, toothache, acute pancreatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General disorders and administration site conditions:</strong> asthenia, infusion site reaction, multi‑organ failure, pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatobiliary disorders:</strong> hepatic failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> bronchitis, bronchopneumonia, influenza, lung infection, pneumonia, nasopharyngitis, respiratory tract infection, rhinitis, sepsis, urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolism and nutrition disorders:</strong> hypercalcemia, hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, tumor lysis syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue disorders:</strong> arthralgia, musculoskeletal pain, musculoskeletal chest pain, myalgia, pain in extremity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system disorders:</strong> hypoesthesia, intracranial hemorrhage, paresthesia, peripheral motor neuropathy, peripheral neuropathy, peripheral sensory neuropathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Psychiatric disorders:</strong> anxiety, confusional state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal and urinary disorders:</strong> acute renal failure, renal failure, renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory, thoracic and mediastinal disorders:</strong> dysphonia, epistaxis, oropharyngeal pain, pulmonary edema, pulmonary hemorrhage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin and subcutaneous tissue disorders:</strong> erythema, hyperhidrosis, pruritus, rash, angioedema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vascular disorders:</strong> embolic and thrombotic events, venous (including deep vein thrombosis and pulmonary embolism), hemorrhage, hypotension</p><p>&nbsp;</p><p>Grade&nbsp;3 and higher adverse reactions occurring at an incidence of &gt;&nbsp;1% include febrile neutropenia, cardiac arrest, cardiac failure congestive, pain, sepsis, urinary tract infection, hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hyponatremia, hypophosphatemia, renal failure, renal failure acute, renal impairment, pulmonary edema, and hypotension.</p><p><em>&nbsp;</em></p><p>Table&nbsp;20 describes Grade&nbsp;3&ndash;4 laboratory abnormalities reported at a rate of &gt;&nbsp;10% for patients who received Kyprolis monotherapy.</p><p>&nbsp;</p><p><strong>Table&nbsp;20</strong><strong>: Grade&nbsp;3&ndash;4 laboratory abnormalities (&gt;&nbsp;10%) with Kyprolis monotherapy </strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td style="vertical-align:bottom"><p>Laboratory abnormality</p></td><td style="vertical-align:bottom"><p>Kyprolis</p><p>20/56&nbsp;mg/m<sup>2</sup></p><p>(N&nbsp;=&nbsp;24)</p></td><td style="vertical-align:bottom"><p>Kyprolis</p><p>20/27&nbsp;mg/m<sup>2</sup></p><p>(N&nbsp;=&nbsp;598)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased lymphocytes</p></td><td style="vertical-align:top"><p>15 (63)</p></td><td style="vertical-align:top"><p>151 (25)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased platelets</p></td><td style="vertical-align:top"><p>11 (46)</p></td><td style="vertical-align:top"><p>184 (31)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased hemoglobin</p></td><td style="vertical-align:top"><p>7 (29)</p></td><td style="vertical-align:top"><p>132 (22)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased total white blood cell count</p></td><td style="vertical-align:top"><p>3 (13)</p></td><td style="vertical-align:top"><p>71 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased sodium</p></td><td style="vertical-align:top"><p>2 (8)</p></td><td style="vertical-align:top"><p>69 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased absolute neutrophil count</p></td><td style="vertical-align:top"><p>2 (8)</p></td><td style="vertical-align:top"><p>67 (11)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Pediatric use</u></em></p><p><u>&nbsp;</u></p><p>The safety and effectiveness of Kyprolis in pediatric patients have not been established.</p><p>&nbsp;</p><p><em><u>Geriatric use</u></em></p><p>&nbsp;</p><p>Of the 2387&nbsp;patients in clinical studies of Kyprolis, 51% were 65 years and older, while 14% were 75 years and older. The incidence of serious adverse reactions was 49% in patients &lt; 65 years of age, 58% in patients 65 to 74 years of age, and 63% in patients &ge;&nbsp;75&nbsp;years of age. Of the 308 patients in CANDOR who received DKd, 47% of patients were 65 years and older, while 9% were 75 years and older. Fatal adverse reactions in the DKd arm of CANDOR occurred in 6% of patients &lt;65 years of age, 14% of patients between 65 to 74 years of age, and 14% of patients &ge; 75 years of age (see section 4.8). No overall differences in effectiveness were observed between older and younger patients.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>&nbsp;</p><p>Reduce the dose of Kyprolis by 25% in patients with mild (total bilirubin 1 to 1.5&nbsp;&times;&nbsp;ULN and any AST or total bilirubin &le; ULN and AST &gt; ULN) or moderate (total bilirubin &gt;&nbsp;1.5 to 3&nbsp;&times;&nbsp;ULN and any AST) hepatic impairment. A recommended dosage of Kyprolis has not been established for patients with severe hepatic impairment (total bilirubin &gt; 3&nbsp;&times;&nbsp;ULN and any AST) (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>The incidence of serious adverse reactions was higher in patients with mild, moderate, and severe hepatic impairment combined (22/35 or 63%) than in patients with normal hepatic function (3/11 or 27%) (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><u>Postmarketing experience</u></p><p>&nbsp;</p><p>The following adverse reactions have been identified during post approval use of Kyprolis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: hemolytic uremic syndrome (HUS), hepatitis B virus reactivation, gastrointestinal perforation, pericarditis, and cytomegalovirus infection including chorioretinitis, pneumonitis, enterocolitis, viremia, intestinal obstruction and acute pancreatitis.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute onset of chills, hypotension, renal insufficiency, thrombocytopenia, and lymphopenia has been reported following a dose of 200&nbsp;mg of Kyprolis administered in error.</p><p>&nbsp;</p><p>There is no known specific antidote for Kyprolis overdosage. In the event of overdose, monitor patients for adverse reactions and provide supportive care as appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX45</p><p>&nbsp;</p><p><u>Mechanism of Action</u></p><p>&nbsp;</p><p>Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N‑terminal threonine‑containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities <em>in vitro</em> in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin-like (CT‑L) activity when measured in blood 1&nbsp;hour after the first dose. Doses of carfilzomib &ge;&nbsp;15&nbsp;mg/m<sup>2</sup> with or without lenalidomide and dexamethasone induced a &ge;&nbsp;80% inhibition of the CT‑L activity of the proteasome. In addition, carfilzomib, 20&nbsp;mg/m<sup>2</sup> intravenously as a single agent, resulted in a mean inhibition of the low molecular mass polypeptide 2 (LMP2) and multicatalytic endopeptidase complex‑like 1 (MECL1) subunits of the proteasome ranging from 26% to 32% and 41% to 49%, respectively. Proteasome inhibition was maintained for &ge;&nbsp;48 hours following the first dose of carfilzomib for each week of dosing.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>In combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma</u></em><em><u> </u></em></p><p>&nbsp;</p><p>ASPIRE</p><p><u>&nbsp;</u></p><p>ASPIRE was a randomized, open‑label, multicenter trial which evaluated the combination of Kyprolis with lenalidomide and dexamethasone (KRd) <em>versus</em> lenalidomide and dexamethasone alone (Rd) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy (A line of therapy is a planned course of treatment [including sequential induction, transplantation, consolidation, and/or maintenance] without an interruption for lack of efficacy, such as for relapse or progressive disease). Patients who had the following were excluded from the trial: refractory to bortezomib in the most recent regimen, refractory to lenalidomide and dexamethasone in the most recent regimen, not responding to any prior regimen, creatinine clearance &lt;&nbsp;50&nbsp;mL/min, ALT/AST &gt;&nbsp;3.5&nbsp;&times;&nbsp;ULN and bilirubin &gt;&nbsp;2&nbsp;&times;&nbsp;ULN, New York Heart Association Class&nbsp;III&nbsp;to&nbsp;IV congestive heart failure, or myocardial infarction within the last 4&nbsp;months. In the KRd arm, Kyprolis was evaluated at a starting dose of 20&nbsp;mg/m<sup>2</sup>, which was increased to 27&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Day&nbsp;8 onward. Kyprolis was administered as a 10‑minute infusion on Days&nbsp;1, 2, 8, 9, 15, and 16 of each 28‑day cycle for Cycle&nbsp;1 through 12. Kyprolis was dosed on Days&nbsp;1, 2, 15, and 16 of each 28‑day cycle from Cycle&nbsp;13 through 18. Dexamethasone 40&nbsp;mg was administered orally or intravenously on Days&nbsp;1, 8, 15 and 22 of each cycle. Lenalidomide was given 25&nbsp;mg orally on Days&nbsp;1 to 21 of each 28‑day cycle. The Rd treatment arm had the same regimen for lenalidomide and dexamethasone as the KRd treatment arm. Kyprolis was administered for a maximum of 18&nbsp;cycles unless discontinued early for disease progression or unacceptable toxicity. Lenalidomide and dexamethasone administration could continue until progression or unacceptable toxicity. Concurrent use of thromboprophylaxis and a proton pump inhibitor were required for both arms and antiviral prophylaxis was required for the KRd arm.</p><p>&nbsp;</p><p>The 792&nbsp;patients in ASPIRE were randomized 1:1 to the KRd or Rd arm. The demographics and baseline characteristics were well‑balanced between the two arms (see Table&nbsp;21). Only 53% of the patients had testing for genetic mutations; a high‑risk genetic mutation was identified for 12% of patients in the KRd arm and in 13% in the Rd arm.</p><p>&nbsp;</p><p><strong>Table&nbsp;21</strong><strong>: Demographics and baseline characteristics in ASPIRE</strong><br />&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:94%"><thead><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>KRd</p><p>(N&nbsp;=&nbsp;396)</p></td><td style="vertical-align:bottom"><p>Rd</p><p>(N&nbsp;=&nbsp;396)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Age, median, years (min, max)</p></td><td style="vertical-align:top"><p>64 (38, 87)</p></td><td style="vertical-align:top"><p>65 (31, 91)</p></td></tr><tr><td style="vertical-align:top"><p>Age &ge;&nbsp;75&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>43 (11)</p></td><td style="vertical-align:top"><p>53 (13)</p></td></tr><tr><td style="vertical-align:top"><p>Males, n (%)</p></td><td style="vertical-align:top"><p>215 (54)</p></td><td style="vertical-align:top"><p>232 (59)</p></td></tr><tr><td colspan="3"><p>Race, n (%)</p></td></tr><tr><td><p>White</p></td><td style="vertical-align:top"><p>377 (95)</p></td><td style="vertical-align:top"><p>377 (95)</p></td></tr><tr><td><p>Black</p></td><td style="vertical-align:top"><p>12 (3)</p></td><td style="vertical-align:top"><p>11 (3)</p></td></tr><tr><td><p>Other or not reported</p></td><td style="vertical-align:top"><p>7 (2)</p></td><td style="vertical-align:top"><p>8 (2)</p></td></tr><tr><td colspan="3"><p>Number of prior regimens, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td><p>184 (46)</p></td><td><p>157 (40)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td><p>120 (30)</p></td><td><p>139 (35)</p></td></tr><tr><td style="vertical-align:top"><p>3<sup>a</sup></p></td><td><p>92 (23)</p></td><td><p>100 (25)</p></td></tr><tr><td style="vertical-align:top"><p>Prior transplantation, n (%)</p></td><td><p>217 (55)</p></td><td><p>229 (58)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ECOG performance status, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>165 (42)</p></td><td style="vertical-align:top"><p>175 (44)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>191 (48)</p></td><td style="vertical-align:top"><p>186 (47)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40 (10)</p></td><td style="vertical-align:top"><p>35 (9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ISS stage at study baseline, n&nbsp;(%)</p></td></tr><tr><td><p>I</p></td><td style="vertical-align:top"><p>167 (42)</p></td><td style="vertical-align:top"><p>154 (39)</p></td></tr><tr><td><p>II</p></td><td style="vertical-align:top"><p>148 (37)</p></td><td style="vertical-align:top"><p>153 (39)</p></td></tr><tr><td><p>III</p></td><td style="vertical-align:top"><p>73 (18)</p></td><td style="vertical-align:top"><p>82 (21)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>8 (2)</p></td><td style="vertical-align:top"><p>7 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance mL/min, median (min, max)</p></td><td style="vertical-align:top"><p>79 (39, 212)</p></td><td style="vertical-align:top"><p>79 (30, 208)</p></td></tr><tr><td><p>30&nbsp;to&nbsp;&lt;&nbsp;50, n (%)</p></td><td style="vertical-align:top"><p>19 (5)</p></td><td style="vertical-align:top"><p>32 (8)</p></td></tr><tr><td><p>50&nbsp;to&nbsp;&lt;&nbsp;80, n (%)</p></td><td style="vertical-align:top"><p>185 (47)</p></td><td style="vertical-align:top"><p>170 (43)</p></td></tr><tr><td><p>Refractory to last therapy, n (%)</p></td><td style="vertical-align:top"><p>110 (28)</p></td><td style="vertical-align:top"><p>119 (30)</p></td></tr><tr><td colspan="3"><p>Refractory at any time to, n (%):</p></td></tr><tr><td><p>Bortezomib</p></td><td style="vertical-align:top"><p>60 (15)</p></td><td style="vertical-align:top"><p>58 (15)</p></td></tr><tr><td><p>Lenalidomide</p></td><td style="vertical-align:top"><p>29 (7)</p></td><td style="vertical-align:top"><p>28 (7)</p></td></tr><tr><td><p>Bortezomib + immunomodulatory agent</p></td><td style="vertical-align:top"><p>24 (6)</p></td><td style="vertical-align:top"><p>27 (7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ECOG&nbsp;=&nbsp;Eastern Cooperative Oncology Group; IgG&nbsp;=&nbsp;immunoglobulin G; ISS&nbsp;=&nbsp;International Staging System; KRd&nbsp;=&nbsp;Kyprolis, lenalidomide, and dexamethasone; Rd&nbsp;=&nbsp;lenalidomide and dexamethasone</p><p><sup>a</sup> Including 2 patients with 4 prior regimens.</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients in the KRd arm demonstrated improved PFS compared with those in the Rd arm (HR&nbsp;=&nbsp;0.69, with 2‑sided P‑value&nbsp;=&nbsp;0.0001) as determined using standard International Myeloma Working Group (IMWG)/European Blood and Marrow Transplantation (EBMT) response criteria by an Independent Review Committee (IRC).</p><p>&nbsp;</p><p>The median PFS was 26.3&nbsp;months in the KRd arm <em>versus</em> 17.6&nbsp;months in the Rd arm (see Table&nbsp;22 and Figure&nbsp;1).</p><p>&nbsp;</p><p>A pre‑planned overall survival (OS) analysis was performed after 246 deaths in the KRd arm and 267 deaths in the Rd arm. The median follow-up was approximately 67&nbsp;months. A statistically significant advantage in OS was observed in patients in the KRd arm compared to patients in the Rd arm (see Table&nbsp;22 and Figure&nbsp;2).</p><p>&nbsp;</p><p><strong>Table&nbsp;22</strong><strong>: Efficacy outcomes in </strong><strong>ASPIRE<sup>a</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:531px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p>Combination therapy</p></td></tr><tr><td style="vertical-align:top"><p>KRd</p><p>(N&nbsp;=&nbsp;396)</p></td><td colspan="2" style="vertical-align:bottom"><p>Rd</p><p>(N&nbsp;=&nbsp;396)</p></td></tr></tbody><thead><tr><td><p>PFS<sup>b</sup></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>c</sup>, months&nbsp;(95%&nbsp;CI)</p></td><td><p>26.3 (23.3, 30.5)</p></td><td colspan="2"><p>17.6 (15.0, 20.6)</p></td></tr><tr><td><p>HR (95%&nbsp;CI)<sup>d</sup></p></td><td colspan="3"><p>0.69 (0.57, 0.83)</p></td></tr><tr><td><p>P‑value (2‑sided)<sup>e</sup></p></td><td colspan="3"><p>0.0001<sup> </sup></p></td></tr><tr><td><p>Overall survival</p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>c</sup>, months&nbsp;(95%&nbsp;CI)</p></td><td colspan="2"><p>48.3 (42.4, 52.8)</p></td><td><p>40.4 (33.6, 44.4)</p></td></tr><tr><td><p>HR (95%&nbsp;CI)<sup>d</sup></p></td><td colspan="3"><p>0.79 (0.67, 0.95)</p></td></tr><tr><td><p>P‑value (2‑sided)<sup>e</sup></p></td><td colspan="3"><p>0.0091</p></td></tr><tr><td><p>Overall response<sup>b</sup></p></td><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>N with response</p></td><td><p>345</p></td><td colspan="2"><p>264</p></td></tr><tr><td><p>ORR (%) (95%&nbsp;CI)<sup>f</sup></p></td><td><p>87 (83, 90)</p></td><td colspan="2"><p>67 (62, 71)</p></td></tr><tr><td><p>P-value (2‑sided)<sup>g</sup></p></td><td colspan="3"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td><p>Response category, n (%)</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>sCR</p></td><td><p>56 (14)</p></td><td colspan="2"><p>17 (4)</p></td></tr><tr><td><p>CR</p></td><td><p>70 (18)</p></td><td colspan="2"><p>20 (5)</p></td></tr><tr><td><p>VGPR</p></td><td><p>151 (38)</p></td><td colspan="2"><p>123 (31)</p></td></tr><tr><td><p>PR</p></td><td><p>68 (17)</p></td><td colspan="2"><p>104 (26)</p></td></tr><tr><td colspan="4"><p>CI&nbsp;=&nbsp;confidence interval; CR&nbsp;=&nbsp;complete response; HR = hazard ratio; KRd&nbsp;=&nbsp;Kyprolis, lenalidomide, and dexamethasone; ORR&nbsp;=&nbsp;overall response rate; PFS&nbsp;=&nbsp;progression‑free survival; PR&nbsp;= partial response; Rd&nbsp;=&nbsp;lenalidomide and dexamethasone; sCR&nbsp;=&nbsp;stringent CR; VGPR&nbsp;=&nbsp;very good partial response</p><p><sup>a</sup> Eligible patients had 1‑3 prior lines of therapy.</p><p><sup>b </sup>As determined by an Independent Review Committee.</p><p><sup>c</sup> Based on Kaplan-Meier estimates.</p><p><sup>d</sup> Based on stratified Cox&rsquo;s model.</p><p><sup>e </sup>The P‑value was derived using stratified log‑rank test.</p><p><sup>f</sup> Exact confidence interval.</p><p><sup>g</sup> The P‑value was derived using Cochran Mantel Haenszel test.</p></td></tr></thead><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>The median duration of response (DOR) was 28.6&nbsp;months (95% CI: 24.9, 31.3) for the 345&nbsp;patients achieving a response in the KRd arm and 21.2&nbsp;months (95%&nbsp;CI: 16.7, 25.8) for the 264&nbsp;patients achieving a response in the Rd arm. The median time to response was 1&nbsp;month (range 1 to 14&nbsp;months) in the KRd arm and 1 month (range 1 to 16&nbsp;months) in the Rd arm.</p><p>&nbsp;</p><p><strong>Figure&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref440963838'></span><span style='mso-element:field-begin;
mso-field-lock:yes'></span><span style='mso-bookmark:_Ref440963838'><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'> SEQ Figure \* ARABIC <span style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>1</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref440963838'></span><span style='mso-element:field-end'></span><![endif]--><strong>: Kaplan‑Meier curve of progression‑free survival in </strong><strong>ASPIRE</strong></p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="599" height="392" vspace="0" hspace="0" border="0" style="width:599px;height:392px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>CI&nbsp;=&nbsp;confidence interval; EBMT&nbsp;=&nbsp;European Blood and Marrow Transplantation;<em> </em>HR&nbsp;=&nbsp;hazard ratio; IMWG&nbsp;=&nbsp;International Myeloma Working Group; KRd&nbsp;=&nbsp;Kyprolis, lenalidomide, and dexamethasone; mo&nbsp;=&nbsp;months; PFS&nbsp;=&nbsp;progression‑free survival; Rd&nbsp;=&nbsp;lenalidomide and dexamethasone arm</p><p>Note: The response and PD outcomes were determined using standard objective IMWG/EBMT response criteria.</p><p>&nbsp;</p><p>Figure&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Ref440963843'><span style='mso-bookmark:_Ref425183790'></span></span><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-bookmark:_Ref440963843'><span style='mso-bookmark:_Ref425183790'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ansi-language:
EN-US'> SEQ Figure \* ARABIC <span style='mso-element:field-separator'></span></span></span></span><![endif]-->2<!--[if supportFields]><span style='mso-bookmark:
_Ref440963843'><span style='mso-bookmark:_Ref425183790'></span></span><span
style='mso-element:field-end'></span><![endif]-->: Kaplan‑Meier curve of overall survival in ASPIRE</p><p>&nbsp;</p><p><img src="data:image/jpeg;base64,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" alt="" width="1855" height="814" vspace="0" hspace="0" border="0" style="width:1855px;height:814px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>CI&nbsp;=&nbsp;confidence interval; HR&nbsp;=&nbsp;hazard ratio; KRd&nbsp;=&nbsp;Kyprolis, lenalidomide, and dexamethasone; mo&nbsp;=&nbsp;months; OS&nbsp;=&nbsp;overall survival; Rd&nbsp;=&nbsp;lenalidomide and&nbsp;dexamethasone arm</p><p><em>&nbsp;</em></p><p><em><u>In combination with dexamethasone for relapsed or refractory multiple myeloma</u></em></p><p>&nbsp;</p><p>The efficacy of Kyprolis in combination with dexamethasone was evaluated in two open-label randomized trials (ENDEAVOR and A.R.R.O.W.).</p><p>&nbsp;</p><p>ENDEAVOR</p><p>&nbsp;</p><p>ENDEAVOR was a randomized, open‑label, multicenter trial of Kyprolis and dexamethasone (Kd) <em>versus</em> bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy. A total of 929&nbsp;patients were enrolled and randomized (464 in the Kd&nbsp;arm; 465 in the Vd arm). Randomization was stratified by prior proteasome inhibitor therapy (yes <em>versus</em> no), prior lines of therapy (1&nbsp;<em>versus</em> 2 or 3), current International Staging System stage (1 <em>versus</em> 2 or 3), and planned route of bortezomib administration. Patients were excluded if they had less than PR to all prior regimens; creatinine clearance &lt;&nbsp;15&nbsp;mL/min; hepatic transaminases &ge;&nbsp;3&nbsp;&times;&nbsp;ULN; or left‑ventricular ejection fraction &lt;&nbsp;40% or other significant cardiac conditions. This trial evaluated Kyprolis at a starting dose of 20&nbsp;mg/m<sup>2</sup>, which was increased to 56&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Day&nbsp;8 onward. Kyprolis was administered twice weekly as a 30‑minute infusion on Days&nbsp;1, 2, 8, 9, 15, and 16 of each 28‑day cycle. Dexamethasone 20&nbsp;mg was administered orally or intravenously on Days&nbsp;1, 2, 8, 9, 15, 16, 22, and 23 of each cycle. In the Vd arm, bortezomib was dosed at 1.3&nbsp;mg/m<sup>2</sup> intravenously or subcutaneously on Days&nbsp;1, 4, 8, and 11 of a 21‑day cycle, and dexamethasone 20&nbsp;mg was administered orally or intravenously on Days&nbsp;1, 2, 4, 5, 8, 9, 11, and 12 of each cycle. Concurrent use of thromboprophylaxis was optional, and prophylaxis with an antiviral agent and proton pump inhibitor was required. Of the 465&nbsp;patients in the Vd arm, 381 received bortezomib subcutaneously. Treatment continued until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>The demographics and baseline characteristics are summarized in Table&nbsp;23.</p><p>&nbsp;</p><p>Table&nbsp;23: Demographics and baseline characteristics in ENDEAVOR</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td style="vertical-align:bottom"><p>Kd</p><p>(N&nbsp;=&nbsp;464)</p></td><td style="vertical-align:bottom"><p>Vd</p><p>(N&nbsp;=&nbsp;465)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Age, years</p></td></tr><tr><td style="vertical-align:top"><p>Median (min, max)</p></td><td style="vertical-align:top"><p>65 (35, 89)</p></td><td style="vertical-align:top"><p>65 (30, 88)</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;65, n (%)</p></td><td style="vertical-align:top"><p>223 (48)</p></td><td style="vertical-align:top"><p>210 (45)</p></td></tr><tr><td style="vertical-align:top"><p>65&ndash;74, n (%)</p></td><td style="vertical-align:top"><p>164 (35)</p></td><td style="vertical-align:top"><p>189 (41)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;75, n (%)</p></td><td style="vertical-align:top"><p>77 (17)</p></td><td style="vertical-align:top"><p>66 (14)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Sex, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td style="vertical-align:top"><p>224 (48)</p></td><td style="vertical-align:top"><p>236 (51)</p></td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>240 (52)</p></td><td style="vertical-align:top"><p>229 (49)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Race, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>White</p></td><td style="vertical-align:top"><p>353 (76)</p></td><td style="vertical-align:top"><p>361 (78)</p></td></tr><tr><td style="vertical-align:top"><p>Black</p></td><td style="vertical-align:top"><p>7 (2)</p></td><td style="vertical-align:top"><p>9 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:top"><p>56 (12)</p></td><td style="vertical-align:top"><p>57 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Other or not reported</p></td><td style="vertical-align:top"><p>48 (10)</p></td><td style="vertical-align:top"><p>38 (8)</p></td></tr><tr><td colspan="3"><p>ECOG performance status, n (%)</p></td></tr><tr><td><p>0</p></td><td style="vertical-align:top"><p>221 (48)</p></td><td style="vertical-align:top"><p>232 (50)</p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>210 (45)</p></td><td style="vertical-align:top"><p>203 (44)</p></td></tr><tr><td><p>2</p></td><td style="vertical-align:top"><p>33 (7)</p></td><td style="vertical-align:top"><p>30 (6)</p></td></tr><tr><td colspan="3"><p>Creatinine clearance (mL/min)</p></td></tr><tr><td><p>Median (min, max)</p></td><td style="vertical-align:top"><p>73 (14, 185)</p></td><td style="vertical-align:top"><p>72 (12, 208)</p></td></tr><tr><td><p>&lt;&nbsp;30, n (%)</p></td><td style="vertical-align:top"><p>28 (6)</p></td><td style="vertical-align:top"><p>28 (6)</p></td></tr><tr><td><p>30 &ndash; &lt;&nbsp;50, n (%)</p></td><td style="vertical-align:top"><p>57 (12)</p></td><td style="vertical-align:top"><p>71 (15)</p></td></tr><tr><td><p>50 &ndash; &lt;&nbsp;80, n (%)</p></td><td style="vertical-align:top"><p>186 (40)</p></td><td style="vertical-align:top"><p>177 (38)</p></td></tr><tr><td><p>&ge;&nbsp;80, n (%)</p></td><td style="vertical-align:top"><p>193 (42)</p></td><td style="vertical-align:top"><p>189 (41)</p></td></tr><tr><td colspan="3"><p>FISH, n (%)</p></td></tr><tr><td><p>High‑risk</p></td><td style="vertical-align:top"><p>97 (21)</p></td><td style="vertical-align:top"><p>113 (24)</p></td></tr><tr><td><p>Standard‑risk</p></td><td style="vertical-align:top"><p>284 (61)</p></td><td style="vertical-align:top"><p>291 (63)</p></td></tr><tr><td><p>Unknown‑risk</p></td><td style="vertical-align:top"><p>83 (18)</p></td><td style="vertical-align:top"><p>61 (13)</p></td></tr><tr><td colspan="3"><p>ISS stage at study baseline, n (%)</p></td></tr><tr><td><p>ISS I</p></td><td style="vertical-align:top"><p>219 (47)</p></td><td style="vertical-align:top"><p>212 (46)</p></td></tr><tr><td><p>ISS II</p></td><td style="vertical-align:top"><p>138 (30)</p></td><td style="vertical-align:top"><p>153 (33)</p></td></tr><tr><td><p>ISS III</p></td><td style="vertical-align:top"><p>107 (23)</p></td><td style="vertical-align:top"><p>100 (22)</p></td></tr><tr><td colspan="3"><p>Number of prior regimens, n (%)</p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>232 (50)</p></td><td style="vertical-align:top"><p>231 (50)</p></td></tr><tr><td><p>2</p></td><td style="vertical-align:top"><p>158 (34)</p></td><td style="vertical-align:top"><p>144 (31)</p></td></tr><tr><td><p>3</p></td><td style="vertical-align:top"><p>74 (16)</p></td><td style="vertical-align:top"><p>88 (19)</p></td></tr><tr><td><p>4</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>2 (0.4)</p></td></tr><tr><td><p>Prior therapies, n (%)</p></td><td style="vertical-align:top"><p>464 (100)</p></td><td style="vertical-align:top"><p>465 (100)</p></td></tr><tr><td><p>Bortezomib</p></td><td style="vertical-align:top"><p>250 (54)</p></td><td style="vertical-align:top"><p>252 (54)</p></td></tr><tr><td><p>Transplant for multiple myeloma</p></td><td style="vertical-align:top"><p>266 (57)</p></td><td style="vertical-align:top"><p>272 (59)</p></td></tr><tr><td><p>Thalidomide</p></td><td style="vertical-align:top"><p>212 (46)</p></td><td style="vertical-align:top"><p>249 (54)</p></td></tr><tr><td><p>Lenalidomide</p></td><td style="vertical-align:top"><p>177 (38)</p></td><td style="vertical-align:top"><p>178 (38)</p></td></tr><tr><td><p>Bortezomib + immunomodulatory agent</p></td><td style="vertical-align:top"><p>159 (34)</p></td><td style="vertical-align:top"><p>168 (36)</p></td></tr><tr><td><p>Refractory to last prior therapy, n (%)<sup>a</sup></p></td><td style="vertical-align:top"><p>184 (40)</p></td><td style="vertical-align:top"><p>189 (41)</p></td></tr><tr><td colspan="3"><p>ECOG&nbsp;=&nbsp;Eastern Cooperative Oncology Group; FISH&nbsp;=&nbsp;Fluorescence <em>in situ</em> hybridization; ISS&nbsp;=&nbsp;International Staging System; Kd&nbsp;=&nbsp;Kyprolis and dexamethasone; Vd&nbsp;=&nbsp;bortezomib and dexamethasone</p><p><sup>a</sup> Refractory&nbsp;=&nbsp;disease not achieving a minimal response or better, progressing during therapy, or progressing within 60&nbsp;days after completion of therapy.</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy of Kyprolis was evaluated by PFS as determined by an IRC using IMWG response criteria. The trial showed a median PFS of 18.7&nbsp;months in the Kd arm <em>versus</em> 9.4&nbsp;months in the Vd arm (see Table&nbsp;24 and Figure&nbsp;3).</p><p>&nbsp;</p><p>Figure&nbsp;<!--[if supportFields]><span style='mso-bookmark:
_Ref440963867'></span><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-bookmark:_Ref440963867'><span style='font-size:11.0pt;font-family:
"Times New Roman",serif;mso-ansi-language:EN-US'> SEQ Figure \* ARABIC <span
style='mso-element:field-separator'></span></span></span><![endif]-->3<!--[if supportFields]><span
style='mso-bookmark:_Ref440963867'></span><span style='mso-element:field-end'></span><![endif]-->: Kaplan‑Meier plot of progression‑free survival in ENDEAVOR</p><p><img src="data:image/png;base64,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" alt="" width="1375" height="752" vspace="0" hspace="0" border="0" style="width:1375px;height:752px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>CI&nbsp;=&nbsp;confidence interval; HR&nbsp;=&nbsp;hazard ratio; Kd&nbsp;=&nbsp;Kyprolis and dexamethasone; mo = months; PFS&nbsp;=&nbsp;progression‑free survival; Vd&nbsp;=&nbsp;bortezomib and dexamethasone</p><p>&nbsp;</p><p>Other endpoints included OS and overall response rate (ORR).</p><p>&nbsp;</p><p>A pre‑planned OS analysis was performed after 189 deaths in the Kd arm and 209 deaths in the Vd arm. The median follow-up was approximately 37&nbsp;months. A significantly longer OS was observed in patients in the Kd arm compared to patients in the Vd arm (HR&nbsp;=&nbsp;0.79; 95%&nbsp;CI: 0.65, 0.96; P‑value&nbsp;=&nbsp;0.01). Results are provided in Table&nbsp;24 and Figure&nbsp;4.</p><p>&nbsp;</p><p>Table&nbsp;24: Summary of key results in ENDEAVOR</p><p>(Intent‑to‑treat population)<sup>a</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Kd<br />(N&nbsp;=&nbsp;464)</p></td><td colspan="2" style="vertical-align:top"><p>Vd<br />(N&nbsp;=&nbsp;465)</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>PFS<sup>b</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Number of events (%)</p></td><td style="vertical-align:bottom"><p>171 (37)</p></td><td colspan="2" style="vertical-align:bottom"><p>243 (52)</p></td></tr><tr><td style="vertical-align:bottom"><p>Median<sup>c</sup>, months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>18.7 (15.6, NE)</p></td><td colspan="2" style="vertical-align:top"><p>9.4 (8.4, 10.4)</p></td></tr><tr><td style="vertical-align:bottom"><p>HR<sup> </sup>(Kd/Vd) (95%&nbsp;CI)<sup>d</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.53 (0.44, 0.65)</p></td></tr><tr><td style="vertical-align:bottom"><p>P‑value (1‑sided)<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>Overall survival</p></td></tr><tr><td style="vertical-align:bottom"><p>Number of deaths (%)</p></td><td colspan="2" style="vertical-align:top"><p>189 (41)</p></td><td style="vertical-align:top"><p>209 (45)</p></td></tr><tr><td style="vertical-align:bottom"><p>Median<sup>c</sup>, months (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>47.6 (42.5, NE)</p></td><td style="vertical-align:top"><p>40.0 (32.6, 42.3)</p></td></tr><tr><td style="vertical-align:top"><p>HR (Kd/Vd) (95%&nbsp;CI)<sup>d</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.79 (0.65, 0.96)</p></td></tr><tr><td style="vertical-align:bottom"><p>P-value (1‑sided)<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.01</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>Overall response<sup>b</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>N with response</p></td><td style="vertical-align:top"><p>357</p></td><td colspan="2" style="vertical-align:top"><p>291</p></td></tr><tr><td style="vertical-align:bottom"><p>ORR (%) (95%&nbsp;CI)<sup>f</sup></p></td><td style="vertical-align:top"><p>77 (73, 81)</p></td><td colspan="2" style="vertical-align:top"><p>63 (58, 67)</p></td></tr><tr><td style="vertical-align:bottom"><p>P‑value (1‑sided)<sup>g</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>Response category, n (%)</p></td></tr><tr><td style="vertical-align:bottom"><p>sCR</p></td><td style="vertical-align:top"><p>8 (2)</p></td><td colspan="2" style="vertical-align:top"><p>9 (2)</p></td></tr><tr><td style="vertical-align:bottom"><p>CR</p></td><td style="vertical-align:top"><p>50 (11)</p></td><td colspan="2" style="vertical-align:top"><p>20 (4)</p></td></tr><tr><td style="vertical-align:bottom"><p>VGPR</p></td><td style="vertical-align:top"><p>194 (42)</p></td><td colspan="2" style="vertical-align:top"><p>104 (22)</p></td></tr><tr><td style="vertical-align:bottom"><p>PR<sup>h</sup></p></td><td style="vertical-align:top"><p>105 (23)</p></td><td colspan="2" style="vertical-align:top"><p>158 (34)</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>CI&nbsp;=&nbsp;confidence interval; CR&nbsp;=&nbsp;complete response; HR= hazard ratio; Kd&nbsp;=&nbsp;Kyprolis and dexamethasone; ORR&nbsp;=&nbsp;overall response rate; PFS&nbsp;=&nbsp;progression‑free survival; PR = partial response; sCR&nbsp;=&nbsp;stringent CR; Vd&nbsp;=&nbsp;bortezomib and dexamethasone; VGPR&nbsp;=&nbsp;very good partial response; NE = non-estimable</p><p><sup>a</sup> Eligible patients had 1‑3 prior lines of therapy.</p><p><sup>b</sup> PFS and ORR were determined by an Independent Review Committee.</p><p><sup>c</sup> Based on Kaplan‑Meier estimates.</p><p><sup>d</sup> Based on a stratified Cox&rsquo;s model.</p><p><sup>e</sup> P‑value was derived using a stratified log‑rank test.</p><p><sup>f</sup> Exact confidence interval.</p><p><sup>g</sup> The P‑value was derived using Cochran Mantel Haenszel test.</p><p><sup>h</sup> Includes one patient in each arm with a confirmed PR which may not have been the best response.</p></td></tr></thead><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;4: Kaplan-Meier plot of overall survival in ENDEAVOR</strong></p><p>&nbsp;</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEA3ADcAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCALeBV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACiiigAorlrj4n+DrG4lt7jxXosE8bFJI5NQiVlI4IILcGmf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsork/wDhbXgj/ocNC/8ABlD/APFUf8La8Ef9DhoX/gyh/wDiqAOsork/+FteCP8AocNC/wDBlD/8VR/wtrwR/wBDhoX/AIMof/iqAOsork/+FteCP+hw0L/wZQ//ABVH/C2vBH/Q4aF/4Mof/iqAOsork/8AhbXgj/ocNC/8GUP/AMVR/wALa8Ef9DhoX/gyh/8AiqAOsorL0PxLpPiaF5tI1Sz1SGNtjyWc6yqpx0JUnBrUoAKKKKACiiigAooooAKKKKACorn/AI95f9w/yqWorn/j3l/3D/KgD4V/YW/Zd+E/xO/Zl8NeJfFngPR9f1++u9SN1qF9D5k0xW/uEBZs84VQPwr3z/hh34C/9Eq8Of8AgN/9euV/4Js/8md+Df8Ar71X/wBOVzX07QB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhn/DDvwF/wCiVeHP/Ab/AOvR/wAMO/AX/olXhz/wG/8Ar17nRQB4Z/ww78Bf+iVeHP8AwG/+vR/ww78Bf+iVeHP/AAG/+vXudFAHhbfsQ/ANTz8LPDYPvbf/AF6T/hiL4A/9Et8Nf+A//wBevB/2oPh6nxo/bw+HXgTVPEHiHR9AuvCd1dzR6FqUlozyJK5Ukrx+ldp/w7R+H3/Q8fEr/wAKiX/4mgD0T/hiL4A/9Et8Nf8AgP8A/Xo/4Yi+AP8A0S3w1/4D/wD1687/AOHaPw+/6Hj4lf8AhUS//E0f8O0fh9/0PHxK/wDCol/+JoA9E/4Yi+AP/RLfDX/gP/8AXo/4Yi+AP/RLfDX/AID/AP1687/4do/D7/oePiV/4VEv/wATR/w7R+H3/Q8fEr/wqJf/AImgD0T/AIYi+AP/AES3w1/4D/8A16P+GIvgD/0S3w1/4D//AF687/4do/D7/oePiV/4VEv/AMTR/wAO0fh9/wBDx8Sv/Col/wDiaAPRP+GIvgD/ANEt8Nf+A/8A9ej/AIYi+AP/AES3w1/4D/8A1687/wCHaPw+/wCh4+JX/hUS/wDxNH/DtH4ff9Dx8Sv/AAqJf/iaAPRP+GIvgD/0S3w1/wCA/wD9ej/hiL4A/wDRLfDX/gP/APXrzv8A4do/D7/oePiV/wCFRL/8TR/w7R+H3/Q8fEr/AMKiX/4mgD0T/hiL4A/9Et8Nf+A//wBej/hiL4A/9Et8Nf8AgP8A/Xrzv/h2j8Pv+h4+JX/hUS//ABNH/DtH4ff9Dx8Sv/Col/8AiaAPRP8AhiL4A/8ARLfDX/gP/wDXo/4Yi+AP/RLfDX/gP/8AXrzv/h2j8Pv+h4+JX/hUS/8AxNH/AA7R+H3/AEPHxK/8KiX/AOJoA9E/4Yi+AP8A0S3w1/4D/wD16P8AhiL4A/8ARLfDX/gP/wDXrzv/AIdo/D7/AKHj4lf+FRL/APE0f8O0fh9/0PHxK/8ACol/+JoA9E/4Yi+AP/RLfDX/AID/AP16P+GIvgD/ANEt8Nf+A/8A9evO/wDh2j8Pv+h4+JX/AIVEv/xNH/DtH4ff9Dx8Sv8AwqJf/iaAPRP+GIvgD/0S3w1/4D//AF6P+GIvgD/0S3w1/wCA/wD9evO/+HaPw+/6Hj4lf+FRL/8AE0f8O0fh9/0PHxK/8KiX/wCJoA9E/wCGIvgD/wBEt8Nf+A//ANej/hiL4A/9Et8Nf+A//wBevO/+HaPw+/6Hj4lf+FRL/wDE0f8ADtH4ff8AQ8fEr/wqJf8A4mgD0T/hiL4A/wDRLfDX/gP/APXo/wCGIvgD/wBEt8Nf+A//ANevO/8Ah2j8Pv8AoePiV/4VEv8A8TR/w7R+H3/Q8fEr/wAKiX/4mgD0T/hiL4A/9Et8Nf8AgP8A/Xo/4Yi+AP8A0S3w1/4D/wD1687/AOHaPw+/6Hj4lf8AhUS//E0f8O0fh9/0PHxK/wDCol/+JoA9E/4Yi+AP/RLfDX/gP/8AXo/4Yi+AP/RLfDX/AID/AP1687/4do/D7/oePiV/4VEv/wATR/w7R+H3/Q8fEr/wqJf/AImgD0T/AIYi+AP/AES3w1/4D/8A16P+GIvgD/0S3w1/4D//AF687/4do/D7/oePiV/4VEv/AMTR/wAO0fh9/wBDx8Sv/Col/wDiaAPRP+GIvgD/ANEt8Nf+A/8A9ej/AIYi+AP/AES3w1/4D/8A1687/wCHaPw+/wCh4+JX/hUS/wDxNH/DtH4ff9Dx8Sv/AAqJf/iaAPRP+GIvgD/0S3w1/wCA/wD9ej/hiL4A/wDRLfDX/gP/APXrzv8A4do/D7/oePiV/wCFRL/8TR/w7R+H3/Q8/Er/AMKiX/4mgD0T/hiL4A/9Et8Nf+A//wBej/hiL4A/9Et8Nf8AgP8A/Xrzv/h2j8Pv+h5+JX/hUS//ABNH/DtH4ff9Dx8Sv/Col/8AiaAPRP8AhiL4A/8ARLfDX/gP/wDXo/4Yi+AP/RLfDX/gP/8AXrzv/h2j8Pv+h4+JX/hUS/8AxNH/AA7R+H3/AEPHxK/8KiX/AOJoA9E/4Yi+AP8A0S3w1/4D/wD16P8AhiL4A/8ARLfDX/gP/wDXrzv/AIdo/D7/AKHj4lf+FRL/APE0f8O0fh9/0PHxK/8ACol/+JoA9E/4Yi+AP/RLfDX/AID/AP16P+GIvgD/ANEt8Nf+A/8A9evO/wDh2j8Pv+h4+JX/AIVEv/xNH/DtH4ff9Dx8Sv8AwqJf/iaAPRP+GIvgD/0S3w1/4D//AF6P+GIvgD/0S3w1/wCA/wD9evO/+HaPw+/6Hj4lf+FRL/8AE0f8O0fh9/0PHxK/8KiX/wCJoA9E/wCGIvgD/wBEt8Nf+A//ANej/hiL4A/9Et8Nf+A//wBevO/+HaPw+/6Hj4lf+FRL/wDE0f8ADtH4ff8AQ8fEr/wqJf8A4mgD0T/hiL4A/wDRLfDX/gP/APXo/wCGIvgD/wBEt8Nf+A//ANevO/8Ah2j8Pv8AoePiV/4VEv8A8TR/w7R+H3/Q8fEr/wAKiX/4mgD0T/hiL4A/9Et8Nf8AgP8A/Xo/4Yi+AP8A0S3w1/4D/wD1687/AOHaPw+/6Hj4lf8AhUS//E0f8O0fh9/0PHxK/wDCol/+JoA9E/4Yi+AP/RLfDX/gP/8AXo/4Yi+AP/RLfDX/AID/AP1687/4do/D7/oePiV/4VEv/wATR/w7R+H3/Q8fEr/wqJf/AImgD0T/AIYi+AP/AES3w1/4D/8A16P+GIvgD/0S3w1/4D//AF687/4do/D7/oePiV/4VEv/AMTR/wAO0fh9/wBDx8Sv/Col/wDiaAPRP+GIvgD/ANEt8Nf+A/8A9ej/AIYi+AP/AES3w1/4D/8A1687/wCHaPw+/wCh4+JX/hUS/wDxNH/DtH4ff9Dx8Sv/AAqJf/iaAPRP+GIvgD/0S3w1/wCA/wD9ej/hiL4A/wDRLfDX/gP/APXrzv8A4do/D7/oePiV/wCFRL/8TR/w7R+H3/Q8fEr/AMKiX/4mgD0T/hiL4A/9Et8Nf+A//wBej/hiL4A/9Et8Nf8AgP8A/Xrzv/h2j8Pv+h4+JX/hUS//ABNH/DtH4ff9Dx8Sv/Col/8AiaAPRP8AhiL4A/8ARLfDX/gP/wDXo/4Yi+AP/RLfDX/gP/8AXrzv/h2j8Pv+h4+JX/hUS/8AxNH/AA7R+H3/AEPHxK/8KiX/AOJoA9E/4Yi+AP8A0S3w1/4D/wD16P8AhiL4A/8ARLfDX/gP/wDXrzv/AIdo/D7/AKHj4lf+FRL/APE0f8O0fh9/0PPxK/8ACol/+JoA9E/4Yi+AP/RLfDX/AID/AP16P+GIvgD/ANEt8Nf+A/8A9evO/wDh2j8Pv+h5+JX/AIVEv/xNH/DtH4ff9Dx8Sv8AwqJf/iaAPRP+GIvgD/0S3w1/4D//AF6P+GIvgD/0S3w1/wCA/wD9evO/+HaPw+/6Hj4lf+FRL/8AE0f8O0fh9/0PPxK/8KiX/wCJoA9E/wCGIvgD/wBEt8Nf+A//ANej/hiL4A/9Et8Nf+A//wBevO/+HaPw+/6Hj4lf+FRL/wDE0f8ADtH4ff8AQ8fEr/wqJf8A4mgD0T/hiL4A/wDRLfDX/gP/APXo/wCGIvgD/wBEt8Nf+A//ANevO/8Ah2j8Pv8AoefiV/4VEv8A8TR/w7R+H3/Q8fEr/wAKiX/4mgD0T/hiL4A/9Et8Nf8AgP8A/Xo/4Yi+AP8A0S3w1/4D/wD1687/AOHaPw+/6Hj4lf8AhUS//E0f8O0fh9/0PHxK/wDCol/+JoA9E/4Yi+AP/RLfDX/gP/8AXo/4Yi+AP/RLfDX/AID/AP1687/4do/D7/oePiV/4VEv/wATR/w7R+H3/Q8fEr/wqJf/AImgD0T/AIYi+AP/AES3w1/4D/8A16cv7EPwEbp8LPDZ+lt/9evOf+HaPw+/6Hj4lf8AhUS//E1j/wDBNu1utE/4Xt4ck1bU9XstA8eXml2Uuq3b3MywRAIgLMeuB270Aa/7KngfQfhr+1l+0b4b8LaXBoeg2sPh2SDT7QbYY2e2nZ2Vc8EnrX11XzD8C/8Ak9z9pf8A69vDX/pLPX09QAUUUUAFFFFABRRRQAUUUUAFRXP/AB7y/wC4f5VLUVz/AMe8v+4f5UAfM/8AwTZ/5M78G/8AX3qv/pyua+na+Yv+CbP/ACZ34N/6+9V/9OVzX07QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8e/EL/lJ58L/wDsSb7/ANGPX2FXx78Qv+Unnwv/AOxJvv8A0Y9fYVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAedeC/jt4U8c33ju2srqW2Hgq+ew1ia8j8qKKRE3swY9VC96l+Cvxm0L48eD/8AhKfDMGoLoUlxJBa3l9atALtUO0yxBuWQkEBu+DX5WfFP4ma3p/xQ+OXgmTTtTtPhjffEOCfxx4i08EeRp7usYgJHQOQ24+gx3r7Q/ab1q+tvEXwC+Bvw31qTwToHjCeYTapobBJYdNtIFk8qBu29W4Yf3R60AfQ+j/GTw9rnxe1/4b2z3P8Awkmi2MGo3atCRF5Upwm1+59RWp8RviHo/wALfB9/4k16aSLT7XYu2FPMllkdwkccajlnZmUADkk18j/szeAdT+Gv7eXxa0TUPEOp+KIY/DOnPZahrEiy3Zty/wAqSSADeVO5d2MkCu4/ayvG8QfH/wDZr8CSM32HVPEd3rM8YPEn2C381QR3GXB/CgD0XwT+1R4G8dfG3X/hRYz3kHjLRIPtFza3UBRCuELBX6MR5i5H19K6LwH8a/DfxG8ceN/CejtdNq3hC5itNTE0JRBJIpZdjfxDA6ivzv8AF1tdeAf2nPjN8btJic6h4C8baWupbQWEmkXUAhu1KjrgFGB/h25r6N/Y5vIdQ/ag/aeu7aVJ7a41jT5Y5IzlWVrdiCD3BFAH2JRXlPxa+Lni/wCH+tWdn4d+E+vePrWaDzXvtLu7aGOF9xHlsJWBzgA8cc1zXhf9oP4h674k0vTr/wCAXirQ7K6uEhm1O61CzaK1RiAZHCuSQo5OOeKAO1+Ofx48H/s7+DU8TeNL+Sy06S6js4lhjMkssrnhVQcnABJ9AKr/ABf/AGiPBXwO8P6Rqvii+uEOsSrDp2n2Ns9xd3bld22OJAWOBjPYZr8+f24NZg/aU0P4oePHvox4Q+HNzB4e8OWyzj/TtQa6h+23mM8hVIiXg5GTnrXpnx58YeIx+3F8D7Dwho2n+KdZj8HzyaPDf3JSztbiQustzIy5O1Yom+7kk4oA+vfgp+0D4N+P2laleeFLy4M2mXH2XUNP1C2e2u7SXGQJInAZQR0PQ4NNvv2hvBlj8cLP4SHUJJ/G11p7akLOGIskcSgnDv0ViFyAexHrXzf4B/aU034Va78edW+J3gfSfCPxP8N2Nne6xfaLcNJBr8BQpZlC3IbcVTBGf3gz0OPLfgn4Ju/CP7anwo8V+LNQgm8d+NtF1bXNePnqVtpZFAhtV54EUe1MeoNAH6A/DX4laN8VvDP9taI8whjuZrK4t7qMxz21xE5SSKRDyrKR0PYj1rrq+U/2fbuTwz+2Z+0R4QjbZpl0dM8RQwr0WaaDbM3sWKr9cV9WUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnvj343eG/hv478E+E9be6h1LxfcS2mmSJCWhMqKGKu/RSQRjPWl8bfGvw54B+IngfwTqTXL+IPGEtxHpkFtCXB8hA8rOf4VCkcn3rw7/AIKQaTcWPwV0L4hacudW+H/iTT/EEBH8SLKI5EJ/ukOCf92uB8UePF1r9r74k/Em2RdRs/hd8M1nsIX5jS7uo2uAfYtHlSfSgD60+MXxi8P/AAN8Jw+IvEzXKadLfW+nr9lhMrebM+xOB2yeTXdqwZQR0IzX5R/F74e+NL39kr4b/FPxD8S/EPiHVPE+uaVf6xpF9MrafsmmDxLBFt/dmP5RkHnJ4r9JfjL4uk+H/wAGfGvieEZl0bQrzUEH+1FAzj/0GgDzL4nftzfC/wCE2lvqet3moPpS65L4e+22do0sbXUSBpQpHVVztLDjcpHavQviB8cPDHw1uPBEWqzTyDxhqkOk6VJaxeajzSruQsR0Ugdelfnp8R/hRpPiL9mz9jjwlq0bT2HirWYbjUGV8PI19EZpG3f3sy9fatFvG2oa54X/AGc/B3iGTPir4f8AxXh8L6huzudYAwglIPZotnPfBNAH6e0V4F4m/aG+Iui+INS0+x/Z/wDFes2VrcPDDqNvqNksdyikgSKGfIDDkZ55pP8AhqLUvDfgDxl4w+IHw01z4eaT4dsvtSPql1bzG+c5CwxiJj8xbaOe7CgDrtU/aJ8E6T8c9J+EUuoSyeN9Ssmv47SOEskcSqzfO/RSQjEA9setcp8Vv21vhl8HfF194Z1e71TUdW02BbnUk0XTZbxNOjbkNOyAhOOcHnFfI/wn8JXuifthfAvxx4v1C1uPHfjm213WdXZbhWFqjW6i1tAc4AjiKrj1LdaPgH4u+LN1rH7SE/gXwP4d8SWa+LdQl1m78QXrxvqEaqVFlCFH/PMH5mOBvA70AfaXj79qz4a/Dj4b+G/Heqa49x4a8RSxw6Xc6bbSXTXTOjOu1EBbopzxweDWF4c/ba+GHivwr4j8R2FzrCaT4e+zvqVxeaTPbiCOWQIsmHUblU8sR0AJNfPlhY+Ifjl8Pv2Y/FXwO8E6XpHh3Sbq/u5tP1K5b7DpM2xocvjLyKshmIC8nAHGa9Q+HvxF8S/FfxF8Vv2fvi9pOjx+IbXRfOOpaBvW01CxuEKb1R/mRlLAcnrQB9V29xFd28c0EiywyKHSRDlWUjIIPcGpq+d/2APHF949/ZL8B3uonffWUE2lSvknd9mmeBWz3JWNT9a+iKACvjf/AIJ7/wDI4ftNf9lO1P8A9Dr7Ir43/wCCe/8AyOH7TX/ZTtT/APQ6AOq+Bf8Aye5+0v8A9e3hr/0lnr6er5h+Bf8Aye5+0v8A9e3hr/0lnr6eoAKKKKACiiigAooooAKKKKACorn/AI95f9w/yqWorn/j3l/3D/KgD5n/AOCbP/Jnfg3/AK+9V/8ATlc19O18xf8ABNn/AJM78G/9feq/+nK5r6doAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+PfiF/yk8+F/wD2JN9/6MevsKvj34hf8pPPhf8A9iTff+jHr7CoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5m+FH7M97b3n7Qem+OLK1uPDnxC1ya5t44ZQ7PavFsyw/hYHkehANeNWH7LPxx8K+DfhzdWf9j634z+EOu3MfhmW6vAkeuaJMoRoZmx+6lCgKM8Ae9ff1FAHyn+zv8LPi1D+0v4++KfxJ0jSNDg8Q6PaWNnpumX4uja+U3+rZsDJxliw4y3FWP2xtPfwz8RvgP8AE8xsbDwt4nNlqM38NvbX0fkNKx7KG2An/ar6krK8S+GdL8ZaDfaJrdhDqek30RhubS4XckqHsaAPAfhv+ztqtv8AEL9oqbxTb2r+GfiHcwrZCKUSM8H2ZopN6/wnLcVw3/BPH9ln4gfsz3HxFi8cz2l4up3FrHp13bXIlM0ECPGpYYyvy7MA819iWtqlnbxW8K7IoUWNFyThQMAZP0qxQB5H8Xv2c9N+Met2ep3vi/xj4de2t/s62/hzWWsoXG4tuZQDluevpiuY8K/sa6L4U8S6ZrMXxD+I2oPY3CXC2uoeJJJreYqc7JEK/Mp6Ed6+g6KAPin9pj/gnD8OvFHwj162+GXw/wBJ07xxcywyWt095NGq/v0aX7zlRlN/bvWt8RP2V9e+HXi74S+PPgtoGkvqPgm0uNNufDF3eNBHeWs4JdUnfdtZXZ2G71r7AooA+SPh3+yjqHxS8XfEnxv8evD2kTT+MUs7KHwnaXLXEFja2pDJvmXbvdnCsccDFYOpf8E7/BOmftNeAfEvhzwNpdl4D0uxuH1KH7bN5hvQwNu4VnJO0jPBx6g19q011DqVIyGGDQB8v/s36TP4p/ag/aA+IgUvpM19Z+GrCfHyyGzhC3G09wJGwT6gjtX1FWN4V8J6R4H0O20bQtPh0zS7csY7aAHaCzFmPPJJZiSTySa2aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDifjV8Oofi58JfF/gydlRdb0yeySRhkRyOhCP/wABbafwr5y/ZF/ZH8S+C/gD4/8ADPxSlhfxX4z8yyvr20nE7C0W1W2t13jqUUMQP9qvsOigD859f/Z1/aV8SfA/wd8G7zw/4XGg+EdUs5V8Rx6v+91S1t5SYwISv7shCCcnnYMda+7/AIl+D08ffDPxR4Xm/wBXrGk3OnN/21hZP/Zq6migD8/vhr8OfFnxw+C/7Mj6bbW8d58MPEos/EVvdTCOS3WyJgICnq21UOPcV0Px8/Y58aeKv2zPAfxP8IGzHhUalp+peI7WW5ET+faMVSZUI+cmJscelfZGi+E9I8O32rXmmafDY3OrXP2u+eEbfPm2hPMYdNxCqM98c1sUAfPfif8AYz0XxR4k1PWJfiL8SLGS/uHuWtrHxJJFBEWYnbGgX5VGeB2q54f/AGOvBVj4d1/w/wCItV8TeP8AQtbWFbnTvFmryXkS+U+9CmNpU7sHg9hXvFFAHxXrv/BO/wAD6b+0h8MPEnhTwLpdj4J0iK8l1mL7bNva52qbR1VnJO1xnggeuaenwh+N3wD8ZfFa2+F/hzQfF/hfx5fSata3WoamLKbR7uVNsu9Cp81ATuAXn5QO9faNFAHxpof7Nfxa/Z7+GfwftfhlrFr4gvfB63K694Zubo2dnrZuWLuyyEHaY3Ziu7rxUnhnwz4x+FviD4yftJ/Fey03QNUm0AWdh4c027+1C1toF3APMAA8kjhMAdCcV9j1keJvCuk+MtLOma5p8Op6c0sczW1wu6NmjcOhI74ZQcHjigDyL9ib4a3fwn/Zf8B6DqCsmptaNqF2rDDLNcyNOyn3Uybf+A17pSAY+lLQAV8b/wDBPf8A5HD9pr/sp2p/+h19kV8b/wDBPf8A5HD9pr/sp2p/+h0AdV8C/wDk9z9pf/r28Nf+ks9fT1fMPwL/AOT3P2l/+vbw1/6Sz19PUAFFFFABRRRQAUUUUAFFFFABUVz/AMe8v+4f5VLUVz/x7y/7h/lQB8z/APBNn/kzvwb/ANfeq/8Apyua+na+Yv8Agmz/AMmd+Df+vvVf/Tlc19O0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfHvxC/5SefC/wD7Em+/9GPX2FXx78Qv+Unnwv8A+xJvv/Rj19hUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWT4l8T6V4N0G91vW76HTNJsozLc3U5wkSjqxPpQBrUV4n/w2r8DMf8AJTtB/wC/5/wpP+G1vgZ/0U7Qf+/5/wAKAPbaK8S/4bW+BmQP+FnaDk9P35/wo/4bV+Bg/wCam6D/AN/z/hQB7bRXiX/Da3wM/wCinaD/AN/z/hR/w2r8DOn/AAs3Qf8Av+f8KAPbaK8S/wCG1PgZ/wBFN0H/AL/t/hS/8NqfA3/opug/9/z/AIUAe2UV4mP21vgZ/wBFO0H/AL/n/Ck/4bV+Bmcf8LO0HP8A12P+FAHttFeJH9tX4GLz/wALO0Ef9tz/AIUv/DavwM/6KboP/f8AP+FAHtlFeJD9tX4GdvidoPv+/P8AhR/w2t8DP+inaD7fvz/hQB7bRXif/DavwM/6KdoP/f8AP+Fes6Br2n+KtGstX0m7jv8ATL2JZ7a6hOUljYZDA+hBoA06KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACikpaACiiigAooooAK+N/wDgnv8A8jh+01/2U7U//Q6+yK+N/wDgnv8A8jh+01/2U7U//Q6AOq+Bf/J7n7S//Xt4a/8ASWevp6vmH4F/8nuftL/9e3hr/wBJZ6+nqACiiigAooooAKKKKACiiigAqK5/495f9w/yqWorn/j3l/3D/KgD5n/4Js/8md+Df+vvVf8A05XNfTtfMX/BNn/kzvwb/wBfeq/+nK5r6doAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+PfiF/yk8+F//Yk33/ox6+wq+PfiF/yk8+F//Yk33/ox6+wqAEor5C0v9pn44fEnx18QNN+HHw08M6pofhDXZ9CnudX1p7eeeSLBJVQpAyCPzr0f4DftRQ/FbxhrngPxN4YvvAPxJ0OJbi80C/kWVZoGwBPbyrxJGSR9NwoA93oqhJr2mwalHp0uoWseoSDKWjzqJWHqEzk/lTtU1rTtDgE2pX9rp8LHaJLqZYlJ9MsRQBdori/ir8VtB+D/AMN9Y8b65M76Jplv9qkNrh3kXjGwZ+YnI6GvIf2jP2o7v4e/Ajwj8QfB1vaX39vanplusN/z5cN1gnIU8OARx60AfSVFUbLWrC+uprOC9tpr23A8+3jmVpIv95Qcr+NXaAFoqCa+trbf5txFEUQyNvcDao6sc9B71HY6rZarZi7sryC8tTnE9vKsiHHX5gcUAWqK+XbT9saY+DfE/jf/AIR9dU8NTeJE8L+CrKwk23mv3XmeUW3N8qI0gfaccKhJrsvhv+0xb643j3TvHWinwF4j8DQx3etWc12tzAtrJGZI545VADKQrAjGQRjvQB7jSV5z4M8c+JfiB8G/+Eqs9Cj0bXNRs5rvStM1Byw2ncbbzsYKl12Egfd3Y7VF+zv8Yk+OXwn0fxVJZHStUk32uqaYx+ayvYnMc8JB5GHU4zzgigD0yiiigAooooAKKKKACq91aQX1u9vcwx3EEg2vFKgZWHuDwasVR1bUk0bS7y/ljmlitYXnaOBC8jBQSQq9yQOB3oAz/wDhA/DX/Qu6T/4BRf8AxNL/AMIJ4Z/6F3Sf/AKL/wCJrxb9n39rZfj18TvFnhL/AIQfWfCJ0Ozt76KTXCsc9zFMSEYwgZjyBnBJOCKh8eftNeKbn4q+IPh58KfAA8da34ZgguNevL3UFsbSzaZS8UCsQS8roCwxwMc0Ae3/APCB+Gv+hd0r/wAAov8A4mj/AIQTwz/0L2k/+AUX/wATXgln+3R4Wb9ne5+J17oWp2V9b6o3h5/Co2vetqwfYLNCOGYnnPpk44pPCP7VfinSfih4Z8F/Fn4byfD+bxbvGgalBqCXttLMq7jbTFQPLlxj2JIAoA97/wCEE8Nf9C9pP/gFF/8AE0v/AAgnhr/oXdJ/8Aov/iaofFT4haZ8Jfhz4i8Y6w4TT9FspLyQZwZCq/LGP9pmwoHqwrF+GPjbW7j4L6V4u+I8Nj4b1OTT/wC09St42Kw2MZBcIxY9VTAb3BoA6n/hA/DP/Qu6T/4Axf8AxNH/AAgnhn/oXdJ/8Aov/ia8L/Zm/bQ0f9pHVfiKkHh+68MaR4R+zzC/1KZR9rtplldJyuB5amOIPyTw454rhJP+CgGsr4bX4lD4Vaifgf8AbvsR8V/bU+1eX5vlfbPsuM+Ru465/CgD6v8A+EE8M/8AQvaT/wCAUX/xNH/CCeGf+hd0n/wCi/8AiatTaobjQX1LSo01QvbG4tEjkCrcZXcgDdAGyOfevln4nftgfFX4P+C9R8V+KvgK+naHY7POnHii3dss4RQqhMsSWAwKAPpz/hBPDP8A0L2k/wDgFF/8TR/wgfhn/oXdJ/8AAKL/AOJrwDxr+1p4k0/VW0fwn8N5vEGt6T4bh8UeJLO51Bbb+zoJF3C3QlT5k5AfA4Hy+9dbqH7Slvq/gn4aan4O0z+2da8fyQNpml3MnltFbFRJczy46LDHnPqxUd6APUv+EE8M/wDQvaT/AOAUX/xNH/CB+Gv+hd0n/wAAYv8A4mvO/wBob4wat8Dbbwt4ma0tbnwU2qxaf4imfd59nDMQkVxHjgqshUMD2bI6V6+kiyIrowZWGQw6EUAYf/CB+Gv+hd0n/wAAYv8A4mte3tYrOCOGCJIYYxtSONQqqPQAcCp6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOC+JXhvx3r0ti3g3xnbeFUjVhcpcaUl55xONpBYjbjn65riZPhz8c9hC/GHTA3YnwxD/8AFVy/xR/ao+IPgO+8SX2m/AfxDrfg7w7LKt7rTX8EElxHGD5k1vAcs6LgnJ6gcCt7xt+2N4S8N/Bvwd490ayvvFUnjSSG18O6HYqFur65kHEJ3cJtIIYnhSKALg+HPxw/6LBpv/hMQ/8AxVMX4c/HMM+74xaYRu+X/imIeB6feql8J/2p5/E/xH1P4efEDwZdfDfxpZ6d/bENrdXkd1bXlnnDSxzIAMqeCpHY1wN5+3tqVx4a1H4g6F8Jdb1z4PabcNFN4sS7jjmliV9r3UNqRuaFCGySQePrQB6XJ8OPjoWj2fGLTAA2XB8MQ8jB4+964qT/AIVz8cP+iwab/wCEzD/8VXrnhnxFp/jDw7peu6RcreaXqVtHeWs6dJIpFDKw+oIrzL4T/GbUfi18TviDZ6ZZ2qeBvC12ujRallvPvNRUZuAo6COPIXPUnPpQBmQ/Dj45iFPM+MWmGQDDFfDEOCf++qX/AIVz8c/MP/F4dM2Y4H/CMQ5z6/erP1z9sjwzp37Unh34I6fp8+savqSyi91S3mUQafKkDzCFwR87lEBIB+Xeua7/AOO3xp0b4B/DjUfFusxy3ghKw2em2uDcX9y5xHBEO7MfyGT2oA5CT4c/HPb8nxh0wHPfwxD/APFU/wD4Vz8cP+iwab/4TMP/AMVXQfs2/G+1/aN+DOgfEKz0ifRLfVzOEsbiVZXj8qeSE5YAA5MZPTvXFfEj9qPVNN+KeofDn4beAbz4j+KtHtEvdZ8u9js7XTkcbo43lcHMrjkIPx70AaSfDn45jO74w6aTn/oWIen/AH1R/wAK5+OXmD/i8Wm7ccj/AIRiHPb/AGq5mx/bh8P6t8I18UWfhvU28VnxAnhI+C5mWO8j1hjgWruRtAxlvMxjAJ7V03w//ag0/VtN+IMfjnSj4E17wCiza/YzXK3MUUDxmSKeOVQA6sqtgYzkY9KACT4c/HPy22fGHTA2OC3hiHj/AMepV+HPxy2jPxh00t3P/CMQ/wDxVdV4f8aeLvGXwT/4Smx8PwaT4pvrCS903R9QlLKCQWgSYjBDMu3cB90tjtS/s/8Axcg+OXwl0HxjFaHTri9jaO909j81pdRuY5oT3G2RWHPOMUAanw38P+MdBsrtPGHiuDxVcySBoJrfTksxEuOQQpO7J7181f8ABPf/AJHD9pr/ALKdqf8A6HX2RXxv/wAE9/8AkcP2mv8Asp2p/wDodAHVfAv/AJPc/aX/AOvbw1/6Sz19PV8w/Av/AJPc/aX/AOvbw1/6Sz19PUAFFFFABRRRQAUUUUAFFFFABUVz/wAe8v8AuH+VS1Fc/wDHvL/uH+VAHzP/AME2f+TO/Bv/AF96r/6crmvp2vmL/gmz/wAmd+Df+vvVf/Tlc19O0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfHvxC/5SefC/8A7Em+/wDRj19hV8e/EL/lJ58L/wDsSb7/ANGPX2FQB8ofsM/8jl+0j/2Ui+/9ASuG+MXigL/wUBi1nwtCuoan4L+HOpXWsGFtyhiHaCCTH8W4qdp55FelXX7DlrF4w8V61oPxW8f+ErbxPqUuq6npWiajHBbyTyH52HybhkYGQc4FeofBf9nTwP8AATRdQsPCumOJdTkM2o6hqEzXN3esRjMsr5Zu/HT2oA/N7wB8K/Gfxq/Z/XxNF8FdT8T/ABD8RJLqdt8Tv+EtiiuUuzIxjkjjxmONCApiHUKe5r334oX1j8TNa8AeAvFHwfX4ufGux8LQXWu2c2qfZNP0oOFV5JZMlWZpM4CgnBHOK9Vs/wBhbSPCuoX6eBviR48+H3h29uGupfDug6oEslkY5cxhlLRg+ikV0vxG/ZJ0jxt8RrTx5pPi7xP4I8Vrpq6Re6j4fvFifULVSCEm3KckED5hg8D0oA+GdF8O/wDCUf8ABO/496P4qsN83gLxZqdro9m949yNLMZiPlJLnMioZZACeCDnFdl+0f8ACfw54H/4J/8Aw4tvDNkdCfXtW8P3d5PbyMXa4kjUNKCxOG78cV9a+Af2OfAfw/8AhR44+HVo2p3vhrxfdT3WoR310ZJt80aI5WTG7PyKcnJzzWLD+xLoVz8IbH4da5408VeJdF0/VLXUrCXU7qN5rQW4AigQhBiIY6Yz70AeMfGb4D+GP2Y/jN+z94t+Ha3mi6nq/iuHw/rEkl5LOdTgnQ7mnLsd7/KeT3b2FfeizxPK0QkRpFGWQMMj6iuA+KXwV0P4tX/gm71ia7ik8Ja3DrtiLZwoeeIEKHyOV5ORXG/s8/CHxD4T8e/Fbx74uYLrni7WybWzjuDLHa6bAvl2yjsHYZZseo9KAPDvj18L9P8AjN/wUQ8G+Ftfu77/AIRk+BZby+0u2unhjvgl2+2OXaRlNxViO+wDpWX8JfD8HwJ/ao+Pnwy8HPNY+Cn8Gx6/aaSZWkSzuvLCMYckkBtxJH09K+trz4J6HefHSw+Ksk13/wAJDZaK+hRwhx5HkNL5hJXGd2T1z0qrp/wB8O6f8cfEHxSWW7k17WtIj0a5t5HBtvIQgghcdTtHegD5u+D3wVuPix+wj8GP+EVvbW08TeHLq18T6VJfKTbyX0E0jNHNt52tvkUkcjOa8u+Lun+L7Pxj8UfEPiqLS5NZGkWniDxfoeju8thBY2asNP04zMAztcS5ll4GI4wAPmr68/Zb+GHiP4IaV4o8B39vHJ4S07VZrrwzqKShneznYy+RIvUNE7MuehBFdPoPwD8Oab4R8Z6DqTXHiGPxhc3Nzrd1qDAzXXnDZsJUDCpHtRAPuhRQB4t8HfiF8T/B3xm+H/hXxz4rtPGOm+PPDU2sxJBp0dqdKuYRG7RRmP70JWQKN3OV961P2L2KeNP2ireEf8S9PiJePHjlfNaGIy4984J+tdF4P/Zjs/g3LeeK9I1HXPHfivStEk0nw7b6/fBks7cDKW0ZwAAWVQXbLYHWuj/Zd+EOofBv4UWum69cRX3i3VLqfWtfvYTlZ7+4cvKQe4GQoPoooA9dooooAKKKKACiiigApKWigD5P+E+T/wAFEPjln/oXdG/9BNeXXXg3xr8cv2tvjDq3wa8Uj4TS6HFBomv6lIn2v+3b0RHy5DASBGIlyofqeor7C0D4M6B4c+Lvib4j2huv+Eh8Q2dvZXm+XMPlwjCbV7H1NcD44/Y78NeJviJqnjnQPEnij4feJdYjEWq3XhbUTbLfgDCmVCCCwAHzAA8UAfKnwp+EurfGr9mu58G+GLSz8N/Fr4RfEA6hLPcXL3Nnq2r27FmmkkbJxLvOf7pUdq0Pi54q+LXxe/aO/Z/8HeMPC2geGNRsdeGuyabpGpG+ulhgXMlxKQAIYuCFB5Yn25+u/Cv7NPhr4ffCG/8AAHg3UNY8KW99I1xca3p94f7TkuGYM87Ttkl22gEntxSfBX9l7wR8C9Q1LV9EgvtT8TaooW+8Qa3dveX1wM52mR+Quedq4FAHnn/BRxmb9mmeJ8fYJte0mO9ycDyTexZz+IWuS/bb8Sa34h8VeDfhxc+EfFuqfC65jTVfE154X003cl8iMfK08YZdqsyBpDnO0rjrX0r8a/hbp/xq+FPifwTqWFt9Ys3gWUjPkzfeilHukgRh/u0fBWHxlZ/C7w7aeP0th4utLVbbUJrOXzIp3T5RKDgffADEY4JI7UAfnNofxMi8SeNv2xdI8PeDPFelyeIvDtpDY202keSNOS30qcGO5AY+TvAxGBndkdK921LXtAj/AOCTDXPn2w01vAC2iHjb9pMQiVP9/wA7A/3q+nPB3wV8PeCfiR498a2H2l9X8aNaNqiXEm+I/Z4jHHsX+EbWOa8fi/4J7fDePU0i/tHxI/gtNT/thfAzam50YXW7dv8AI9N3O3OPagD0/wDZis7vSf2dfhfp2pBotSg8M6ek0Mp/eKRboCCDzx0rxD4sMf2lv2wPCvw0gPneC/hsIvFHiTPMVxfniytWHQlQfMIPGCR2r3i/+BuiX/xx0v4pNealHren6S2jRWcdyVszEXZtzRdCw3nn6egp/wAJPgb4d+Dcnii60dru71PxLqkmr6pqGoTGWeeZ8DG7sij7qjgZNAHkvxm+CPjvT/iV4x8deAdc0HT7Txd4fTRdeXxAJFWwWIOFvYmQ/MUR2GxsA9c183/CnRfFMnjD4T6H4d8QP4cTxLpV3pnh7xG1qkt1Z6Dp6IxeKKQFVkvJmEpJGQioK/QX4mfD+z+KXgrUvC2pXV3aaZqSrFd/Y32SSw7gXi3Y4VwCpxzhjXNfE79n7w58TLPw2BNfeGNU8MuW0TV9Bm+zXNgrJ5bxowGNjIApUjBAHpQB8v8AxA+IWs+Pf2E/jzpPjm9j1fXPBuo33hyTWEhEK38lvJE0E2xeFY74wQP4lNfZfw4kuJfh74Ye6G25bS7Yyj/a8pcj8814L8SP2VZr74c+E/hR4Uj8rwNd64NU8XatqF4XvruNZPPcZIzJJPKFDMSMAV9MwwpbwpFGoSNFCKo6AAYAoAlooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopKAPm39rb42X+m6efhL8PIP7c+LHi+2ktbS0hOU0u2dSsl7ct0jRFJIz1OK8d8dfCuz+BXxc/Yn8GrOJtD0K41SymuZvuzXrWqFXweheUyEDtnFeizf8E99DXx14i8X2HxO+IWj67r0xlv7uw1ZY3l+YlULbM7VzgDPAArv/En7Jvhrxt8H9K8CeJdd8Qa/LpN2b/T/ABNeXxOrWtyHZklScD7y7to4xgAUAeR/H/QovGH7fnwl0SCQo8/hHW4tSaH7620sTRoT7bzxXlHi68+Nn7Kn7Iviz4Z654U8NXfhTS9NvNMtPGsuqbUuLefzFjUWmNzTt5gATOM4znk19d/Bj9l3QvhF4t1Xxfda7rnjjxtqUC2c3iLxLcie5W2XGIUwAqLkAnA5wM1i/wDDGfhnXviMni/xt4k8TfEKe1vmvtM0vxDf+Zp+nOW3KI4FAUheMbskYoA6L9kvwnqPgX9l74a6JqqNFqVnoNsJon+9Gxj3bD7rnH4V8yfBP4pa/wDCX9gnxB4o8K+HL7xN43u/EOrRJZ2Fu07reSXsqedIqgkqigMfXaB3r75VQvAGOOleGfAT4U+IPgr8RPiNosdvHcfD/XNRbxFpN4Jh5ttcT4+02rJ/dDjerDsxFAHwRpXjzwn8K/jn+zjcQeGfH19q2n3evaj4j1LUvDc0V/rl9dWqK00UbMTJtYHIH3EC17F42+MyeLP2nNY8RfEHwF8QJvDPgcS2XhHTdP8ADc1xby3RBWbUpWBALDG2McgA7utfZHjb4K6J47+KXw+8eX895Hq/gpr5tOihcCJ/tUSxSeYMc/KoxjFd7cQC5t5YWJCyIUJHBGRigD42/wCCU3j+z8Qfsp6D4di0/VbW50J7jz7y8s2itLjzr25dfIlPEu0cNj7rHFX9Y8B/Fv8AZ9/aD+InjnwB4W0zx94V8ei1ury3vNTWxn0y6gjMe4uwIaIglj3H4c9xdfsUeEpP2ddE+DVtrviLTfDmkXv22C8sr3yrtmM8kxRnAwVLStxj0PUVufGL9l+z+NmqWo1zxx4vtPDKWq2tx4Z0vUjbWd4FJO6XaN7E5Gfm5xQB8c/s5fCzxv8AtAaH8TfiPp8+j2HiSP4kw+I9FaMyPpV5cWiOksayY3NC4laPzQMkjOO1Q/FyHxfoHiP4s+KPEY0u51S3tLHxJ4v0XTS82nRrbr5el6YZWAaQySkzynAG2NVx81fo34N8F6L8PfC+m+G/DmnQ6TounQiC1tLddqRqP5nuSep5ri9H/Z68MWnw+8W+E9V+0eIbXxZcXVzrd3fMPPu3n4OWUDGxdqpj7oRcUAeS/B3x18TfBvx28M+BfHfiy18aWXizws+vwyRafHatp1zG6CSJDHw8REgxu5G33qx+w2226+PFvC7PYQ/EnUxAD91SUhZwvtuJP1NdF4X/AGbU+C1vq3ivQb/WvH3jiz0RtH0L/hIr4MLa3XmK2QgAKu7buc5Ygcmuq/Zl+ENz8FfhDpegapPHfeJLiSXUtbvo+Rc307mSZ84GQC20H0UUAer18b/8E9/+Rw/aa/7Kdqf/AKHX2RXxv/wT3/5HD9pr/sp2p/8AodAHVfAv/k9z9pf/AK9vDX/pLPX09XzD8C/+T3P2l/8Ar28Nf+ks9fT1ABRRRQAUUUUAFFFFABRRRQAVFc/8e8v+4f5VLUVz/wAe8v8AuH+VAHzP/wAE2f8Akzvwb/196r/6crmvp2vmL/gmz/yZ34N/6+9V/wDTlc19O0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfHvxC/wCUnnwv/wCxJvv/AEY9fYVfHvxC/wCUnnwv/wCxJvv/AEY9fYNAHI6R8V/CPiDx7q/gnT9fs7vxZpESz32kxsfOt4224Zhjp8y/99Cjx98WfB/wtbSF8WeILLQW1e6FlYC7cg3ExxhFAHXkfnX5vN4gufh/+2d4i+NySG30WH4jt4J1ydXOz7LNaxRq0vYIkiK2T3xU37f2pXPxT+JHjHxTDO0vhj4PtpFlA6HMX9pXV5C85B6ZWMIp9DgUAfqTkdaK+UPj5+09q2h/G7SPhP4a8V+FPAM39jjWtW8VeLJY/Kt0LbYoIYnkRZJXxk5PC81xWg/t9X/hL4cfGSbxPPoHjbX/AIfPbJZ6v4ZmH2DWluiFt2+VmCNvOHVWOOR2oA+r/jF8XPD3wL+HeqeNfFU08GhaaYhcPbxeZIDJKkSYXPPzOtXm+JHhkeOLfwa2t2q+Kbiy/tGPSS/79rcHBkx6Zr8+f225P2ho/wBjrWNW8f6h4V1XQdcawbUtJ0uwkgn0QG6hkiKTFz53zBI2yoxuyM19MXnjXyP26PDPhUaDo7/aPBMt8dZa1B1BNs23yll7Rnrt9aAPpWivgz4+ftZeP/2eb59av/if8O/FElvqaxXfgDTbUrdx2rSBDicSMwlUEMQ6gdfTnu/ir+0H8U7r9qfQPhJ8ObXQ47XXvCEevf2rrETv/ZpM8ivMUVh5gCoqiPj5nBJxQB9c1l+IvEeleEdFu9X1zUrXSdLtU3z3l5KsUUa+pYnAr58/Zx+NHxBv/jJ8QPhF8T/7L1DxF4bt7fUrPXdGhMEN9aTZwWiJOxlO0YB9fTJ4r9rTT0+L37V3wN+EWuSs/gi6S88Qappm7EeoyW65hjk/vKCCSvcMc0Aey+CP2xvgr8RvE0Hh7w78RtG1HWZ22QWu94jM2cYjLqA5J7KTmu1+J3xf8F/BnQ01fxt4jsfDenyP5cUt4+DI/wDdRQCzH2ANeQ/tr/BDwl4z/Zj8Z79JsdOvvDukT6ro9/BCsMlhPbxmRDG6gFAdm047GvnzVLP4heOvDv7Nv7Rdn4Pk+JsWheGjFrPhd2UXHmPGA19bq2Q8hwWxgkhVx14APtj4U/G7wL8cNLvNR8C+JLTxJZ2kvkXElsHUxPjO1lYAg/hXddK8e/Z0+O3w++O2lazqPgq0k0nUrOdYdZ0q+sRZ31rNjgTx+uAQDk9D6V63eStDaTun30RmGfUCgCbNFfnt4c/aa/aR8bfs7+IfjJYS+DtP0bwxNdFtHksZZJtXht5SJWL78Q4UEAAHcVJyK3vEP7Tnx08I+AfAfxq1e28Lx/DzxFfWcVz4TtoHe8srO5IEU32kt88hyCVCgDIHNAH3ZRXy/wCPPjZ8Q/iD+0VqHwf+FE2k6H/wjunQ6h4l8UavaNdi0eYBoLeKEMoZ2Uhsk4wT6c3/ANnj46eNNX+Lvjj4P/Eu302Txh4Zghv7bWdIRooNUspeFl8ok+W4JXIBIycdskA+kaKKKACiiqmqapaaLpt1qF9cxWljaxPPPcTMFSKNASzMT0AAJJoA5b4o/GLwZ8E9Bh1vxx4htPDmmTTLbRXF1uO+Q5IUBQSTgHtWR8VP2jPhx8E7jToPG3im38PzahG0tqs0MsnmqCASNiNjkjrX5s/ta+OdI/ae+C/xH+LuqeItPi07TXttK8B+Fzfxm58oahAtxqEkOdwklUOAMZEYPbmv1EuvFHhhvAsniqe807UdAsbKS7k1GN454RFGpLkOMjA2nOD2oA5X4XftR/Cv41eJLjQPBXjG01/WLe2a9ltIYZkdYVZUL/OijG51H416Nrmvad4Z0i61TV7+30zTbVPMnvLuVY4ol9WYnAFfLv7DPhu48bN4x+PeuWKWWq/EC6xpVqIwv2PR4Tst0HHV8bye/wAprz39urWPE/xQ/aS+FXwY0Dw9b+J7I2k3iXUNI1C7a3sbvaWSH7UygkwoyMxUAliwFAH1p8K/j14B+ODav/wgviS38RrpMixXctrFII0Zs4AdlCv908qSOK9Br5d+A3xy8V6P8Y5/gp8SPBegeE/EC6SNW0e58JyM+nXVqrbGQBgGRl+nOD07/UVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUNY1ey8P6XealqV1FY6dZxNPcXM7BEijUZZmJ6AAGuZ8EfGLwX8SPAr+M/DniOz1LwrH5u/VgxjhXyz+8LFwMBcHJNfMX7SfxL0P48fF4fA1/FWmaB4K0UR3/AI5vLvUI7Vrofeh02IswLbzhpMdFGM54r5j0zxhY2v8AwTRvvCWiarawHVfGjaTeQ2NwhltbKW/zuKg5VWVQuSMENQB+h3w5/a1+Enxa8WHwz4U8bWWqa2yNJFa+VLEbhFzuaFpEVZQMHlCehr1i+vrfTLK4vLueO1tbeNpZp5mCpGijLMxPAAAJJNfGP7efhPR/h/4C+Cer+HtPt9L1Hwz4x0m10uW1QI8ULfI0QI5Ksqrkd8V1/wDwUq1a70/9knxDDa3D2y6le2FhcPGxB8mW4RZFyOxHB9iaAPRPh7+138Ifip4uHhjwv44sdT1yQO0Ft5csQuQpwxhZ0VZcYP3Cehr2Ovin9ubwVo/w++FPwY1vw5bWuk6j4Q8W6PFpTWsSpmJv3bQjH8LDBI77a+1VO5QT1IoAWiiigAooooAKKKKACiiigAr43/4J7/8AI4ftNf8AZTtT/wDQ6+yK+N/+Ce//ACOH7TX/AGU7U/8A0OgDqvgX/wAnuftL/wDXt4a/9JZ6+nq+YfgX/wAnuftL/wDXt4a/9JZ6+nqACiiigAooooAKKKKACikyPWjNAC1Fc/8AHvL/ALh/lUtRXP8Ax7y/7h/lQB8z/wDBNn/kzvwb/wBfeq/+nK5r6dr5i/4Js/8AJnfg3/r61X/05XNfTtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHx78Qv+Unnwv/AOxJvv8A0Y9fYNfH3xC/5SefC/8A7Em+/wDRj19hUAfGWl/sm+JvEX7Pv7RPg7xFbW8Gr+OPFmq69pGZ1kQbzE9oxYfdw8S8HkVhH9jfxtH/AME+/FPw6uRb6r8UPFFyusam8lwAkt4buKUgydDtSJRnoSD6191UlAHxn8bP2e/Gdp8ZtC+MPh3wPoPxInuNAi0XxD4R1mSNHaRCGS5gkkUpvXlTnHA4zmr3iD4Ba7+0H+zr4+8I6j8MtD+DGramYX0xLGeG482SFxLG05hQADeoGOTgk19f0UAfn38cvBv7UP7SXwBu/htqPw/0TwtJbi1+36h/bCTDWTDIhCwKP9WpZRIS5/hwOte2+LPgf4v8QftXad45sxHp2iL4EudCN+swMtteSOSpCdSBnOfavpbNFAH5i/8ADL/xwT9l/U/gnYfCrw3YX6XQnv8Axo2qxs+s7bgSB0G3f5hAUZkIwq49q+odP+B/iy3/AG1vDHxHe0hHhex+Hi+Hp5/PXzBeC4aTYE6kbSPmr6Zo3DpnmgDwHwf8I/Emkftm+PfiHc20S+GNW8O2WnWs4lBdpo3y4KdQMd6q/tWfs7+IfihfeDfHnw+1S30X4neCbp7nSpb0kW13C4xNazYBIVwMZ7ZI719E0lAHxd8RbL9o/wDah8IT/DjVfAWl/CbQNUxBr3iB9XS+lktsjzI7aJO79MucYJr1DxpqPxU+Btr4Y8O/DD4Zab458EaZpENgi/2utnfQSRDYAQ42FNipyOc7vavoKk3D1oA+Eo7Xx/8As5+H/jj+0R4w0nTNM8f+MFsbLSPCenSG5hhkXFvbLKy482RndS23sp554+yfBsPiCT4faRH4ne3l8TPp0f8AaLWi7IftJjHmbB2XcSB7VuXljb38ax3NvFcxqwdVmQMAwPB57irHagD5E+Ff7Ovjbwt+wn40+GOoWVvH4s1O21mO2t1uFaNjcNIYgXHAyGH0p3xY/Z38a+K/2JfAXw406zt5PFOkroourdrhVjX7O0Zmw54ONpx619c0ZoA+T/H/AMMfib8Hf2jta+L3wx0C28b6Z4t022svEnhia+W0n+0W6hILmF3G3AQbSp9T1zxs/s4/B3xyPjB44+M/xLtbPRvEniS1g0yw8O2M/wBoXTbKLBCySjhnZgCdvAx15r6YpN1AC0UlFAC1R1jR7LxDpV5peqWcN/p17C9vc2txGHimjZdrI6ngqQSCD1Bq9SZoA+Tv2lv2A/AHxG+C/iDw/wDDzwD4M8KeL7s2/wBi1ZdMjtzAEuI3k+eNCw3Rq68Dndius/aB/Zw1Dx38EdI+FHw+TSPBnhS4v4E1mK2QwKmnCTzJ4rdI1xudvXAOTnrX0LS0AcvrPh2/0f4b3uieCTZ6Pqdrpb2eitNHm3tpVi2wFkA5RWC5HoK+cvEH7O/xh1aw+GHxEHiTw6/x38J29xaajcPC6aXrFrKxzbuUUMoAwQwUfNuOBmvrWigD5s+EHwF8e3nx2vfjJ8WtQ0X/AISaPS/7E0nQ/DPmPZWNsX3u5klAd5GPsAMn2x9J0UUAFFFFABRRRQAUUUUAFFFFABRSFgBknApFkWRcqwYeoOaAHUU1nVerAfU0LIrcBlJ9jQA6imeagcIXUN/dzzTqAForNj8SaTNr02hx6nZvrMMK3MunrOpuEiY4WRo87gpIwCRitBZEZioZSw6gHkUAOopKRpFUgFgCemTQA6imtIq9WA+poVlboQfoaAHUUlJ5iFioZdw6rnmgB1FJTfNQvsDqX/u55oAfRSZrN1jxNpHh6O1k1TVLPTY7q4W1t2u7hIhLM33Y1LEZY4OFHJoA06KKKACiiigAooooAKKKKAPLPFH7Lvwi8Zaxf6xrfwy8KavrN6xkuL690mGSWZ8Y3O5XJPTmvAfh3/wTv0bS/wBmHxf8N9dtNFsfEuvXE8h8QaPb/vI1Fx51oC5CswjIX5emMivtGigD4+s/2d/jT8XfE3w9t/jPrXhdvCHgi7j1JIfDrTvc63eQjEMtyZFAjA+8VXIJJ9sdh46+Afj/AOOWifGDwf8AETxBpjeDdckhbwj/AGbFi50zZ8weX5RuIcIcZbODyM19I0UAfHVj+zn8a/ixrvw3sfjJrHhNvCfgO/h1WIeHvPe51q6gUrBJcLIoWPA+YhcgljX2JS0UAFFFFABRRRQAUUUUAFFFFABXxv8A8E9/+Rw/aa/7Kdqf/odfZFfG/wDwT3/5HD9pr/sp2p/+h0AdV8C/+T3P2l/+vbw1/wCks9fT1fMPwL/5Pc/aX/69vDX/AKSz19PUAFFFFABRRRQA12KqSF3EDIHrXyx8Jf2g/it4i/a21H4a+PPC+j+FdJfwpJ4jsLKzuTdXSKLxbdPOlB2EkbyVUccc9a+qa+UM/wDG0of9kk/9y1AH0l438XWHgHwdrXiXVWZNN0izlvbhl5PlxoWbA7nAr4r1H9qT4++Hfg/p3x81PSPC3/CtLm5huZvC8MMx1ODTJZRGkxm3bS+GViNuAD9a99/ak1rSvGvwi+KHw30jV7S68czeF7q5TQoZ1N4YihCuIwd2CeOncV83+PvjF4a1L/glbp8Nhe217qOp+H7Pw3b6akgM7XxZIGiCZzuVgzEY6LmgD740rUrfWtMtNQtJFmtbuJJ4pFOQyMoZT+RFTXf/AB6zY67G/lXlEPwTl8Sfs6+Gvh5qPiHXfDc9rpNhaTap4ZvjZ3iPDGgOyUA4BKkHjkEivLLj/gn/AGEdvK3/AAvL41nCE4PjJ/T/AK50AT/8EwWLfsSfD8k5Jk1LJP8A2ELmvqmvlX/gl9x+xD8PR6PqI/8AKhc19VUAJS1z/jjRNW8ReF73T9D1yTw1qkygQ6nFAszQHIJIRuDkZHPrXhGo/Dn48+C9e8O3+m/Eebx5YLef8TLTbyxtrNfI2k53AZPOBgUAfS9FeM+IvHXxisI4To/w403VWYkOsurLBsHYjIOa84l/bQ1Lw94jk8P+J/B8mlazbSBLqKHzJYYzjPyzBdrcd/U0wPq2krxnwv8AtXeBvF0s8WnrrDSwKDIJNLmQDPoSvP4VU179sj4b+GdSWx1O51S2kLqnmHTZTECxAAL4wOTSA9yorJh8WaJcSRxx6xYvJIQqILlMsT0AGeta1ABRSdKKAFopKKAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD49+IX/KTz4X/APYk33/ox6+wq+PfiF/yk8+F/wD2JN9/6MevsKgD5F/Za+OFlD4y+PFh418c2sMlj48vLbTrbWtSRDDbKqbUjV2GEBzgDiqHgz4t3niz9uT4qaZpHi19Y8KWfgiG6tLazvfOtIbjcoZ0CkqH9SOa5b9mH9nn4cfF74iftD6l418F6X4jv7f4hX0EFxqEG9lj2qdoJ7ZJP41H8K/hz4b+F/7e3xf0PwnodroGip4BhlWzso9kQdmXcQPU0Aeb/Dvw34mvv2JY/jrc/Hzxpo3jO3srzU40vtYEthNNBNKscBhcfN5nlquMkkt0Nff/AMB/GWs/EL4K+CPE/iOx/s3XNW0i2vL222FAkjxhmwp5APXB6ZxX5veAf2RPCvjT/gnPpHxK0fSGtviXodvd67bXzSySLO9tdSuY2gYmNg0ce3G3rj8f0j+CPxCi+L3wa8I+L7dRCNa0mC6eJePKkaMb0/4C24fhQB8tR+O/EHj74T/tK/GKDW9RsRDFqGheGrW3uWWKzt7JWX7QgBwJZZdzFuoCgCuZ8MfGzxx+0V8Pvhl8G/ht4juovEMug2Go+OvHEc5abSrdkUmJX5zcy898j8SRZ+FrHT/+Ce/x18NzBl1Tw/eeJNPvI2++JN7uMj3Vwa4TwT8MZ/2Ufg78Hf2h/hxpU0lkmh2sPjzRINzm/s5sM93jOfMiZs+wA6AGgD7E+JX7RHgv9mWPwt4Ju/8AhIfFniW6tALLSNLt5NS1O4hjG1p5TnJyQcsx5OcdDXif7Mfxog+M37dXxV1DSrnV4dGTw1YoNJ1WKS3e0nVlWRWhf7rZ7jr61jaR8XvCHw3/AG7NX+I3i7V7e38F/EPwjYt4S8VXXy2kMaBPNtmkIxGWYFzux2z1rM+F/wAfPBx/bH/aF+KWnzvN4R03wfb3P9oLCY0vfJ2qzRFgN4Zl2qehPSgDsv2kG8bfG/4g/FLS/BPiXVvD9h8OPCxaKbRrp4GuNamAuBGxU/PthjCle3mnua7zTf2q7eL9gm3+Ml/dK1//AMI7lmUZMmpY8gIAO5nGPbPtXU/sbfD+88IfBW11XWxu8S+MLqbxNq5bqJrtvMEZz/cjKJ/wE18N6b4L1S4+Pt3+yYlnNB4Rj8fHxm0m0mGPR1iFwLZP9lpGA46MDQB9NfDn4/W37MfwU+Gnhn4jXviPxv8AFPxBYnUpNH06B9R1JvMJkbcuflRAQnJ6qcdK5L4MfEyw/aU/a++Llpp2oa/p2hXXgy3spNPuxLZXWnXHmbHPlnmOQZzuHt1q5rvjLRP2f/8Agol4h8SfEe5j0Tw94r8L2tl4e8QXy7bS2aIr5tuZT8sZJUtzgcj1pn7OHxG8OfFL/goR8WvEXhZzdaLN4YsoY9RELRx3rRyKjSxkgb1yNoYcHbxxQB7R+xh8RNX8bfCm80XxJdPfeJ/BurXXhnUbyTlrprdsJMe+WjKE+4NZ3xK17VvHn7XHgX4dWOo3Fh4f8PaVJ4v1tbWVozdv5nkWsDlSDt3b3KnghRmsr9heNtSh+MviePcdL13x9qU9jJnKSxoVjLr6gsrDPtU+lzDwv/wUM1y3vGYL4p8C281hJIflL2ty6yxL74kD49yaAPO/Ac3xY/a+tfHvjjRfirqHw7sNJ1m80jwzomk28LxBrY4869LqTJvYjKdAOnWuf8SftheLPGP7G/w98UQ6/b+BfF2s+K4PDGr6xF5RitWSZ0nmUSAqAUQNyMDd7Vl/tF6L8Lfg34w8aweB/iN4ys/GXiG4aW6+F/gu7LC/1CVQQWVULW4k3KWYEHB47CvRvhD4B+FX7L37Nfw5+Hvxzk8MpfahJcai0PiS3jmtEvGPmSKHlBRWRZFTcSM496AO48Arrfgnwj4t8fQ/HC6+MWk6bo13JFYNFZ/Z1njXzA2+Bc7vkK4J6Ma8p+F/xO8e+Cte+AninxF8QrrxPp3xUsri61rTb9YltdP/ANGFyj2wVQY1jB2NkkHHPPSr+zTpPhDxJ+2f441L4MWEcHwafw0tjr/2GIx6Re6qZTt8hD8rERZBKDb97+9zr+P/ANl3wJH8TvDHwx8IWOoyvdwTXWpNdalLPB4e0Nn/AH8FqjMRC10/7rjnZ5mOBQB7H+z98SJ/iR4i17xZrGujT7fX5fL8M+Fbi6RXXTYSVW78nht053SZ7Js+p639pL41WX7PPwT8T+Pb2A3Z0u3H2a1/573DsI4Y+Oxdlyewya/Pu50rwrb+D/EdrNbRQ/tF2/xOht9HjKEanDCl5EsAi/iFoLRWA/gwPpX21+238G9Y+O37M/ivwtoJU+INkN9Yxt0lmgkWUR/V9pUe7CgDzTwb+yj8Qvi14asfFnxV+MPjTSvFmqRLdNo/ha+FhY6WHG5YEQA7ioIBYnkjv1pnjzU/EXw7/bE/Zh8BW/izWtR0afSdXh1L7bdFjqbRWjFZbgDAd9w3ZI4Nb/wj/wCCgnwr8R+CrNvGviG1+H/jCygWHV9A1xXtZbe5UYkVA4+dcg4xk4IzzXGfFbxNpvjf9vD9k/xDolyL/R9S0nWrq2uo1YLJG9m5U8jjIPQ80AemfsveINW8NfEf4sfCPXNTutXbwvqMWpaPeXkhklbTb1WkjjLMSW8pw6ZJ6Yr6Pr5k+EU3/CTftvfG7WbMB9O0jSdI0KSdR8r3IWSZ1B7lA6g+mQK+m6ACiiigAooooAKKKKACiiigAooooAKKKKAPkb9sS+v/AIj/ABp+DPwOh1O70rQfFdxealr8tjO0Ms9paxbxbh1IIWQ7g2PQVh+BfC9p+yz+29ofw+8Hz3dr8P8Ax14envP7BuLl54rO+t2J8yEuSVDIORnksfbHX/tdeC/E2hfEr4T/ABp8J+H7rxVc+CLq6t9W0bT033Vxp91GI5HiTq7x8sFHXPtXOeCV8SfHb9qUfGaXwTrvhrwd4M8OXGm6Pa69aG1vtVvJcs7pC3KoF+QE9Tj8AD6E+LvwD8FfHS302Dxlp93fxaezvbi11K5s9pYAMSYZE3dB1zXx1+z/APDnR9N+O3xg+I/wxsNRHgrwLplxoWj2U2p3V2mq6ukZa4kAlkYlVOIx2OQR3r2bxt8fPiP4u/ZDvvFXhv4beItA+I2ts+k6d4fa2ea5s5XkMQuX+QbEVMybnAAwPUZ9Y/Z0+Ddl8Bvg54a8G2aqZrK2D31xnLXN2/zTysT1LOWP0wO1AHwZ4W+GvgP4g/sV6v8AG/XPHl2vxea2u9XbxW2svFcWOoRs5js1j37VTKqnl7ckHjtX3d+zX8Rr/wCKH7PfgPxjrIUanqmiwXV4yrtDS7BvYDsCQT+NfGfxs+BugfHjxjr/AIZ+F/7P1x4e17UL57XWviF4j042lhaxFyJprWNmImlYbtrKoxuDA55r748D+BdN+H/gHRfCGko0elaTp8enW4fk+WiBASe5IGT9aAPhSx+KeqeEv2O/jr+0JbybPGvifVri3tNR25ktbVbpbK0jQ9ljDFh/tEk1X+NHwLsv2QvhP8PPi74T1TVrfxxpeq6cPEmpT6hNN/bcVwyrcLOjsVOWbjAGBWv8O/hDffFD9iX4u/ASJo4PGHh3Wr+zSznYISwuheWr+0cny7W6Hn0o8f8AiDx7+1t4D+Hnwib4ZeKPDOowalYz+MdT1ywNvp9rDakGQRSk4lMjLlQvUCgD6w/aQ+M0HwF+Bfivx9LCLiTS7LfbW7dJLhyEiU+29lz7Zr4h+AfxE+Gkfi/wb4y+MF7471zx1rd4kll4x1y2urPw7BdScpBaDcqCMfdDMuDjPANe7ftEWfin9qTwp8Z/gxZ+B9S0E6NbWdxoviPUcrZaxOpWXy0O0DGV2ZBYc846V5n8ZvGHjL9q34H6N8E9P+D/AIp8NeKtQmsbfWNQ1vTDDpmipA6NLNHOeJPuYQLyQx+hAI/2rrzwc/7XdxefFnQ/F+ofDvTfCkEUE+hR3wtY7pp2d5JHtmXoh5yT24r63/Zx0X4c6T8K9On+FVz9s8Hag7XlvP8Abp7vczYDZeZmcEbcFSRgg8CuK+IX7T5+F2ral4Rf4VfEHxPd2NvHDZ3Wl6I1xZaoTEMBZgSANxKtu6YPWvG/hLeeKP2F/wBldNR1rwvDc+LPF/jHzLLwhb3OyOxe9lVY7ZXAb7ioWwB1JFAH0n+1R8UL34L/ALPPjvxlpiqdU0vTXazLDKrOxEcbEdwGYHHtXxp8UP2eU+Av7Kuh/HTQdb1g/GHRY7DXtT1y61CV/wC1TNJH59vMhbb5WJDhQMgLjuTX2v8AtEfCuX44fAfxj4JWRbW91nTXhgkY/LHcABoyfbeq59q+O/GXin4n/H79nrQf2fv+FYeJvD3jK5Nlo/iPW9Qsiml2dpbuhkuorg/LL5gjXCj+8fQUAfW3xt+I2raJ+zH4t8ceGYi2sReGptTsVT5yjmDerAd9uc++K+D/ABx4F8EfDf8AYr8MfHfwx4wu/wDhb0cGn6q/iNtblkuNRu5Hj+0W0kbOQyjc4Me3gJ9c/c2j/Ei/tPitrHwwl+Hurjwno3h+O5i8Typ5lne4VVNso24ZsEjGSTtbgDFfGOvfs0+GP2kvE9poXw4+AN78MPDE9/HceIPGXiSwaylMCOHMFjbOx5fABcAAcjFAGx+0J+0hP8WvjRpnw1nvPGFl4S0vRLXVtZ0vwHZyy6rrFxPGriDen+qgRXUsSQSTj0I9T8F6H8Ivjh+yD468J/DCzvNNtbEXBk03VDN/aGmapGvmRvJ5rM6yB0Ugg44OO9V9S0/WP2U/2qvGfjv/AIQfXfFngPxrpVnAL3wzYm9uNNubZRGI5Yl+by2UZDDjOBWN8N5Nb+Hvh39pj9oPxZoU/gaz8XRpJpPh7UF8q4EdvbvFDLLHn5ZZ3dfl65J65oA+k/2WviJefFj9nvwD4r1B/N1HUNLia7k/vzKNkjfiyk/jXqteOfsf+Brz4b/sy/Drw/qMDWuoW+lRSXMDjDRySZkZSPUFyK9joAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvjf/AIJ7/wDI4ftNf9lO1P8A9Dr7Ir43/wCCe/8AyOH7TX/ZTtT/APQ6AOq+Bf8Aye5+0v8A9e3hr/0lnr6er5h+Bf8Aye5+0v8A9e3hr/0lnr6eoAKKKKACiiigArnf+Ff+Hv8AhPP+E1/smD/hK/7O/sn+1OfN+yeZ5nk9cbd/zdOtdFRQByMPwn8J2/xKuPiBHoduvjK4sRpsurjPmtbhgRH1xjIHOM8Vx+n/ALJXwg0r4iP45tfAGkx+J2nN0LzyyVSY9ZViJ8tX77guc89a9eooAKhvP+PSf/cb+VTVDef8ek/+438qAPlv/gl//wAmR/D7/rpqX/pwua+qq+Vf+CX/APyZH8Pv+umpf+nC5r6qoAKTbS0UAFM2+36U+igBm30Fc3rnw38N+JdBvdE1HSYbnTL2cXM8DA7XlDBg/wBdwB/CunooA8D8d/sd+D/E1nZjRg/hy+tJ1uIb22AaSN1O5GQnowYDn68Vj6X+zr8TZL4pqXxj8RQ2uzIltZ43bdngYaIdq+lKKAPlTVfDPxL+DPxG0DU4/FHjL4heHlWX7TYG2WdZiYyqhvKTMe1mDAn7xH1rsLj9pnXdPKib4OePL7f0Om6buC+zeYU5+me9e9UtMD571j9qq/8AD+jz6zq3w28TaPpNunnTzX9lJGYF/wBshSoPrhiM11ukftRfC7W4LVrLxlpl1POiubW3nEsseRnDKucY6H3r0zUdNtdWs5bO+tYby0mG2SC4QSI49Cp4IrnU+EvgiNgyeDtBRhyCumwg/wDoNAFrw38RPDfjC8ubLRtZtNQvLZFlmt4ZAZI1bIVivUA4PPtXRZrxDxF+zTCvjifxh4S1d/DmtNaG1RYoxsUFixC9lBOONp6Vzlx8K/j9ok2jalpfxXj12eO6BvtH1ixt47ZoecgSxxB2PTj5ep5oA+ks0V8//Fj4ofE74R6Pa+INQ0vTtW0W3uFk1GPSrSWWVLZcmUglwFwoJDHjjnrU2g/tn/DjxFqFjZ2Wo+bLdBGGJEOzcATuG7+HPP0oA97orFj8aaBNCJV1qw8s8BzcoB+ZNL/wmnh//oO6b/4GR/40gNmio7e4ivIUmglSaFxlZI2DKw9QR1p9AC0UmaKAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+PfiF/yk8+F/8A2JN9/wCjHr7Cr49+IX/KTz4X/wDYk33/AKMevsKgCpZ6Zaae07WtrDbPcOZZjDGE8xz1ZsDk+5pBpNit7LeiztxeSp5clx5S+Y6f3S2Mke1PuNSs7WMyT3UEMYbYXkkCjd6ZJ61Orq6hlYMrDIIOQaAKtrpVlYWIsrazgt7IAqLaGJVjAPUbQMYOT+dPsdPtdLtUtrO2itLaPhIYECIvOeABxUzTIsgjLqHbopPJ/Chpo0ZVZ1Vm+6pIyfpQB53ovwP0Tw/8UvFvjWzmuVfxVawQato8m17K4liBVZ9hHEhQ7SehAGRXeLptotj9iW1hWy2eX9mEYEe3GNu3pjHalh1SzuLl7eK7gluE+9Ekil1+oByK8X8P/GzW9U/a78WfC6a3sk8P6V4bttYhuFRvtBlkk2sGO7G3HtQB6xfeDNA1TS4tMvNC02702E5js57SN4UPqEIwPwFVNe+G/hbxRot1pGq+HtNvdMuokt5rZ7ZQkkSsGVCAOVDAHb0roRPG0XmCRTHjO/cMfnSSXUMUBmeWNIQNxkZgFA9c+lACxxrDGscaBEUBVVRgAAYAqt/ZNiNSOoiyt/7Q2eUbvyl83Z/d34zj26VPa3cF7Cs1vNHPE3SSJgyn8RXlf7RPxlvfhB4Z0NND0yLXfFviPV7fRdG0yaQokk0pyzuQMhI0DOx9h60Aej634b0rxNZi11jS7PVrUHcIL63SZAex2sCKyvEXgOw1jw5qmmWP/FPT31k1gNS0uJI7m3jYYHltt4xnjsDXkX7TH7YGlfsx2dqNT8K6/wCKL1rZLq6bR7XFtaRM/lh5Jmwq5fIC5Jr3rS75dU0yzvEUotxCkwU9RuAOP1oAwfhn8OtG+E3gPRfCHh6BrfR9Jt1t4FY5dgOS7nHLMxLE9yTWN8Rvg1o/xF8UeDvEk1xdaX4g8K3pu7DULJlDlWXbLA+4ENG64BHXgEEGu+muIrWFpZpUiiXlnkYKo+pNef8Axi+Imu+BvAo13wf4Uk+IF+buGAabY3SRkxu4VpN5yMKDmgDsLfw3pFvq1xqkOlWUOpzkedex26CaTAwNz4yeOOTRrfhvSfEtr9l1fS7LVbbOfJvrdJkz/usCKsSahDaWqT3kkdkpAz50gUKT2z0zXjPgX43a14o/ao+I3w3nt7IaB4e0nT7+zuIVbzpGnXLb2zgj0wBQB7JpOj2OhWUdnptjb6daR8Jb2sKxRr9FUACnRaXaW99Pex2kMd7OqpLcpGBJIq52hmHJAycZ6ZqQajaNeG0F1CbrGfI8wb8eu3OaW6vrexi8y5nit4843yuFGfqaAKjeH9LbVl1VtNs21RV8sXxgTzgvoHxux7ZrR4r5lX9oXx3rPxu+Ongbw/pOlahJ4L0aw1HRIZA6NeyzQiVo5HDEYPRSAMZ5zXsPwT+Ken/Gz4V+HPGumRNb2+rWwle2c5a3lBKyxN7o6sv4UAber+A/DXiC8S81Tw5pOpXifduLuxilkX6Myk1ek0Kwaa2mWxtlubVGS2m8hd8AIwQhx8ox2FaNFAHAfB34N6P8FvD19pmkz3d/cajqE+qajqWoOHuLy5lbc8jkAD0AAAwFFd/RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA3FHNOooAbzTqKKAG/XNLmlrxz9qb47v8As/8AwyGsafpq634m1W/g0XQtLZtour6clY1J/ujBY47LigDvbH4d+HdM8can4xtNLjtvEup20dne38bMGuIoyTGrrnaSuTg4zjjNdJ1r5N8M/G74w/CX41eCfBXxpj8NappfjhZIdK1jw1FJD9ivY13m3mVydwYEAMO/449T/aj+PJ/Z7+F769aab/bmv395DpOjaZv2Lc3kzbYwx7KOSe+BQB697UtfJnhv43fGH4TfGvwN4M+NC+GNT0vx0ksOm6r4bilhFjexqH+zyiQncGBwCO9XPjn+0T8Ufhz8efh94cs/CWmWHgHXvEVtob61fXHm3V80ib3MMSkeWqjI3NnJ6DigD6nrC8ReCNC8W6hod7rGmw6hc6LdfbtPabJFvPsZPMC5wWCs2CQcZyOa8m/ak+PGufCePwd4Y8F6da6p8QPG2pHTNHiv2ItoAoDS3EoXkpGpBIHXNch8Nfj/APEDwP8AGy++FnxqGh3F9Nor+INI8ReHonitp4IsieKSNzkOuCQRwQKAPqem18IzftVfHnxD8LdX+PPh3RPDKfCjT55J4PDd4sp1W806KTZLcGUHYjEBmAxwF79/tPwR4tsfH3gzQvEumNv07WLGC/tmPeOVFdf0IoA2/wA6ME+1OooAbXO+Nvh74f8AiNp9nY+JdMj1aytLyK/it5mYJ58R3RuyggNg84bIyBxxXSUUANA29qdRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfG//BPf/kcP2mv+ynan/wCh19kV8b/8E9/+Rw/aa/7Kdqf/AKHQB1XwL/5Pc/aY/wCvbw1/6Sz19PV8u/AbP/Db/wC056eR4Z/9I5q+oqACiiigAooooAKKKKACiiigAqG8/wCPSf8A3G/lU1Q3n/HpP/uN/KgD5b/4Jf8A/Jkfw+/66al/6cLmvqqvlX/gl/8A8mR/D7/rpqX/AKcLmvqqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAr3VnDf2s1tcwx3FvMhjkhmUMjqRghlPBBHGDXGat8DPh7rdn9muvBWhiLcHBt7GOBww5BDIAw/Ou7ooA8y1b9mv4Z69ZLZ6j4Qs722VtwimeRgD6/erzjxJ+wr8O767muNI0PTLFHXaLKa2LxLkYJDBtwPfvzX0pRQB8s3f7Ft14a8N2uneD/AIjeMbNLchI7WTVjHBHHg5ChU45xj8a2bHwV+0N4Z8PW9hpHi7wvcwWMJSP+2bKa4u58cjdIrgEnpk4r6NooA+f2/aM1L4ax6NZ/EzQ7ixuLpNh1Cwt3kR3HBJjUHYMkfxGvcNG1qy8QafFfafcx3drIMrJGcjp09j7U3xB4f0/xTo13pOq2kd9p12hjnt5c7XU9QcV5N4s/ZpttStLhPDXizxB4OfG+2h0q7McCSBNq7lIO5eBkdaYHtdJmvlLwx8CP2gvD1lDbTfFHStTKMS9xdLOZHGc4JxgcHFdBDb/tHahrV7aWOteFNNsLXCxXGraTNI02OMhkkG7pnOBwaAPo2jNfK2qeIv2hdH1g6dc+KfBiyh1RZV8NXrRMTj+IP79aLX9pD4l/D7xJqvhrxj4Mg8aajBKvkX3hORbeF1KKduydtxIJIJ6UWA+qaK+cNK/bu+HV1psEt/aeIdN1AjbPp/8AZE87wsCQVLIpVsHuDirP/DdfwsRl82TxBboSFMs2h3KIuTjLMVwB7mkB9D0VnaJ4i0vxJatcaTqNrqUCttaS0mWRQcZwSD1wa0M0ALRSZooAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+PfiF/wApPPhf/wBiTff+jHr7Cr49+IX/ACk8+F//AGJN9/6MevsKgD89v2df2c/B/wAfvin+0Q3xCF14q0bTvHN7bWPh+6vphbWjuQzzhFcfO3CgngBDitz9k3xp8RfBPgr4seDPBmkv8UV8E+NptG0hdU1hbcrY4J2GeTO4xkAbf9rjpWJ8Cf2bdQ+InxK/aB13TvGniv4ba1J47vrR7zR2CJfWmFZQUkUqcMzFXXkZNfYvwN+Bvhj9n3wPH4Y8Lw3H2YzPdXV5eyma5vLhzl5pXP3mP9KAPln9p3WfiRpngjwV8cvEPhM+BfEvw/8AEsRutMsNWF/Fd6POUjuC5TC9WHUfKAT3rV0vx1pfxI/am+JHxS1fV5E+GPwq8Pf2fbSwSMbeS6liM91P8p+Z0jOzAyRle9fXHjTwjp3j7whrXhrV4fP0vV7OWyuY/WORSrY98Hr9K8x+Fv7Jvgf4W/AfUfhNbQXGqeGtUS5XUZLxh5935+Q7Oy4+bbgA9go9KAPgfx5b2/hVvhP8Wfhn8I774ZaLfeKtPjh8VahrbNqOs207HKTWxkZmjlXDhnJOOwzX0dqTNH+3R8bWQlXHwxiKspwQcseK3Y/+CeWj3mi+HtG134k+MvEGjeGbu3uvD9heXEYi07yWBRQAvz4UBAW6LnHWvbbH4E6JZ/G7Xvicbi6m1fWdGi0S4s5CDb+SjbgQMZye9AHyf8L9auf+HROq6hLfzfa/+EW1XF3JMxk3ebMB8+c5zgDmuI8SeIPEHj62/ZU+GD6DqPjDw3eeAbXX9S0CHVo7D+25FtkVYpJZHUOqY8xk3ZbdyK92X/gnB4Tj0nXPC8XjjxfB8N9SkmnTwXFegWVtLJkhlONxVWO8ITjIBOec9/40/Y68J+Mfh34A8OpqmsaJq/gO0htfD/ifTLgRX9p5cSxZLYwwZUG5SMGgDzv9lf4T+PPhh8cvEsln8P5/ht8ItU0uN4/D8+twX8dvqSOAZIUjkfy1dCcgYGR9K2vjdI0/7c37O1tcNi0jsdeuIEJwrT+RGpOO5Cn9TXqfwb+DOsfDG41K61r4j+JvH11eKka/248YigVST8iIowxJ5P0rnv2ofhV4h8YW/grxj4It4bjx34J1mPUrCGaQRC6tn/d3dqXPCiSM9T3QUAcr/wAFJf8Akzbx5/26f+lUVemeLvEvjrwv8N/DVx4C8GW/jbU3hgSayudUSwWOPyh8+9wQTnAx71ofGz4P6Z+0B8K9T8Fa9NdadYaqsRne0YCWMo6yAAnI6riu402xTTNOtbOMlo7eJYVZupCgAfyoA+N/2m/BPxi+OHwr8Halqnw9jK6LrjXniD4c2euq41mxVfkAnTaGIOT5fckeleWfF3xt8PdS/YO11fhRompeA7fTfF1jaan4fuzLDdabefaYvMiYF22jG3hTt6+9fbPxk+EOqfFD+x5tH+IHiPwDfaa0hE2hSR7LhXCgiWN1IbG35TxjLetedv8AsM+C5vgxqvw+l1TWLj+2tYj1/V9euJw99f3qyLJ5jsRjBKgYAwAPxoA8s1jwPpX7Uf7cnjTwb8RDPrHgzwNoNjNpvhd7h47W4nnAZ7mVFILld2Bk4HH4+feE9Li/Zl+OH7Wx8G3l1Onh/wAGWt/pkN3cNcvZN5DSJCGcklEJ+VTnC4FfVfxi/ZL0n4nePNN8d6J4n1z4feObO1+wSa54flVXu7bqIpkYFXAPIz0/AYi+E37Gfg/4S+KfFmuw6jrHiK68WacthrY1y4Fx9u5YvI5wDubcRgYAGABxQB8YeHfgP448bfAXwr4p8E/CXWF+LV5Baazb/EybxdbefdSsyyOZFM+7ymQlfLK8DAIzmvYbHwNaftXftjeO/D3xXSTVNB8CaPpwsfCX2p0tGuZ4w8txIqEeYwbIB6civTfDf7ELeBZ4dP8ACnxd8eeHfBcM/mw+GbW8jeGFS24xRyuhdUz27A4rpPi7+yTpXxH+INn4+0HxVr3w88cRWv2GfWfD8qhry3HRJkYFXxxgnpj2GADxH9j34d6Z8K/23v2h/DOjXV3daVZ2GkG3W9uGuJIEeIuIQ7EsVTdtUE8KAO1ekfsDMyeC/ibaRZGnWnxA1mGyXGFWLzFYhfbez9Ku+E/2XYP2b7f4heMvh0dW8VePPEGmJCY9bvg5u7xN22aSRsYLM+5ugAGABXon7Nvwhb4H/Bnw94VuJxeatCj3Wp3ecm4vJnMs757/ADucewFAHqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyJ/wUMX+wLH4L+N7vd/YHhXx9pt7q0n8MFuxK+c3spx/wB9V9d1keJ/Cuk+NNAvtD13TrfVtIvomhubK6QPHKh6gg//AKxigD5O/au1jT/iB+0Z+zP4c0DUIdU1SPX5dcljspRL5NnFECZX2n5VOcAnr2qn+3p420HXfA/w/wDFWkarZazovgz4iadJrs1nMsq2QRyriXbnaVLLnPTNfQfwl/Zl+GXwL1C9vvA/hGy0O+vIxDNdxl5JTGDkRhnYkJkD5RgcCtDQPgH8P/DGgeKNE07wrYw6T4oupbzWbN0Mkd5LIMOzhieuO3TtQB88/tbeINO+IXx4/Zp8I6Bc22q6r/wlA8RyNbSCTybO3j3M7Fc4Vt3BPUitf9uAj/hYf7Nef+ihWv8A6LavXPhN+y/8LvgdqV3qPgnwdY6HqNzH5Ml3Hukl8vOdis5JVfYYHA9K6/xX8PPDvjm90K717SINSudDvV1HTpJs5trhRgSLgjkAnrQB8x/ta3MPgr9rT9mLxzq8v2fw5a6hqukXNzMQsUE91bBICxPAy2eT/drlv2g7YfFj9tjQ9E8NXC6heaL8PtZN89owdYGuY2ihRiMgMWIIBr7E+IPw38M/FbwvdeHPF2iWuvaLc4MlpdpuXI5DA9VYeoINYfwj+AngH4E2N7aeBfDNp4fS9dXupIdzyzlQdu93JY4ycAnAyaAPj34b/Fzwzo3/AASl1VLq9tYL3T/DWo6BcadI4Eq3zebCsTR8NlmdTjHQ19XfsreGr3wd+zX8MNF1KMw39n4eso7iJhgxv5KkqR7E4/CqGqfse/BvWviE/je9+H+k3PiR7gXcly6NsknBz5rRZ2M2e5XmvYgNvAGBQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr43/AOCe/wDyOH7TX/ZTtT/9Dr7Ir43/AOCe/wDyOH7TX/ZTtT/9DoA6b4Df8nwftO/9cPDP/pHNX1FXy78Bv+T4P2nf+uHhn/0jmr6ioAKKKKACiiigAoopKAFoopKAFqG8/wCPSf8A3G/lU1Q3n/HpP/uN/KgD5b/4Jf8A/Jkfw+/66al/6cLmvqqvlX/gl/8A8mR/D7/rpqX/AKcLmvqqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACk20tFADeazNW8L6Rr0bx6hplrdq4wxliBJ/HGa1aKAMqLw/b2GgtpWmbtNhWJoong+9Fnuue496wtP8D3txp+paV4n1VfFOj3kXkm3vLZVLKfvB8cEGuyooA+WPEH7KvhGPxndLYeFPEuhadeTIok8L641pa/dC+Y0KEBcY5PtV6z/Z8+K3h3RDpHh/4+3zS2UGy1tr7S4JSo/gEjklyO245NfTFcj4o+HNp4i1BNUt7u50bWkAVdQsmwxA6BlPDAehpgY3iLxtrfwn+HWh3Or6NqvjrW/3Vpe/8I7aBneXyyXm2EjCZX/x4VyHg/8AbI+H3iHUb7S9bupvA+t2twts2leIlEFwzMAQQoJ45Few2el3tvoJsZdUmuL3ymT+0GjUPuOcNtHHHH5V5zrf7OukeNNN1ax8WXra7HqKKr3As4be5RlIIdZkXcDwB16UgPWldWXKkEeoNLXgPgH9nDxP8MfDtxo+hfEbUWgeeSdWvF8x8twAWbceFCjj0ziszxD8D/jNZ2fn6P8AGvWNQu2f5rSawtY40U5zh9uTg469RTA+kaK+YF179oL4U+H2S+s/D3i6zhfe+sa1qBgnG4gbSkSbdo9fTNR6b+1F8RfDviOax8Y/DJtT097VJ7XUPBEj6hE7En5WY4AwAffpSA+pKK8L8H/theAvEWq6lpetSXfgfVbLyS1l4ljFrJIJN2CgJ5+7z9RXuC3ETqGWVGU9CGBFAElFIGDDIORRkUALRSZooAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPj34g/8pPPhf8A9iTff+jHr7Cr4i+OXjjw98Pf+CkPwy1fxNrVloOlp4MvY2vL+YRRhmlk2ruPc19A/wDDXXwV/wCio+F//BnH/jQB61zj1p1eR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlFeR/8ADXXwV/6Kj4X/APBnH/jR/wANdfBX/oqPhf8A8Gcf+NAHrlfG/wDwT3/5HD9pr/sp2p/+h17Z/wANc/Bb/oqPhf8A8Gcf+NeE/wDBOHV7LXtc/aO1LTbuG/068+JGo3FtdW7bo5o3O5XU9wQQQfegDsPgN/yfB+07/wBcPDP/AKRzV9RV8u/Ab/k+D9p3/rh4Z/8ASOavqKgAoorJ8UeLNG8E6LPq+v6na6PpcJUS3l5KI4kycDLHgZJAoA1qK8s/4am+D/I/4WV4Z46/8TKL/Gu58K+NNA8daaNQ8O61Ya5ZHj7Rp9ykyA+hKk4P1oA2CwVSScAcmvGNM/bG+DusfERfBFn44sJ9ee4azjADeRLcA4MKTY2NID/CDU/7X/inUPBf7L/xP1nSnaHULfQrnyZU+9GzIU3j3Xdn8K+ZPi98J/DWg/8ABKnTobPT7eOfTfDmnazb3sSgSi9YxStOsg5DMztyDnDYoA++2dVUsxCheST0FeH237a3wXvPGsfheLxzZNqElz9ijuNji0kuc7fJW42+WXzxjdXQSXsXiz9mk3XiLVjoUWpeFN9/qjNg2oktf3k2fVclvwr809R8b65qf7HPhT4b+IfA58O/CldVt7Rfi5b2bG3a0iud0d2tuP3sbSlQu88fMTQB+vuRxUV5/wAek/8AuN/KqUGqadZ6HbXjX9uNO8lCl3JKqxspA2tuJxzx+dUbrxx4ba1mA8Q6Vkow/wCP6L0/3qAPnb/gl/8A8mR/D7/rpqX/AKcLmvqqvlX/AIJf/wDJkXw9/wCumpf+nC5r6qoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCKWFJ42jkRZI2G1kcZBB6gg1zFj8MfD2l6vHqNjaSWU0b+YEt5nSIt6lAcGusooA4rxx8H/CfxEuI7rWtHgnvUXaLpUVZccYBbGTjHGeleMeKf2QLK+1Jp7eOfUfMB3Szazc25Xk7QFRscDHPevpyigD5l0n9m/wCKPg3wxBp/h/4zamIbVSLfT57GFlTJyV81ssQMnk1DP8H/AI+toeqTx/Fq4i1SGItZWgs7do7iTBwrOR8gzgZ96+oKKAPCofGnxc8I/D+G717w5pd1qFjZr9ruFuywkkCgFiFHQnk4965Hwb+3Npt14atp/FXgvxRpmtfP9ot9O0ae4t1AY7SsmPmBXBr6bvLOLULWa2uI1lgmQxyI3RlIwRWdovhyHwzof9m6W0ixIG8r7TI0uzOcDn+EenpTA8x0v9sP4Nalptrd/wDCwtEtDcRLL9nu7kRzRZAOx1P3WHQjsQa7DwP8bfAXxKurm28LeLdK124t0Ek0dlcq5RScAn8ayfDHw7K6jLbeIfCPhW5tlQsupWtjGrSvkcNGV44J5zXHfEr4U/BnxR4ot7LX9PTR9StF8qNtP32COHw2C0QUP269KQHvC3kDMAs0bE9AHGal3CvmXxL+w/okN7o2qeAPEmr+C9a06489br7VJeLJxgKUkYjrzVfwfrH7UvhfQ007U/CPhTxVdRyP/wATS61wwSSqWJXKLHgYGBx6UAfUVFfL/iX49fHP4e/2bc+JfhDp93ptxdJDNJ4d1N72aJOrN5YQHgZx74FdDD+2p4Ct9b03S9dsfEfhKbUJfJhn17SXtbfOM5MjHaBQB9AUVzvhX4ieF/HH2j/hH9f07Wfs+PN+xXCybM5xnB4zg10IYN0INAC0UmaM0ALRSZpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOB+IPwH+HvxX1C2vvGPg7SfEd5bxeTDNqFuJGRMk7QT2ySfxrlv+GM/gb/0Szwz/wCAC17PRQB4x/wxn8Df+iWeGf8AwAWj/hjP4G/9Es8M/wDgAtez0UAeMf8ADGfwN/6JZ4Z/8AFo/wCGM/gb/wBEs8M/+AC17PRQB4x/wxn8Df8Aolnhn/wAWj/hjP4G/wDRLPDP/gAtez0UAeMf8MZ/A3/olnhn/wAAFo/4Yz+Bv/RLPDP/AIALXs9FAHjH/DGfwN/6JZ4Z/wDABaP+GM/gb/0Szwz/AOAC17PRQB4x/wAMZ/A3/olnhn/wAWj/AIYz+Bv/AESzwz/4ALXs9FAHjH/DGfwN/wCiWeGf/ABaP+GM/gb/ANEs8M/+AC17PRQB4x/wxn8Df+iWeGf/AAAWj/hjP4G/9Es8M/8AgAtez0UAeMf8MZ/A3/olnhn/AMAFo/4Yz+Bv/RLPDP8A4ALXs9FAHjH/AAxn8Df+iWeGf/ABaP8AhjP4G/8ARLPDP/gAtez0UAeMf8MZ/A3/AKJZ4Z/8AFo/4Yz+Bv8A0Szwz/4ALXs9FAHjH/DGfwN/6JZ4Z/8AABaP+GM/gb/0Szwz/wCAC17PRQB4x/wxn8Df+iWeGf8AwAWj/hjP4G/9Es8M/wDgAtez0UAeMf8ADGfwN/6JZ4Z/8AFo/wCGM/gb/wBEs8M/+AC17PRQB4x/wxn8Df8Aolnhn/wAWj/hjP4G/wDRLPDP/gAtez0UAeMf8MZ/A3/olnhn/wAAFo/4Yz+Bv/RLPDP/AIALXs9FAHjH/DGfwN/6JZ4Z/wDABaP+GM/gb/0Szwz/AOAC17PRQB4x/wAMZ/A3/olnhn/wAWj/AIYz+Bv/AESzwz/4ALXs9FAHjH/DGfwN/wCiWeGf/ABaP+GM/gb/ANEs8M/+AC17PRQB4x/wxn8Df+iWeGf/AAAWj/hjP4G/9Es8M/8AgAtez0UAeMf8MZ/A3/olnhn/AMAFo/4Yz+Bv/RLPDP8A4ALXs9FAHjH/AAxn8Df+iWeGf/ABaP8AhjP4G/8ARLPDP/gAtez0UAeMf8MZ/A3/AKJZ4Z/8AFo/4Yz+Bv8A0Szwz/4ALXs9FAHjH/DGfwN/6JZ4Z/8AABaP+GM/gb/0Szwz/wCAC17PRQB4x/wxn8Df+iWeGf8AwAWj/hjP4G/9Es8M/wDgAtez0UAeMf8ADGfwN/6JZ4Z/8AFo/wCGM/gb/wBEs8M/+AC17PRQB4x/wxn8Df8Aolnhn/wAWj/hjP4G/wDRLPDP/gAtez0UAeMf8MZ/A3/olnhn/wAAFo/4Yz+Bv/RLPDP/AIALXs9FAHjH/DGfwN/6JZ4Z/wDABaP+GM/gb/0Szwz/AOAC17PRQB4x/wAMZ/A3/olnhn/wAWj/AIYz+Bv/AESzwz/4ALXs9FAHjH/DGfwN/wCiWeGf/ABaP+GM/gb/ANEs8M/+AC17PRQB4x/wxn8Df+iWeGf/AAAWj/hjP4G/9Es8M/8AgAtez0UAeMf8MZ/A3/olnhn/AMAFo/4Yz+Bv/RLPDP8A4ALXs9FAHjH/AAxn8Df+iWeGf/ABaP8AhjP4G/8ARLPDP/gAtez0UAeMf8MZ/A3/AKJZ4Z/8AFo/4Yz+Bv8A0Szwz/4ALXs9FAHjH/DGfwN/6JZ4Z/8AABaP+GM/gb/0Szwz/wCAC17PRQB4x/wxn8Df+iWeGf8AwAWj/hjP4G/9Es8M/wDgAtez0UAeMf8ADGfwN/6JZ4Z/8AFo/wCGM/gb/wBEs8M/+AC17PRQB4x/wxl8Df8Aolnhn/wAWu7+H/wq8I/CnTrmw8IeHbDw5ZXEvnSwafEI0d8AbiB3wAK6yigD5d+A3/J8H7Tv/XDwz/6RzV9RV8u/Ab/k+D9p3/rh4Z/9I5q+oqACvnL/AIKBWmoXn7Kvi+GzsZtRt2a2/tGG1iEswsROhuGRSD8wj3HPbGa+ja8w/aM+NFl8AfhHrXjK+0ybWha+Xbw6bBjddTSuI448noCzDPtmgD4j+ONv+xbL+zZqreEIPCkuvPpzL4fj0mPdqj3xUeSu0DeWL43Buo3V33wR+Hth8Iv2pPhZb+HdHHhXUvFHgKa98XaFp6NHaC4TydkxjztVy7Opx6e9UPDfw7+O9rrUHi3Tf2afgzo2ty4uFmku2S6hY8jO0YDDPbvX2/4Xhv7rRtLv/EGn2Nn4lazRb1bM+YkUhAMkaSEZKbunrigA8c+D7D4geC9d8Maqhk0zWLGbT7lV6+XKhRse+DXxl/wyj8c/E3wv0b4FeJfEvhs/CfTpoYZ9es/N/te+06GQPHa7CNiEBVXeD0WvuqkoA8C8e/B/x/8AELXvFfgy71fS7H4Lar4UbR7W0tof9Pt7tgEEm49VC54zg8V4zffs5/tE+KPgbbfAnWNS8EW/guO3i0ufxVbCZr2exiZSqi3I2rIVUDdntmvuSigDhNW+CvhDxJ8LbL4ea5pKaz4UtbW3tBY3bsQ6QhRHuIIJI2A9a8uuv+CfP7PKW8rD4XaSGCMR883p/v19GVDef8ek/wDuN/KgD5b/AOCX3H7EPw9HYPqQH/gwua+qq+Vf+CX/APyZH8Pv+umpf+nC5r6qoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKrXNhbXoH2i2in2nK+YgbH51ZooAwvFXhf/hJ7KKAaheaa8MnmxzWUmxg2CBn1HPSs7w74b8S6TqSNfeJjqunIpHky2yrI3oSwrrqKAOW8TaL4l1G/STR9fj0q2CBWhe1EuWyctnP0/Kuc8QeDfEevXEFtrVn4c8V6NvUGHUbT54xwGdcgjPXj8K9MooA+WfiZ+yP8LNFutS1ez0XXtKvtX3l5/Ds8qRW77cKxijI+UE52+xrF8P8Aw7+PXgf4WwHwJ8TNG8Q2NhGRZ2mraWYZJF3/ADCSaQkgjLHJ9MV9f1XurGC9tJbWeFJbaVSkkTD5WU9QR70AeCWfxW+OUNrCLn4RadqEhVSbiw8QRNG3HJyR61laL+2cdNuNU0/xt8OPF2havZ3Jg8rS9Km1CF1AHzCVFAPOR+Ga9P1r4J6abO4fw/Pd6Hf4DQeRdOIEYHIymcYqTT/iNreltb2viPwzewyecLeS/tAHtyzNtVhznB4pgcFZ/tu/Dl9ZsNP1WDxF4WF87JFe+IdGlsrbcFzgyPwK7L/hqD4S/wDRQdB/8DFrsvFWh+HPEUNtbeIrLTb+INuhi1FEcbu5UN3rJHwY+H7AEeDdCIPT/iXxf/E0gIPDHx4+HvjTW7fR9C8YaTq2qXAYxWlrcB5H2qWbAHoAT+Fd3Xk/jf8AZh+HvjixtbZtGGgS2s/nxXnh9vsNyrbGUjzIwDtIY5HfiuG0z9krxPotjFY6f8efH1rZw5EUKywMEHPGWQk9e9AH0jRkV86zfsv+NvJk8n9oDx6ZQp2bnt8bscZ/d+tZPgvQv2ofCPhu00m41Dwh4jlty+dS1WeZribLlhvKgDjOB7AUAfUGRRkV8jfEX4gftUeCGsGs/CPh/wATi637k0SGST7Ptx98uy/eycY9DXaWf7SXjlbOEXXwI8atchF80x/ZwpbHzYy/TNAH0LmjNfOusftYeIPDemXOp6v8E/G2n6ZaoZLi6ZYGESjqxAbJH0rUsf22Pg/dWNvPL4p+yySxq7QS2VxvjJGSrYTGR0oA93orwmf9t74J2rqs3jm1gZuQsttMp+vKV6lb/Ejwpd28U8XibSGjkQOp+3RcgjIP3qAOkorEtvHHhy8uI4LfX9LnnkYIkcd5GzMx6AANya26ACikzRmgBaKKTcKAFoopKAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+XfgN/yfB+07/wBcPDP/AKRzV9RV8u/Ab/k+D9p3/rh4Z/8ASOavqKgArxn9qXwT/wALi+Cvirwdpd/osWrTLDtk1S4Kx2cgkV0kYodysMZX3Ar2avnP47fAHwxp/g/4leIdI+Hd14917xYbR9W0SDU3tn1AQsAuxi2Iyoy2BjJFAHkun2f7XOm6fb2v/C5vhfdeTGsYmuLRWkfAwCxGMk+tfZXgtdV/4RLRv7du7W/1r7JF9turFdsEs20b2jHZSc49q/O3wH4K/Y58QalDoXjHwTq/wq8VyEIdH8ZXV3ZgtnH7uYv5br/tZAr9FfCOjaX4d8L6TpeiBV0eztY4LMRyeYvkqoCYbJ3DGOc80AbNFFFABRRRQAVDef8AHpP/ALjfyqaobz/j0n/3G/lQB8t/8Ev/APkyP4ff9dNS/wDThc19VV8q/wDBL/8A5Mj+H3/XTUv/AE4XNfVVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUwoGGCMjOafRQBi+IvB+keLIo49WsY71Y8mPfnKZ6kEdKWy8MwaT4dbSNMklsYQjpFIGLvEWJOQWz0J4rZooA5bwv4d17RbyX+0PET6zYmPCRzQKsgbI5LjqMZ4qnr/iXxXo+pzi18LLrGmqR5cltdqkrcc5Dcdc12tJigDjv+FnaTZ+H9O1TVEudKN4GAtp4GMiupwykAevQ962/DfibTvFmmi+0u4+0W+9kJwQQw4IIPQ1pSQpNjzI1fHTcAcVk6v4ZS+0m4srC5l0N5nEhuLAKrhs5z0745oA2aWsLwrpWs6Razxavq41lt/7mTyRGwXHRsdTnvWbo3j6W+1pdK1DQNT0q5kZhHJJHvgYAE58wcD6GgDrJIlmRkdQ6MMFWGQfwqt/Ymnf8+Fr/AN+V/wAKn+1w/aPI86Pz9u/ytw3bfXHXFS5oA888c/s9/Dr4k6jBf+JfCGm6tdwxeRHLNFgqmSccY7k1zn/DHPwZ/wCifaT/AN8t/jXs2RRQB8+eLf2JPh7qUFhN4Usl8B63Y3cd3BrGkRgzIyZIA3Ejrg/hTv8Ahm3x3/0Xrxh/36g/+Jr6BpaAPmLwj4Z/aX8Aw6lpyar4X8aWjXsk1rqXiC5nF0ISAEQiMBRwM/VjTtS+JX7SPhPxPpy6j8MdD8VaKyO9z/wjN8Y5QdpCrunYAHdtJ46V9N0UAfPn/DQXxU/6N48Qf+Duy/xrNi/bW0/w74tOhfEPwPr/AMPJPsgu0uL5VukbLbQuYA2M/Mc5/hr6VqvNY29y2ZreKU9MyIG/nQB4fJ+3B8G4ULyeK2jQdWewuAB+JSvXbHxpoWpWVvdwaxYvBcRrLG32hBlWAIOM+hqDxR8P/D3jLQb3RdX0e1u9NvE8ueExgb164yOe1eSat+w78ItR0m7srfw0dMkmiaKO7tbmQSQEjAdMsRkdRkdqAPe45ElRXRg6MMqynII9aXNfPdj+ydqul2NvZ2nxr+I0FrbxrFDEmox7URRgKPk6AAD8Kzrj4E/GHwX4qs9S8G/Fe+1+yEDx3Fn40ma5jLk8MqxhRwPWgD6VzS18r+HfjX8e/CfiDXtO8X/CmfxXawSrHY6h4cZII5AM7nPmMSQflx0xzXSf8NJfEH/ogXiv/wADLf8AxoA+hKSvnz/hpL4g/wDRAvFf/gZb/wCNYmvftqXPgPUtGi8dfC/X/BmmalceQupX1xFJHHj7zFUBJwO1AH09S15J4R/as+FPjnUprDSvGmnm5iiM7i6Y2yhAQCd0gUd+mc16jpuqWWtWEN9p93Bf2Uw3RXNrIskbjplWUkEcdqALVFJuHrRQAtFJmjNAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfLvwG/5Pg/ad/64eGf/SOavqKvl34Df8nwftO/9cPDP/pHNX1FQAV5z8YPG2vaP4J10/D46Dq3jOxaFFsdYvlit7fzGA3zkMGQBSWGeTjivRq+dvjp+z/4btfCPxJ8QaB8Nv8AhO/Efiw2b6vop1N7U6mIGXaFcttjZVyRjGSOc0AeP6p+zPr/AO0WsL/tC/GnSNR0uNg8XhXwe8FnaIckkSTN+8kxxjofevs7wb4e0zwn4T0fRNEGNH0+1itbMeaZf3KKFT5iTu4A5r88fAfhj9jrXtWg0Dxl8ONU+FPieQ7P7N8ZNd2kbSD7yx3Bfy3GehyM9q/RHwnpOlaD4X0rTdCWNdFtbWOGyWGTzEEKqAm1sncMY5zzQBsUUUUAFFFFABUN5/x6T/7jfyqaobz/AI9J/wDcb+VAHy3/AMEv/wDkyP4ff9dNS/8AThc19VV8q/8ABL//AJMj+H3/AF01L/04XNfVVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFN5p1FAHMeKPh3oni24S5vrZ1vIxtS6t5WjlA7DcDyPrWBH4J8ReEb+5uvDeorqFvNCqfYdZmdlEm7JcMORxxj3r0aigDjI9W8ZWOiy3F9olhf6gJgFtdOuSoaPHJ3P3B7VteGdYvNa043F9pM+jTK5U21w6u2MdcrxWzTdtAHL6J8StA8QaoNNt7uSPUTuxa3ELxudvU8jFdBLqdnb3CW8t1BFcONyxPIocjpkDOTUpgTzA/lpvHRtoz+dYviLwLoXiqRJdV02K7mVdizNkOq5zgMORzQBvZozWTqWgC70D+yrW6uNNRUWOOe2fEkYXGME/TFYlv4O16y0m4tIPFt3JcPIrR3V1CkjxqOq++eOvpQB2ORRuFYfhjR9W0qGZdW1ltZkdgUdoFi2D0wOtZ1nqfjCPxB9nvNGsZNKeVgt1b3JDxx84LKRyenSgDrc0tc34o8d6Z4Pmtk1FboJMpPnQ27SImP7xHStex1iz1DS4dQgnVrKVBIkzZUFT35xj8aALtFMjmSaMPG6uh6MpyDTqADmiijNABUF1YwXiqtxBHOFOQJUDAfnU+aM0AcJ4s+BPw88eX8d94h8FaHrF5HH5Sz3VijsFyTjOOmSfzrxvw/+yL4p+FsOq23w4+KeqaBpU/7y20u6to7lI2CnC73yQNxPQd6+oKKAPnPT779qSzsLa3m0b4b3s0MaxtdS3l2rykAAuwUYBPUgcc1dj8QftLRriTwh8PJm/vR6rdIPyKGvf6SgD5yi/aF+I/g3UrzS/HHwo1DUL1NkkFz4ND3doyEdC8m07ge2KueFf23/AIY6tHqEXiHU38D6tY3b2k2la6hjuAVCndhQQBlsdeqmvoDBrLuPCujXczzT6PYTzOdzSSWyMzH1JI5NAHC+HP2nvhX4u1S003R/HGl3+oXcohgto5G3yOeigEda9QrzT4jfs5+APina2kGuaBGv2WXzoptOkazlDYI+/EVJ69M1xn/DDfwp/wCfPXv/AAor7/47QB79RXyB8Q/+Cd+j+INWt5/CnjPXPCVkkOyW1N3NeeZJknfukkyOCBgccVy3/Ds/UP8Aorut/wDfpv8A45QB9z0bhXyz8Of2SfiH8KdJuNN8N/Gq+trO4mNxItzpMVwxcgDIaRiQMAcVctdP/aY8Baprixah4b+IWkkK9ncaqDaTqFXLgRxLjJJxyT0HrTA+ms0V8y+E/wBrrxBB4ftW8Z/CPxvaa58wnXSNGee3zuONp3bumOtazftjWEKl5fhl8R4o1GWdvD0gCgdzzSA+hM0tfNvgD9v74SePtbk05dTuNDZIml+0azGtvCcEDaG3H5uelem6f+0X8MdWv7aysvHeh3N3cyLDDDHeIWkdjhVAzySeKAPRaKKSgBaKSjNAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8u/Ab/k+D9p3/rh4Z/9I5q+oq+XfgN/yfB+07/1w8M/+kc1fUVABXmv7QnxB1n4Y/CzVNe8PjRDrUbwwWv/AAkV59lsfMkkVP3kmR69AckgAV6VXj/7WHw1T4vfAfxL4UfU9J0b7esQXUNaH+jwMsisHJBGGBHykHrigDxib9jX4ifHeFH+P3xWuNY0mZllm8H+E4FstO4ORE0uPMkUY6/KeOtfWPhnw5YeD/DumaFpUP2bTNNt47S2h3FtkaKFUZPJwB1NfFWi+H/jx4c0O1sF/ax8AzwWcIjE13p1s8m1RgFnL8nA6mvs7wTJdyeD9Fa/1a212+aziM+p2agQ3T7RmVACRtY8jHY0Abm4UZFcx8TvHVl8L/h34l8XagN1loenT6hKg6uI0LbR7nGB9a+JNS+K/wC0V4J+A+kftFax4t02/wBFm+z6rf8Aw9TSkijj0yZ1CrHccuJQjq2T7+mCAfoFuFG4Vz8njfSbXwKfF91cra6Gmn/2nJcSdEg8vzCx+i18efD34++P/wBovxnpWpwfFTwp8IvD17dJLo/g2Zbe71zVLMMCJJg7gxGVclQoyAQcHrQB9yVDef8AHpP/ALjfyqX8aivP+PSf/cb+VAHy3/wS/wD+TI/h9/101L/04XNfVVfKv/BL/wD5Mj+H3/XTUv8A04XNfVVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMZdy4IBHoRmq2o6XbatYS2N3Cs1pKux4mHykelXKKAOZ8NfDzRfCF7Nc6VbyWrTLsePznZMZzwpOAfpVfXPhppniDUpb25uNRjmlADLBePGnAxwoOBXXUUAY+j+Hl0HRzp1rdXMi/NsmuZDI659z6VleHPDfiPSNS33/iZtWsNpH2eW1RX3djvHPFdbRQByfiK+8YWepZ0fS9Nv8ATto/11w0c27v2xitTWtYuNG0cXi6ZcahMu3fa2mGfnqRnritikx2oA4E/GTSrdc3+la3piA4eS7sGVE9yQTx7121jqNrqlqlzZ3Ed1buMrLC4ZT+IqWaBLiN45UWSNxhkYZBHoRXEWvwlsdL1P7TpmratpVqbj7QdPs7nZbE8ZGzHQ46UwO63CjcKwvFWl63qUMH9i6vHpMqMS5ktxKJB2HJ4qbSIdZtNBK6hcW9/qyq5EkaeVG5/hGO3bNIDXzRmuW8N654lvNSNrrPh2PToRGW+2Q3ayozcfKFxkfj6VHr3xEg8N6o9pc6Pq8sKKCby2tDJDyM4yD/AEoA66iuQ0v4qeGdTaZP7SSyeHG4X4+z9emN+M9K6XT9Us9Wt/PsrqG8hzjzIJA659MigC1RSbhRkUALTcUuaNwoAOaQruBBGQeopc0tAHNXnw18Jag4a68MaROwGN0ljGf/AGWuJ8e/sq/DH4jPYPqvhiGB7Is0L6XI9k2TjqYiu7oMZ6V63RQB4L/wxH8LP+fPXP8AwoL3/wCO1yOn/sd+KvAfjfU9Y+HnxTv/AAxpt0gji0y8tzqKwrhdwzM5ySRnPXnFfVFFAHxHrGiftn6Tq2oRab4j0bU9OhmYQXMttaK00YPDbCh2kjt2rtvgz+3FoviS/uvD/wASbVfh54ottz+VqWYYJIgFw++TbhmJbC46DINfUtc7rnw58LeJ7z7XrHhzStVuyoQz3lnHK+0dBlhmgDCt/wBoP4YXSlk+IfhcAHHz6vAh/IuKtwfG34d3SlofHvhmVc4ymsW5Gf8Avuq9x8BfhtdSB5vAPhuVsYy+lwnj/vmqs/7N/wAKrpg0vw48LSNjGW0iA8f980AbsPxX8E3ClovGOgyqOMpqcBH/AKFVuH4geF7hN8XiTSJVzjcl9ER/6FXGTfsufCKZtx+HHhtf+uenxoPyUCqk37JPwfnk3H4f6On+zHCUX8gcUAep6fqtlq8BmsbyC9hB2mS3kWRc+mQatV846N+xLofhVr5PDPj7x54Wsbu4a5bT9G1jyIFZvRQnpgDPYCtP/hlCb/osfxR/8KI//EUAe90leC/8Mnzf9Fj+KP8A4UR/+Ipv/DI8EvNz8UviVdv0Dy+IWyB6cLQB75RmvjfxZ8G/j38FLrVtW+GPjW98bWl9PHFHo+uuLqe3iAJLiSZgvX0AzkeldheftG/Ffwj4bGo+IfgfqQt7OJDe3kGq27+gZxEmW684GaAPpmivCV/bQ+HBUH/ioB/3Abr/AOIqO6/ba+GNjbvPcz65bQRjLyzaHdKiD1JKYAoA95pa57wj8QPDXj61e48N6/puuxRhfNbT7pJ/LLDIDbSdp9j6V0NABRSbhRmgBaKTNLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8u/Ab/k+D9p3/rh4Z/8ASOavqKvl34Df8nwftO/9cPDP/pHNX1FQAVwXxus/AGofDXVYPidJp8fgtvL+3Nqk3lW/3xs3NkY+bHeu9rxDwP8AEqw+Pvij4teD/EPhXTbnwv4R1WLSy+oFbmO9YRLK5khddqhTjB5/SgD41/aK8LfsNWvwf8TP4evvDI8SrZyPpP8Awj99JcXLXYX90oRWIYF9oIYbcE198fs/zXtx8DPAMupacmkX7aHZmewih8lYH8lcoE/hx6dq+HIfilrF8nib4q/Cb9nH4d3Pwt8J3c4j1S4s4bbVL+O3/wBfPblU+QDDY4PT1yK/QTwH4wsfiJ4J0HxPpm8afrFlDfQCThgkiBgD7gHFAHFftTeBb34lfs5fEXw1pqtJqWoaLcpaxr1eUIWRPxKgfjXxx8SP2ivCXxA/4JyaN4P0bUYL/wAfa1pVh4Zi8LW5DX4vkaOOVPJHzKF2MckAYx64r9GsVx1j8GfAml+MpfFtn4O0O18TylmfV4rCJbksereYBnJ7nrQB4Z8Wta0jUvgT4s+AOjaul58UbTwCXGiwo5lZFgCAhsbSSeNuc8jjmvk/xRD+z1L/AME9NLg0mDSYvibFY2sFnDZKo19NbV0UqR/rc+ZnOeNnTtX6dp4L0KPxXJ4nTR7FPEUluLN9VECi5aAHIjMmMlc84zWJD8Evh/b+Mj4ti8FaDH4nZzIdWTT4hc7z1fftzu9+tAGDJb/E7/hQuhxaDPpMfxJXTLITy64rtam4CJ5+8Jzn7+Md68puLH9sPyJd2p/CvbsbP7i89K+qMVHef8ek/wDuN/KgD5b/AOCXuf8AhiH4eZ679Rz9f7Quc19VV8q/8Ev/APkyP4ff9dNS/wDThc19VUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlJinUUAZuqeH9N1pAl/p9teKCCBPErjP4j3rmrf4VWGl62L/Sb+/0eEyrLJYWUuy3kI65THeu3ooAwPFGj63qi2/8AY2u/2IyFvMzapOJM4x97pjnp61PZWer2vh9oJ72G+1dY323TReXGz87SVHQdK2KKAOV8MR+L0vmGvvpclrs+VrIOH3Z9+3Wm65rXirT9WePT/DkGqaf8u2b7asT++QR25rrKKAPOtQ+JureHZIpte8KzaXpDTCF79bpJxHnozIoziu30jW7DXrKK70+6iu7eQbleNs/n6fjVtk3DBAI9D0rJ0PwjpHhue7m0ywispLtg03l5w5Gccdup6etAGxkUZrkZPhvaNrw1WLVdXt5fPE7QR3jeS5zkqVP8J9BV/wAVeH9R1xbc6drtxokkRYsYI1cSZxjIb0x+tAG/uHrRWPYWGq2Hh9rd9RXUtVWNgl3cRBFZudpZV7Djp6VneGf+EyXUGTXxo72ew7ZNP8wPu9w3brQB1NG4etcl4kuPGkOoONEs9KnsdoIa6ldZC2ORgcVVuPiLcaLaWP8AbHh7U0vZovMlWxh+0RxnJG0sO/GfxoA7fNLWTe+IrTTdBOr3XmQ2gjWRgYyXUHGAVHOeareF/G+keMlnOlXDz+QVEgeF025zj7wGenagDforF/4TXQP7SbTv7ZsRfrJ5RtjOok35xt25znNadxfW1nt8+eODd93zHC5/OgCeio4p45ow8brIh6MhyPzp+aAFopM0ZoAKTbnqM06igBnlJ/dX8qqarolhrum3Gn6jZW99Y3CGOa3uIw6SKeoYEYIq9RQB87yfsO+ArfXNU1TRNR8ReFpNRl82W30LUfssCkZwFRVwAMnAqY/sd6bg7fiN8QA3Y/263B9elfQVFAHzH4N+B/x48BWFxp+nfFzT9Ss2uHmjk1vTnu51U9F3s/QAD9aj8ZeJvj78E7WPxLqsmkfEvw7bh21HT9KtRZXMaYwrIxLbvmI4AJ4r6gppUemaAPGPh5+1t8NfiFfQ6ZDro0rXPsouptP1SCW1MQ4DDfIqq2C3Y89a9Fj+JPhKVwieJ9HdycBVv4if/QqxvGnwJ8AfEXVl1TxL4U03WdRWMQrc3MWXCAkhc+nJ/OsCT9kv4PyIUPw+0baR2iIP86APQv8AhNvD3T+3dN/8C4/8aX/hMvD/AP0HNN/8C4/8a8a8YfsOfCHxV4du9Lt/DEegTT7duoaY5W4iwwJ2liRyBg5HQmvNf+HXfw0/6GHxR/4FRf8AxugD6v8A+Ey8P/8AQc03/wAC4/8AGj/hMvD/AP0HNN/8C4/8a+UP+HXfw0/6GHxR/wCBUX/xuj/h138NP+hh8Uf+BUX/AMboA+r/APhM/D//AEHNN/8AAuP/ABrY3AjIOR618cf8Ou/hpwf+Eg8Ucc/8fUX/AMbrZt/2PfiVpPiGPUNL/aE8RR21tOZbW1vrM3KqoPypJmYLJgYByoB9BQB9X0m4V4R/wqX42/8ARdIf/CTt/wD45Ucnwb+Nc3LfHxocdoPCloM/XcxoA98orwH/AIUr8af+jgrr/wAJayo/4Ur8af8Ao4K6/wDCWsqAPfqK8B/4Ur8af+jgrr/wlrKj/hSvxp/6OCuv/CWsqAPfqTcPWvAv+FK/Gn/o4K6/8JayrifH2l/tK/CG6g17RPFcfxZ0m3iJutHn0qC0md2IVQiwruYDO7hh070AfWeaWvn7Tf2pNcOm2v8AaHwV+I63/lL9oFtpMZi8zA3bCZc7c5xntVr/AIak1D/oi3xN/wDBRF/8eoA93orwj/hqTUP+iLfE3/wURf8Ax6j/AIak1D/oi3xN/wDBRF/8eoA93pM14T/w1JqH/RFvib/4KIv/AI9We/7aXhjRPEGn6Z4y8LeKvh9HfLI0N/4lso4Lc7BkjKyMfQdOpFAH0PRWboHiDTvFGj2mqaRew6jp11GssNxbuGR1YAgg/QitKgAooooAKKTNLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHy78Bv+T4P2nf8Arh4Z/wDSOavqKvl34Df8nwftO/8AXDwz/wCkc1fUVACGvlP4ufsT614u8eeKtf8AAnxV1j4c2fjGNE8S6ZZ26TJdsq7PMjYkGJinBI+tfVteY/tF/Gy1/Z7+EuseNbnTZ9ae0aKG2063YK9xPK6xxpuwcAsw5xQBSuP2f9O0H9m+9+Efgq5HhyxbRptItbx4/NaPzFZXlYZG52LMxPq2a7D4W+B4/hn8N/DHhKG4N3FomnQWAnIwZPLQLux2zivnGx+I37YerWqXi/CfwNpaTDzEs7zXmaaJTyFcrxkDrX1F4Wn1a48N6XLr1vBaa29vGb23tX3xRzbRvVGPVQcgGgDXooooAKKKKACobz/j0n/3G/lU1Q3n/HpP/uN/KgD5b/4Jf/8AJkfw+/66al/6cLmvqqvlX/gl/wD8mR/D7/rpqX/pwua+qqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooASloooAKbg06igBu3PUUixqpO1Qv0GKfRQBmSeG9KmvFu5NMs3u1fzBO0Clw3XIbGc+9ReIPCWk+KoYotWsY71IySnmZ+Un0wa2KKAOCt/h3qfh3QbTS/DfiCTTo4ZZJHe4hExcMchRnoB7da6ez0/U4fD/ANluNRWfVPKZft3lBRvOcNs6ccce1a1FAHL+GND8SabeSSax4gTVoCm1YVtVi2tn72R7ZqpqnxO0zQdcm07WILvSkBAhvLiI+RPxztYdMH1rs6huLWK6j8ueJJo/7kihh+RoApaF4l0zxNbSXGl3kd7BG+xpIjkBsZxWbY/Efw7qesrpVrqSTX7MyCFVbqM5GcY7Vu2tjb2MZjt4IreMnJWJAo/IU2PTbWGTfHbQxvnO5YwDn16UAZHiXx5ovhCaGPVbs2zzKWT92zZA+grY0/UINUsILy2fzLedBJG+CMqehwakkt45uXjRz23KDWOvhG3XxKNaF3eiYJ5YthORbgYx/q+maANyiuZ8UeA7XxXdxXFxqGqWbRpsC2N20KnnOSB1NaF94div/D/9kvdXccXlrH9oimKz/Ljnf1yccmgDWzRXP+FfBdt4R+1fZ77ULz7Rt3fb7pptuM/dz0znn6Cs+T4Z2c2u/wBqHVdYWXzvP8kXzeTnOcbem32oA7CjNYHinwbb+LFt1uL6/sxCWI+w3Bh3Zx97HXpVfSfCd7od9YC0126fSbeNleyulErzMSx3GU/Nxkce1AHT7hRmuX8UWfi2W8jk8P32m29uEw0V7EzEtnrkH0rRvJNZtfDqvBb217rKxpui3mOJ343YJzgdcUAa+aM1geF9U13UvtA1vRI9HZCBH5d2s4k65PAGMY7+tYuofEi802/uIJPCOtTRRSMi3FvErrIAcbhz0NAHc5orI0bXjq+if2idPvLM4Y/ZblNs3Ge2e+OK5b/hbTDOfCPiIKO/2Qf/ABVAHoFLWRH4kt/+Ed/ti4iuLW2ERleOWI+Yg9Co5z7VU8L/ABA0TxjNLFpV088kS7nV4XjIH/AgKAOiorBuvHnh6x1J9PudYtIL1GCNBJIAwJ6DFat5qVppyK91cxWysdqtK4UE9cc0AWaKiguobqPfDKkqf3o2DD8xT1dW5BB+nNADqaFNOooAKKKKACiiigArnvGngLQPiJodxpHiPSrfVdPnXY8U69sg4BHI5A6HtXQ0UAfNPhn9jvVPh+mo2fgv4ra/4V0S6vJLxNLtLaF44S2PlUvk4ACj8K1f+GffigOB8ftdx2/4lFt/jX0DRQB8/wD/AAz/APFH/ov2uf8Agntv8aQ/AH4ppynx91osOgfR7bH4819A0UAfIXwr+PniP4O/EbxL4F+Oni/S2MUKahpusTERmSN2KrGQoAzhd3qM9a+qvDnibSvF+iWmsaLfwappd2m+C7tXDxyLnGQR7g/lVLxJ4K0fxNDcte6Pp17dyQNEk91apIy5BA+YgnAzXzp8IdI+Pvwh+HOjeELXwJ4X1KDS0eNLqXWzG0gLs2SoQ4+9QB9V0V4P/wAJp+0J/wBE38Kf+FA3/wAbo/4TT9oT/om/hT/woG/+N0Ae8UV4P/wmn7Qn/RN/Cn/hQN/8bo/4TT9oT/om/hT/AMKBv/jdAHvFFeD/APCaftCf9E38Kf8AhQN/8bo/4TT9oT/om/hT/wAKBv8A43QB7xRXg/8Awmn7Qn/RN/Cn/hQN/wDG6P8AhNP2hP8Aom/hT/woG/8AjdAHvFFeD/8ACaftCf8ARN/Cn/hQN/8AG6P+E0/aE/6Jv4U/8KBv/jdAHu+aWvCvh/8AGjx7efGSLwB458I6Vodxc6RJq0FzpupNcgqkiptIKDqSe/avdKAFooooAKKKKAPl34Df8nwftO/9cPDP/pHNX1FXy78Bv+T4P2nf+uHhn/0jmr6ioAK8k/am+Feq/Gn4G+JPCGiS6bb6pfpGbe61UuIYHSRXEuUGQy7cqfUDPFet186/t+alqmlfst+K5tMub2xhaS1i1K607P2iKwadFuWTHOfLLfhmgDxHwt43/aUkvbXwrYfHb4I63rlui2/kP5sl3Kw+XLBcZY45wOvavuDwpFrMPhnSo/EU1rc6+ttGt/NYoVgefaN5jB5C7s4z2r4Y+MHwb/ZE8PfszX/iDQx4d0v7PphudD1zSL7OpG7CZgaNg+9pC4Xg9z2r7A+Aeo61q3wR8B3viPzTr0+iWkl6ZxiQymJSxYf3s9fegDv6KKKACiiigAqG8/49J/8Acb+VTVDef8ek/wDuN/KgD5b/AOCX/wDyZH8Pv+umpf8Apwua+qq+Vf8Agl//AMmR/D7/AK6al/6cLmvqqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAE/CkwadRQA3mlpaKAExSbRu3ADPTPenUUAZt14d0u8uDPPptpNPkHzXhUvkdDnGaNa8O6b4it0g1OyhvoUbcqTLuAOOorSooAy9H8Oaf4f09rHTrSOztGLMYo8gZPU15p4r8NWXwz1LQdZ0z+047Rb3bepFLJOoiKt1TnvXr9N20AY/hfxdpvjCykutNkkeKNzG3mwvEQ2AejAHvTbDxx4f1S9FnZ6zZXN2WKeTHMpfcOoxnrW1tPTtWZD4X0i3vkvItKsortCWWeOBVcE9TkDvk0AXZr+2tZFSa4iidhlVkcKT+dTLIrqGUhlPQryKwfEfgPQvFsscur6bFeyRrsRpCQVHXHBq1N4Zs38P/wBjQ+bZ2QjESC2lKPGo6bW6igDVzRkVzvhbwXD4Ua4MOpanfrMANuoXRmCY/u5HFZbyeJdB8ZruD614f1GTaAigSWDe/qh9aAO3opMjFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgWrH/AIzf8P8A/YlXP/pUte+1wl18LIbr4z2PxCN9ILi10aTRxY7BsZXlEm/dnORjGK7ugAooooAKKKKAPl34Df8AJ8H7Tv8A1w8M/wDpHNX1FXy78Bv+T4P2nf8Arh4Z/wDSOavqKgArwzxl8UviPZn4k2lr8IZNestHFvHoytexhdfWXiYAMMKEBOQc5r3OvkH9v3Rfjjq/hPyfh3c6H/wirGz+1W83mJqP2lboMGjkDBfLxs3A84DetAHhOj+CNR8P+LIvEth+wjbW+sxTm4jnOroyJITncI2JQc/7PFfo34R1K/1nwvpN/qmmnR9SubWOW509nDm2kZQWjLDg7TkZHpXyZ4o8G/tl+MvDOpaDda/8MrC11O1ks5rq0troTRJIpVmQ54YAnB7GvqD4U+Dp/h78NfC/hi71B9VutI02CylvpCS07ogUuc88kE880AdZRSbhWXH4q0SXWm0dNYsH1ZRlrBbpDOOM8x53dPagDVopM1UvtXsdLaBb29t7RrhxFCJ5VTzHPRVyeT7CgC5UN5/x6T/7jfyqXcKivP8Aj0n/ANxv5UAfLf8AwS//AOTI/h9/101L/wBOFzX1VXyr/wAEv/8AkyP4ff8AXTUv/Thc19VUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFN29KdRQBxt+3ibSPGUM1uP7X8P3xWOW3+VJLJv74PdTzmuw3etG05yK4XxIfE3hrxEdX02ObXtIuFCXGlqQJISBw8XqPUUAd3mjcK53wr4ou/EUlyt1oF/ovkhdpvQo8zOc7cHtj9ateHPE1r4mjvWtVdfsdy9rIJBj5lPUe3SgDZopMijNAC0UmaKAFopM0UALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8u/Ab/AJPg/ad/64eGf/SOavqKvl34Df8AJ8H7Tv8A1w8M/wDpHNX1FQAV4t+198KdX+NXwB8SeEvD9rBda5d+S9kLi6Nsscscqusm8A/d25x0PTvXtNfPn7d3izWfBn7M/ia/0TU7jRJZZbW0utVtQTLZWss6RzzLjoVRm57UAeTeF/iN+15aw22hy6Z8Kdc1i3URORrhSdyowS0a5weMnFfYvhWTVp/DOlyeIILe21xraNr6GzcvCk20bwjHqobOD6V8OfFH9jj9nn4efAjU/G3hzWm8Pa/o+nPqeneNrXWWe7luVTfG5bfiQu2PlA53Yr69+A/iTVvF/wAFfAuua7n+2dQ0W1ubssu0mV4lLHHbJOce9AGf+0r8Qrn4UfAHx/4tsP8AkIaVo1xPanqBNsIjJ9gxX8q+IfHv7NPh/wCHf7COkfFzTBPa/GLTLCy8Vv4zWZjfy3cpR5VdyTuTbIU2njCivvr4w/Du3+LPwr8W+Dbp/Ki1zTLiw83/AJ5s6FVf6qxB/CviPVNH+O3xH/Zw0T9nG++F2oaJqipa6Fqnje4uYm0pdPgdB9ojKtvd2jQDZjrn1FAH3H4V8a22pfDPSPFmpzxWFrcaTDqVzNMdscStEJGYk9AATX5v/H7UPEXx98bfCr40agLvTfBS/EXSND8G6TIpX7TaGZml1CRT3leNdn+yvvX2P4i8Oap4+17U/gXrvgW/X4Rv4Zhi/wCEtt73yjPKpRfswCncpwP0PY18/wD7RX/BO/S7XRvhzZ+AB4y1WG38U6et/by+IppI7HTV3CWWJWOI2QbdrLyO1AH2v8TvFOt+C/B97q3h7wtdeMtVhKCLR7OdIZJgWAJDv8owCTz6V4RcftN/GSSCRT+zJ4lAKEf8huz9PrX0Z4U8NW3g/wAM6XodlNdXFpp1ultFLeztNMyouAXkblm45J5NaF5/x6T/AO438qAPlz/gl9/yZD8PD0JfUTj0/wCJhc8V9VV8q/8ABL//AJMj+H3/AF01L/04XNfVVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU3FOooAbiuAi+Ft9p+rXVzpnizUdNtLm6N3JZRxxshYkFuSM4OK9BooAxPFGh32vafHb2Os3OiTLIHNzaorMwAOVwwxg5/Sn+G9GvNE0w217q1xrM28t9quVVWwe2F44rYooA4/QfBes6TrCXl14v1DVLZd2bOeKNUOQccgZ4/pU/irwnq2vXkU1j4ovtDjVNrQ2saMrHP3juHWupooA4r4iatqPg/4ez3lpdGW/sxCPtEqgmTDKGJHTnn8662ymN1Z28xGDJGrkfUVHqmk2mtWMlnfQLc2smN8Un3Tg5/nVmOMRxqijaqjAA7CgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHy78Bv+T4P2nf+uHhn/wBI5q+oq+XfgN/yfB+07/1w8M/+kc1fUVABXnH7QnxG8J/Cr4P+JfEfja2GoeG4LYxXNgYhKbvediwhDwS7MF59a9Hrwr9tXwTqPj39nXxJpei6Ff8AiPXVe3utOsdNaMSm5jmR42PmHaUVgCw6lQcc4oA+EbTwH4V8AzW/xB8S/sh+KNN8AWkgv283xA13HYw5BEz2RbG1Qd23HAFfqX4U1/TPFXhnSdZ0WaOfSNQtYrmzkjG1WhdQVIHbgjiviDx58cf2pviB8GNV8Lj9nGfT9f1fT5NPutSfU4GgVZEKSOkRbOSCcAnAJ7163+yl40+I9np/h34f+Ifgvq3gbw7omkJaxa5f6rb3AdolVFUpGc5bk+nFAH05TdtOooAbg0Yp1FABUN5/x6T/AO438qmqG8/49J/9xv5UAfLf/BL/AP5Mj+H3/XTUv/Thc19VV8q/8Ev/APkyP4ff9dNS/wDThc19VUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHy78Bv8Ak+D9p3/rh4Z/9I5q+oq+XfgN/wAnwftO/wDXDwz/AOkc1fUVABXhf7aHxG174X/s967q3hi9j0rWrie102HU5QCtj9onSIz8/wBwOTn1Fe6V4v8Atg+ItO8Lfs8+LdQ1nwlH430RYUTUNHkmEXmW7OokcMe6A7hjnK8c0AfPHj79ie7+FPw31n4iaD8cvGlv420Wwl1U61qeq+ZZXbohfZJEflEbEY49e9fW/wAFPGl38SPhD4M8U6hEsF7rGkW19PHGCFEkkas2B6ZJr4y8Jfst/ALxdpulTzfH7V/Enw5yLq18Hal4qhFkin5ljdSRJhc/dY+xr7z0GHTrfRbCLSBbjSUgRLQWhBhEQACbCONuMYxQBpUUUUAFFFFABUN5/wAek/8AuN/KpqhvP+PSf/cb+VAHy3/wS/8A+TI/h9/101L/ANOFzX1VXyr/AMEv/wDkyP4ff9dNS/8AThc19VUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHy78Bv+T4P2nf8Arh4Z/wDSOavqKvl34Df8nwftO/8AXDwz/wCkc1fUVACV8cftBfGjxV8WvGfi34S+Avg9p/xQ0jw+ID4km1+9+zWbSsBKlvEAQWfAByeMjBr7Ir47vfgv+0X8Pfi58SNd+GOq+Bh4e8WaomqeVr6TtcRuIljI+RcY+X1oAr/s7fs//s4/tAfDtfEUfwR0Xw/qVrez6Xqmj3cG6WxvIW2yxMQecHBz6EV9d6DoVh4Z0Wx0jSrWOx0yxhW3trWEYSKNRhVA9AAK+KPhv8Gf2uvhafFJ0jV/hnIfEWt3GvXf2iO5O24mChwmF4X5BgfWvtLwrHrC+GtLHiB7V9dFtH9uayB8gzbRvKZ527s4z2oA1qKKKACiiigAqG8/49J/9xv5VNUN5/x6T/7jfyoA+W/+CX//ACZH8Pv+umpf+nC5r6qr5V/4Jf8A/JkXw+/66al/6cLmvqqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+XfgN/yfB+07/1w8M/+kc1fUVfLvwG/wCT4P2nf+uHhn/0jmr6ioAKKKKACiiigCK4uIrO3lnnkWKGJS7yOcKqgZJJ9AK+a9L/AOChHwq1TWtPgEXiS18P6hqH9l2fi670d4tFnuN20KtyTjBbjJAHB9DXYftnalqGk/so/Fa60zet2vh67AZPvKjRkOw+iFj+FeBfG3QtEtf+CT1ta20UP9nReENLntzgAGXELhx1+YuSc+pNAH2zq2sWuh6ReandyFLOzge4mdFLkRqpYkBQSeAeAMmvnCx/4KEfDabVtHt9R0Xxp4d0jWLpbSw8Ra14fltdMnkY4QCYnox6EgevSvbvhTNdX3ws8ITX+43kuj2jTb+TvMK7s59818xftratF8etd8O/s5+D401LxDe39rq2vXURBh0LT4JFcvIw+7I/AVOpz2yKAPr7UtYsdFs2vNQvbews1xuuLmVY4xngZZiBzXP3fxR8GG1mA8XaFnY3/MSh9P8Aeqfxp8O/DvxH8JTeGfFGl2+uaHMEEtndLlJNhBUn6EA15PdfsJfAJLaVh8LtBBCEj9yfT60Acn/wS/5/Yh+H3/XTUv8A04XNfVVfKv8AwS+4/Yh+HoHQPqQH/gwua+qqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5d+A3/J8H7Tv/AFw8M/8ApHNX1FXy78Bv+T4P2nf+uHhn/wBI5q+oqACiiigAooooAzvEGg2XifQdR0fUoFutO1C3ktbmFxkSRupVlP1BNfIlh+wX4on0HSPhxrvxXuNX+CGk3q3cHhn+zVjvbiFHLx2k10G+aJWx0XkADjAx9mUUAeLa58GvHd18Vtf8S6N8TLrRdAu/DR0bTfD4tfNttPu8/LeBCwVmX0wCemcV4n8Iv2JfjH8EbLU4PC/x8sI5tVu2vdRv73wbHc3d5Kf4pJpLgs2OwzgV9q0UAV7GGaGzgjuJhcXCxqsswTZ5jActt7ZOTj3p15/x6T/7jfyqaobz/j0n/wBxv5UAfLf/AAS//wCTI/h9/wBdNS/9OFzX1VXyr/wS/wD+TI/h9/101L/04XNfVVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8u/Ab/k+D9p3/rh4Z/9I5q+oq+XfgN/yfB+07/1w8M/+kc1fUVABRRRQAUUUUAFFFFABRRRQAVDef8AHpP/ALjfyqaobz/j0n/3G/lQB8t/8Ev/APkyP4ff9dNS/wDThc19VV8q/wDBL/8A5Mj+H3/XTUv/AE4XNfVVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8s/A24jtv22v2n5JZFijWDwzl3YAD/RJh1NfT1rf216rG3uIrgKcMYnDY+uK+NNIt9Euv2jv2w4fEhsRozaX4dEx1IoIAfsc2wsXZQPn24JYc45Fe1fsxrdw+FZxqWj+CdFv5khugng7YomhcN5cs6ICqsdpxtdwcHmgD2miiigAooooAKKKKACiiigAqG8/49J/9xv5VNUN5/wAek/8AuN/KgD5b/wCCX/8AyZH8Pv8ArpqX/pwua+qq+Vf+CX//ACZH8Pv+umpf+nC5r6qoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPg7xBDA3x0/a7e7jsHtoU8H3Un9pSmKJVjUuXDhl2uu3KEkAOFycZr1P8AYmvm8Taf4q8TT2WnWd7qUkC3i6dMjx/aE8wSCMRyOghycqRtLZYkc5Pnl9Hq8nx8/a4/sO8ax1MWnhVkcSLGJEEUheIufuLIm5CwyQHJAJAFeifsK/aLj4c3t5DYW+g+HrxorrTdDsrtrmC1Vwzu4Miq6FywJjYYBHHU0AfTtFFFABRRRQAmaYJ4zIYw6mQDJTI3Y+lcD+0D8RpPhH8EPG/jKFBJdaNpNxdW6MMhpgh8sH237a+FfF3wO1T4a/shaZ+0Ja+L/EDfGe3tbTxTeatcalK8FwZ3R5LV4CdhiCSbdoA5HvQB+lW6m/aI/MMe9fMxnZkbseuK8u+IPxgk8M/s0az8TLWKP7Rb+G21mGJ+U8wwb1B9txFfEviT4Gat4T/Y9sP2hrHxb4hn+M0Nrb+LLrVptTlMM6ySLJJbmDOzyhExAXHb3oA/S7dUV5/x6T/7jfyrhP8AhdXhjR/g/pHxF8Tarb+HvD17YWt7Jd3h2pF56qVB+pcCvPrn9vb9nyS3lUfFfw8SUYD9+3p/u0Acv/wS/wD+TI/h9/101L/04XNfVVfKv/BL8/8AGEPw9PYvqRH/AIMLmvqqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+BfHlrHffGH9rm2mu7qySZPBqGW0iEjEkkBGBZQI2OFdty7ULHIxmvWv2K9Li8MzfEDQ1LXJtNQUi/VUEdyhaQIybbiXC4XhW2sFKZznNHwRhjuP21v2moZUWWJ7Tw2rI4BVlNpPkEHqDX0lpui2Gi25t9OsrfT7ctuMVrCsa59cKAM0AXqKKKACiiigDgvjt8Of+FvfBvxp4MDrFLrelXFnDI3RJWQiNj9H2n8K+F9e+JPjr4qfst6V+zfD8OfE9l8UZILTw3qV1eWDJplrBA6K941z91kZI84HOWr9I9tGD60AfNvjW4PjKy8S/s123hrWbeI+CTFB4smhA01mMQiSPd13Zwf8AgJr5r1z4jeO/HX7Kmm/s2Wnw68UWPxSkhtvDV/cT2DDTbe1jkVZLr7T9xkMS9ufm9q/SfFGO3agDm9C8A6RpXgPR/CdxZW+paTp1lBZLb3kKyxusSKq5VgQfuiqlz8JfA/2eXb4L8Pbtpx/xKoD2/wByuwooA/PL9hn9rb4Z/A39mLwp4I8a6te6H4n0mW/S80+bS7gtCWvZ3UEhCPuup/Gvev8Ah4j8Cv8AobLj/wAFV1/8br6Hk0exmkZ3srd3Y5ZmiUk+5OKT+xdP/wCfC1/78r/hQB87Tf8ABRj4C20Zkm8YSwxDrJLptyij6kx4FOX/AIKJfAllDL4suGU8hl0q6II9f9XVH/go1pdlb/sa/EZ47S3jcW8GGSJQR/pMXfFe4/DfR7Bvh34XJsbbJ0u1JPkrz+6X2oA8d/4eI/Ar/obLj/wVXX/xuj/h4j8Cv+hsuP8AwVXX/wAbr6G/sXT/APnwtf8Avyv+FH9i6f8A8+Fr/wB+V/woA+ef+HiPwK/6Gy4/8FV1/wDG6P8Ah4j8Cv8AobLj/wAFV1/8br6G/sXT/wDnwtf+/K/4Uf2Lp/8Az4Wv/flf8KAPnn/h4j8Cv+hsuP8AwVXX/wAbo/4eI/Ar/obLj/wVXX/xuvob+xdP/wCfC1/78r/hR/Yun/8APha/9+V/woA+ef8Ah4j8Cv8AobLj/wAFV1/8bo/4eI/Ar/obLj/wVXX/AMbr6G/sXT/+fC1/78r/AIUf2Lp//Pha/wDflf8ACgD55/4eI/Ar/obLj/wVXX/xuj/h4j8Cv+hsuP8AwVXX/wAbr6G/sXT/APnwtf8Avyv+FH9i6f8A8+Fr/wB+V/woA+ef+HiPwK/6Gy4/8FV1/wDG6P8Ah4j8Cv8AobLj/wAFV1/8br6G/sXT/wDnwtf+/K/4Uf2Lp/8Az4Wv/flf8KAPnn/h4j8Cv+hsuP8AwVXX/wAbo/4eI/Ar/obLj/wVXX/xuvob+xdP/wCfC1/78r/hR/Yun/8APha/9+V/woA+ef8Ah4j8Cv8AobLj/wAFV1/8bo/4eI/Ar/obLj/wVXX/AMbr6G/sXT/+fC1/78r/AIUf2Lp//Pha/wDflf8ACgD55/4eI/Ar/obLj/wVXX/xuj/h4l8Cv+hruf8AwVXX/wAbr6G/sXT/APnwtf8Avyv+FRXWi6eLaY/YbX7jf8sV9PpQB89Qf8FGPgLdRiWDxhLPEekkWm3LqfoQmKk/4eI/Ar/obLj/AMFV1/8AG65//gmXplncfsZ+CnltIJHNzqXzNEpJ/wBPn74r6m/sXT/+fC1/78r/AIUAfPP/AA8R+BX/AENlx/4Krr/43R/w8R+BX/Q2XH/gquv/AI3X0N/Yun/8+Fr/AN+V/wAKP7F0/wD58LX/AL8r/hQB88/8PEfgV/0Nlx/4Krr/AON0f8PEfgV/0Nlx/wCCq6/+N19Df2Lp/wDz4Wv/AH5X/Cj+xdP/AOfC1/78r/hQB88/8PEfgV/0Nlx/4Krr/wCN0f8ADxH4Ff8AQ2XH/gquv/jdfQ39i6f/AM+Fr/35X/Cj+xdP/wCfC1/78r/hQB88/wDDxH4Ff9DZcf8Agquv/jdH/DxH4Ff9DZcf+Cq6/wDjdfQ39i6f/wA+Fr/35X/Cj+xdP/58LX/vyv8AhQB88/8ADxH4Ff8AQ2XH/gquv/jdH/DxH4Ff9DZcf+Cq6/8AjdfQ39i6f/z4Wv8A35X/AAo/sXT/APnwtf8Avyv+FAHzz/w8R+BX/Q2XH/gquv8A43R/w8R+BX/Q2XH/AIKrr/43X0N/Yun/APPha/8Aflf8KP7F0/8A58LX/vyv+FAHzz/w8R+BX/Q2XH/gquv/AI3R/wAPEfgV/wBDZcf+Cq6/+N19Df2Lp/8Az4Wv/flf8KP7F0//AJ8LX/vyv+FAHzz/AMPEfgV/0Nlx/wCCq6/+N0f8PEfgV/0Nlx/4Krr/AON19Df2Lp//AD4Wv/flf8KP7F0//nwtf+/K/wCFAHzw3/BRL4EopZvFlwqgZLNpd0AB6n93TYf+Ci/wFuIxJD4wlmiPSSLTbl1P0Ijwa9e+K2kWCfC/xgy2NqCNIu+fJX/ni3tXi/8AwTn0uyuP2Mfhq8tnbyObWfLPEpJ/0mXvigC7/wAPEfgV/wBDZcf+Cq6/+N0f8PEfgV/0Nlx/4Krr/wCN19Df2Lp//Pha/wDflf8ACj+xdP8A+fC1/wC/K/4UAfPP/DxH4Ff9DZcf+Cq6/wDjdH/DxH4Ff9DZcf8Agquv/jdfQ39i6f8A8+Fr/wB+V/wo/sXT/wDnwtf+/K/4UAfPP/DxH4Ff9DZcf+Cq6/8AjdH/AA8R+BX/AENlx/4Krr/43X0N/Yun/wDPha/9+V/wo/sXT/8Anwtf+/K/4UAfPP8Aw8R+BX/Q2XH/AIKrr/43R/w8R+BX/Q2XH/gquv8A43X0N/Yun/8APha/9+V/wo/sXT/+fC1/78r/AIUAfPP/AA8R+BX/AENlx/4Krr/43R/w8R+BX/Q2XH/gquv/AI3X0N/Yun/8+Fr/AN+V/wAKP7F0/wD58LX/AL8r/hQB88/8PEfgV/0Nlx/4Krr/AON0f8PEfgV/0Nlx/wCCq6/+N19Df2Lp/wDz4Wv/AH5X/Cj+xdP/AOfC1/78r/hQB88/8PEfgV/0Nlx/4Krr/wCN0f8ADxH4Ff8AQ2XH/gquv/jdfQ39i6f/AM+Fr/35X/Cj+xdP/wCfC1/78r/hQB88/wDDxH4Ff9DZcf8Agquv/jdH/DxH4Ff9DZcf+Cq6/wDjdfQ39i6f/wA+Fr/35X/Cj+xdP/58LX/vyv8AhQB88/8ADxH4Ff8AQ2XH/gquv/jdH/DxH4Ff9DZcf+Cq6/8AjdfQ39i6f/z4Wv8A35X/AAo/sXT/APnwtf8Avyv+FAHzqf8Ago18BBOID4ykE5XeIf7Nud+3127M496k/wCHiPwK/wChsuP/AAVXX/xuuQ17TbP/AIefeGYfstuIv+Fbzt5flLtz9tbnGOtfWv8AYun/APPha/8Aflf8KAPnn/h4j8Cv+hsuP/BVdf8Axuj/AIeI/Ar/AKGy4/8ABVdf/G6+hv7F0/8A58LX/vyv+FH9i6f/AM+Fr/35X/CgD55/4eI/Ar/obLj/AMFV1/8AG6P+HiPwK/6Gy4/8FV1/8br6G/sXT/8Anwtf+/K/4Uf2Lp//AD4Wv/flf8KAPnn/AIeI/Ar/AKGy4/8ABVdf/G6P+HiPwK/6Gy4/8FV1/wDG6+hv7F0//nwtf+/K/wCFH9i6f/z4Wv8A35X/AAoA+ef+HiPwK/6Gy4/8FV1/8bo/4eI/Ar/obLj/AMFV1/8AG6+hv7F0/wD58LX/AL8r/hR/Yun/APPha/8Aflf8KAPnn/h4j8Cv+hsuP/BVdf8Axuj/AIeI/Ar/AKGy4/8ABVdf/G6+hv7F0/8A58LX/vyv+FH9i6f/AM+Fr/35X/CgD55/4eI/Ar/obLj/AMFV1/8AG6P+HiPwK/6Gy4/8FV1/8br6G/sXT/8Anwtf+/K/4Uf2Lp//AD4Wv/flf8KAPnn/AIeI/Ar/AKGy4/8ABVdf/G6P+HiPwK/6Gy4/8FV1/wDG6+hv7F0//nwtf+/K/wCFH9i6f/z4Wv8A35X/AAoA+ef+HiPwK/6Gy4/8FV1/8bo/4eI/Ar/obLj/AMFV1/8AG6+hv7F0/wD58LX/AL8r/hR/Yun/APPha/8Aflf8KAPnn/h4j8Cv+hsuP/BVdf8Axuo/+HjXwEEwgPjKQTsNwhOm3O8j1C7Mke9fRX9i6f8A8+Fr/wB+V/wr5D8cadZr/wAFOPhxELS38k+BrwmPyl2585+cY60Adt/w8R+BX/Q2XH/gquv/AI3R/wAPEfgV/wBDZcf+Cq6/+N19Df2Lp/8Az4Wv/flf8KP7F0//AJ8LX/vyv+FAHzz/AMPEfgV/0Nlx/wCCq6/+N0f8PEfgV/0Nlx/4Krr/AON19Df2Lp//AD4Wv/flf8KP7F0//nwtf+/K/wCFAHzz/wAPEfgV/wBDZcf+Cq6/+N0f8PEfgV/0Nlx/4Krr/wCN19Df2Lp//Pha/wDflf8ACj+xdP8A+fC1/wC/K/4UAfPP/DxH4Ff9DZcf+Cq6/wDjdH/DxH4Ff9DZcf8Agquv/jdfQ39i6f8A8+Fr/wB+V/wo/sXT/wDnwtf+/K/4UAfPP/DxH4Ff9DZcf+Cq6/8AjdH/AA8R+BX/AENlx/4Krr/43X0N/Yun/wDPha/9+V/wo/sXT/8Anwtf+/K/4UAfPP8Aw8R+BX/Q2XH/AIKrr/43R/w8R+BX/Q2XH/gquv8A43X0N/Yun/8APha/9+V/wo/sXT/+fC1/78r/AIUAfPP/AA8R+BX/AENlx/4Krr/43R/w8R+BX/Q2XH/gquv/AI3X0N/Yun/8+Fr/AN+V/wAKP7F0/wD58LX/AL8r/hQB88/8PEfgV/0Nlx/4Krr/AON0f8PEfgV/0Nlx/wCCq6/+N19Df2Lp/wDz4Wv/AH5X/Cj+xdP/AOfC1/78r/hQB88/8PEfgV/0Nlx/4Krr/wCN0f8ADxD4Ff8AQ2XH/gquv/jdfQ39i6f/AM+Fr/35X/Cj+xdP/wCfC1/78r/hQB86x/8ABRn4CTM6R+MZJHjOHWPTblih9CAnB9jUn/DxH4Ff9DZcf+Cq6/8Ajdcx+x3ptnN8bv2mVe0t3VfGCBVaJSAPJHA44FfVv9i6f/z4Wv8A35X/AAoA+ef+HiPwK/6Gy4/8FV1/8bo/4eI/Ar/obLj/AMFV1/8AG6+hv7F0/wD58LX/AL8r/hR/Yun/APPha/8Aflf8KAPnn/h4j8Cv+hsuP/BVdf8Axuj/AIeI/Ar/AKGy4/8ABVdf/G6+hv7F0/8A58LX/vyv+FH9i6f/AM+Fr/35X/CgD55/4eI/Ar/obLj/AMFV1/8AG6P+HiPwK/6Gy4/8FV1/8br6G/sXT/8Anwtf+/K/4Uf2Lp//AD4Wv/flf8KAPnn/AIeI/Ar/AKGy4/8ABVdf/G6P+HiPwK/6Gy4/8FV1/wDG6+hv7F0//nwtf+/K/wCFH9i6f/z4Wv8A35X/AAoA+ef+HiPwK/6Gy4/8FV1/8bo/4eI/Ar/obLj/AMFV1/8AG6+hv7F0/wD58LX/AL8r/hR/Yun/APPha/8Aflf8KAPnn/h4j8Cv+hsuP/BVdf8Axuj/AIeI/Ar/AKGy4/8ABVdf/G6+hv7F0/8A58LX/vyv+FH9i6f/AM+Fr/35X/CgD55/4eI/Ar/obLj/AMFV1/8AG6P+HiPwK/6Gy4/8FV1/8br6G/sXT/8Anwtf+/K/4Uf2Lp//AD4Wv/flf8KAPnn/AIeI/Ar/AKGy4/8ABVdf/G6P+HiPwK/6Gy4/8FV1/wDG6+hv7F0//nwtf+/K/wCFH9i6f/z4Wv8A35X/AAoA+ef+HiPwK/6Gy4/8FV1/8bqNf+CjXwEaZoR4xkaZRlohptyXUepXZkD619Ff2Lp//Pha/wDflf8ACvlP4a6bZt/wUS+MEbWluY18LaUQvlLgcnnGKAOm/wCHiPwK/wChsuP/AAVXX/xuj/h4j8Cv+hsuP/BVdf8Axuvob+xdP/58LX/vyv8AhR/Yun/8+Fr/AN+V/wAKAPnn/h4j8Cv+hsuP/BVdf/G6P+HiPwK/6Gy4/wDBVdf/ABuvob+xdP8A+fC1/wC/K/4Uf2Lp/wDz4Wv/AH5X/CgD55/4eI/Ar/obLj/wVXX/AMbo/wCHiPwK/wChsuP/AAVXX/xuvob+xdP/AOfC1/78r/hR/Yun/wDPha/9+V/woA+ef+HiPwK/6Gy4/wDBVdf/ABuj/h4j8Cv+hsuP/BVdf/G6+hv7F0//AJ8LX/vyv+FH9i6f/wA+Fr/35X/CgD55/wCHiPwK/wChsuP/AAVXX/xuj/h4j8Cv+hsuP/BVdf8Axuvob+xdP/58LX/vyv8AhR/Yun/8+Fr/AN+V/wAKAPnn/h4j8Cv+hsuP/BVdf/G6P+HiPwK/6Gy4/wDBVdf/ABuvob+xdP8A+fC1/wC/K/4Uf2Lp/wDz4Wv/AH5X/CgD55/4eI/Ar/obLj/wVXX/AMbo/wCHiPwK/wChsuP/AAVXX/xuvob+xdP/AOfC1/78r/hR/Yun/wDPha/9+V/woA+ef+HiPwK/6Gy4/wDBVdf/ABuj/h4j8Cv+hsuP/BVdf/G6+hv7F0//AJ8LX/vyv+FH9i6f/wA+Fr/35X/CgD55/wCHiPwK/wChsuP/AAVXX/xuj/h4j8Cv+hsuP/BVdf8Axuvob+xdP/58LX/vyv8AhR/Yun/8+Fr/AN+V/wAKAPnVv+CjXwEWYQnxjIJ2GViOm3Idh6hdmSPepP8Ah4j8Cv8AobLj/wAFV1/8brmfH2m2a/8ABRv4XRC0txG3g7UiU8pcH951xjrX1Z/Yun/8+Fr/AN+V/wAKAPnn/h4j8Cv+hsuP/BVdf/G6P+HiPwK/6Gy4/wDBVdf/ABuvob+xdP8A+fC1/wC/K/4Uf2Lp/wDz4Wv/AH5X/CgD55/4eI/Ar/obLj/wVXX/AMbo/wCHiPwK/wChsuP/AAVXX/xuvob+xdP/AOfC1/78r/hR/Yun/wDPha/9+V/woA+ef+HiPwK/6Gy4/wDBVdf/ABuj/h4j8Cv+hsuP/BVdf/G6+hv7F0//AJ8LX/vyv+FH9i6f/wA+Fr/35X/CgD55/wCHiPwK/wChsuP/AAVXX/xuj/h4j8Cv+hsuP/BVdf8Axuvob+xdP/58LX/vyv8AhR/Yun/8+Fr/AN+V/wAKAPnn/h4j8Cv+hsuP/BVdf/G6P+HiPwK/6Gy4/wDBVdf/ABuvob+xdP8A+fC1/wC/K/4Uf2Lp/wDz4Wv/AH5X/CgD55/4eI/Ar/obLj/wVXX/AMbo/wCHiPwK/wChsuP/AAVXX/xuvob+xdP/AOfC1/78r/hR/Yun/wDPha/9+V/woA+ef+HiPwK/6Gy4/wDBVdf/ABuj/h4j8Cv+hsuP/BVdf/G6+hv7F0//AJ8LX/vyv+FH9i6f/wA+Fr/35X/CgD55/wCHiPwK/wChsuP/AAVXX/xuj/h4j8Cv+hsuP/BVdf8Axuvob+xdP/58LX/vyv8AhR/Yun/8+Fr/AN+V/wAKAPnn/h4j8Cv+hsuP/BVdf/G6ZN/wUY+AttGZJvGMkES9ZJdNuUUemSUwK+if7F0//nwtf+/K/wCFfMX/AAUo0uyt/wBiv4ivFZwRyBLPDJEoI/0yHuBQBrf8PEvgScEeLLhgehGlXRB/8h0v/DxH4Ff9DZcf+Cq6/wDjde2eDNH09vB+hE2NsSbCA/6lf+ea+1bX9i6f/wA+Fr/35X/CgD55/wCHiPwK/wChsuP/AAVXX/xuj/h4j8Cv+hsuP/BVdf8Axuvob+xdP/58LX/vyv8AhR/Yun/8+Fr/AN+V/wAKAPk/9kfxxpXxU/ag/aF8aeG2ubvw1qUXh+G0v5rWSFJnit5lkVd4BO0kZ+or69qG3s4bWMpBFHCpOSsahQT68VNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByXxS+GGgfGTwLqng/xRbSXmhakqpcQxyGNmCsHGGHI5UV0Gl6bBoumWen2qlLa1hSCJSckIoAUfkK+R/iouq/tL/tcXXwfk8Qat4e+H/hHQotX1mPRLlrW41G8mbEUTSrysaoQ3HUg1qfsi+INf8D/GH4s/AzXdcvPE1l4SktdR0HVNSl8y6Njcx7vIkY8sYzgbjycn2oA+saKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApkiiRSpHysMGn18oftxftLXvwnl8G+A/D3iC18KeIvGE0nm+ILuIzLpdlEB5kiRgEvM5IWNQDlqAPffhL8KfDvwT8CWPg/wpayWWh2LzPBDLIZGBklaR/mPJyztXZV8tfsY6l8M2uvE1p4T+I3ibxr4tbyn1qDxfcyrfRFc4kFtIq+WrF/4RjlfavqWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKOsaTba9pF7pl4hktLyB7eZAcZR1KsM9uCawPhf8ADPQPg74D0nwf4Xtns9C0tGjtoZJDIyhnZzljyfmY18i/8FJLPx/4X0LSfGml/EbVNH0GHWdNsbfw7piiBXkkkYSyTSj5nGAAq9Bk9a+pvi/8L7j4veDYNAj8W614Rt3njlu7nQZhDcXEIU7oPMIJVWyMleeKAPQN1LXxB8O/DOofs4/tveHvhr4U8Wa94h8HeIvDlzqmp6Prt+961hJGxEc6u3Khjhce59q+36ACiiigAooooAKKKKACiiigAooooAKKKKACiiigBC1G6o5o5HhkWOTy3KkK2M7Tjg4718WfAPT/ABv4I/bs8VeFPFnxD1bxy0vgqPVpjdgRW0Vw90qlYIV+VEVRgd8E5NAH1DcfCHwzefFy0+JctpIfFtrpTaNFdeadgtmkMhXZ0zuJ561227tXwb+0NrukeIP2sNT8KfGvxvrXw++G8Ghw3PhYafqEmnWmp3Gf9JkkuE5MqE7QhPTn0z6r/wAE+9f8T+Ifgzq82talqOueHofEF7b+FNZ1fP2q/wBGVgLeWQnk5+cAnqBQB9PUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJS0yRC0bqGKkggMOo96AHZ9q4fUPg94X1X4taX8SbizkbxZpmnyaXbXQlIVYHYsylOhOSea+O/2qv2eZ/gL8GvEfxbsfi/44l+IWjvHdwalqGqnyLmRplUQG2GI9pDbQoHavfPjJ+0Lqnw3+C/hW5stO/tD4o+MYILHQdDVOZtQliVnZh/DHFuLsegAAPWgD6AzS18ef8E5L/xg+g/FbSvG/iW68Ua7o/i+ewlvbiQuNyxpuCA/dXdnAHFfYdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU0NnpTq+cf2sPh78Pta/s/xD8Tvihrngfw1bxG1isrLWm061lnyzeYSo3M+3jGeg6UAes+BvhL4b+HXiDxbrWiWkltqHim+Go6m7ylxJMF2ggH7vHYV2m7vivz1+E/x98afCH9iX4r+OZb/AFLxNoOl6pPZ+ANW1vm5vLN5Eht5nJ5dFkfIJ5OxhUfxQ+Gfi/8AZJ+FXhL452vxB8TeIfF9ld2M3jGz1PUWms9VguHVZ40hPyx7WcbSOwzQB+h9FQ2twt1bQzp9yVA6/QjNTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACVxek/CXw1ovxQ1z4gWtpInifWrOGxvLhpSVaGL7gCdB9a8o/ay8A/DzWotM174nfE7W/A3hy3RrWK1stabTraeY5beSvzM+0HjPQdK8k/Zk+OWufCr9j34kfEDxLf6j4p8JaBq1+3hC+1aT/S9S0xWVLUyMecNIcZPPJ9BQB9zbvalr86vgL8TPB3xD8eeEPFPxU+NWvXvjrU547rTdHs/tGn+HYJiRts4W2COdlyA2WILA1+itABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUm6lryL9pb45L8EfAcc2nWh1jxlrlwul+G9FjGXvb5+EGP7ifeY9gPegDqNT+EvhvVvilpHxDubSRvFGlWMum2twJSEWGRsspToTnvXabvavir9ggePdQh+O3hrxt4xvdX8S2GvtYvqiybxaytBlzAG4VVdiQOnAri/2mPgze/sk+E/D/AMS/BfxM8Y6p8QRrlnZCy1vVXuotfaaUK8Bg+6CRk/KOACKAP0KoqK3kaSCNnTY7KCy+hI5FS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADd1cj8Vvhb4e+NHgHU/B3iq2kvNB1MRi4gjkMbNsdZFww5HzItYf7QXxt034C/De88SXdvJqWpSSJY6TpNvzPqN9IdsMEY7lm6+gBNfM37DeofE21+NXx40b4g+IZvEHiWzg0y9NpJMTbWk9xFLMYIh0VVLKnHZKAPtyws4tNsbe0gUpBbxrFGvXCqMAfkKsbq/I8eNLTVfg/q3i/VPij4xsf2rIdXktovCsd9Krpe/atsVpHY/caExbeemM88V+rXhSbVbjwvo8uuxRwa09nC19FCcok5QeYF9g2cUAa9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8ZfEjXX/AGXf20NQ+Jeu6Zql58PvHHh+HTrrUtMtJLr+z7+3b5BKiAsEaPocdT7Vr/sh2Op/Ev43fGD443ej3uh6D4me00nw/balA0NzNaWqFWuGRuVEjYIB9DX1m0YkUqwDKeqsMil24wBwPSgB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8cftXaC3w4/aa+FPxx1Lw7d+JfCGi2l1o+qixtTdT6a0mWhuxEASQGZgWHI49q+x6aV3cHkYwRQB8UfDTVIv2h/25rT4p+CtF1DTvBvh7wzLpOo67f2D2Z1W5kkJSJFcBpAi4O4jjaB6V9s0xYljXCqFXsFGBT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+SP8AgpnpF/rf7PukwadY3N/OPFGmSGK1haVgokOWwoJwPWvSP2rP2hpf2b/hK+v2Ph3UPFGu3J+yabp1jbvKpnKEhpSoJWMYyT3wAOTXtpjDdefqKRo1b7wDfUZoA+Df2G/ih4MuPHdxNrUnirxF8Z/HBabVdc1Pw7Pa2luscbSC0hdhiOFApAH8RA9q+9ajWFF5VVU+oAqSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+VfD+lXq/wDBSjxTqJsrhdPb4e20K3ZibyWk+1g7A+MFsds5r6qpuwZzjn1xzQB8A+MLzw14O/a++JN/+0L4dvte8O6hZ2y+C7+402XUdNtrQRkXEKIisI5WfGcjJIPOMV6L/wAE9vD+s6TpPxIv7XT9U0H4XalrzT+DdG1lWSe2tQCJCsbcxxM23ah6BTX1vJCsgw6q49GGacFxQA6iiigAooooAKKKKACiiigAooooAKKKKACiiigAqrqWoRaXp11ez7vJt4mmcIpZtqgk4A6njpVqm7c9aAPzD8QftVeGfj58aI9a+KGh+M9O+G3hS8Wfw94Tt/DlzMNUuF6Xl4QMYU/di7c5r6b8Vfs433xw+I+gfGrwv8UfEHg64udDih0yzfSoZPsVvKodtscwzE7gjdxntX0/5Ef9xf8AvkU7aBwOB9KAPiD/AIJ+/DPxn4X8e/GS/wBc8XaveWMXiu9t5LC+09IY9SlOz/Td2AcnGML8tfcNNVQucDGTk06gAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+f/j9+0L8K/A/iAeEPiRoGo6nC9qt7HJJ4ekv7Js7htV1RgJOOnuK+gKjkhSXAdFcDpuANAH5s+A/gT4n+Mn7Nf7Ren+GtD1Twt4P8R6qmpeBNE1VGhcCBhKwSJjmJJXQKBwM81sfFz43XP7YPwX8HfBfw34Z8Qaf42167sIPEqX2lzQQaJDbur3EjysoVhujwuD8wPrX6IbRwBwOlIsKKxYKoY9WA5NAEdparZ2sMCfciRUXPoBj+lT0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgPx+/aE+FngTxBH4R+I+gajqkUlqt7FK3h6TULNiSy7FdUYCTA6ejDnmvknwb8D/F/xg/Zl/aW0/wAKaBqfh/wJ4o1GG88C+F9UDQyr5EommKRv/qkmZECqcAYx71+mEkKTDDorj0ZQacFAx7dKAPzZ+OHxV0b9pz9n/wAE/B/wJ4H13T/iHJe6dGtjNoktqnh1oHUzTGVlCqqhWAIPIOa/SWFTHCisclVAJ/ChYUVmcKodurAcmn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzr8YP2T9Y+Jnxo0z4kaV8UdY8J6npdgbCwtbewt7qG1DZ8x4xKDtdxgE9cDFfRVFAHwJ+yL4U8W/Cb4jftDeLvE3i/wAQarouh6xcz3tm+kora2yQbvtK4XJfCkBY+Ca858F/tTeH/ij8cYvij8YtH8YWsOgTvH4O8G2nhy5nt9PBOPtk8gXEk57cfLx6Cv0+8sc8DnrxSfZ4/wDnmv8A3yKAIrC8TULG3uog6xzxrKqyLtYBgCMjseelWaTbS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgHx8/ZZ1D40fEjwj4z0/wCIuqeEL/wxFIthb2tlDdQpM+Q0+2UECTaQoPUY4r5q+Enwd+Lej/tH/tGy6X8QtYu9ctdMtVtr6+02KGHW7prGVbcuwXCiFyv+r9Oa/RSmeWMkjg+tAH5O2cnwun/ZPuPB+r+APE0n7RLCVWdtIuW1h9aLkrcrd7ceXu2878BeMV+l3wU03xJo/wAIfBll4xuGuvFVvpNtFqczNvZrhY1Dkt3Oc5Pc12fkp5m/Yu/puxz+dPxQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACbvajdXxd8M/25PEfir9t7xF8GNa0XS7Lw7b3N7ZaZqUAkE808CCTYxLFclNx4A6CpPjf+3Hrvw/8A2yPBXwf8PaRpmpaPf3Nhaazf3IkM1rNcuxEaFWCg+UFYZB60AfZ1FcR4k+N3w/8AB3iSHw/rvjTQtI1ubGywvNQiimOenyk5Gferfiv4s+C/As0sXiLxVo+iSxW4unjv72OFhCW2h8Mc7c8Z9aAOq3Ubq+ff2if2wfC3wd+BUnxE8P6novixZp4YNPt4dQQLeEzIkmxgTkor7iB0xzWZrH7YGlab8efCXhz+1vDy/D/VvDFxrlx4hkvBtjljl8sIsm7Ztzwe+RQB9L0Vyum/FTwdrPg6XxZY+KNJuvDEQYyavHeRm2TBwd0mcA5I4PqKXwL8UvCHxOtbi58JeJdL8SQW7BJn0y6ScRk9A208ZwevoaAOn3Ubq+av2y/2prn4A2fhLRfDN54d/wCEy8SatBYxp4guvLgsbZ9+66lVSGEYZNu7p19K9O0z44eD9L0bSYvEvjjwvFrskVrFcra6hGInuZYwyiIFtxV+SvqMUAek0VxF78cPh9pvi9PCt3410G28SM4jGlSahEtxuPRdm7OT6dan8W/GDwP4BmuIfEni3RtDnt41mlhv76OJ0RjhWKk5wTnH0oA7CiuAk+P3w1jvNHtX8e+HVuNYQSafGdShzcqTgFPm5BII+oxXdyybInYDOASPyoAfupa+CfB37VX7S/jj4K33xZ0bwj8P7/wvYteSSacZ7qO9eG2kdZduWK7sRkjn/Cvpvwf+094F174N+E/iNretWPg/SfEVolxBHrN2kTKxHzR5JG4qcjI+vegD1uiuWs/il4Q1HwvD4ltfE+kz+HppFij1SO8jNuzltoXfnGS3GM5zVfwj8YPA/j7V7zSvDXi7Rte1Kz5uLXT72OaSMA4JKqTxnigDr91Lmvm79qT9sDQfgz8NfFF/4S13w5r/AI20Wa2jk0Ka8V3XfcRxPvRGDZUOfoRzXrXij4zeCfh7b6YfF3izRvDdzqESyQw6jeRwtJkclQxyRnjNAHcUVzms/Efwr4dsbC91TxHpWn2V+pe0ubq8jjjuFC7iUYnDDbzx2rm/+GkPhZ/wjra9/wALC8N/2Mtx9kN7/acXl+djOzO772OcelAHou4U6vMPHXxE1a21L4ey+EtQ8L3eia9qKxXlxqV/see2KZBstpxLJ7elXLz9oj4X6fezWdz8QvDNvdwyGKSGTVYVdHBwVILcEHjFAHodJurhvFnx1+HfgPVrfS/EfjbQdE1GdVeO1vr+OKRlb7p2k5wfU15x8dv2uPDvwW8efDbw/JfaPcp4pvxBeXE2oJH9htWQstyRnlCRgE8H1oA9/wB3tTq8v8C/ETVtb8b+PYtV1Dws3hPShbzaXc6ZqHmXKwvEXd7wE7Yx0KkcFea3/BPxj8DfEm6vLXwp4u0bxDc2YzcQ6bexzPEM4yQpzjPegDsaK89k/aE+GUWoafYt4/8ADgvNQYraw/2nDumYMVIUbufmBH1Feg0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfkl4whbwv8UPjL8T4Mxy+A/izpeoXFwv3ktJd0My5/uncoIppiPjT4yeBPi59+38afGkDTJ+01haKIYXHsSHGPavvJv2OPCs2l/GjT7rU9Qurb4pTGfUlk8s/ZG2lVMPy/wAJIYbs8gVTtP2J/Clj4N+Dnhy31jVIrT4Y6kuqafIvl77yUMWPnfLjBJJO3HWgD5f8D/Dfwr8Uv2Zf2rfG/i6xs9S8VXGt+IC+r3kIkmsRaxbrdIyeUEZAIAx1qv8AAbwrpPxu/aT+C1x470m28RtH8HLO78vUovNR5hNsWVkbhiQSefXNfQvj39g208UeIPGn9h/ETxF4Q8IeN7o3viXwzpyxGC8mbHmujspMZkx82M5r0/w7+zT4a8JfGDR/H2lXF3ay6T4Yj8KWmlLt+zJao4ZW6btwwB1xQB+cXjzwL4ctv2T/ANpKGLRLFYtB+Jnk6SvkjFgj3NsrrDn7gZflIHUcV9GeK/g34G1H9ur4ReGJ/CmlN4csvA95dwaP9mUWqy+cTu8oDaeWY8jrzXsWsfsQ+E9c+GnxS8F3Wtas1l4+1pteurlWjWWzuC6OvlELgqrRrw2c81seBf2XU8LfELwl431nxrrfivxJ4e0a40RbrUFiH2mKWQvukCr95eFGD0HNAHxXp/wbPjT4a/G/wT4Xv9E0NNL+MRutK8Oaxci207VDGEP9nkZHyuOQi5yUA9x7b+y3feH4/wBqbxFbaz8PdQ+EPxSbw5HHdeHbKWGXRdQtEkG27haNR84OF55A465r0XxJ+wp4R8SeHvGlhJrmsW2oeIPFX/CZWuqwOiT6TqIACPBgYKjnhs9T7V0HwZ/Zfk+HfxE1H4geKvG+rfELxtdWC6VFqWpRxwpa2ituMcccYAyzcknPTtzkA8n/AG/fh/4Z8QePv2fL3VNA07Ubu+8dWOmXM9zbq7zWhEjGByR80eSTtPGTXN/Bn4H+BfFv7cHx/udZ8MadqS+HI9Hi0m3uIA0Nn/o3BjTopAjUA44HSvqj4vfA7TPjHqngS91LULyxk8I69D4gtVtdmJ5YwQEk3A/Kd3bBpPAvwL0rwD8WviD4+tL+8udR8aG0N3azbPJg8iMovl4GeQcnJNAH5/eC/hj4U8Zf8E2fiX4/1nT7WXxvPfarrUmvPHi8hvIbpvK2y/eX7qjAP8ZFd18JvB+ifHD9sTS9W8eaPa+JLqT4QaVfPDqMIliNxKUDyFGGN2GYc9Nxr1rWv+CeumalPrWh2nxC8R6Z8Ltb1X+2NS8D2/l/ZpZi4kdFlxvWJnVSVH517Nov7P8AomgfHC/+Jlnd3UV9daBD4dGmKEFrFbxPuVl43buMdcYoA/NTTvhD4Lsv+CanjnxPH4csf+Ejg8SzJBqrx7rmBY79I0WNz8yAJkYX1PrX6yeH3Z/CGmuxLO1hGSx6k+WK8PX9inwwv7OetfB3+3tW/sTVdQk1GS//AHX2lHe4E5Vfl24DDHI6V77Y6ethpdvZK7PHDCsIZvvEBcAmgD8p/hX8P/jdrX7AviXVfCnxO0/SvBiLrEsvhk6Mi3MsKXEpuIxe7iQXAfGF/ixmvQtP1D4d+IIP2b18NfDnUvHHjOPwa02h+Crq8hGl2duw2S3V1LIpywdTggZOOmcV9ifC/wDZr0L4XfAm9+FdpqN9qGi3aX0cl3dbPPxdM7PjaAOPMOOOwry1P2Brfw7a/D+fwd8R/EHhbxF4P0ybRIdbhhgklurGSQyeVIhXblSxwQPrk0AfGOqaZewfsc/tBaHq+m2eivD8V4IpdH0mVjaWTNPbh4oDxhB0BAHSvob4neB9A+Cf7YngC48BaFZeG5n8A60Xj02ARrOYYS0W9V+8QQOTzwK9As/+Cdfh618K+N/DL+O/E11ovirVbXW7mO5eKSVL2J1d5g5TlpGUbs/hXtfiT4D6R4n+NHhT4kXV9dLqPh7TrrTIbFQht5o5xhy+RnIHTBAoA/OLxJ8G/Bf/AA6t0Txx/Y9nP4xnvYNRn19ox9snuJNR2PvlPzN8rFcE/wAI4r6D+D/gHw58Yv2uPj8/jfSbPxI2l6ZpWlWMGpwCZba1e2LOIwwwu48kjmtnVv8AgmrpmqeHb/wYnxQ8WWPwze+Oo2HhK3MRgspTL5m1XZSWjDFsKehbPXmvQfiZ+x/J4m8fXnjTwT8Qtc+G+v6rp0el6zNpMcciajDGNqMyuPlkUcB17UAfDPw90Ky8feBv2ZPCniCP+3PD9l8RtY02G3uyXR7WNiyRnPVB0x0xxXtfhH4A/Di8/a7/AGl9Pn8GaRLpul6Bp81lYNbKba2kmtCZXSL7qsxRfmAz19a+h9H/AGLfBfhvS/hLp2kXeoWNr8Or6XUbNQyu19PKD5rzkjJLMS3y45PpxXW6P+z/AKRo/wAVPiN46j1K9fUPG9ja2F5bPs8q3SCJo1aPjOSGyck0AfBvwxZpPgb+w9vJcr4vnVSTnADzAD6AYH4V6J8XfgT8O/2h/wBq3S/hr4W8E6HZaT4XuF8Q+PNctbRI5biRyTDYb1GS0hJZ+en0r3vw9+xZ4Z8O+D/hJ4eg17VpLf4b6pJqunzP5e+5kcuSsvy4xlz93B4Fcn4V/YLv/Aepa/d+Gvjj490Vtc1KTVdQEBtSZ7hzkszNESfTk0AeA/FnT/DviTU/2j3+HPw0/wCFh36rPb+JPGHiy4ijtNIkhgI+y2K7DI/lqoPGMEDJxiq174B8M+KPBH7D93rGg6fqt3qdxb2N9NeW6yPc26wErFISPmQHopr6R1v9g+3vfEXjY6T8SvE/hzwh41la71/w5p5iCXVw6bZZFlZSyB+rAdemcVNqH7C9pefCD4c+DIviF4istT8A3xvdF8RwLELqMfMFjZdu0qFIA4z8o96APkj9oW4k8L2P7Z9tpB/s6Br7w1p+y2+QLbuUjZBjou0kY9K9z+MXw88M/BP9o79mC+8B6VZ+H7m9mvNEu102ERfbbL7KvEoX74U/MCc8nNexyfsW+E9Ws/ijb6/q2qa8vxDt7OLVGuGRGjkt49qTRFVGH3APznkenFU/hb+x2/hH4iaH4x8Y/EPXfiPqfhuyksPD0erJFHFpsci7HcKg+eQoApc9hQB8IyfCjwha/wDBKzxV43Tw/Y/8Jc2utMuttEDdRsusJCNknVRsyMDjk+tfrtYZ+w2//XJf5CvnqT9ibwvJ+yzqHwMOvav/AMI/eXRun1L919qVjeC6wPl243KF6dPevoqGIQwxxg5CKFB+goAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVBdXkFlEZbiaOCIcF5XCr+ZoAnorM/wCEn0f/AKC1j/4Ep/jR/wAJPo//AEFrH/wJT/GgDTorM/4SfR/+gtY/+BKf41Wl8c+HIHKS+INLjcdVa8jBH/j1AG5RWB/wn/hj/oY9J/8AA6L/AOKo/wCE/wDDH/Qx6T/4HRf/ABVAG/RWB/wn/hj/AKGPSf8AwOi/+Ko/4T/wx/0Mek/+B0X/AMVQBv0Vgf8ACf8Ahj/oY9J/8Dov/iqP+E/8Mf8AQx6T/wCB0X/xVAG/RWB/wn/hj/oY9J/8Dov/AIqj/hP/AAx/0Mek/wDgdF/8VQBv0Vgf8J/4Y/6GPSf/AAOi/wDiqP8AhP8Awx/0Mek/+B0X/wAVQBv0Vz7fEDwui7j4j0kD1+3Rf/FVe0XxHpfiS2a40nUbTU7dW2NLZzrKob0ypPNAGlRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfK//BR/TLbWf2ftO068j86zvPFOkW88WSN8b3KhlyOeQa+qK+Yf+Chn/JEtC/7G/Rf/AErWgC4v/BOj9nYqD/wrSx6f8/dz/wDHKX/h3P8As7f9E0sf/Au5/wDjlfRyt8q/QU+gD5u/4dz/ALO3/RNLH/wLuf8A45ViL/gnr+zzDGEX4ZaYQO7SzsfzMlfRNFAHzz/w76/Z6/6JhpP/AH3N/wDF0f8ADvr9nr/omGk/99zf/F19DUUAfPP/AA76/Z6/6JhpP/fc3/xdH/Dvr9nr/omGk/8Afc3/AMXX0LnjNLQB88/8O+v2ev8AomGk/wDfc3/xdH/Dvr9nr/omGk/99zf/ABdfQ1FAHzz/AMO+v2ev+iYaT/33N/8AF03/AId+fs9f9Ev0r/vub/4uvobdXn37Qt5c6b8B/iFd2dxLa3UGg3skU8LlHjYQOQysOQQe4oA87/4d9/s9f9Ev0r/vub/4uk/4d+fs9f8ARMNJ/wC/k3/xdfNvgj4oeKf2j/hz8I/gZ4K8S30GotoVnq3j3xdbXbm6sLUAMtsJQdwnmO3nOQD6E1778RP2qo/hf48b4W+B/h94j+I+o+HtJiutYOlSqzafblcRhnkbMkpUbsZyc9c5oA1v+Hfn7Pe4H/hWGk/99zf/ABdcb/wT18P6d4Tt/jXouj2qWGlWHj2+t7W1jzsijVUCqM9gBWj/AME2fF2o+Of2Z4NY1PUb7U57jW9RKzajM0syx+e21CWJIwOMdqP2F/8AkK/Hv/somofySgD6oooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmH/AIKGf8kS0L/sb9F/9K1r6er5h/4KGf8AJEtC/wCxv0X/ANK1oA9i+KHh3xv4isdPTwT4qtfC1xGxNxJdWIuhKpAwACRjB7157/wrP49/9Fe0n/wnk/8Aiq98UfKPpTqAPAf+FZ/Hv/or2k/+E8n/AMVR/wAKz+Pf/RXtJ/8ACeT/AOKr36igDwH/AIVn8e/+ivaT/wCE8n/xVH/Cs/j3/wBFe0n/AMJ5P/iq9+ooA+f/APhX37QcHyx/FLw7Ov8Aen0EhvyDUf8ACB/tD/8ARTfC/wD4I2/+Kr3/ABS0AfP/APwgf7Q//RTfC/8A4I2/+Ko/4QP9of8A6Kb4X/8ABG3/AMVX0BRQB5z8K/D/AMSNFur9vHfinSfEMMiKLVNNsDbGNgTuLZJznimftJNt/Z8+JJ9PD1//AOiHr0fbUN9p9tqlnPaXkEd1azo0csEyBkkUjBVgeCCOxoA/LL4c/CmD9kn4KfBP9pHwPb3E0S2ccfjuzLvIb2xu2XdOB0HktjAxjhT2JPtPws+L3gv4c/ti/HXVvE/iTT9J0vxRpGk63ouo306xw39mLcgtC54cAnGBX2xH4W0ePw6dATS7NdDMBtjpot1+z+URgx+XjbtIJGMYrnNa+CPw+8SQ6RDqvgrQdQh0hdmnx3GnROtquc7YwVwq57DigDwP/gmPqFvq37MYvbPi0uPEOqSwjGPka5YjjtwatfsL/wDIV+Pf/ZQ9Q/klfS+g+G9K8LWAsdG0200myDtJ9nsoFhj3McsdqgDJPNfNH7C//IV+Pf8A2UPUP5JQB9U0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFfP/7aX7VDfsj/AAz0jxaPD/8AwkYvtYi0s2vn+SUDxSyFwcHJHlYx70AfQFFeBfE79qyy8E+H/g7rWk6Wuuab8RdYsdNglE+z7PHcpvEvQ7sDtxXuialayfaNlzC/2c4m2yA+WR2bnj8aALNFZ8niDTIYUlk1GzjikRpEka4QKyDqwOeQPWqTeOvDa6fBft4g0oWM7+VDdfbYvKkf+6rbsE+woA3aK8f+Jn7QEXw6+Nnwp8CSafFNaeN11R31WS5EaWS2dus2cEYYNux1GK9S0vW9P1yyF5p19bahZsSBcWsyyRnHX5lJFAF6isrSfFWja9LcRaZq1jqUtucTJaXKStEfRgpOPxp0PiTSbi8htItUspbqYM0cCXCGRwv3iqg5IHf0oA06Kp6lq1notnJd6hd29jax8vPcyrHGv1ZiAK4z4ofGTRfhv8IvEXj5bi21fTtK0+a9iW1ukK3TIhYRo+cEtjFAHf0V5Z+zb8UvEnxj+FuneLPE2gaf4cudS23FrZadqS3y/ZnjR42dwBtchjlOoxXkF/8AtZ/Evx5418eab8HfhdY+MNB8F3j6Zf6tq2sfYftV5GMywW6bG3FemTgdPUUAfWVFeYfs/wDx40r49fCXw542gtn0Q6t5kTabesFlinjdo5I+cbsMpxgcjBrV+MnxQh+FPww8Y+Ko4YtTuvD+lT6mdO84I8gjQtg9SoOMZxQB3VFcR8LfippXxJ8H+GdUW6srXVdY0m11R9JW7SSaATRLJtK53EDdjOO1M+HnjfX/ABNf+L4vEHh6Lw/a6TqklpYXC3qTi9tlAInYL/q88/K3IxQB3VFZej+J9I8Red/ZWq2Op+S2yX7HcpN5bejbScH602LxVo1xq8mlRavYSapHy9it0hnX6pncPyoA1qK8k+Hv7ROjfEL41fEf4dWsKQXfg77Bm8N1G6X/ANpgab90oOf3YUhvQ16LpnizRdavJ7TTtX0+/uoDiaC1ukkeP/eVSSPxoA1qKhuLqKzhkmnlSCGMFnkkYKqgdyT0FZmm+MtC1myuLvT9b02/trfPnTWt3HIkeP7zA4H40AbNFeU/s5/tA6X+0V4El8Sadaf2aY765smspLhJJB5UhTedp4DYyK4b4zftKeOfCXx4034W+APh7Z+NNZutAOvu95rC6eqRCdoiAWUgnIX8z6UAfR9FfL3w5/a+8SeNrH4maBffDebQ/in4Jgjnl8Mz6jGYbxZATG0dxgKAcdSMcivfLLxtaWfhfR9S8TXNh4aur63jeS3u72NVjlZQWjVyQGwTjI60AdLRXkHxD+Py+Cfjd8IvAMGmJqUHj7+0iNSScAWwtYFmBAAO8Nux14r1VNStZLuS1S5he5iAaSESAugPQleozQBaopu7pTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmH/goZ/wAkS0L/ALG/Rf8A0rWvp6vmH/goZ/yRLQv+xv0X/wBK1oA+nE+6v0p1c/4n8TT+G7e2eDRr7WTKcFLFQxTAHJyRXPr8VbsZ8zwX4hj9P9HVv5NQB6BRXD2fxMmvLyCA+FNehEsioZJLYBUycZPPQV2N5dG0s55liedo0ZxFHyzkAnaPc0AT0VznhXxZceJGuFn0LUdG8oKQb5FXzM5+7gnpj9af4r8UXHhqO3aDRL/WTKWBWxUMUxjlskdf6UAdBRVHR9SfVNNt7qS0msXlXcbe4ADp7HHeuc17x9eaLqs1nF4W1jUkjxi5tI1MbZGeCT2oA7GivPv+Fp6h/wBCN4g/79J/8VXReFfFE/iSO4afRb/RjEQAt8oUvnuME0Ab9I2dpxye1LRQB4t+zv8AtGp8bPC/jPUNR0f/AIRzUfCet3mjajZmbzQrQAHzA2BwQfTsam/Zp/aEX4+fCK38fX2lxeFrC8vbi3tI7i6Db4o5CgkLEAAsVbj2r49+KnxAH7L/AMRP2tPD5VopfF2hW3iLw8q/xTXA+xSke4nlVseiGrGrfBDTbz4rfsvfs/eKI5b7whpfhS51XVNNjmeKG/vRH8xfaQSBIGPXofegD7C+Gvx4HxC+OPxW+Hy6ULZPA/8AZhXUVn3i8F5btNkLj5du3HU5zXmP7C//ACFfj3/2UPUP5JXHfsS/DfTvhH+1f+094W0eWeTSLOTQWtFuZ2meGOS3ndYtzEttQNtUE8Kq12P7C/8AyFfj3/2UPUP5JQB9U0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfHX/BSuzg1Hwn8FLS6jWa2uPido8UsbDIZWScEEfQ19i15J+0L8Abb9oCx8FW11rE2jDwz4ms/EqNDCsnntbhwIjkjAO/qPSgD8+fE95L8OvGHwz+BepzNJfeBfi7Yz6U7kkTaRdF5bYgnqUJdWHbAFe9/CFyY/21vmY/8TrUMcnj/Q2r1T46fsT+H/jV8ePAHxVOs3Gh654XngkliggWRNQSGUSxK+SNpB3jIycN7CuZ8WfsV+Lbrxx8Sbnwh8WLrwl4R+Ibm41zTE01Li4WYoUcwSsRsDgkHjODigD5o8CeAtG+KGofsTeHvElu2o6Lc+HNUkubNpGVLgIoYI+CCVyBkd+hqzpf7NPw4vPEX7Y2iXHhyKfRvCFr9o8Pae8rmDSpZrGSZ5IEzhG3onPooHSvrfwN+xvY+CNY+C2oR+KLq6Pwz02702GNrZFF+J12l3OfkI9s1tWX7LdpZ658ctTHiC4ZvilAkE8f2dcafttngyhz8/D7ucdKAPkD/hB9N+Nlx+wZoXi531PTbzQdUlvIZ5W3XaxWVu4jZgclW2AMM8rkVyPxm1i5/ZlP7WngH4dfaND8OtDoM9lbWTkJprXZSO5SLn5PMV2A9OPSvrTxT+w3cX3h34KweH/iHfeHtc+FdlPb6XqcdjHJ9pkkSJd0qE8LiLBUdQ5FWNB/YbsdW+H3xT0v4i+JpvF/ij4kSRS6xrkNstuIWgA+yiCME7ViIBAJ5xg0AeI/Dj4P6v4N+Pnwj1bwV8HLv4T6JY2V3p+vz3mq25bVoTb/ACM6I5Mrq+WJwTlq6T/gmf8AAPwVJ4BHxQutLN/43OtanDb6pdSu7WkQlkj8uFc7VUhmJ45LGvUvh/8Asm+K0+JHhPxd8TviN/wnVx4NsprHw9BBpq2gTzIxG09wQxMkpUAZGB3r0z9nH4Gwfs8fDVPCFtq82txLfXV99rniWJszSGQrgHHGcUAeGftWaLa/Fj9rX4DfDLxGPtfgi5i1LWr/AEhnIi1CaCIGFZB/EqkbtvfJr58+IXwu8MaDcftjfDmLSbabwb4d0m08V6Fpe5/J0i/ks5NzxLnCkl2IHTpxX27+0J+zzc/F7WPBvirw34kfwd498H3MtzpGsC2W4jKyrsmhmjJG6NwADzn864zwv+xnNH4F+L1t4q8Zy6940+KEBh1nxBFZLCkCiIxxJDDnGxFY4BNAHbfse+AvD3gH9nHwFF4d0mDSItR0ez1K7S3zia5ktozJKck8sQM14TH8HPHHgvx14+8efsyePdB1vTdY1WefxB4N1rMtt/aSnMoilU/u5CSchumR1AFfXfw58Ip8PvAHhrwvFctexaLptvpy3MihWlEUapvIHQnbnHvXzld/sg+O/AvjDxnqHwi+LMngfQvGF7JqWpaTeaWl6La5k/1s1q5I2Mx55BA49KAPFJ/j1a/tCax+zBr0Og/8Irqlj48vNL1jRYxhLa8ihzIq4xkHcGyeeeeRVv8AaQY/8L3/AGohvO3/AIVCCBngfe5xXrGr/sA6fpnwe8FeGfBXi270Hxb4T10+JLXxRdQieS7vmz5rzpkZDZXjPRAOak039hvU77Ufifrfi/4mXviPxF8QPDbeH9Quhp0cMVoCMBoEDcKowAp9zmgD5y8VfBTwr8Avg3+yl8RPCFi1v42vPEWhW9/rEczGfUYruAtNG7Z+ZOAqr0C4FYXxI8Xav4b+Dv7TdppUl4kuu/F4aRN9il2TNBKyF40f+HeF2fRjX0x4d/Yn1nwvL4Ch8afFW88V/Dj4auuq6Ro8mmpFP50KfIZpVJLpGAdigZA4rgf2ffhDpH7Vfw3/AGjLG7k1LS9A8T+Pp9U0XWFgaCZCnlvFcRq4GQGA47gkUAYmk+Ctf+Evxks/GngX4Q3Hwe8O2PhDVLfVbOfU7dlv3jgaS3kMSOS7K6jL4J6Zrd/Zu/ZR8DeMP2cvhL8Rb3Vx4Y+ITajH4jn8ZLKv2u8meVy1vK7sN6OCEK/7PHeva/A/7KPiC/8AiNbeN/i345j8f6xpujT6DpcNrpq2UEVvMMSyyAEl5nUkE8D2rjvCf7BWtaTb+E/B2tfEqTXPhJ4T1lNc0vw62mqly8qSNJHDPPu+aJWZiABz/IA8i0H9nPwxdftCftfaf4T0zTfDOvaPpelxeHNTM7QLpc95psondZC3y+YzHcT0zxiq37N+heDfAfxw+DWjeIfA+t/Bf4l6VZ3NgbqCJJtL8Ys0O12a5VjvJIMqn+8/0r6K8efsUy+Nfix8SfEQ8c3dj4W+ImnRWPiLw6tmjeaYbUwQPHKTlShIfpycg8VX+H/7Hvi2z8Y/Dy/8f/EseL9B+HYI8O6XbaWtoxbyvKSS5kDHeyqFxjAyKAN79vT/AIQ64+Actn4517VtG0G81S0ha10OLzbvVZC+VskTPPmYOfZTXzX8D/Buh6p+2prnhVvhM3wz8FeIfhoZrjwjeMqm9Vb1YxPNFG2I2I3JtznC5PWvsH9p79n5P2ifAem6RDrc3hzWtF1e313SNViiEv2e8g3eWzIfvLhmGPeuA8F/so+NdI/aA0j4weI/im2u+JP7LfRtWs49IjgtJrPO5YoFDExAOA5PJJz60AcZ/wAEufhv4X8OfBXU/EWmaLb2Wt3mtahZXF5Hu3yQRXLCJDk4wo4FY3x6j+I0n/BRDw8vwvl0GHxF/wAK7k8xvEKu1v5H25t2AnO7O3Htmvcv2Zf2bdX/AGcZvEmmR+N5/EPhC+vJb3TtIuLNI3sZJZC8n7wHLg57+ma6e5+Bdvc/tKWXxeOrzLdWvht/Dg0oQr5bK0/nebvznPbGMUAfAdw2sw+E/wBs9PiI3n/FyPSbYahdafgaabIxj7OtsM7hgfe3c8j0NdH46+Ht3/wknw58eeJPhxJ8bPh7D8PbHTZvDthOs15o8xjDNdC1LDIZeN4GefYV9MePP2MbPxt4u+MGtDxVc2EfxG0WDSbu1W0RxaNEAFlRifmOAeD61l6z+x94m8N+M9G8Y/DD4ir4W8TQeHLbwxqL6jpa3lvfW8IASXZuGyQYBHbigD471v4j6P8ACqy/ZK134ZSa78TYdJfxVaaVp99Dt1D7TLGkcdrKgyVEbyAH/YXIr6Q/Y3+G/h345fs3eLdb1LXNUfx945up4fF+rRSmDULG6STH2WPvEkYA2r6HP07n4bfsL6R8OfEHwm1uDxTfXupeCLvWNRu5p7dN2sXWoxhJZHIP7vbgYC54FbM/7JVxpHjT4qa74N8eaj4Oi8f26NdWllbIws79SM3kLE8Mw3bhjndnPFAHunhfQY/CvhvStGhuJ7uLTrWK0Se6ffLIEUKGdu7EDJPrWtWT4W0m50DwzpWmXeoTavd2drFbzahcACS5dVCtIwH8TEZP1rWoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+YP+ChXzfBPQv+xv0X/wBK0r6frxX9rT4MeIPjr8KY/D3hfUtP0rWrfVbPU4LjVEd4MwSiTDBeTkgUAe0L91fpS18uf8I/+2D/ANDb8Kv/AAWXn/xVL/wj/wC2D/0Nvwq/8Fl7/wDFUAfUVJgV8vf8I/8Atg/9Db8Kv/BZe/8AxVH/AAj/AO2D/wBDb8Kv/BZe/wDxVAH1FRXy7/wj/wC2D/0Nvwq/8Fl7/wDFUf8ACP8A7YP/AENvwq/8Fl7/APFUAfUVIK+Xv+Ef/bB/6G34Vf8Agsvf/iqafDX7YNxhT40+FlqOpkXSbxz9MFqAPqTNH418uf8ACHftff8ARRvhj/4Ibr/4uj/hDv2vv+ijfDH/AMEN1/8AF0AfUeaM18uf8Id+19/0Ub4Y/wDghuv/AIuj/hDv2vv+ijfDH/wQ3X/xdAEP7U/7Eo/aO+MXw68aLr0WlWvh50TU7N4WZtQt0uEmEYIOByrDn1HpXV/tGfs7+IPiT4u8E+PPAPia18KePvCLTJZz6hbG4s7i3mULJFKikHGBxj1rmv8AhDf2vv8Aoo3wx/8ABBdf/F0f8Ib+19/0Ub4Y/wDghuv/AIugDZ/Zj/Zm8R/BL4ifEzxh4o8Zr4y1jxw1jcXMy2vkeVLCsodVXJHljzQqDqFQZrB/YXP/ABNfj3/2UTUP5JUv/CG/tff9FG+GP/gguv8A4uus/ZO+Bvir4J6P40bxlrml69rvibX59cnn0e3eCBGlVdyhX5HKk/Q0Ae8UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJtpaKAE20baWigBMUYpaKAE20YpaKAExRilooATFG2looATbRilooAbt60u0UtFADTGGUg8g9QabHDHDGEjRY0HRVGAPwqSigBNtG0HrS0UAN2il20tFACbaNtLRQAgWjbS0UAJtpNop1FACbaNtLRQAmKWiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApNtLRQAlFLRQAlFLRQAlFLRQAlGKWigBKKWigBKKWigBKKWigBKQLinUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmfxp+Omm/BOTwYmo6fc3/wDwk+uwaFbm2KjypZc4ds/wjHaqGvftFaVYfHzRfhLpOmXWv+I7q0bUNSltHUQaRbD7rzsehb+Fep49a8F/4KeaxrHh/wAH/CXUvD2nDV9etvG9nLYWBz/pE4STYn0LYrH/AGEvEUnhTw58c/8AhMbMxfHTS9RuNQ8UyXLh5LpfLZ7Z4v8ApgFBUAcD8RQB9UfHz40af+z/APC3VfHGq2FzqVjp7Qq9vaECRvMkWMYzxwWFd3p98uo6fa3aKVSeJZQrdQGAOD+dfkl4t+C48af8E/rn44at4m1+/wDH+tXaX+pXE2pSm2uYWvgggMBOwKoCkYGQV9OK/WPwxz4a0j/rzh/9AFAGpXJ/FT4maH8Hfh7rvjLxJc/ZdG0e2a5mYcs+B8qIO7McKB3JFdZXwz+1J4+8N/Gn45P8L9Y8R6TpfgnwJYtrniGDUr6K1Ooam0RaxtFDsDIqg+a2AR90HnFAHudh+1/4Jk/Zps/jZqC3ml+GbqIvDayIHupH80xJEiA/M7MOAPWq3wj/AGvdH+JXxGXwJq3hLxH4B8U3On/2pYWPiO2WI31tnl4yrEZHUqeQAfSvgK+8aT/8MR/sqWHhVdN8R65a+OYD/Yz3AZGuhPcG3huFU5QMWBwcHHNfU1r8UPiB8E/2lfBug/HCfwr4psPEmm6hdaN4p0vS/ss+kyW8RluLbqWaPyyPm6ncPegD2r4+ftXeDv2e/EPgnQNcFxe634s1COxsrKzALorOqGZ8nhAzqPfJ9K9pr8jfit4x8P8AxeXQ/jdr3iLRW1vWviFpNroWltqUBuNI0CCZ8M8e7MRkYGR8jj5c9a/WjTtUtNXsbe+sLqG+sbhBLDc20gkjkQjIZWBwQfUUAWqKKKACiiigAooooAKKKKACiiigAooooAKKKKAPLP2jf2ivC37Mfw1ufGXip5GtVmS2t7O3wZ7qVjgIgPcDcx9AprC+Jv7WvhX4X/D7wV4ku9O1TVb/AMZLD/Ynh/TIBNfXbSRrJtC5/hDDcegyK+Mv2svH3hr9oq4+M2t6n4k0hPDPw70m60Xwxo9zfRRz32ssALq6WEsHYIv7pOOTkjvX074Z1P4SaH8CPhV8ZPGF9pkv/CD+Hoo7PWUuBMLWSW2jimiQISGkbhNvUH0xQB1Hwr/bC8I/ESPxtb6rp+q+BNb8GW/2zXNI8RQiGe2t9pbzhgkMmF6j1HrXK+B/2+/C/i/xD4Rtrzwb4s8NaB4wuvsXh7xJq1ksdlqEp+4qkMWXf/Dkc5GK5X4A/Du+/aB+J3xL+NPj3wydF8IeL9Hj8N6PoOprsmudLBy01yn8JkwuAeQCR6VyP7V39ueEfiV8GLLxV4dsfDv7P/hfxXpzaTqmhz+bcJcRxbbVbiM/6uFW3L8ueMUAffVFIrBgCOQaWgAooooAKKKKACiiigAooooAKKKKACiiigAr5z+Jn7a2heBfG/iLwxovg7xR49u/DEC3PiG48O2iyQ6WjLvAkZmG5to3bVya+i6+cPj14R8Y/D/wv4s1D4F+BvDuo6/4mFxL4iuLu7MM7SeVtSRF5EkmGb5TgdPWgDR8TftleGNJ8DeDvF2heGfFXjbQ/FFs11aTeHdLa5aELgFZgD8jAkjHqp9Ko/C79uTwb8SvFfiDQJ9A8S+EbrQdJfW9Qk8R6ebVILZSMs3JIyCSOOQDjpWB+yd8RvA3ww/YO0bxXpt5fS+GfDulXVxePfIFuPtEbu08e0cZ83cq465FTfsg/C9vFHwR1rxn8SrSPUvEfxS36prK3bbsafKCLW0JPSNICvy8Y3kUAHhP/goJ4S8R6t4Ye+8IeLPDfhLxTejT9C8WatYiOwvZmJEYyGLIHIwCwwfpX1LXwB+19ba/4S1b4baF4g8Naf4e/Zz0DxNppttS8Pz+deZRQIEkibiOLzCVJXJxg19/IwaNSv3SMigB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFJQB4D8V/2wNI+HfxGuvAui+D/ABN8QPEun2K6lqlr4ctVkFhbt91pGZh8xHO0c4Ip+qftrfDrT/gLo3xWglv9R0fWbhbDT9NtbYtfXF4zlPswiz98MrA89jVr4veFfE3gmTXvFvwX8FeHNX+Imt+XDrFzqt41uzwxxsImOM7mU4AU4FeOfsU+AfAni/8AZe0OzOknXvE3hfXru9mt/ECiJrbxAjMz7dpwFVnABH8PPWgD2b4NftV6P8VvGmseC9R8Na94E8aaZZrqMmh+IrdY5ZbVjtE0bKSrqCQDg8E/XHnOmf8ABRnwr4g3zaJ8OviHrmni4e3XUNP0JpYJCjlWKuDggEGuE+HN/wCMNT/bc1i5+LmlW/hv4i33gqXT/CWn6POJ9MmsxIzzM0x+bzRJzgjG0n0rmbLRf2hf2Gf2bdJ8U3/iTw9qWg+GbnfqfgmCxVjJbTXR3Mt794yZk3dAAOO3IB+ikbeYitgjcM4PWnVR0XVodc0ew1K3z5F5AlxHnrtdQw/Q1eoAKKKKACiiigAooooAKKKKACiiigAooooAK4z4vfFrw58D/h7q3jTxVdNaaLpqK0jRoXkkZmCpGij7zMxAA967OuY+IHgLwx8SPD50XxZpdrq+kNNHP9lvP9WZEYMh69QQKAPIvhb+2Ro3j/4haZ4K1vwd4m+H+v6zZvf6ND4ktViXUYVGWMbKxwwHO04OAawfGH7f3hHwvrPiQ2fhPxT4j8JeGbz+z9c8XaTZCTT7GYEB1JLBn2E4YqCBXlvivXPGLftvfC+4+L2i2nhvTre31O18FNoFx9phu7lkw32pmAZG8vbhRxn61k/s4wx3n/BMv4qSXSqHuE8STTswzukzJyffgflQB9N/Fj9rHw18Nrrwjpml6XqvjzxH4sgN5pGi+HIllmuLYKGM5LEKqYPUn1rf+A37Qfh79oDQdVvNHtr/AEnU9GvW07VtF1WHyruxuFGSjrkj6EcHBr4S8G6h4jm8Sfsu3PwttYNa+LNj8PVa+stal8nTBpLJtDSOAXEnmHjb+Ne9/sEzTReMPjhbeK43tPivJ4jF34lsoiGs4g6E2/2Zhy0ZTPLfN60AfYVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJ/FL4naD8G/h/rfjPxPdGz0PSIPPuJFXcx5AVVXuzMQoHckV4x8M/wBuLw/468e+H/Ces+DvFHgO+8SQPcaDN4is1hh1JVXcQjBjhtvIU88j1FexfFj4c+FPit4F1Hw743sob/w1NsnuobiUxx4jYSBmYEYClQ3XHFfK0OtT/tqftHeBNZ8JWLw/CL4Y6hNdHxNKmwavqAQIIbUHrEmBl+h59qAOq17/AIKGaB4ah1C41H4XfEm2srASNPeSaAywoiZ3OWJwFwCc11XiL9tLwxpHgr4f6xp3h3xDr+s+O42m0LwzY2o+3zxqNzOysQEUDByTjkVyf7WmrXHxc+L/AMNv2fLKaSDTdedtf8UywuQx0u2bctuQP4ZpAFJ/2feqGrQxr/wU+8Iaf5CJYab8M5pLKMLhYnN40bbB0HyADjtQB7f8Bf2hNA+P2j6xPpdnqGi6vol62n6voerxCK7sZwM7XXJ4I6MODg+lepV8kfA1Rbf8FBP2jo4GxFNpmhTTIowvmC3IB+uD+tfW9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4o8YaH4I0mTU/EOr2Wiachw11qE6wxg9cbmIGeDxWxWF4w8C+HviBpP9l+JtGstd03zBL9lv4Vlj3Do20jGRk0Acf8AAv8AaC8MftCeG9b8QeFJJJtF03VrjSlvZBhLkxBSZo/9hgwIJrx/UP8Agol4KsZr3VV8KeKrn4d2Opf2Tc+PIbEHTI5w+wnO7cYw2BvAxz+FcV+x3t8L/s2ftBLpESWCad4s8SC0igXCwhIxsCjsBgYHtXhnwT8UfGTwP+wdonxA02LwhqXwv0WGU3fgnUtOM02p263TCe4e4J+V/MLMFC4AUGgD7Z+L37YGg/DLxzp3gvSPDWv/ABA8W3lh/ah0vw1brM0NoSQJXYkAA449ePWu0+A/x78M/tD+CW8R+GWuYVt7qSxvtP1CEw3Vjcx/fhlQ/dYZB+hFeV+O/ir8J/gdotn8bBozy+M/Gmk2tlpem2IMl9qYMavDbRxjoB8uWAwO/YVf/Yn+EPin4b+CfFPiDxxbxad4v8da/c+Jb/Sbdgyab5pAS33AncwAyT6nHOM0AfRtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXk3x3/aO0P4Et4esLnS9U8TeJvEVw1tpPh/Q4BNd3bKMuwBICqoIyxOOa9Zr4F/aEvPHuof8FHvBekeAZdLtdbk8ETJBqOsxGeDTEaeQy3KxAje+1QgXPO7ngUAfRHw3/a+8GePPB/jnW9Qt9R8HXHgdmXxHpevQiK5sMIXBIBIYMAdpB5IwK5j4f8A7dnhvxl4x8KaJqfg3xX4PtfF5YeHNX1yyWK21MgZAUhiVLDGAw5yK+Q/2mvix4ph+CH7Qvw38f2miT+PNCvNDlvNe0O0FquvWUs6NG8qg/KyjapGf4sV7Vq3xA+MHwg8UfBnVviraeDvEHg3xXrNno9vpNjpvlz+F7uZP3HlTEnzMAMC3H3TjtQB910UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHKfEL4qeEvhVpDal4t8Rad4ftNjujX9ysRk2jLBATliMjgZ6iud+Fn7QHhn4pfBO1+KULyaN4Wmt7i7ebUMKYYYZHR3bHQfuyfpWh8YPhn4T+IXhW8bxP4c03XzYWlxJa/2hbLN5LFOSuRwTtHT0r4k8DyPD/wAEa70xsUJ0K/UkHHym9lBH0xxQB7x4J/b68K+LPEXhe2vvCPirwv4d8V3Js/D/AIm1iyEVjqMvOxVIYsu/Hy7hzkV9QV8IftW2dtbfsW/A94AI3s9X8NPaspwUYKo4/Amvu2PmNfoKAHUUUUAFFFFABRRRQAUUUUAFFFFAHin7SnwO1T41XHw3k03ULWwHhjxRa67cfaVY+dHFuyi4/iOe/FYfxW/Zr1HxB+0F4V+KnhO/sbC7Wyl0LxPp92jbNV02QYxlekiZJUn0XsK99k1C1iuorSS5hju5VLR27SAO4HUqvU4ol1C1t7uG1luYY7qfJigeQB5McnavU474oA+Cda/Yf+NknwTvvgfpnjjwynw1t777Xp19c2kp1KSDz/NW1lwdgCtk7gMnGOlfeekWjafpNlauwd4IEiLL0JVQDj8qfdX1tYLG11cxW4kkEaGZwgZz0UZ6k+lWaAFrzX4g/s/+AfiCmrXmqeDNB1DXL6B4/wC0L2wjkl3lNisWIzxhfyr0qo5JFhVndgiLyWY4AHqaAPjXS/8Agn+NP/ZP8NfD601HTdE+IWgajDrlp4n0+1IRtQhmkaGSQfecBJCnPTt0rq/Cf7PvxG+IXxs8O/EX40aj4duV8Ladc2OjaD4fikNuZbhBHcXMrSckunG3oOPSvp9ZEaMOrBkIzuzxj1zTYbiK4jEkUiyIeAyHcPzFAHzF+0J+w74P+J2i+Gbbwp4X8L+HbvT/ABDZ6nez/wBnIpubWNiZYMqBneCODxxX0vpOj2Og6Xa6bptpDYafaRrDb2tugSOJFGAqqOAAO1WufSnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgPx9/ZD8EfFT4a+MdL0fwn4b0zxVrNpLHb6zLpyb4pnOfNLAbs5ycg15Z8Y/2MfGuveBfg14b8Baj4W0jT/BO2+v9N1GxZ7LUNQWONUnaNfvAMJWw3UvzX2ZJMkMbO7KiLyWY4Ao85fK8zevl43b88Y9c+lAHzHpXwZ+OPxH8OeLvCPxh8YeGb3wrrWizWUDeGbF7W6tbpmTy5gxPRMMcdziuMf8AZX+NHxH8P+Avh58S/FXhi++HvhO/true802CYahrcdt/qYpgx2pxjcRycZ619nRypNGrxusiNyGQ5B/GhbiOSZ4lkQyoMtGGBZc+o7UASqoVQAMAcCloooAKKKKACiiigAooooAKKKKACiiigAooooAK+T9U+Avxo+G3xG+ImsfCrxL4du9B8cy/a57LxUk7SaTdFNjSwFDh1OSdhwOBX1hVeW6ht2QSSpEZDhd7Abj6DPWgD5N8RfsV6xafsQj4F+GfEdt/adxIkl9rF5Eyxys1yJ5yFXkAnKgelfQPi74WWPi/4O6j8PpbiawsbzSDpP2m0O2SFfL2B09COCPpXbfQUfd7UAfE0n7J/wAavHvgfwb8KvH3izwxc/Dvw3e21xLqunwTHVNUhtmzDFIHOxDjALDJO2vtpEEaqo6KMCmecnmCPcvmY3bcjOPXHpUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSUtFAHy74t+B/xb8D/AB18ZfEX4Ua7oF3B4xs7eDUtF8Vef5drPAmyOeAxn06qRg5PtXIr+wr4l0P4L6BYaH46SH4n6V4qfxnJrcsLLZ3l87EyQvEpB8ojA/DPevsm4uobVQ88scCk7Q0jBQT6c1IzYBJ49aAPlvwz+zf4/wDiF8YLr4j/ABh1fRYbuHQLjw9pOi+FVlWG1ScYmnaWQ72cgkAds+wrgpf2Q/jZ4k+FenfBHxF440C4+F1tdobnXIop21u9skm81bZtxKK3Qb+uFHbivt6KaO4jEkUiyxt0dGBB/EUguYmuGhEqGYDcYww3AeuKAG6fp8Ol2FtZWy+Xb28Swxp6KowB+QqzRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5J+098D5/2gfhLe+F7HXZvDWrrcQ32n6pDk+TcRNuTcARuU8gj0Net02gD5S0X9n34sfE74vfD7xf8AGHV/DC2PgMSyafp/hqGUtf3UkYQzzNIfkHAO1eM1yF5+yH8XvDHhHx58K/Bfirw3F8L/ABdqFxd/btSgmOp6VDcNmeCJVOxwRkAt03HvX2vDdQ3G7ypY5dpw2xwcH3xUv4UAfKnir9lPxV4A8f8AgXx38HNT0eLVfDfhxfCtxpPiWOQ219ZrjY2+PDI4bnjg4HvXX/sz/APxF8MvEXxB8c+ONXsdV8ceOL2K6vo9JiZLO0iiTbFDHuO5goJ+Y9eK94lmSGNpJXWNF6s5AA/E0sciyKrowdGGVZTkEfWgCWiiigAooooAKKKKACiiigAooooAKKKKACiiigDyL9qz4W+JPjX8CPE/gnwpq9voeq6zHHbm+uQxVYfMVpV+Xn5kBX/gRryz4P8Awt/aW+H914V0a88U/D6LwNpbQQT6bpejvFJ9lTAZIznAYqOp7819W/SmQ3EVwziKVJCh2sEYHafQ46UAeF+B/wBn7WNI/a08f/F/XNUtr631XSrXRdDs41bzLK2Ta0ysTx80iBuPU1T+P3wH8X+Ivix4J+K3w21TSrHxl4bgn0+ax1pJDaajZy8mJ2T5lKklgR3r6Aa4jjmSJ5UWWT7qFgC2OuBRJMkMbPIVjjUcsxAA/E0AeHfs1/AfXvhvrnjvxz461Wz1r4heN72G41GXTUZLW2ghTZb20QbkqikjceTxnpXu9RqyugZSGVhkEcgipKACiiigAooooAKKKKACiiigAooooAKKKKACiikz60AeH/s4/AG9+EPhHx9oeu3trqkXibxLqWsL9nUgJBdEYjbPVgAc9ua8Etf2NPjHpfwhu/gNY+MfDcXwkuryQjWDay/2xFYvMZXtQmfLySSN/wDtHtX3PHKkm7Y6ttJU4OcH0+tJJPHDt8yRI9x2jcwGT6D3oA+NfiZ+yf8AFlPj5pPjz4beIfCthp2g6BBoGiWPiGykujYxoBvdB0DsR94c44r6B+Bel/FbS9G1FPivrmg65qbTg2cug2jW8aRbRkMCeTnJr0ia4itU3zSJDHnG6Rgoz+NSGgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACV88/H74A+KvEnxU8GfFn4barpmm+O/DcE2ny2usxu1nqdlJyYZCnzIVJYhh6+wr6HqGSZIUZ5HVEUZLMcAe+aAPkW0/Yj1T4jeEPjJP8U9bsLrxn8TFt1lm0WJxbaSlsM2scO87mCsFJJ+9tp2nfs3/ABh+I/iT4ZW/xb8SeGrzwt8Pr+LVIP7FglF1rF5CpWCafedse3qQvUk19cxukqh0IdG5DKcg02O4jlZ1jkSRkOHCsCVPv6UAT0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFDXLF9U0XULNGCPcW8kKs3QFlIBP514L8Jv2Vz4b/AGOIvgf4q1KO7M2nXmn3N/p6kKPOlldXQN3XevXuK+iMUnNAHxbpP7KPxf8AF9j8M/BHxG8UeGrn4e+Ar+3vorjSbeUX+sG24tkmDnZGFGASvX619p02n0AFFFFABRRRQAUUUUAFFFFABRRRQB8gftw7vAvxT/Z6+J0LtB/Y/isaNdyAkKba9Ty23+w2nr03Gsnx74strr9vbXPFF40kvhv4QeALjUb8xtxFczhpNmOm4wAn8K9Z/bo+H7fEf9lfx/p0EbSX1rZf2pZmMZdZ7ZlmXb7nYR+Jr5m/Zt8IeJ/j7+yl+0R441TTp7XxX8So7qC1gZCskgt7TyYEGR93fuUUAc18bPjx8Vvi/wCDfgdr3ivwHp/hrwX4k8d6PqGi3+m6g8lxHH5jGOO5QjrIjFgy8fL05Ffp1X5Za3+0J4e8f/s//s1/DbRbPUbvxdoHiHw7b67Zvp0yf2V9lIhcyMV2gswGME8E9K/U2gAr4T/4KUfEbWvFXhTW/hP4PuWt5rPQbjxT4o1CFj/ollACYbckdGmlA4PO1c9DX3ZX58/tNfsm/ETwh4S+P3jvQviqV03xTa3GoanoX9hxTS3UKRFUthOSXVQnyjaB1zigDI/aF+IunWPwb/ZV8FeKtbvtH8DeItOtbrxEbGSUT3tvBZRMttmP5z5juBgck4rrv2fde+Fvh/WPi94p+FXiXVdB0qx8PPcX/wAO9WtJrZrKaONmW8jSUkgMFx8vrzjIrzvxJ4J8Q/DbwD+yb8TPHd7ceMPDvhWeOXUrqDSwraTZ3FtD5CvEgJZYmUAuRnIHfFdzoHjQ/GL9rfx98V/hRo7eLfDui/D99KE01rJBa6tqBkMiW6l1Uv8AKNp44/KgDxH9l7RP2ZpND+F0vjPTvG1t4w1SSDZ4lvptRt9JuNQL7kjSXzBGecL02nBzxk1+s4+6K/Nz47ftHeHf2q/gH4I+HXhPR7mP4o6prWnfaPDFvpk0baJJFKGndiUCoiBW5z0OTiv0ft0aKCJGOWVACfoKAJaKKKACiiigAooooAKKKKACiiigAooooAKKKKAPgH/gpd8QNb8eeHfEXwu8HX8tlb+HdGbxP4vvoSVEcC/8eloCOrSSfORx8qg89Kf8QVf4qap+yP8AB3Uru5i8J+INF/tnXLe3maNr1LWxR4YXYEHYzbtwzz+FYP7SP7I/xM+Hnwt+OvivTfi219pviUXGq6ro7aDFJcXidI7f7QSXCouFUDgDOBzUF7pniH4D/wDDKPxb8canc+JvD+h2Nxpmsanb6eUbTbe8tVFqGjQElY8lWfGTj1IoA6fQfCniH4T/ALSHxq+C3wrvTo9p4i8EDxJ4dtbyeT7NpN4ZPsztETkqpZt3HAKj0rjPi5+z3pH7MGn/ALP03hPULwfHK+8TWFte3EeozTPrAcZvTKrNzDuxzjgHHc12Xhz4vWfij9ob4z/tG6BZ3ur+CPCHgddB0u5+zyouq3Af7S4hDKDgOAhOP4s1xn7Kvx0+ENv4qtfiN8TPEeq+KPjb4hZU8+60a5MGirIcJZ2o2bUVQ2C465POKAP0sXOBnrS0incAaWgAooooAKKKKACiiigAooooAKKKKACiiigAr4Q/aK+Dfw98J678UfiJ+0D4vt9QTXLd7fwdZG6nik06OOI/u7eNW5mLlDuUdT7mvu+vjX4h/tXeCtP8WfEv4ffHzwzaaRbaeWXw+bjTJrqPWrOSM4aNtjDzCcKcY5+lAHhXxS1i9l/ZJ/Zc8P8Axbl1u4j1bXI7jVYrV5W1C6so4pjFF+6O9nZJIhxznGea94/Y/wBH+Ca3fju1+DMWv+EfHUNmttfaf4ua8e5tAwYwzG3uJCCu7ng5OMHGRXnvwL+KHiP9l39mn4H3XjzwhPceFLvULxdQ1e+t5Jrrw/bSSO9o5QAsqlSATjjgdcCu1+A/iOy+OX7dnjP4oeDEuLvwFZ+FLfQ21prWSCC9vPNEmE3qpbYowTjjj2oAyvgb4f8AHnhP/got4i07x747bx3qUvw/F1Fcx2QsYII2vY1ESQqxUY2k7up3GvumvlDTbOcf8FOtYufIkFufhlEgm2HZu+3jjd0z7V9X0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFJQB8l/EL9lKz+J3xw8feOfjRfw3/wAOLXS4Lfw9ZnVJbeLT0CZuZpACoRt3Rsn+VfKPh3xV4j8Sfs7fBrwPrOvauPh54p+JM+jxatPcvFPeaLG/7iFpODtc7gDnoteoftYfHDw144/aUu/hh8TNb1bw98JvC8FvdXunaXY3Eh8RXjhZBFM8anEKAqSvc5/DvPjl8Xvg38Qf2Z9EvLfwDdeNPhVZ63baTeLZwT2EmhRquBdRqqCQCMFR8uPvdaAMjT9A0/8AZ4/bw034e/DS7bRNE8ZeEbm5u9BNw81raX0ZfyLlUZjsJCYIGM8nvXj/AMY/hP4f+B/g/wAKeHdI8WN4i/a6uPEdtc2+oWF5Kbq6mln3HzlZsLB5J+63Gce9dR8DvAXgrxB+1YvjH4DaZfa54e8IeF7xrrxDq0tzINT1WZSsNv5k/wA7YQc44HPtWb8ff2hvB37T37Oa+H7jwk9p+0bdXkNra+H7TS5lv7G+S4Cl0mZRtQIDli/QkGgD9NIWfyk3/fwN31xzUlZfhm2vLLw3pVvqMnm6hFaRR3Emc7pAgDHPuc1qUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFePftWfD7xv8VPgzqfhXwDrEeg6zqU8EM9807Qslr5gMwR1BIYqCv4kV7DXiX7Ynxu1H9n/wCAXiHxZoti2oa4uyzsIxGzrHNKwQSsACSqAlsd9uO9AHzbefCfwp+zv+2j8DfDfwonvLDUNQtLtPFOlw30tws1kkWUnuFZjhi5JDHGSB7V4boV98APFfir4o+JvjDpfjbVL2TxvqUba1pLagum6dZiYJCkskLqi4wT0JwRXv8A+xt8T/gd4Q12GysfEmr+MvjB4ukA1XxPq2k3SS31wRu8sO6YiiB4CggcDNUPiV+2F4f1j4C/FX4deLvDEnhb4p3H27RbfwfYaZPI1/JJlIJ4iEKuHyG3Z7ZGaAMn9pXx18PP+Gh/hx4E8YX+oX/wi0Lwimq6foWltPdNrdwzeXbqRGS0wWNNw3HHDEnk17n+wlbeCI/DvjSf4c+MNQ1nwlcauZIPDWqQyRT+HJdvz2xWQlgCcEDp6d6+fNH0Y/so/HT4EeN/ifa3Fj4ej+Hcfhu61f7M9xFp2oRjdsl2KxUlW2g4559DXsn7E7L42+Nvx++JuiWNxa+BvE2qWcWkXU9u8C3rQQlZp0RgDtLN97HJz6UAfYdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkv7U3grxv8Rvgb4k8M/DvU4dG8UamkVvDfzztCIojIpmIdQSCYwyjA718p+IPhB4X/Zt/au+AOg/CW4vrXxPqBuIfEmmpeyXCXenLDlri5VmIVt24huMn6Cvqb9rL4yX3wF+APivxnpVl/aGs2UKR2FuY2kBnldY0JVeSFLbj7Ka+X/2Ofi18D/B2vWr3PifWPGPxl8YTRxar4k1LSLkSTTyEfuI2ZMRQqcAAYHAJoAofFz9lfSvC3wd+NPxQ+OGus/jq6u7y+0LV7HVZh/ZyAZsLe3XKgNv+UqAc9OgrB+K2uXl5pf7JV/8eLq7h+HN5pLnxILl5Ejl1E2ym3N0ifMc/KTkdS2azLj9ob4a/F39ojxH4n+OGqasfD3hHVZbHwl4LXSriWyPlkA6hMFQiSRmB2g9PwFelfFj4peGYv2q/g/8X/E5urn4MXfhe5t9J1C4sJXt7DU2lYmWWPaWRmj2oCV7cdKAOt/4J0zRXcXxan8J3d5d/B8+JCnhE3srOQir/pAj3ncIt+3aG7V9k18a/sW3Fr4t+P8A8d/G3gqxuLD4T6xc2K6YzW7W1ve3yRH7VcQxMBgFjywA3E569PsqgAooooAKKKKACiiigAooooAKKKKACiiigAri/it4f8Y+JvCclj4G8V2/gzXHkUjVLjTlvgqc7lEbEDJ457YrtKTFAHyL/wAE111eH4YfEW317WZvEOr23jzVbe61S4yGuZE8sNJgk7dxBOO2a8G/ag+Juv8Axi/aU+GmsaPdtH8MvCfxD0/wzbSQsQupamzF7qQH+JIgiRjtktjqa9z/AGKPDup6p8JPjhpVtcz6FqGoeOdfitb5ojugZ9qpMoOM4JBHrivm/wCOH7JvxR+B/hf4K+F7H4r/ANr6Ovjqzj02GLw9Eh0+6kMj/bJHBJlwSxIc4O7mgD3rxH4N0r9pj9vDxh4S8apLq/g/wR4atTbaI1xIlubu5+Zp2VSMsEOAe3HpXTfsB6tqem6b8Vvh5e6hd6npvgbxddaVpEt9IZJo7EgNFEznltvzcn1rg7jxnZfsm/tpeIvEfxN1GaLQfGPhOxiHin7DIYJ7+1ASRCsSsEZgN2AO4rv/ANgXSNR1DS/ip8Rbuxu9P03x34uutW0eK+QxzSWIwkUrIeV3Ybg9gD3oA+rqKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmz9pz4K2fxI8beE/E3j/xRa6d8HPCsE91q2iXM0kEd5ct8sTzOpAMaHb8p75HevpOvnT9oD9o4fA/4o+GdK8ceH4T8I9espUufEhtpLkWl+rZWKZFBAjZduDtJJz6UAfGtp8SNU+Hf7Lf7S2t/C/V763+HDeJLfT/CuomV3W0glkSO8a3LfMqDfhT2zxyK9E+K3gHwd+yP48/Zs8SfDq9m0y717XLbQ9W230kw1mynVfMnmyxDlWYNu9WFQfCu40/UF/au8beCvAEvjH4P6klkum+GPLa0t9XkjhIv5LdGT5cZZuF+Y4xg9OB0PwN8Ffiv8TfgXpHwP0jWLzUrHX7XX9cm1KW9uF0KxtgZGsy0/wAqK0hAwvUqPagD9VqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBK/L/wCOV18KPE37Y3xik+K+jeMPEdjodnpcNnb+F/tjC0XyC80svkOoVeV+8fX3r9QK+T9a/bP8M/CT4r/Evwx8UdDTwc9mIp9G1K1sZZz4htmQ4wyod0inC7Scc47UAez/ALOlv4Ft/gv4XX4aXTXnghrcy6bK9zJcPtZ2ZgzyEvuDFgQxyCMdq9Kr5g/4Jz+B9c8B/svaLBr2nzaPPqV9eapb6bOMPbW80zPGpH8JKndjtur6foAKKKKACiiigAooooAKKKKACiiigBrIGBBGQeoNIkKRqFRQijoFGBT6KAK0em2kMkkkdrCkkh3OyxgFj6k45NWaKKACmtGrqVYBlPBB5zTqKAIpLeKaFonjV4mG0xsoKkemKba2NvYwiK2gjt4gciOFAq/kKnooAqxaXZwXT3MdpBHcv96ZY1Dt9TjJq1RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANaNXUhgGB6g8imSWsM0JhkiSSJhgxsoKkemKlooAghsba2t/Iht4ooP8AnkiAL+Q4pBp9sCCLeIH/AHBViigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKq3Wl2d8yNc2kFyyfcMsasV+mRxVqigCOa3iuIXiljWWJhho3UFSPQg021s4LGERW0EdvEORHEgVfyFTUUAMESB9+1d+Mbsc49KfRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQPZW8jFngjdj1ZkBNL9jgMLReTH5TcNHsG0/UVNRQBBa2NtYxeVbQR20ec7IUCjP0FMXS7Nbs3QtIBdHrOI13/APfWM1aooATFLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHJDHMu2RFkX0YZFSUUAQLY28bBlgiVh0KoAaZJpdnNdLcvawvcr92Zo1Lj6HGatUUAQ3Vnb3sJiuII7iInJjlUMv5GnQ28dvEsUUaxRqMKiAKo+gFSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJIUlUq6h19GGRUa2NsjBlt4lYdCEHFT0UAVzp9qzZNvCT6+WP8ACiewtrq38ia3img/55SIGX8jxViigCKC1htYlihiSGJeFSNQqj6AVLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMSJI8hFCgnJ2jHNDxJJjcobByMjOD60+igCvdafa38YS6t4rlAchZkDgH1wRUqxqqhVAVVGAFGAB6U+igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhubOC8hMVxDHPEeSkqhl/I1NRQBFDbRWsSxQxpDEowEjUKo/AVHa6ZZ2LO1taw27ScuYo1Ut9cDmrNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVbrS7O+dHubWG4dOUaWNWK/TI4q1RQAm0DpxS0UUAFFFFABRRRQB//9k=" alt="" width="1375" height="734" vspace="0" hspace="0" border="0" style="width:1375px;height:734px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>CI = confidence interval; HR = hazard ratio; Kd = Kyprolis and dexamethasone; mo = month; &nbsp;OS = overall survival; Vd&nbsp;=&nbsp;bortezomib and dexamethasone</p><p>&nbsp;</p><p>The median DOR in subjects achieving PR or better was 21.3&nbsp;months (95% CI: 21.3, not estimable) in the Kd arm and 10.4&nbsp;months (95% CI: 9.3, 13.8) in the Vd arm. The median time to response was 1&nbsp;month (range &lt;&nbsp;1 to 8&nbsp;months) in both arms.</p><p>&nbsp;</p><p>A.R.R.O.W.</p><p>&nbsp;</p><p>A.R.R.O.W. was a randomized, open‑label, multicenter superiority trial of Kyprolis and dexamethasone (Kd) once weekly (20/70&nbsp;mg/m<sup>2</sup>) <em>versus</em> Kd twice weekly (20/27&nbsp;mg/m<sup>2</sup>) in patients with relapsed and refractory multiple myeloma who had received 2 to 3 prior lines of therapy. Patients were excluded if they had less than PR to at least one prior line; creatinine clearance &lt;&nbsp;30&nbsp;mL/min; hepatic transaminases &ge;&nbsp;3&nbsp;&times;&nbsp;ULN; or left‑ventricular ejection fraction &lt;&nbsp;40% or other significant cardiac conditions. A total of 478 patients were enrolled and randomized (240 in 20/70&nbsp;mg/m<sup>2</sup> arm; 238 in 20/27&nbsp;mg/m<sup>2 </sup>arm). Randomization was stratified by current International Staging System stage (stage 1 <em>versus</em> stages 2 or 3), refractory to bortezomib treatment (yes <em>versus</em> no), and age (&lt; 65 <em>versus</em> &ge; 65 years). Arm 1 of this trial evaluated Kyprolis at a starting dose of 20&nbsp;mg/m<sup>2</sup>, which was increased to 70&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Day&nbsp;8 onward. Arm 1 Kyprolis was administered once weekly as a 30‑minute infusion on Days&nbsp;1, 8 and 15, of each 28‑day cycle. Arm 2 of this trial evaluated Kyprolis at a starting dose of 20&nbsp;mg/m<sup>2</sup>, which was increased to 27&nbsp;mg/m<sup>2</sup> on Cycle&nbsp;1, Day&nbsp;8 onward. Arm 2 Kyprolis was administered twice weekly as a 10‑minute infusion on Days&nbsp;1, 2, 8, 9, 15, and 16 of each 28‑day cycle. In both regimens, dexamethasone 40&nbsp;mg was administered orally or intravenously on Days&nbsp;1, 8, 15 for all cycles and on Day 22 for cycles 1 to 9 only. Concurrent use of thromboprophylaxis was optional, prophylaxis with an antiviral agent was recommended, and prophylaxis with a proton pump inhibitor was required. Treatment continued until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>The demographics and baseline characteristics are summarized in Table&nbsp;25.</p><p>&nbsp;</p><p>Table&nbsp;25: Demographics and baseline characteristics in A.R.R.O.W.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td style="vertical-align:bottom"><p>Once weekly Kd 20/70&nbsp;mg/m<sup>2</sup><br />(N&nbsp;=&nbsp;240)</p></td><td style="vertical-align:bottom"><p>Twice weekly Kd 20/27&nbsp;mg/m<sup>2</sup> (N&nbsp;=&nbsp;238)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Age, years</p></td></tr><tr><td style="vertical-align:top"><p>Median (min, max)</p></td><td style="vertical-align:top"><p>66 (39, 85)</p></td><td style="vertical-align:top"><p>66 (35, 83)</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;65, n (%)</p></td><td style="vertical-align:top"><p>104 (43)</p></td><td style="vertical-align:top"><p>104 (44)</p></td></tr><tr><td style="vertical-align:top"><p>65&ndash;74, n (%)</p></td><td style="vertical-align:top"><p>90 (38)</p></td><td style="vertical-align:top"><p>102 (43)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;75, n (%)</p></td><td style="vertical-align:top"><p>46 (19)</p></td><td style="vertical-align:top"><p>32 (13)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Sex, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td style="vertical-align:top"><p>108 (45)</p></td><td style="vertical-align:top"><p>110 (46)</p></td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>132 (55)</p></td><td style="vertical-align:top"><p>128 (54)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Race, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>White</p></td><td style="vertical-align:top"><p>200 (83)</p></td><td style="vertical-align:top"><p>202 (85)</p></td></tr><tr><td style="vertical-align:top"><p>Black</p></td><td style="vertical-align:top"><p>3 (1)</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:top"><p>30 (13)</p></td><td style="vertical-align:top"><p>15 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Other or not reported</p></td><td style="vertical-align:top"><p>7 (3)</p></td><td style="vertical-align:top"><p>19 (8)</p></td></tr><tr><td colspan="3"><p>ECOG performance status, n (%)</p></td></tr><tr><td><p>0</p></td><td style="vertical-align:top"><p>118 (49)</p></td><td style="vertical-align:top"><p>118 (50)</p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>121 (50)</p></td><td style="vertical-align:top"><p>120 (50)</p></td></tr><tr><td><p>2</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td colspan="3"><p>Creatinine clearance (mL/min)</p></td></tr><tr><td><p>Median (min, max)</p></td><td style="vertical-align:top"><p>70.80 (28, 212)</p></td><td style="vertical-align:top"><p>73.20 (29, 181)</p></td></tr><tr><td><p>&lt;&nbsp;30, n (%)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td><p>30 &ndash; &lt;&nbsp;50, n (%)</p></td><td style="vertical-align:top"><p>48 (20)</p></td><td style="vertical-align:top"><p>34 (14)</p></td></tr><tr><td><p>50 &ndash; &lt;&nbsp;80, n (%)</p></td><td style="vertical-align:top"><p>91 (38)</p></td><td style="vertical-align:top"><p>111 (47)</p></td></tr><tr><td><p>&ge;&nbsp;80, n (%)</p></td><td style="vertical-align:top"><p>99 (41)</p></td><td style="vertical-align:top"><p>91 (38)</p></td></tr><tr><td colspan="3"><p>FISH, n (%)</p></td></tr><tr><td><p>High‑risk</p></td><td style="vertical-align:top"><p>34 (14)</p></td><td style="vertical-align:top"><p>47 (20)</p></td></tr><tr><td><p>Standard‑risk</p></td><td style="vertical-align:top"><p>47 (20)</p></td><td style="vertical-align:top"><p>53 (22)</p></td></tr><tr><td><p>Unknown‑risk</p></td><td style="vertical-align:top"><p>159 (66)</p></td><td style="vertical-align:top"><p>138 (58)</p></td></tr><tr><td colspan="3"><p>ISS stage at study baseline, n (%)</p></td></tr><tr><td><p>ISS I</p></td><td style="vertical-align:top"><p>94 (39)</p></td><td style="vertical-align:top"><p>99 (42)</p></td></tr><tr><td><p>ISS II</p></td><td style="vertical-align:top"><p>80 (33)</p></td><td style="vertical-align:top"><p>81 (34)</p></td></tr><tr><td><p>ISS III</p></td><td style="vertical-align:top"><p>63 (26)</p></td><td style="vertical-align:top"><p>54 (23)</p></td></tr><tr><td colspan="3"><p>Number of prior regimens, n (%)</p></td></tr><tr><td><p>2</p></td><td style="vertical-align:top"><p>116 (48)</p></td><td style="vertical-align:top"><p>125 (53)</p></td></tr><tr><td><p>3</p></td><td style="vertical-align:top"><p>124 (52)</p></td><td style="vertical-align:top"><p>112 (47)</p></td></tr><tr><td><p>&gt;3</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Prior therapies, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Bortezomib</p></td><td style="vertical-align:top"><p>236 (98)</p></td><td style="vertical-align:top"><p>237 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Transplantation</p></td><td style="vertical-align:top"><p>146 (61)</p></td><td style="vertical-align:top"><p>157 (66)</p></td></tr><tr><td style="vertical-align:top"><p>Thalidomide</p></td><td style="vertical-align:top"><p>119 (50)</p></td><td style="vertical-align:top"><p>119 (50)</p></td></tr><tr><td style="vertical-align:top"><p>Lenalidomide</p></td><td style="vertical-align:top"><p>207 (86)</p></td><td style="vertical-align:top"><p>194 (82)</p></td></tr><tr><td colspan="3"><p>ECOG&nbsp;=&nbsp;Eastern Cooperative Oncology Group; FISH&nbsp;=&nbsp;Fluorescence <em>in situ</em> hybridization; ISS&nbsp;=&nbsp;International Staging System; Kd&nbsp;=&nbsp;Kyprolis and dexamethasone</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy of Kyprolis was evaluated by PFS using IMWG response criteria. Efficacy results are provided in Table&nbsp;26 and Figure&nbsp;5.</p><p>&nbsp;</p><p><strong>Figure&nbsp;5: Kaplan‑Meier plot of progression‑free survival in</strong> <strong>A.R.R.O.W. </strong></p><p><img src="data:image/jpeg;base64,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" alt="" width="1890" height="1925" vspace="0" hspace="0" border="0" style="width:1890px;height:1925px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>CI&nbsp;=&nbsp;confidence interval; HR&nbsp;=&nbsp;hazard ratio; Kd&nbsp;=&nbsp;Kyprolis and dexamethasone; PFS&nbsp;=&nbsp;progression‑free survival</p><p>&nbsp;</p><p><strong>Table&nbsp;26: Summary of key results in A.R.R.O.W. (Intent‑to‑treat population)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Once-weekly Kd 20/70&nbsp;mg/m<sup>2</sup><br />(N&nbsp;=&nbsp;240)</p></td><td style="vertical-align:top"><p>Twice-weekly Kd 20/27&nbsp;mg/m<sup>2</sup><br />(N&nbsp;=&nbsp;238)</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>PFS</p></td></tr><tr><td style="vertical-align:bottom"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>126 (52.5)</p></td><td style="vertical-align:top"><p>148 (62.2)</p></td></tr><tr><td style="vertical-align:bottom"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>11.2 (8.6, 13.0)</p></td><td style="vertical-align:top"><p>7.6 (5.8, 9.2)</p></td></tr><tr><td style="vertical-align:bottom"><p>HR (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.69 (0.54, 0.88)</p></td></tr><tr><td style="vertical-align:bottom"><p>P‑value (1‑sided)</p></td><td colspan="2" style="vertical-align:top"><p>0.0014</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>Overall response<sup>a</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>N with response</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>97</p></td></tr><tr><td style="vertical-align:bottom"><p>ORR (%) (95% CI)</p></td><td style="vertical-align:top"><p>62.9 (56.5, 69.0)</p></td><td style="vertical-align:top"><p>40.8 (34.5, 47.3)</p></td></tr><tr><td style="vertical-align:bottom"><p>P‑value (1‑sided)</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>Response category, n (%)</p></td></tr><tr><td style="vertical-align:bottom"><p>sCR</p></td><td style="vertical-align:top"><p>4 (1.7)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:bottom"><p>CR</p></td><td style="vertical-align:top"><p>13 (5.4)</p></td><td style="vertical-align:top"><p>4 (1.7)</p></td></tr><tr><td style="vertical-align:bottom"><p>VGPR</p></td><td style="vertical-align:top"><p>65 (27.1)</p></td><td style="vertical-align:top"><p>28 (11.8)</p></td></tr><tr><td style="vertical-align:bottom"><p>PR</p></td><td style="vertical-align:top"><p>69 (28.8)</p></td><td style="vertical-align:top"><p>65 (27.3)</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p>CI = confidence interval; CR&nbsp;=&nbsp;complete response; HR = hazard ratio; Kd = Kyprolis and dexamethasone; ORR = overall response rate; PFS&nbsp;=&nbsp;progression‑free survival; PR = partial response; sCR&nbsp;=&nbsp;stringent complete response; VGPR&nbsp;=&nbsp;very good partial response</p><p><sup>a</sup> Overall response is defined as achieving a best overall response of PR, VGPR, CR or sCR.</p></td></tr></thead></table><p>&nbsp;</p><p>The median DOR in subjects achieving PR or better was 15&nbsp;months (95% CI: 12.2, not estimable) in the Kd 20/70&nbsp;mg/m<sup>2</sup> arm and 13.8&nbsp;months (95% CI: 9.5, not estimable) in the Kd 20/27&nbsp;mg/m<sup>2</sup> arm. The median time to response was 1.1&nbsp;months in the Kd 20/70&nbsp;mg/m<sup>2</sup> arm and 1.9&nbsp;months in the Kd 20/27&nbsp;mg/m<sup>2</sup> arm.</p><p>&nbsp;</p><p>Kyprolis is not approved for twice weekly 20/27&nbsp;mg/m<sup>2</sup> administration in combination with dexamethasone alone.</p><p>&nbsp;</p><p><em><u>In combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma</u></em></p><p>&nbsp;</p><p>The efficacy of Kyprolis in combination with daratumumab and dexamethasone or daratumumab and hyaluronidase-fihj and dexamethasone (DKd) was evaluated in three open‑label clinical trials (CANDOR, EQUULEUS, and PLEIADES).</p><p>&nbsp;</p><p>CANDOR</p><p>&nbsp;</p><p>CANDOR was a randomized, open‑label, multicenter trial which evaluated the combination of Kyprolis 20/56&nbsp;mg/m<sup>2 </sup>twice weekly with intravenous daratumumab and dexamethasone (DKd) versus Kyprolis 20/56&nbsp;mg/m<sup>2 </sup>twice weekly and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy. Patients who had the following were excluded from the trial: known moderate or severe persistent asthma within the past 2 years, known chronic obstructive pulmonary disease (COPD) with a FEV1 &lt; 50% of predicted normal, and active congestive heart failure. Randomization was stratified by the ISS (stage 1 or 2 vs stage 3) at screening, prior proteasome inhibitor exposure (yes vs no), number of prior lines of therapy (1&nbsp;vs&nbsp;&ge; 2), or prior cluster differentiation antigen 38 (CD38) antibody therapy (yes vs no).</p><p>&nbsp;</p><p>Kyprolis was administered intravenously over 30 minutes at a dose of 20&nbsp;mg/m<sup>2</sup> in Cycle 1 on Days 1 and 2; at a dose of 56&nbsp;mg/m<sup>2</sup> in Cycle 1 on Days 8, 9, 15 and 16; and on Days 1, 2, 8, 9, 15 and 16 of each 28‑day cycle thereafter. Dexamethasone 20&nbsp;mg was administered orally or intravenously on Days 1, 2, 8, 9, 15 and 16 and then 40&nbsp;mg orally or intravenously on Day 22 of each 28‑day cycle. In the DKd arm, daratumumab was administered intravenously at a dose of 8&nbsp;mg/kg in Cycle 1 on Days 1 and 2. Thereafter, daratumumab was administered intravenously at a dose of 16&nbsp;mg/kg on Days 8, 15 and 22 of Cycle 1; Days 1, 8 and 15 and 22 of Cycle 2; Days 1 and 15 of Cycles 3 to 6; and Day 1 for the remaining cycles or until disease progression. For patients &gt;75 years on a reduced dexamethasone dose of 20&nbsp;mg, the entire 20&nbsp;mg dose was given as a daratumumab pre-infusion medication on days when daratumumab was administered. Dosing of dexamethasone was otherwise split across days when Kyprolis was administered in both study arms. Treatment was continued in both arms until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>A total of 466 patients were randomized; 312 to the DKd arm and 154 to the Kd arm. The demographics and baseline characteristics are summarized in Table 27.<em> </em></p><p><u>&nbsp;</u></p><p>Table 27: Demographics and baseline characteristics in CANDOR</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:87%"><thead><tr><td style="vertical-align:bottom"><p><strong>Characteristics</strong></p></td><td style="vertical-align:bottom"><p><strong>DKd</strong><strong> </strong></p><p><strong>(N = 312) </strong></p></td><td style="vertical-align:bottom"><p><strong>Kd </strong></p><p><strong>(N = 154)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Age at randomization (years)</p></td></tr><tr><td style="vertical-align:top"><p>Median (min, max)</p></td><td style="vertical-align:top"><p>64 (29, 84)</p></td><td style="vertical-align:top"><p>65 (35, 83)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Age group &ndash; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>18 &ndash; 64 years</p></td><td style="vertical-align:top"><p>163 (52)</p></td><td style="vertical-align:top"><p>77 (50)</p></td></tr><tr><td style="vertical-align:top"><p>65 &ndash; 74 years</p></td><td style="vertical-align:top"><p>121 (39)</p></td><td style="vertical-align:top"><p>55 (36)</p></td></tr><tr><td style="vertical-align:top"><p>75 years and older</p></td><td style="vertical-align:top"><p>28 (9)</p></td><td style="vertical-align:top"><p>22 (14)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Sex &ndash; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>177 (57)</p></td><td style="vertical-align:top"><p>91 (59)</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td style="vertical-align:top"><p>135 (43)</p></td><td style="vertical-align:top"><p>63 (41)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Race &ndash; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:top"><p>46 (15)</p></td><td style="vertical-align:top"><p>20 (13)</p></td></tr><tr><td style="vertical-align:top"><p>Black or African American</p></td><td style="vertical-align:top"><p>7 (2.2)</p></td><td style="vertical-align:top"><p>2 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>White</p></td><td style="vertical-align:top"><p>243 (78)</p></td><td style="vertical-align:top"><p>123 (80)</p></td></tr><tr><td style="vertical-align:top"><p>Other</p></td><td style="vertical-align:top"><p>16 (5)</p></td><td style="vertical-align:top"><p>9 (6)</p></td></tr><tr><td colspan="3"><p>Geographic region &ndash; n (%)</p></td></tr><tr><td><p>North America</p></td><td style="vertical-align:top"><p>21 (7)</p></td><td style="vertical-align:top"><p>12 (8)</p></td></tr><tr><td><p>Europe</p></td><td style="vertical-align:top"><p>207 (66)</p></td><td style="vertical-align:top"><p>103 (67)</p></td></tr><tr><td><p>Asia Pacific</p></td><td style="vertical-align:top"><p>84 (27)</p></td><td style="vertical-align:top"><p>39 (25)</p></td></tr><tr><td colspan="3"><p>ECOG performance status &ndash; n (%)</p></td></tr><tr><td><p>0 or 1</p></td><td style="vertical-align:top"><p>295 (95)</p></td><td style="vertical-align:top"><p>147 (95)</p></td></tr><tr><td><p>2</p></td><td style="vertical-align:top"><p>15 (4.8)</p></td><td style="vertical-align:top"><p>7 (4.5)</p></td></tr><tr><td><p>Missing</p></td><td style="vertical-align:top"><p>2 (0.6)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td colspan="3"><p>Risk group as determined by FISH &ndash; n (%)</p></td></tr><tr><td><p>High-risk</p></td><td style="vertical-align:top"><p>48 (15)</p></td><td style="vertical-align:top"><p>26 (17)</p></td></tr><tr><td><p>Standard-risk</p></td><td style="vertical-align:top"><p>104 (33)</p></td><td style="vertical-align:top"><p>52 (34)</p></td></tr><tr><td><p>Unknown</p></td><td style="vertical-align:top"><p>160 (51)</p></td><td style="vertical-align:top"><p>76 (49)</p></td></tr><tr><td colspan="3"><p>ISS stage per I x RS at screening &ndash; n (%)</p></td></tr><tr><td><p>I or II</p></td><td style="vertical-align:top"><p>252 (81)</p></td><td style="vertical-align:top"><p>127 (82)</p></td></tr><tr><td><p>III</p></td><td style="vertical-align:top"><p>60 (19)</p></td><td style="vertical-align:top"><p>27 (17)</p></td></tr><tr><td colspan="3"><p>Number of prior regimens &ndash; n (%)*</p></td></tr><tr><td><p>1</p></td><td style="vertical-align:top"><p>144 (46)</p></td><td style="vertical-align:top"><p>70 (45)</p></td></tr><tr><td><p>2</p></td><td style="vertical-align:top"><p>99 (32)</p></td><td style="vertical-align:top"><p>46 (30)</p></td></tr><tr><td><p>3</p></td><td style="vertical-align:top"><p>69 (22)</p></td><td style="vertical-align:top"><p>37 (24)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Prior Therapies</p></td></tr><tr><td><p>Lenalidomide</p></td><td style="vertical-align:top"><p>123 (39)</p></td><td style="vertical-align:top"><p>74 (48)</p></td></tr><tr><td><p>Refractory to lenalidomide</p></td><td style="vertical-align:top"><p>99 (32)</p></td><td style="vertical-align:top"><p>55 (36)</p></td></tr><tr><td style="vertical-align:top"><p>Bortezomib</p></td><td><p>287 (92)</p></td><td><p>134 (87)</p></td></tr><tr><td><p>Prior CD38 antibody therapy &ndash; n (%)</p></td><td style="vertical-align:top"><p>1 (0.3)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td><p>Prior stem cell transplant (ASCT) &ndash; n (%)</p></td><td style="vertical-align:top"><p>195 (62)</p></td><td style="vertical-align:top"><p>75 (49)</p></td></tr></tbody></table><p>DKd = Kyprolis, daratumumab and dexamethasone; ECOG&nbsp;=&nbsp;Eastern Cooperative Oncology Group; FISH&nbsp;=&nbsp;Fluorescence <em>in situ</em> hybridization; ISS&nbsp;=&nbsp;International Staging System; Kd = Kyprolis and dexamethasone</p><p>*Subjects with number of prior regimens &gt; 3 was 0 in the DKd arm and 1 in Kd arm.</p><p>&nbsp;</p><p>Efficacy was assessed by an IRC evaluation of PFS using the IMWG response criteria. Efficacy results are provided in Table 28 and Figure 6. The median duration of response has not been reached for the DKd arm and was 16.6 months (13.9, NE) for the Kd arm. The median (min, max) time to response was 1.0 (1, 14) months for the DKd arm and 1.0 (1, 10) months for the Kd arm.</p><p>&nbsp;</p><p>Figure 6: Kaplan-Meier plot of progression-free survival in CANDOR</p><p><img src="data:image/jpeg;base64,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" alt="" width="616" height="591" vspace="0" hspace="0" border="0" style="width:616px;height:591px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>Table 28: Summary of key results in CANDOR<em> </em></p><p>(Intent‑to‑treat population)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>DKd </strong></p><p><strong>(N = 312)</strong></p></td><td style="vertical-align:top"><p><strong>Kd</strong></p><p><strong>(N = 154)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>PFS</p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td><p>110 (35%)</p></td><td><p>68 (44%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td><p>NE (NE, NE)</p></td><td><p>15.8 (12.1, NE)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td colspan="2"><p>0.63 (0.46, 0.85)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value (1‑sided)<sup>a</sup></p></td><td colspan="2"><p>0.0014</p></td></tr><tr><td colspan="3"><p>Overall response</p></td></tr><tr><td style="vertical-align:top"><p>N with response</p></td><td><p>263</p></td><td><p>115</p></td></tr><tr><td style="vertical-align:top"><p>ORR (%)</p><p>(95% CI)</p></td><td><p>84%</p><p>(80%, 88%)</p></td><td><p>75%</p><p>(67%, 81%)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value (1‑sided)<sup>b</sup></p></td><td colspan="2"><p>0.0040</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td><p>89 (28%)</p></td><td><p>16 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td><p>127 (41%)</p></td><td><p>59 (38%)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td><p>47 (15%)</p></td><td><p>40 (26%)</p></td></tr><tr><td style="vertical-align:top"><p>MRD [-] CR rate at 12 months n (%)<sup>c</sup></p><p>(95% CI)</p></td><td><p>39 (12%)</p><p>(9%, 17%)</p></td><td><p>2 (1.3%)</p><p>(0.2%, 4.6%)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value (1‑sided)<sup>b</sup></p></td><td colspan="2"><p>&lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p>MRD [-] CR<sup>d</sup></p></td><td><p>43 (14%)</p></td><td><p>5 (3.2%)</p></td></tr></tbody></table><p>CI&nbsp;=&nbsp;confidence interval; CR&nbsp;=&nbsp;complete response; HR = hazard ratio; DKd = Kyprolis, daratumumab, and dexamethasone; Kd = Kyprolis and dexamethasone; ORR&nbsp;=&nbsp;overall response rate; PFS&nbsp;=&nbsp;progression‑free survival; PR = partial response; MRD [-] CR = minimal residual disease negative-complete response; NE = non‑estimable; VGPR&nbsp;=&nbsp;very good partial response</p><p>&nbsp;</p><p><sup>a </sup>The P-value was derived using stratified log-rank test.</p><p><sup>b </sup>The P‑value was derived using stratified Cochran Mantel-Haenszel Chi-Squared test.</p><p><sup>c </sup>MRD [-] CR (at a 10<sup>-5</sup> level) is defined as achievement of CR per IMWG-URC and MRD[-] status as assessed by the next‑generation sequencing assay (ClonoSEQ) at the 12 months landmark (from 8 months to 13 months window).</p><p><sup>d </sup>MRD[-]CR (at a 10<sup>-5</sup> level) is defined as achievement of CR per IMWG-URC and MRD[-] status as assessed by the next‑generation sequencing assay (ClonoSEQ) at any timepoint during the trial.&nbsp;</p><p><strong>&nbsp;</strong></p><p>EQUULEUS</p><p>&nbsp;</p><p>EQUULEUS was an open‑label, multi‑cohort trial which evaluated the combination of Kyprolis with intravenous daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy. Patients who had the following were excluded from the trial: known moderate or severe persistent asthma within the past 2 years, known chronic obstructive pulmonary disease (COPD) with a FEV1 &lt; 50% of predicted normal, or active congestive heart failure (defined as New York Heart Association Class III-IV).</p><p>&nbsp;</p><p>Kyprolis was administered intravenously over 30 minutes once weekly at a dose of 20&nbsp;mg/m<sup>2</sup> on Cycle 1 Day 1 and escalated to a dose of 70&nbsp;mg/m<sup>2 </sup>on Cycle 1, Days 8 and 15; and on Days 1, 8, and 15 of each 28‑day cycle. Ten patients were administered daratumumab at a dose of 16&nbsp;mg/kg intravenously on Cycle 1, Day 1 and the remaining patients were administered daratumumab at a dose of 8&nbsp;mg/kg intravenously on Cycle 1, Days 1 and 2. Thereafter, daratumumab was administered intravenously at a dose of 16&nbsp;mg/kg on Days 8, 15 and 22 of Cycle 1; Days 1, 8, 15 and 22 of Cycle 2; Days 1 and 15 of Cycles 3 to 6; and then Day 1 for the remaining cycles of each 28‑day cycle. In Cycles 1 and 2, dexamethasone 20&nbsp;mg was administered orally or intravenously on Days 1, 2, 8, 9, 15, 16, 22 and 23; in cycles 3 to 6, dexamethasone 20&nbsp;mg was administered orally or intravenously on Days 1, 2, 15 and 16 and at a dose of 40&nbsp;mg on Day 8 and 22; and in cycles 7 and thereafter, dexamethasone 20&nbsp;mg was administered orally or intravenously on Days 1 and 2 and at a dose of 40&nbsp;mg on Days 8, 15, and 22. For patients &gt; 75 years of age, dexamethasone 20&nbsp;mg was administered orally or intravenously weekly after the first week. Treatment continued until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>The EQUULEUS trial enrolled 85 patients. The demographics and baseline characteristics are summarized in Table 29.</p><p>&nbsp;</p><p>Table 29: Demographics and baseline characteristics in DKd 20/70&nbsp;mg/m<sup>2</sup> regimen of EQUULEUS (combination therapy for relapsed or refractory multiple myeloma)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:81%"><thead><tr><td style="vertical-align:bottom"><p><strong>Characteristics</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of patients (%) </strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>Age (years)</p></td></tr><tr><td style="vertical-align:top"><p>Median (min, max)</p></td><td style="vertical-align:top"><p>66 (38, 85)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Age group &ndash; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 65 years</p></td><td style="vertical-align:top"><p>36 (42)</p></td></tr><tr><td style="vertical-align:top"><p>65 ‑ &lt; 75 years</p></td><td style="vertical-align:top"><p>41 (48)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 75 years</p></td><td style="vertical-align:top"><p>8 (9)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sex &ndash; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td style="vertical-align:top"><p>46 (54)</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td style="vertical-align:top"><p>39 (46)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Race &ndash; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:top"><p>3 (3.5)</p></td></tr><tr><td style="vertical-align:top"><p>Black or African American</p></td><td style="vertical-align:top"><p>3 (3.5)</p></td></tr><tr><td style="vertical-align:top"><p>White</p></td><td style="vertical-align:top"><p>68 (80)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ECOG score, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>32 (38)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>46 (54)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>7 (8)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>FISH, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>67</p></td></tr><tr><td style="vertical-align:top"><p>Standard-risk</p></td><td style="vertical-align:top"><p>54 (81)</p></td></tr><tr><td style="vertical-align:top"><p>High-risk</p></td><td style="vertical-align:top"><p>13 (19)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Number of prior regimens</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>20 (23)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>40 (47)</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>23 (27)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 3</p></td><td style="vertical-align:top"><p>2 (2.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior therapies</p></td></tr><tr><td style="vertical-align:top"><p>Bortezomib</p></td><td style="vertical-align:top"><p>85 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Lenalidomide</p></td><td style="vertical-align:top"><p>81 (95)</p></td></tr><tr><td style="vertical-align:top"><p>Prior stem cell transplant (ASCT)</p></td><td style="vertical-align:top"><p>62 (73)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory to lenalidomide</p></td><td style="vertical-align:top"><p>51 (60)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory to both a PI and IMiD</p></td><td style="vertical-align:top"><p>25 (29)</p></td></tr></tbody></table><p>ECOG&nbsp;=&nbsp;Eastern Cooperative Oncology Group; FISH&nbsp;=&nbsp;Fluorescence <em>in situ</em> hybridization; PI = proteasome inhibitor; IMiD&nbsp;=&nbsp;immunomodulatory agent.</p><p>&nbsp;</p><p>Efficacy results were based on overall response rate using IMWG criteria. Efficacy results are provided in&nbsp;Table&nbsp;30. The median time to response was 0.95 months (Range: 0.9, 14.3). The median duration of response was 28 months (95% CI: 20.5, not estimable).</p><p>&nbsp;</p><p>Table 30: Summary of key results in EQUULEUS<em> </em></p><p>(Intent‑to‑treat population)</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Study patients</strong></p><p><strong>n (%) </strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>Overall response</p></td></tr><tr><td style="vertical-align:top"><p>N with response</p></td><td style="vertical-align:top"><p>69</p></td></tr><tr><td style="vertical-align:top"><p>ORR (%) (95% CI)</p></td><td style="vertical-align:top"><p>81% (71, 89)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Response category, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>sCR</p></td><td style="vertical-align:top"><p>18 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>12 (14%)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td style="vertical-align:top"><p>28 (33%)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>11 (13%)</p></td></tr></tbody></table><p>CI&nbsp;=&nbsp;confidence interval; sCR&nbsp;=&nbsp;stringent complete response; CR&nbsp;=&nbsp;complete response; ORR&nbsp;=&nbsp;overall response rate; PR&nbsp;=&nbsp;partial response; VGPR&nbsp;=&nbsp;very good partial response</p><p>&nbsp;</p><p><u>PLEIADES </u></p><p><u>&nbsp;</u></p><p>The efficacy of Kyprolis with daratumumab and hyaluronidase-fihj plus dexamethasone (DKd) was evaluated in a single-arm cohort of PLEIADES, a multi-cohort, open-label trial. This cohort enrolled patients with relapsed or refractory multiple myeloma excluding patients with left ventricular ejection fraction (LVEF) less than 40%, myocardial infarction within 6&nbsp;months, uncontrolled cardiac arrhythmia, or uncontrolled hypertension (systolic blood pressure &gt; 159&nbsp;mmHg or diastolic &gt; 99&nbsp;mmHg despite optimal treatment). Patients received Kyprolis administered by IV infusion at a dose of 20&nbsp;mg/m<sup>2</sup> on Cycle 1 Day 1 and if a dose of 20&nbsp;mg/m<sup>2</sup> was tolerated Kyprolis was administered at a dose of 70&nbsp;mg/m<sup>2</sup> as a 30-minute IV infusion on Cycle 1 Day 8 and Day 15, and then Day 1, 8 and 15 of each cycle; daratumumab and hyaluronidase-fihj1,800&nbsp;mg/30,000 units administered subcutaneously once weekly from Weeks 1 to 8, once every 2 weeks from Weeks 9 to 24 and once every 4 weeks starting with Week 25 until disease progression or unacceptable toxicity; and dexamethasone 40&nbsp;mg per week (or a reduced dose of 20&nbsp;mg per week for patients &ge; 75 years or BMI &lt; 18.5). The major efficacy outcome measure was ORR.</p><p>&nbsp;</p><p>A total of 66 patients received the DKd regimen. The median age was 61 years (range: 42, 84); 52% were male; 73% were White and 3% Black or African American; and 68% had ISS Stage I, 18% had ISS Stage II, and 14% had ISS Stage III disease. A total of 79% of patients had a prior ASCT; 91% of patients received a prior PI. All patients received 1 prior line of therapy with exposure to lenalidomide and 62% of patients were refractory to lenalidomide.</p><p>&nbsp;</p><p>Efficacy results are summarized in Table 31. At a median follow-up of 9.2 months, the median duration of response had not been reached and an estimated 85.2% (95% CI: 72.5, 92.3) maintained response for at least 6 months and 82.5% (95% CI: 68.9, 90.6) maintained response for at least 9 months.</p><p>&nbsp;</p><p><strong>Table 31: Efficacy results from PLEIADES in patients who received DKd</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:504px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DKd</strong></p><p><strong>(N=66)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate (sCR+CR+VGPR+PR), n (%)<sup>a</sup></p></td><td style="vertical-align:top"><p>56 (84.8%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(73.9%, 92.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Stringent complete response (sCR)</p></td><td style="vertical-align:top"><p>11 (16.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response (CR)</p></td><td style="vertical-align:top"><p>14 (21.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Very good partial response (VGPR)</p></td><td style="vertical-align:top"><p>26 (39.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response (PR)</p></td><td style="vertical-align:top"><p>5 (7.6%)</p></td></tr></tbody></table><p>CI = confidence interval</p><p><sup>&nbsp;a</sup> Based on treated patients</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Monotherapy for relapsed or refractory multiple myeloma </u></em></p><p>&nbsp;</p><p>Study&nbsp;PX‑171‑007</p><p>&nbsp;</p><p>Study&nbsp;PX‑171‑007 was a multicenter, open‑label, dose escalation, single‑arm trial that evaluated the safety of Kyprolis monotherapy as a 30‑minute infusion in patients with relapsed or refractory multiple myeloma after 2 or more lines of therapy. Patients were excluded if they had a creatinine clearance &lt;&nbsp;20&nbsp;mL/min; ALT &ge;&nbsp;3&nbsp;&times;&nbsp;upper limit of normal (ULN), bilirubin &ge;&nbsp;1.5&nbsp;&times;&nbsp;ULN; New York Heart Association Class&nbsp;III&nbsp;or&nbsp;IV congestive heart failure; or other significant cardiac conditions. A total of 24&nbsp;subjects with multiple myeloma were enrolled at the maximum tolerated dose level of 20/56&nbsp;mg/m<sup>2</sup>. Kyprolis was administered twice weekly for 3 consecutive weeks (Days&nbsp;1, 2, 8, 9, 15, and 16) of a 28‑day cycle. In Cycle&nbsp;13 onward, the Day&nbsp;8 and 9 Kyprolis doses could be omitted. Patients received Kyprolis at a starting dose of 20&nbsp;mg/m<sup>2 </sup>on Days&nbsp;1 and 2 of Cycle&nbsp;1, which was increased to 56&nbsp;mg/m<sup>2</sup> for all subsequent doses. Dexamethasone 8&nbsp;mg orally or intravenously was required prior to each Kyprolis dose in Cycle&nbsp;1 and was optional in subsequent cycles. Treatment was continued until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Efficacy was evaluated by ORR and DOR. ORR by investigator assessment was 50%&nbsp;(95%&nbsp;CI: 29, 71) per IMWG criteria (see Table&nbsp;32). The median DOR in subjects who achieved a PR or better was 8.0&nbsp;months (Range: 1.4, 32.5).</p><p>&nbsp;</p><p>Table&nbsp;32: Response categories in study&nbsp;PX‑171‑007&nbsp;(20/56&nbsp;mg/m<sup>2</sup> monotherapy regimen)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:52%"><thead><tr><td style="vertical-align:bottom"><p><strong>Characteristics</strong></p></td><td style="vertical-align:bottom"><p><strong>Study patients<sup>a</sup></strong></p><p><strong>n (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Number of patients (%)</p></td><td style="vertical-align:top"><p>24 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Overall response<sup>b</sup></p></td><td style="vertical-align:top"><p>12 (50)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI<sup>c </sup></p></td><td style="vertical-align:top"><p>(29, 71)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Response category</p></td></tr><tr><td style="vertical-align:top"><p>sCR</p></td><td style="vertical-align:top"><p>1 (4)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td style="vertical-align:top"><p>4 (17)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>7 (29)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI = confidence interval; CR = complete response; PR = partial response; sCR&nbsp;=&nbsp;stringent complete response; VGPR&nbsp;=&nbsp;very good partial response</p><p><sup>a</sup> Eligible patients had 2 or more prior lines of therapy.</p><p><sup>b</sup> Per investigator assessment.</p><p><sup>c</sup> Exact confidence interval.</p></td></tr></tbody></table><p>&nbsp;</p><p>Study&nbsp;PX‑171‑003 A1</p><p>&nbsp;</p><p>Study&nbsp;PX‑171‑003 A1 was a single‑arm, multicenter clinical trial of Kyprolis monotherapy by up to 10‑minute infusion. Eligible patients were those with relapsed and refractory multiple myeloma who had received at least two prior therapies (including bortezomib and thalidomide and/or lenalidomide) and had &le;&nbsp;25% response to the most recent therapy or had disease progression during or within 60&nbsp;days of the most recent therapy. Patients were excluded from the trial if they were refractory to all prior therapies or had a total bilirubin &ge;&nbsp;2&nbsp;&times; ULN; creatinine clearance &lt;&nbsp;30&nbsp;mL/min; New York Heart Association Class III to IV congestive heart failure; symptomatic cardiac ischemia; myocardial infarction within the last 6&nbsp;months; peripheral neuropathy Grade&nbsp;3 or 4, or peripheral neuropathy Grade&nbsp;2 with pain; active infections requiring treatment; or pleural effusion.</p><p>&nbsp;</p><p>Kyprolis was administered intravenously up&nbsp;to 10&nbsp;minutes on two consecutive days each week for three weeks, followed by a 12-day rest period (28‑day treatment cycle), until disease progression, unacceptable toxicity, or for a maximum of 12&nbsp;cycles. Patients received 20&nbsp;mg/m<sup>2</sup> at each dose in Cycle&nbsp;1, and 27&nbsp;mg/m<sup>2</sup> in subsequent cycles. Dexamethasone 4&nbsp;mg orally or intravenously was administered prior to Kyprolis doses in the first and second cycles.</p><p>&nbsp;</p><p>A total of 266&nbsp;patients were enrolled. Baseline patient and disease characteristics are summarized in Table&nbsp;33.</p><p>&nbsp;</p><p>Table&nbsp;33: Demographics and baseline characteristics in study&nbsp;PX‑171‑003 A1<br />(20/27&nbsp;mg/m<sup>2</sup> monotherapy regimen)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td style="vertical-align:bottom"><p>Number of patients (%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Patient characteristics</strong></p></td></tr><tr><td style="vertical-align:top"><p>Enrolled patients</p></td><td style="vertical-align:top"><p>266 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Median age, years (range)</p></td><td style="vertical-align:top"><p>63 (37, 87)</p></td></tr><tr><td style="vertical-align:top"><p>Age group, &lt;&nbsp;65 / &ge;&nbsp;65&nbsp;(years)</p></td><td style="vertical-align:top"><p>146 (55) / 120 (45)</p></td></tr><tr><td style="vertical-align:top"><p>Sex (male / female)</p></td><td style="vertical-align:top"><p>155 (58) / 111 (42)</p></td></tr><tr><td style="vertical-align:top"><p>Race (White / Black / Asian / Other)</p></td><td style="vertical-align:top"><p>190 (71) / 53 (20) / 6 (2) / 17 (6)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Disease characteristics</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of prior regimens (median)</p></td><td style="vertical-align:top"><p>5<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Prior transplantation</p></td><td style="vertical-align:top"><p>198 (74)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory status to most recent therapy<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Refractory: Progression during most recent therapy</p></td><td style="vertical-align:top"><p>198 (74)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory: Progression within 60&nbsp;days after completion of most recent therapy</p></td><td style="vertical-align:top"><p><br />38 (14)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory: &le;&nbsp;25% response to treatment</p></td><td style="vertical-align:top"><p>16 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Relapsed: Progression after 60&nbsp;days post treatment</p></td><td style="vertical-align:top"><p>14 (5)</p></td></tr><tr><td style="vertical-align:top"><p>Years since diagnosis, median (range)</p></td><td style="vertical-align:top"><p>5.4 (0.5, 22.3)</p></td></tr><tr><td style="vertical-align:top"><p>Plasma cell involvement (&lt;&nbsp;50% / &ge;&nbsp;50% / unknown)</p></td><td style="vertical-align:top"><p>143 (54) / 106 (40) / 17 (6)</p></td></tr><tr><td style="vertical-align:top"><p>ISS stage at study baseline</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>I</p></td><td style="vertical-align:top"><p>76 (29)</p></td></tr><tr><td style="vertical-align:bottom"><p>II</p></td><td style="vertical-align:top"><p>102 (38)</p></td></tr><tr><td style="vertical-align:bottom"><p>III</p></td><td style="vertical-align:top"><p>81 (31)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>7 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Cytogenetics or FISH analyses</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Normal/Favorable</p></td><td style="vertical-align:top"><p>159 (60)</p></td></tr><tr><td style="vertical-align:top"><p>Poor prognosis</p></td><td style="vertical-align:top"><p>75 (28)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>32 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance&nbsp;&lt;&nbsp;30&nbsp;mL/min</p></td><td style="vertical-align:top"><p>6 (2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>FISH&nbsp;=&nbsp;Fluorescence <em>in situ</em> hybridization; ISS&nbsp;=&nbsp;International Staging System</p><p><sup>a</sup> Range: 1, 20.</p><p><sup>b</sup> Categories for refractory status are derived by programmatic assessment using available laboratory data.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was evaluated by ORR as determined by IRC assessment using IMWG criteria. Efficacy results are provided in Table&nbsp;34. The median DOR was 7.8&nbsp;months (95%&nbsp;CI:&nbsp;5.6,&nbsp;9.2).</p><p>&nbsp;</p><p>Table&nbsp;34: Response categories in study&nbsp;PX‑171‑003 A1 (20/27&nbsp;mg/m<sup>2</sup> monotherapy regimen)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:65%"><thead><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td style="vertical-align:bottom"><p>Study patients<sup>a</sup></p><p>n (%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Number of patients (%)</p></td><td style="vertical-align:top"><p>266 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Overall response<sup>b</sup></p></td><td style="vertical-align:top"><p>61 (23)</p></td></tr><tr><td style="vertical-align:top"><p>95%&nbsp;CI<sup>c</sup></p></td><td style="vertical-align:top"><p>(18, 28)</p></td></tr><tr><td style="vertical-align:top"><p>Response category</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>1&nbsp;(&lt;&nbsp;1)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td style="vertical-align:top"><p>13 (5)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>47 (18)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI = confidence interval; CR&nbsp;=&nbsp;complete response; PR = partial response; VGPR&nbsp;=&nbsp;very good partial response</p><p><sup>a</sup> Eligible patients had 2 or more prior lines of therapy and were refractory to the last regimen.</p><p><sup>b</sup> As assessed by the Independent Review Committee.</p><p><sup>c</sup> Exact confidence interval.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Study&nbsp;PX‑171‑004 Part 2</p><p>&nbsp;</p><p>Study&nbsp;PX‑171‑004 Part 2 was a single‑arm, multicenter clinical trial of Kyprolis monotherapy by up to 10‑minute infusion. Eligible patients were those with relapsed or refractory multiple myeloma who were bortezomib‑na&iuml;ve, had received one to three prior lines of therapy and had &le;&nbsp;25% response or progression during therapy or within 60&nbsp;days after completion of therapy. Patients were excluded from the trial if they were refractory to standard first‑line therapy or had a total bilirubin &ge;&nbsp;2&nbsp;&times;&nbsp;ULN; creatinine clearance &lt;&nbsp;30&nbsp;mL/min; New York Heart Association Class&nbsp;III&nbsp;to&nbsp;IV congestive heart failure; symptomatic cardiac ischemia; myocardial infarction within the last 6&nbsp;months; active infections requiring treatment; or pleural effusion.</p><p>&nbsp;</p><p>Kyprolis was administered intravenously up&nbsp;to 10&nbsp;minutes on two consecutive days each week for three weeks, followed by a 12‑day rest period (28‑day treatment cycle), until disease progression, unacceptable toxicity, or for a maximum of 12&nbsp;cycles. Patients received 20&nbsp;mg/m<sup>2</sup> at each dose in Cycle&nbsp;1, and 27&nbsp;mg/m<sup>2</sup> in subsequent cycles. Dexamethasone 4&nbsp;mg orally or intravenously was administered prior to Kyprolis doses in the first and second cycles.</p><p>&nbsp;</p><p>A total of 70 patients were treated with this 20/27&nbsp;mg/m<sup>2</sup> regimen. Baseline patient and disease characteristics are summarized in Table&nbsp;35.</p><p>&nbsp;</p><p>Table&nbsp;35: Demographics and baseline characteristics in study&nbsp;PX‑171‑004 Part 2&nbsp;<br />(20/27&nbsp;mg/m<sup>2</sup> monotherapy regimen)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:607px"><thead><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td style="vertical-align:bottom"><p>Number of patients (%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Patient characteristics</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Enrolled patients</p></td><td style="vertical-align:top"><p>70 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Median age, years (range)</p></td><td style="vertical-align:top"><p>66 (45, 85)</p></td></tr><tr><td style="vertical-align:top"><p>Age group, &lt;&nbsp;65 / &ge;&nbsp;65&nbsp;(years)</p></td><td style="vertical-align:top"><p>31 (44) / 39 (56)</p></td></tr><tr><td style="vertical-align:top"><p>Sex (male / female)</p></td><td style="vertical-align:top"><p>44 (63) / 26 (37)</p></td></tr><tr><td style="vertical-align:top"><p>Race (White / Black / Asian / Hispanic / Other)</p></td><td style="vertical-align:top"><p>52 (74) / 12 (17) / 3 (4) / 2 (3) / 1 (1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease characteristics</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of prior regimens (median)</p></td><td style="vertical-align:top"><p>2<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Prior transplantation</p></td><td style="vertical-align:top"><p>47 (67)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory status to most recent therapy<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Refractory: Progression during most recent therapy</p></td><td style="vertical-align:top"><p>28 (40)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory: Progression within 60&nbsp;days after completion of most recent therapy</p></td><td style="vertical-align:top"><p><br />7 (10)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory: &le;&nbsp;25% response to treatment</p></td><td style="vertical-align:top"><p>10 (14)</p></td></tr><tr><td style="vertical-align:top"><p>Relapsed: Progression after 60&nbsp;days post treatment</p></td><td style="vertical-align:top"><p>23 (33)</p></td></tr><tr><td style="vertical-align:top"><p>No Signs of Progression</p></td><td style="vertical-align:top"><p>2 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Years since diagnosis, median (range)</p></td><td style="vertical-align:top"><p>3.6 (0.7, 12.2)</p></td></tr><tr><td style="vertical-align:top"><p>Plasma cell involvement (&lt;&nbsp;50% / &ge;&nbsp;50% / unknown)</p></td><td style="vertical-align:top"><p>54 (77) / 14 (20) / 1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>ISS stage at study baseline, n (%)</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>I</p></td><td style="vertical-align:top"><p>28 (40)</p></td></tr><tr><td style="vertical-align:bottom"><p>II</p></td><td style="vertical-align:top"><p>25 (36)</p></td></tr><tr><td style="vertical-align:bottom"><p>III</p></td><td style="vertical-align:top"><p>16 (23)</p></td></tr><tr><td style="vertical-align:bottom"><p>Unknown</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Cytogenetics or FISH analyses</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Normal/Favorable</p></td><td style="vertical-align:top"><p>57 (81)</p></td></tr><tr><td style="vertical-align:top"><p>Poor prognosis</p></td><td style="vertical-align:top"><p>10 (14)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>3 (4)</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance &lt;&nbsp;30&nbsp;mL/min</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>FISH&nbsp;=&nbsp;Fluorescence <em>in situ</em> hybridization; ISS&nbsp;=&nbsp;International Staging System</p><p><sup>a</sup> Range: 1, 4.</p><p><sup>b</sup> Categories for refractory status are derived by programmatic assessment using available laboratory data.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was evaluated by ORR as determined by IRC assessment using IMWG criteria. Efficacy results are provided in Table&nbsp;36. The median DOR was not reached.</p><p>&nbsp;</p><p>Table&nbsp;36: Response categories in study&nbsp;PX‑171‑004 Part 2 (20/27&nbsp;mg/m<sup>2</sup> monotherapy regimen)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:65%"><tbody><tr><td style="vertical-align:bottom"><p>Characteristics</p></td><td style="vertical-align:bottom"><p>Study patients<sup>a</sup></p><p>n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients (%)</p></td><td style="vertical-align:top"><p>70 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Overall response<sup>b</sup></p></td><td style="vertical-align:top"><p>35 (50)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI<sup>c</sup></p></td><td style="vertical-align:top"><p>(38, 62)</p></td></tr><tr><td style="vertical-align:top"><p>Response category</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td style="vertical-align:top"><p>18 (26)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>16 (23)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI = confidence interval; CR&nbsp;=&nbsp;complete response; PR = partial response; VGPR&nbsp;=&nbsp;very good partial response</p><p><sup>a</sup> Eligible patients had 1‑3 prior lines of therapy and were refractory to the last regimen.</p><p><sup>b</sup> As assessed by an Independent Review Committee.</p><p><sup>c</sup> Exact confidence interval.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Carfilzomib at doses between 20&nbsp;mg/m<sup>2</sup> and 70&nbsp;mg/m<sup>2</sup> administered as a 30‑minute infusion resulted in dose‑dependent increases in maximum plasma concentrations (C<sub>max</sub>) and area under the curve over time to infinity (AUC<sub>0-INF</sub>) in patients with multiple myeloma. A dose‑dependent increase in C<sub>max</sub> and AUC<sub>0-INF</sub> was also observed between carfilzomib 20&nbsp;mg/m<sup>2</sup> and 56&nbsp;mg/m<sup>2</sup> as a 2‑ to 10‑minute infusion in patients with relapsed or refractory multiple myeloma. A 30‑minute infusion resulted in a similar AUC<sub>0-INF</sub>, but 2‑ to 3‑fold lower C<sub>max</sub> than that observed with a 2‑ to 10‑minute infusion at the same dose. There was no evidence of carfilzomib accumulation following repeated administration of carfilzomib 70&nbsp;mg/m<sup>2</sup> as a 30‑minute once weekly infusion or 15 and 20&nbsp;mg/m<sup>2</sup> as a 2‑ to 10‑minute twice weekly infusion.</p><p>&nbsp;</p><p>Table 37 lists the estimated mean average daily area under the curve in the first cycle (AUC<sub>C1,avg</sub>), average daily area under the curve at steady-state (AUC<sub>ss</sub>) and C<sub>max</sub> at the highest dose in the first cycle (C<sub>max,C1</sub>) for the different dosing regimens.</p><p>&nbsp;</p><p>Table&nbsp;37: Carfilzomib exposure parameters for different dosing regimens</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Estimated parameters (%CV)</p></td><td><p>20/27&nbsp;mg/m<sup>2</sup> twice weekly with 2- to 10-minute infusion</p></td><td><p>20/56&nbsp;mg/m<sup>2</sup> twice weekly with 30- minute infusion</p></td><td><p>20/70&nbsp;mg/m<sup>2</sup> once weekly with 30- minute infusion</p></td></tr><tr><td><p>AUC<sub>C1,avg </sub>(ng&bull;hr/mL)</p></td><td><p>95 (40)</p></td><td><p>170 (35)</p></td><td><p>114 (36)</p></td></tr><tr><td><p>AUC<sub>ss</sub> (ng&bull;hr/mL)</p></td><td><p>111 (34)</p></td><td><p>228 (28)</p></td><td><p>150 (35)</p></td></tr><tr><td><p>C<sub>max,C1</sub> (ng/mL)</p></td><td><p>1282 (17)</p></td><td><p>1166 (29)</p></td><td><p>1595 (36)</p></td></tr></tbody></table><p>CV&nbsp;=&nbsp;Coefficient of variation</p><p>&nbsp;</p><p><u>Distribution</u></p><p><strong>&nbsp;</strong></p><p>The mean steady-state volume of distribution of a 20&nbsp;mg/m<sup>2</sup> dose of carfilzomib was 28&nbsp;L. Carfilzomib is 97% bound to human plasma proteins over the concentration range of 0.4&nbsp;to 4&nbsp;micromolar <em>in vitro</em>.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Carfilzomib has a half‑life of &le;&nbsp;1&nbsp;hour on Day&nbsp;1 of Cycle&nbsp;1 following intravenous doses &ge;&nbsp;15&nbsp;mg/m<sup>2</sup>. The half‑life was similar when administered either as a 30‑minute infusion or a 2‑ to 10‑minute infusion. The systemic clearance ranged from 151 to 263&nbsp;L/hour.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>&nbsp;</p><p>Carfilzomib is rapidly metabolized. Peptidase cleavage and epoxide hydrolysis were the principal pathways of metabolism. Cytochrome P450 (CYP)‑mediated mechanisms contribute a minor role in overall carfilzomib metabolism.</p><p>&nbsp;</p><p><u>Excretion</u></p><p>&nbsp;</p><p>Approximately 25% of the administered dose of carfilzomib was excreted in urine as metabolites in 24 hours. Urinary and fecal excretion of the parent compound was negligible (0.3% of total dose).</p><p>&nbsp;</p><p><u>Characteristics in patients</u></p><p>&nbsp;</p><p><em>Specific populations</em></p><p>&nbsp;</p><p>Age (35‑89 years), sex, race or ethnicity (80% White, 11% Black, 6% Asians, 3% Hispanics), and<em> </em>mild to severe renal impairment (creatinine clearance 15‑89&nbsp;mL/min) did not have clinically meaningful effects on the pharmacokinetics of carfilzomib.</p><p><strong>&nbsp;</strong></p><p><em>Patients with </em><em>hepatic impairment</em></p><p>&nbsp;</p><p>Compared to patients with normal hepatic function, patients with mild (total bilirubin&nbsp;1 to 1.5&nbsp;&times;&nbsp;ULN and any AST or total bilirubin &le; ULN and AST&nbsp;&gt;&nbsp;ULN) and moderate (total bilirubin&nbsp;&gt;&nbsp;1.5 to 3&nbsp;&times;&nbsp;ULN and any AST) hepatic impairment had approximately 50% higher carfilzomib AUC. The pharmacokinetics of carfilzomib has not been evaluated in patients with severe hepatic impairment (total bilirubin&nbsp;&gt;&nbsp;3&nbsp;&times;&nbsp;ULN and any AST).</p><p><strong>&nbsp;</strong></p><p><em>Patients with </em><em>renal impairment</em></p><p>&nbsp;</p><p>Relative to patients with normal renal function, ESRD patients on hemodialysis showed 33% higher carfilzomib AUC. Since hemodialysis clearance of Kyprolis concentrations has not been studied, the drug should be administered after the hemodialysis procedure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Embryo-Fetal Toxicity</u></p><p>Carfilzomib administered intravenously to pregnant rats and rabbits during the period of organogenesis was not teratogenic at doses up to 2&nbsp;mg/kg/day in rats and 0.8&nbsp;mg/kg/day in rabbits. In rabbits, there was an increase in pre-implantation loss at &ge;&nbsp;0.4&nbsp;mg/kg/day and an&nbsp;increase in early resorptions and post-implantation loss and a decrease in fetal weight at the maternally toxic dose of 0.8&nbsp;mg/kg/day. The doses of 0.4 and 0.8&nbsp;mg/kg/day in rabbits are approximately 20% and 40%, respectively, of the recommended dose in humans of 27&nbsp;mg/m<sup>2</sup> based on BSA.</p><p>&nbsp;</p><p><u>Carcinogenesis, mutagenesis, and impairment of fertility</u></p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with carfilzomib.</p><p>&nbsp;</p><p>Carfilzomib was clastogenic in the <em>in vitro</em> chromosomal aberration test in peripheral blood lymphocytes. Carfilzomib was not mutagenic in the <em>in vitro</em> bacterial reverse mutation (Ames) test and was not clastogenic in the <em>in vivo</em> mouse bone marrow micronucleus assay.</p><p>&nbsp;</p><p>Fertility studies with carfilzomib have not been conducted. No effects on reproductive tissues were noted during 28-day repeat-dose rat and monkey toxicity studies or in 6-month rat and 9-month monkey chronic toxicity studies.</p><p>&nbsp;</p><p><u>Animal toxicology and/or pharmacology</u></p><p>&nbsp;</p><p><em>Cardiovascular toxicity</em></p><p>Monkeys administered a single bolus intravenous dose of carfilzomib at 3&nbsp;mg/kg (approximately 1.3 times recommended dose in humans of 27&nbsp;mg/m<sup>2</sup> based on BSA) experienced hypotension, increased heart rate, and increased serum levels of troponin‑T.</p><p>&nbsp;</p><p><em>Chronic administration</em></p><p>Repeated bolus intravenous administration of carfilzomib at &ge;&nbsp;2&nbsp;mg/kg/dose in rats and 2&nbsp;mg/kg/dose in monkeys using dosing schedules similar to those used clinically resulted in mortalities that were due to toxicities occurring in the cardiovascular (cardiac failure, cardiac fibrosis, pericardial fluid accumulation, cardiac hemorrhage/degeneration), gastrointestinal (necrosis/hemorrhage), renal (glomerulonephropathy, tubular necrosis, dysfunction), and pulmonary (hemorrhage/inflammation) systems. The dose of 2&nbsp;mg/kg/dose in rats is approximately half the recommended dose in humans of 27&nbsp;mg/m<sup>2</sup> based on BSA. The dose of 2&nbsp;mg/kg/dose in monkeys is approximately equivalent to the recommended dose in humans based on BSA.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>sodium sulfobutylether beta-cyclodextrin: 3000&nbsp;mg</p><p>Anhydrous citric acid: 57.7&nbsp;mg</p><p>Sodium hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p><p>Dilution of reconstituted Kyprolis for injection into 0.9% sodium chloride is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial

36 months.

Reconstituted solution

Shelf life after reconstitution: 4 hours at room temperature (15 °C to 30 °C( or 24 hours at 2 °C to 8 °C.

A total time from reconstitution to administration should not exceed 24 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vial</u></p><p>&nbsp;</p><p>36 months.</p><p>&nbsp;</p><p><u>Reconstituted solution</u></p><p>&nbsp;</p><p>Shelf life after reconstitution: 4 hours at room temperature (15&deg;C to 30&deg;C( or 24 hours at 2&deg;C to 8&deg;C.</p><p>&nbsp;</p><p>A total time from reconstitution to administration should not exceed 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kyprolis (carfilzomib) is supplied as an individually packaged single‑dose 50&nbsp;mL vial containing 60&nbsp;mg of carfilzomib as a white to off‑white lyophilized cake or powder.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>yprolis vials contain no antimicrobial preservatives and are intended for single-dose only.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Reconstitution and </u><u>Preparation for intravenous</u><u> </u><u>administration</u></p><p>&nbsp;</p><p>The reconstituted solution contains carfilzomib at a concentration of 2&nbsp;mg/mL. Read the complete preparation instructions prior to reconstitution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p><p><u>Reconstitution/Preparation Steps:</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove vial from refrigerator just prior to use.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the dose (mg/m<sup>2</sup>) and number of vials of Kyprolis required using the patient&rsquo;s BSA at baseline. Patients with a BSA greater than 2.2&nbsp;m<sup>2</sup> should receive a dose based upon a BSA of 2.2&nbsp;m<sup>2</sup>. Dose adjustments do not need to be made for weight changes of less than or equal to 20%.</p><p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Aseptically reconstitute each Kyprolis vial only with Sterile Water for Injection, USP using the volumes described in Table 38. Use a 21‑gauge or larger needle (0.8&nbsp;mm or smaller external diameter needle) to reconstitute each vial by slowly injecting Sterile Water for Injection, USP through the stopper and directing the Sterile Water for Injection, USP onto the INSIDE WALL OF THE VIAL to minimize foaming. <strong>There is no data to support the use of closed system transfer devices with Kyprolis.</strong></p><p><img alt="" width="150" height="244" src="data:image/jpeg;base64,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" /></p><p><strong>Table 38: Reconstitution volumes</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>Strength</strong></p></td><td style="vertical-align:top"><p><strong>Amount of Sterile Water for Injection, USP required for reconstitution</strong></p></td></tr><tr><td><p>60&nbsp;mg vial</p></td><td><p>29&nbsp;mL</p></td></tr></tbody></table><p>&nbsp;</p><p>4. Gently swirl and/or invert the vial slowly for about 1&nbsp;minute, or until complete dissolution.&nbsp;DO NOT SHAKE to avoid foam generation. If foaming occurs, allow the solution to settle in the vial until foaming subsides (approximately 5&nbsp;minutes) and the solution is clear.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>5.&nbsp; &nbsp; Visually inspect for particulate matter and discoloration prior to administration. The reconstituted product should be a clear, colorless solution and should not be administered if any discoloration or particulate matter is observed.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard any unused portion left in the vial. DO NOT pool unused portions from the vials. DO NOT administer more than one dose from a vial.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer Kyprolis directly by intravenous infusion or in a 50&nbsp;mL to&nbsp;100&nbsp;mL intravenous bag containing <strong><u>5%</u></strong><u> <strong>Dextrose Injection, USP</strong></u>. Do not administer as an intravenous push or bolus.</p></td></tr><tr><td style="vertical-align:top"><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When administering in an intravenous bag, use a 21‑gauge or larger gauge needle (0.8&nbsp;mm or smaller external diameter needle) to withdraw the calculated dose from the vial and <strong>dilute into 50&nbsp;mL or 100&nbsp;mL intravenous bag containing </strong><strong>only </strong><strong>5% Dextrose Injection,</strong> <strong>USP</strong> (based on the calculated total dose and infusion time).</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flush the intravenous administration line with normal saline or 5% Dextrose Injection, USP immediately before and after Kyprolis administration.</p><p>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not mix Kyprolis with or administer as an infusion with other medicinal products.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The stabilities of reconstituted Kyprolis under various temperature and container conditions are shown in Table&nbsp;39.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>39:</strong><strong> Stabili</strong><strong>ty of reconstituted Kyprolis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p>Stability<sup>a</sup> per container</p></td></tr><tr><td style="vertical-align:bottom"><p>Storage conditions of reconstituted Kyprolis</p></td><td style="vertical-align:bottom"><p>Vial</p></td><td style="vertical-align:bottom"><p>Syringe</p></td><td style="vertical-align:bottom"><p>Intravenous bag (D5W<sup>b</sup>)</p></td></tr><tr><td><p>Refrigerated (2&deg;C&nbsp;to&nbsp;8&deg;C)</p></td><td><p>24&nbsp;hours</p></td><td><p>24&nbsp;hours</p></td><td><p>24&nbsp;hours</p></td></tr><tr><td><p>Room temperature (15&deg;C&nbsp;to&nbsp;30&deg;C)</p></td><td><p>4&nbsp;hours</p></td><td><p>4&nbsp;hours</p></td><td><p>4&nbsp;hours</p></td></tr><tr><td colspan="4"><p><sup>a</sup> Total time from reconstitution to administration should not exceed 24&nbsp;hours.</p><p><sup>b</sup> 5% Dextrose Injection, USP.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Onyx Pharmaceuticals, Inc. 
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
USA


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>